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   Lyme	   disease,	   caused	   by	   Borrelia	   burgdorferi,	   is	   the	   most	   prevalent	  
arthropod-­‐borne	   disease	   in	   the	   U.S.	   In	   nature,	   B.	   burgdorferi	   is	   maintained	   in	   an	  
enzootic	   cycle	   between	   Ixodes	   ticks	   and	   mammalian	   hosts.	   In	   order	   to	   cause	  
infection	   in	   mammals,	   B.	   burgdorferi	   spirochetes	   within	   a	   feeding	   tick	   sense	  
environmental	   changes	   and	   subsequently	   alter	   their	   gene	   expression	   and	   protein	  
profiles.	  As	  part	  of	  this	  adaptation,	  spirochetes	  within	  the	  tick	  midgut	  downregulate	  
outer	  surface	  protein	  (Osp)	  A	  and	  upregulate	  OspC.	  Although	  OspC	  is	  an	  essential	  B.	  
burgdorferi	  virulence	  factor	  needed	  for	  early	  mammalian	  infection,	  it	  is	  also	  a	  target	  
for	   the	  mammalian	   acquired	   immune	   response,	   and	   thus,	   OspC	   is	   repressed	   soon	  
after	   B.	   burgdorferi	   establishes	   infection.	   It	   has	   been	   shown	   that	   the	   central	  
Rrp2/RpoN/RpoS	  pathway	  is	  essential	  for	  the	  upregulation	  of	  OspC	  and	  other	  genes	  
important	   for	   mammalian	   infection.	   However,	   many	   key	   aspects	   in	   the	   strict	  
regulation	  of	  OspC	  remain	  undefined.	  In	  order	  to	  investigate	  the	  complex	  regulatory	  
mechanisms	  controlling	  OspC	  expression,	  we	  adapted	  the	  lacZ	  reporter	  system	  from	  
Escherichia	  coli	  for	  use	  in	  B.	  burgdorferi.	  Using	  this	  lacZ	  system	  and	  other	  molecular	  
genetic	  approaches,	  we	  identified	  BBD18	  as	  a	  novel	  factor	  that	  has	  the	  potential	  to	  
negatively	   regulate	   OspC.	   Expression	   of	   BBD18	   in	   B.	   burgdorferi	   repressed	  
transcription	  of	  ospC	   and	  abrogated	   infection	   in	  mice.	  We	  determined	   that	  BBD18	  
likely	  interfaces	  with	  the	  central	  Rrp2/RpoN/RpoS	  pathway	  and	  exerts	  its	  effect	  on	  
OspC	  through	  the	  repression	  of	  RpoS.	  Structural	  modeling	  indicated	  that	  BBD18	  has	  
a	   putative	   DNA-­‐binding	   motif,	   and	   site-­‐directed	   mutagenesis	   within	   this	   domain	  
abrogated	   BBD18’s	   ability	   to	   repress	   OspC	   and	   prevent	   infection	   of	   mice.	   We	  
propose	   that	   the	   BBD18	   protein	   acts	   in	   concert	   with	   other	   regulatory	   factors	   to	  
precisely	  control	  gene	  regulation	  in	  B.	  burgdorferi	  during	  the	  enzootic	  cycle.	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CHAPTER	  ONE:	  INTRODUCTION	  
	  
The	  Biology	  of	  Borrelia	  burgdorferi	  
	   Tick-­‐borne	  spirochetes	  in	  the	  genus	  Borrelia	  fall	  into	  two	  major	  groups,	  one	  
containing	  the	  causative	  agents	  of	  Lyme	  borreliosis	  (referred	  to	  as	  Lyme	  disease	  in	  
the	  United	  States),	  which	  are	  collectively	   referred	   to	  as	  Borrelia	  burgdorferi	  sensu	  
lato	  (s.l.),	  and	  the	  other	  containing	  the	  spirochetes	  responsible	   for	  relapsing	   fever.	  
The	  B.	   burgdorferi	   s.	   l.	   complex	   includes	  more	   than	   20	   species,	   but	   three	   species	  
predominate	   as	   the	   human	   pathogens:	   B.	   burgdorferi	   sensu	   stricto	   (s.s.)	   in	   the	  
United	   States	   and	   Western	   Europe,	   and	   Borrelia	   garinii	   and	   Borrelia	   afzelii	   in	  
Eurasia	  (1).	  Hereafter,	  B.	  burgdorferi	  is	  used	  to	  refer	  to	  B.	  burgdorferi	  s.l.	  
	   Borrelia	   species	   are	   neither	   Gram-­‐negative	   nor	   Gram-­‐positive.	   Although	  
Borreliae	   have	   a	   double	   membrane,	   they	   are	   distinguished	   from	   Gram-­‐negative	  
bacteria	   by	   the	   absence	   of	   lipopolysaccharide	   (LPS)	   (2).	   A	   thin	   outer	   membrane	  
surrounds	  the	  protoplasmic	  cylinder,	  which	  includes	  a	  peptidoglycan	  layer	  and	  the	  
cytoplasmic	  membrane,	   enclosing	   the	   cellular	   cytoplasm.	  The	   flagella,	  which	  wrap	  
around	   the	   cytoplasmic	   cylinder	  multiple	   times	  within	   the	   periplasmic	   space,	   are	  
attached	   at	   each	   pole	   and	   give	   spirochetes	   their	   characteristic	   helical	   shape	   and	  
motility	  (Figure	  1-­‐1)	  (3)	  	  
	   B.	   burgdorferi	   spirochetes	   are	   transmitted	   to	   mammalian	   hosts	   by	   hard-­‐
bodied	  ticks	  of	  the	  genus	  Ixodes	  (see	  below)	  and	  do	  not	  survive	  in	  nature	  outside	  of	  
these	   environments	   (4).	   Due	   to	   the	   nature	   of	   this	   life	   style,	   combined	   with	   a	  
relatively	   small	   genome	   (see	   below),	   B.	   burgdorferi	   have	   few	   biosynthetic	  
capabilities	  and	  require	  amino	  acids,	  nucleotides,	  and	  fatty	  acids	  from	  their	  hosts	  for	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Figure	  1-­‐1:	  Structure	  and	  Morphology	  of	  Borrelia	  burgdorferi	  (5)	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Figure	  1-­‐1	  legend:	  A.	  Scanning	  (left)	  and	  transmission	  (right)	  electron	  micrographs	  
of	  Borrelia	  burgdorferi.	  The	  helical	  shape	  of	  Borrelia	  (visible	  in	  the	  scanning	  electron	  
micrograph)	  is	  imparted	  by	  the	  periplasmic	  flagella,	  which	  can	  be	  seen	  in	  the	  cross-­‐
sectional	   view	   of	   the	   spirochete	   in	   the	   transmission	   electron	   micrograph.	  
Micrographs	   provided	   by	   David	   Dorward	   and	   Elizabeth	   Fischer,	   Rocky	   Mountain	  
Laboratories,	   NIAID,	   NIH.	   Left-­‐hand	   panel	   is	   reproduced	   with	   permission	   from	  
Nature	  11	  Dec	  1997	  (cover	   image)	  ©	  Macmillan	  Magazines	  Ltd.	  B.	  Diagram	  of	   the	  
spirochete.	  Flagellar	  insertion	  points	  are	  located	  near	  the	  termini	  of	  the	  spirochete.	  
Bundles	   of	   flagella	  wind	   around	   the	   flexible,	   rod-­‐shaped	   protoplasmic	   cylinder	   of	  
Borrelia	   and	   overlap	   in	   the	   middle.	   The	   outer	   membrane	   constrains	   the	   flagellar	  
bundles	   within	   the	   periplasm.	   C.	   Detailed	   diagram	   of	   flagella.	   Each	   flagellum	   is	  
inserted	  into	  the	  cytoplasmic	  membrane	  and	  extends	  through	  the	  cell	  wall	  into	  the	  
periplasm.	   Flagella	   are	   multi-­‐component,	   complex	   structures.	   Spirochete	   motility	  
results	  from	  coordinated	  rotation	  of	  the	  flagella.	  Part	  C	  is	  modified	  with	  permission	  
from	  (6)	  ©	  (2002)	  Annual	  Reviews.	  This	   figure	  was	  reprinted	  by	  permission	   from	  
Macmillan	  Publishers	  Ltd:	  Nature	  Reviews	  Microbiology	  (5)	  ©	  2005.	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growth.	  Additionally,	  B.	  burgdorferi	  only	  utilizes	  a	  limited	  number	  of	  carbon	  sources	  
and	   the	   fermentation	   of	   glucose	   to	   lactic	   acid	   is	   the	   primary	   source	   of	   energy	   for	  
these	  obligate	  extracellular	  parasites	  (2,	  7).	  	  
The	  Life	  Cycle	  of	  B.	  burgdorferi	  
	   B.	  burgdorferi	  spirochetes	  exist	  in	  an	  enzootic	  cycle	  between	  hard	  bodied	  tick	  
vectors	   and	   vertebrate	   hosts	   (Figure	   1-­‐2)	   (4).	   The	   primary	   tick	   vector	   for	   the	  
transmission	  of	  B.	  burgdorferi	  s.s.	  is	  Ixodes	  scapularis	  in	  the	  eastern	  and	  midwestern	  
portions	   of	   the	   United	   States,	   and	   I.	   pacificus	   in	   the	  western	  U.S;	   I.	   	   ricinus	   and	   I.	  
persulcatus	   are	   primarily	   responsible	   for	   transmission	   of	   B.	   burgdorferi	   s.	   l.	   in	  
Europe	  and	  Asia,	  respectively	  (8).	  	  
	   Ixodes	   ticks	   undergo	   a	   three-­‐stage	   life	   cycle:	   larva,	   nymph,	   and	   adult,	   with	  
one	  blood	  meal	  per	  stage.	  B.	  burgdorferi	  is	  not	  transmitted	  from	  an	  infected	  adult	  to	  
eggs	  (transovarial	  transmission)	  so	  larval	  ticks	  are	  not	  infected	  with	  B.	  burgdorferi	  
when	  they	  hatch.	  Thus,	  larval	  ticks	  acquire	  B.	  burgdorferi	  by	  feeding	  on	  an	  infected	  
reservoir	  host.	  Although	  larval	  Ixodes	  ticks	  feed	  on	  many	  different	  animals,	  the	  main	  
reservoir	   for	  B.	  burgdorferi	  s.s.	   in	   the	  northeastern	  U.S.	   is	   the	  white-­‐footed	  mouse,	  
Peromyscus	  leucopus	  (9);	  several	  species	  of	  rodents,	  small	  mammals,	  and	  migratory	  
birds	  act	  as	  the	  reservoirs	  for	  B.	  burgdorferi	  s.l.	  strains	  in	  Europe.	  Once	  larval	  ticks	  
acquire	  B.	  burgdorferi,	   the	  spirochetes	  are	  maintained	   throughout	   subsequent	   tick	  
stages	   (transstadial	   transmission).	   After	   molting	   to	   the	   nymphal	   stage,	   ticks	  
transmit	  spirochetes	  to	  the	  animal	  that	  provides	  their	  next	  blood	  meal.	  Humans	  act	  
as	   incidental	   hosts	   for	   infected	   nymphs	   and	   are	   generally	   thought	   of	   as	   dead-­‐end	  
hosts	  and	  not	  part	  of	  the	  enzootic	  cycle	  of	  B.	  burgdorferi.	  Adult	  Ixodes	  ticks	  are	  not	  
traditionally	  important	  in	  the	  maintenance	  of	  B.	  burgdorferi,	  as	  they	  predominantly	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Figure	  1-­‐2:	  The	  enzootic	  cycle	  of	  B.	  burgdorferi	  (10)	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Figure	  1-­‐2	  legend:	  Graphical	  representation	  of	  the	  infectious	  cycle	  of	  B.	  burgdorferi.	  
This	   figure	   was	   reprinted	   by	   permission	   from	   Macmillan	   Publishers	   Ltd:	   Nature	  
Reviews	  Microbiology	  (10)	  ©	  2012.	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feed	   on	   incompetent	   hosts	   for	  B.	   burgdorferi,	   such	   as	   deer.	   However,	   since	   adult	  
ticks	  mate	  on	  these	  larger	  animals	  (10),	  they	  are	  important	  for	  the	  maintenance	  of	  
the	  tick	  population	  and	  thus	  indirectly	  for	  the	  enzootic	  cycle	  of	  B.	  burgdorferi.	  	   	  
Epidemiology	  
	   Lyme	  disease	   is	   the	  most	   common	  arthropod-­‐borne	  disease	   in	   the	  U.S.	  The	  
incidence	  of	  Lyme	  disease	  has	  increased	  dramatically	  since	  the	  Centers	  for	  Disease	  
Control	   and	   Prevention	   began	   surveillance	   in	   1982,	   with	   approximately	   32,000	  
confirmed	   and	   probable	   cases	   in	   the	   U.S.	   for	   2011.	   Since	   B.	   burgdorferi	   is	  
transmitted	  by	  Ixodes	  ticks,	  most	  cases	  of	  Lyme	  disease	  occur	  during	  early	  spring	  to	  
summer,	   when	   outdoor	   activities	   coincide	  with	   nymphal	   ticks	   searching	   for	   their	  
blood	   meal.	   Ixodes	   ticks	   typically	   feed	   for	   3-­‐7	   days,	   depending	   on	   the	   life	   stage;	  
transmission	  of	   spirochetes	  generally	  occurs	  after	   ticks	  have	  been	  attached	   for	  48	  
hours	  or	   longer	  and	  rarely,	   if	  ever,	  occurs	  during	  the	  first	  24	  hours	  (11,	  12).	  Upon	  
initiation	  of	  feeding,	  B.	  burgdorferi	  within	  the	  tick	  midgut	  undergo	  rapid	  replication	  
and	  subsequently	  migrate	  to	  the	  tick	  salivary	  glands,	  a	  process	  that	  takes	  ~48	  hours,	  
accounting	  for	  the	  delay	  in	  transmission	  of	  B.	  burgdorferi	  (13,	  14).	  Thus,	  the	  chance	  
of	   acquiring	   Lyme	   disease	   is	   greatly	   reduced	   if	   ticks	   are	   removed	   shortly	   after	  
attachment.	  	  	  
Lyme	  disease	  
	   Lyme	  disease	  was	   first	   recognized	   in	   the	  U.S.	   in	  1977	  when	  an	  epidemic	  of	  
childhood	   arthritis	   occurred	   in	   Lyme,	   Connecticut	   (15).	   It	   was	   subsequently	  
discovered	   that	   an	   antibiotic-­‐sensitive	   organism	   transmitted	   by	   Ixodes	   ticks	   was	  
responsible	   for	   the	   disease	   (16).	   In	   1982,	   Burgdorfer	   and	   colleagues	   successfully	  
isolated	   the	   etiological	   agent	   of	   Lyme	   disease,	   which	   was	   named	   Borrelia	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burgdorferi,	   from	  the	  midgut	  of	  I.	   scapularis	   ticks	  collected	  from	  Shelter	  Island,	  NY	  
(4).	  	  
	   During	  tick	  feeding,	  B.	  burgdorferi	  are	  deposited	  into	  the	  bite	  site.	  Although	  
these	   tick-­‐inoculated	   spirochetes	   can	   cause	   chronic	   infection	   in	   a	  wide	   variety	   of	  
mammals,	  the	  disease	  manifestation	  depends	  on	  the	  recipient	  animal.	  The	  reservoir	  
hosts	   remain	   persistently	   infected	   without	   showing	   any	   overt	   symptoms.	   All	  
laboratory	   strains	   of	   mice	   (Mus	   musculus)	   are	   susceptible	   to	   infection,	   but	   the	  
development	   of	   clinical	   symptoms	   in	   immunocompetent	   mice	   is	   highly	   strain	  
specific.	  	  
In	   humans,	   Lyme	   disease	   is	   a	   multi-­‐system,	   multi-­‐stage	   disorder	   that	   can	  
affect	   the	   skin,	   joints,	   heart,	   and	   nervous	   system	   and	   is	   generally	   subdivided	   into	  
three	   stages	   (17).	   During	   stage	   1,	   70-­‐80%	   of	   patients	   develop	   a	   localized	  
inflammatory	  reaction	  in	  the	  skin	  called	  erythema	  migrans	  (EM)	  around	  the	  site	  of	  
the	  tick	  bite.	  Stage	  1	  manifestations	  can	  also	  include	  mild	  influenza-­‐like	  symptoms,	  
occurring	  with	  or	  without	  the	  characteristic	  “bull’s	  eye”	  EM	  rash	  (18).	  Within	  weeks	  
to	  months,	  B.	   burgdorferi	  will	   disseminate	   through	  a	   transient	  blood-­‐borne	  phase,	  
and	  thus,	  symptoms	  associated	  with	  stage	  2	  Lyme	  disease,	  which	   include	  arthritis,	  
carditis,	   and	   neuropathies,	   revolve	   around	   the	   organ(s)	   that	   spirochetes	   have	  
colonized.	  If	  untreated,	  Lyme	  disease	  can	  progress	  to	  stage	  3.	  Patients	  with	  this	  late-­‐
persistent	   disease	   suffer	   from	   chronic	   arthritis	   and	   neuroborreliosis,	   which	   can	  
manifest	  as	  menigioencephalitis,	  facial	  paralysis	  (Bell’s	  palsy),	  or	  radiculoneuritis.	  A	  
skin	   condition	   known	   as	   acrodermatitis	   chronica	   atrophicans	   (ACA)	   is	   a	   common	  
manifestation	  of	  B.	  burgdorferi	  infection	  in	  Europe	  but	  rarely	  occurs	  in	  the	  U.S.	  The	  
prevalence	   of	   particular	   symptoms	   varies	   between	   the	   geographic	   locations,	  with	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arthritis	  more	   common	   in	   the	  U.S.	   and	  neurological	   symptoms	   and	   skin	  disorders	  
(e.g.	   ACA)	   more	   common	   in	   Europe	   (17),	   presumably	   reflecting	   distinct	   clinical	  
manifestations	   that	   result	   from	   infection	   with	   different	   B.	   burgdorferi	   s.l.	  
genospecies	  (19).	  	  	  
	   The	  B.	  burgdorferi	  genome	  does	  not	  encode	  any	  known	  toxins	  or	  the	  delivery	  
system	   required	   to	   secrete	   them	   (2,	   20)	   and	   thus,	   Lyme	   disease	   is	   thought	   to	   be	  
mediated	   by	   the	   mammalian	   inflammatory	   response	   elicited	   by	   the	   spirochetes.	  
Several	   studies	   have	   associated	   the	   variation	   in	   severity	   and	   symptoms	   of	   Lyme	  
disease	  with	  a	  disregulation	  in	  the	  balance	  of	  pro-­‐	  and	  anti-­‐inflammatory	  responses	  
(21-­‐24).	  Still,	  the	  symptoms	  of	  Lyme	  disease	  respond	  to	  antibiotic	  therapy	  in	  most	  
patients,	  suggesting	  that	  disease	  manifestations	  are	  the	  direct	  results	  of	  spirochetal	  
infection.	  A	   2-­‐4	  week	   course	   of	   antibiotics	   is	   generally	   effective	   for	   stage	   1	   and	  2	  
Lyme	   disease,	   although	   some	   patients	   develop	   chronic	   symptoms	   that	   are	  
unresponsive	   to	   antibiotic	   therapy,	   suggesting	   the	   possibility	   of	   infection-­‐induced	  
autoimmunity	  (17).	  	  
The	  B.	  burgdorferi	  genome	  
	   Spirochetes	   of	   the	   genus	  Borrelia	   are	  unique	   in	   that	   they	  possess	   the	  most	  
complex	  genomes	  of	  all	  characterized	  bacteria.	  More	  than	  20	  coexisting	   linear	  and	  
circular	  genetic	  elements	  have	  been	  identified	  in	  the	  B.	  burgdorferi	  type	  strain	  B31	  
(Figure	  1-­‐3).	  This	   includes	  a	  small	   (~910	  kilobase	  pairs,	  kbp)	   linear	  chromosome,	  
12	   linear	  plasmids	   ranging	   in	   size	   from	   five	   to	  56	  kbp,	  and	  nine	  circular	  plasmids	  
ranging	   from	   nine	   to	   32	   kbp	   (2,	   20).	   Additional	   plasmids	   have	   been	   described	   in	  
other	  B.	  burgdorferi	  isolates	  (25,	  26).	  In	  total,	  these	  plasmids	  comprise	  610	  kbp	  and	  
account	  for	  ~40%	  of	  the	  genetic	  content	  of	  B.	  burgdorferi	  (20).	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Figure	  1-­‐3:	  The	  Unique	  Genome	  of	  Borrelia	  burgdorferi	  B31
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Figure	   1-­‐3	   legend:	   Graphical	   representation	   of	   the	   segmented	   genome	   of	   B.	  
burgdorferi	  (not	  to	  scale).	  Numbers	  represents	  the	  approximate	  size	  of	  the	  circular	  
plasmid	   (cp)	   or	   linear	   plasmid	   (lp)	   in	   kilobase	   pairs	   (kbp).	   This	   figure	   closely	  
resembles	  a	  figure	  from	  reference	  (27).	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The	  chromosome	  encodes	  the	  majority	  of	  housekeeping	  genes	  and	  is	  fairly	  
well	   conserved	   across	   the	   Borrelia	   genus	   (28).	   More	   than	   half	   of	   the	   predicted	  
chromosomal	   open	   reading	   frames	   (ORFs)	   were	   assigned	   functions	   based	   on	  
homology	   to	  genes	   in	  other	  organisms	  (2).	   In	  contrast,	  when	  originally	  annotated,	  
only	  8%	  of	  plasmid-­‐encoded	  ORFs	  had	  homologs	  in	  other	  bacteria	  and	  less	  than	  6%	  
of	   those	  had	  an	  assigned	   function	  (2,	  20).	  Although	  these	  numbers	  have	   increased	  
somewhat	  with	   the	   addition	  of	  many	  new	  bacterial	   genome	   sequences,	   the	  highly	  
segmented	  genome	  structure	  has	  remained	  unique	  to	  Borrelia	  (26).	  	  
Much	   of	   the	   content	   of	   these	   plasmids	   contains	   non-­‐coding	   DNA	   and	  
pseudogenes.	   In	  addition,	   there	   is	  high	  degree	  of	   redundancy	   in	   the	  plasmid	  DNA,	  
with	   a	   large	   number	   of	   paralogous	   gene	   families	   distributed	   throughout	   the	  
plasmids,	   and	   large	   stretches	   of	   essentially	   identical	   DNA	  within	   the	   nine-­‐32	   kbp	  
circular	  plasmids	  (20,	  26).	  Still,	  a	   large	  proportion	  of	  plasmid-­‐encoded	  genes	  have	  
been	   shown	   to	   be	   differentially	   regulated	   in	   response	   to	   environmental	   cues	   that	  
distinguish	   various	   stages	   of	   the	   infectious	   cycle	   (29-­‐37),	   suggesting	   a	   role	   for	  
plasmid-­‐encoded	  genes	  during	  the	  infectious	  cycle	  of	  B.	  burgdorferi.	  	  
Although	  linear	  chromosomes	  and	  plasmids	  have	  been	  described	  in	  very	  few	  
bacteria,	   the	   replication	   initiation	   mechanisms	   for	   the	   B.	   burgdorferi	   linear	   DNA	  
elements	   appear	   to	   be	   similar	   to	   standard	   circular	   bacterial	   chromosomes	   and	  
plasmids.	  Picardeau	  and	  colleagues	  mapped	  the	  chromosomal	  origin	  of	  replication	  
to	   a	   central	   location	   and	   showed	   that	   replication	   proceeds	   symmetrically	   and	   bi-­‐
directionally	   from	   that	   region	   (38).	   Origins	   of	   replication	   were	   subsequently	  
identified	   for	   lp17,	   lp25,	   lp28-­‐4,	  and	   lp54,	  supporting	  the	   idea	  that	  both	  the	   linear	  
chromosome	   and	   linear	   plasmids	   use	   similar	   mechanisms	   for	   bi-­‐directional	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replication	   (39).	   The	   B.	   burgdorferi	   linear	   DNA	   molecules	   have	   covalently	   closed	  
hairpin	   ends	   referred	   to	   as	   telomeres.	   At	   each	   end,	   the	   two	   DNA	   strands	   are	  
connected	  and	   form	  a	  near-­‐perfect	  AT-­‐rich	   inverted	   repeat	   (40-­‐43).	  Bi-­‐directional	  
replication	  is	  thought	  to	  create	  a	  head-­‐to-­‐head	  and	  tail-­‐to-­‐tail	  circular	  dimer,	  which	  
then	   must	   be	   resolved	   into	   two	   linear	   DNA	   molecules	   (44).	   An	   enzyme	   called	  
telomere	  resolvase	  cleaves	  the	  duplex	  DNA	  in	  the	  telomeric	  regions	  and	  regenerates	  
the	   covalently	   closed	   hairpin	   loops	   in	   the	   progeny	   molecules	   (45).	   Synthetic	  
telomeres	  have	  been	  a	  key	  tool	  in	  the	  investigation	  of	  the	  mechanisms	  of	  telomere	  
resolution	  (44).	   In	  addition,	   truncated	  versions	  of	   lp17	  created	  by	   the	   insertion	  of	  
these	   synthetic	   telomeres	   have	   been	   used	   to	   ascribe	   functions	   to	   some	   lp17-­‐
encoded	  genes,	  including	  the	  genes	  necessary	  for	  autonomous	  replication	  (46).	  	  
The	  putative	  origins	  of	  replication	  for	  B.	  burgdorferi	  circular	  and	  linear	  DNA	  
molecules	  are	  all	  located	  within	  the	  vicinity	  of	  a	  homolog	  of	  parA,	  an	  ATPase	  that	  is	  
involved	   in	   plasmid	   partitioning.	   Furthermore,	   this	   gene	   clusters	   with	   other	  
members	   of	   a	   paralogous	   gene	   family	   thought	   to	   encode	   proteins	   involved	   in	  
plasmid	   replication	   and	   partitioning.	   Indeed,	   autonomously	   replicating	   shuttle	  
vectors	  have	  been	  developed	  using	  regions	  from	  cp9	  (47),	  cp32-­‐3	  (48),	  lp25,	  lp28-­‐1	  
(49),	   cp26	   (50),	   and	   lp38	   (51)	   that	   contain	  members	   of	   several	   paralogous	   gene	  
families	  and	  the	  putative	  origin	  of	  replication	  for	  each	  native	  plasmid.	  These	  shuttle	  
vectors	   are	   incompatible	  with	   the	  native	  B.	   burgdorferi	   plasmids	   from	  which	   they	  
were	  derived,	   indicating	  a	  role	  for	  members	  of	  the	  paralogous	  gene	  families	   in	  the	  
maintenance	   and	   compatibility	   of	   the	   many	   co-­‐exiting	   DNA	   elements	   in	   B.	  
burgdorferi	  (48,	  52).	   In	  addition,	  shuttle	  vectors	  derived	  from	  linear	  B.	  burgdorferi	  
plasmids	   lp25	   and	   lp28-­‐1	   exist	   in	   a	   circular	   form,	   indicating	   that	   replication	   and	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partitioning	  mechanisms	  are	  conserved,	  regardless	  of	  DNA	  form	  (49).	  Beaurepaire	  
and	   Chaconas	   reported	   that	   the	   transcription	   of	   genes	   varied,	   depending	   on	  
whether	  the	  gene	  was	  located	  on	  a	  linear	  or	  a	  circular	  plasmid,	  and	  suggested	  that	  
the	  different	  topologies	  present	  in	  the	  B.	  burgdorferi	  genome	  might	  play	  a	  role	  in	  the	  
complex	  genetic	  regulation	  that	  the	  spirochetes	  undergo	  as	  they	  moves	  from	  vector	  
to	  host	  and	  vice	  versa	  (53).	  
B.	   burgdorferi	   linear	   and	   circular	   plasmids	   vary	   in	   their	   stability	   during	   in	  
vitro	   growth	  and	  some	  plasmids	  are	   frequently	   lost	   in	  a	   few	  generations.	  The	   fact	  
that	   most	   plasmids	   can	   be	   lost	   indicates	   that	   they	   are	   not	   required	   for	   bacterial	  
growth	   in	  vitro	   (54-­‐56).	  However,	   the	   loss	  of	  certain	  plasmids	  has	  been	  associated	  
with	   a	   loss	   of	   infectivity	   in	  mice	   (see	   below)	   (54,	   57-­‐61).	   Thus,	   it	   is	   necessary	   to	  
demonstrate	   that	   the	   plasmid	   content	   of	   all	   relevant	   B.	   burgdorferi	   strains	   are	  
identical	  to	  those	  with	  which	  they	  are	  being	  compared	  in	  molecular	  genetic	  studies.	  
Certain	  B.	  burgdorferi	  plasmids,	  like	  cp26	  and	  lp54,	  are	  rarely	  if	  ever	  lost	  in	  
natural	   isolates.	   The	   only	   copy	   of	   the	   B.	   burgdorferi	   resT	   gene,	   encoding	   the	  
telomere	   resolvase	   (see	   above),	   is	   located	  on	   cp26	   (2,	   20,	   45),	   providing	   a	   simple	  
explanation	  for	  its	  universal	  retention.	  However,	  resT	   is	  not	  the	  only	  gene	  encoded	  
on	   cp26	   that	   makes	   it	   an	   essential	   plasmid,	   as	   a	   cp26-­‐derived	   shuttle	   vector	  
harboring	  a	  copy	  of	  resT	  was	  still	  unable	  to	  displace	  the	  native	  cp26	  in	  B.	  burgdorferi	  
(50).	  Further	  studies	  showed	  that	  an	  incompatible	  plasmid	  containing	  bbb26,	  bbb27,	  
and	   resT	  was	   able	   to	  displace	   cp26,	   indicating	  one	  or	  both	  of	   these	   cp26-­‐encoded	  
genes,	   in	   addition	   to	   resT,	   is	   required	   for	   spirochete	   viability	   (62).	  Of	   note,	  bbb26	  
and	  bbb27	  refer	  to	  the	  26th	  and	  27th	  genes	  encoded	  on	  cp26,	  which	  is	  designated	  by	  
the	  third	   ‘b.’	  For	  clarity	  in	  naming	  genes,	  each	  B.	  burgdorferi	  plasmid	  was	  given	  an	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arbitrary	  letter,	  with	  the	  letter	  ‘a’	  designating	  genes	  on	  lp54,	  ‘c’	  genes	  are	  located	  on	  
cp9,	  and	  so	  forth.	  	  
The	  gene	  encoding	  outer	  surface	  protein	  (Osp)	  C,	  which	  is	  not	  essential	  for	  in	  
vitro	   growth	   but	   is	   required	   during	   early	   stages	   of	   infection	   in	   the	  mammal	   (see	  
below),	  is	  also	  located	  on	  cp26	  (63,	  64).	  At	  least,	  two	  other	  genes	  encoded	  on	  cp26,	  
guaA	  and	  guaB,	  which	  are	  involved	  in	  the	  purine	  salvage	  pathway	  (65),	  are	  essential	  
for	  mammalian	  infectivity	  and	  provide	  a	  growth	  advantage	  for	  B.	  burgdorferi	  within	  
ticks	  (66).	  	  
Although	   lp54	   is	  usually	  very	  stable	  during	   in	  vitro	  growth,	   it	  has	  been	   lost	  
from	  at	   least	  one	  highly	  attenuated	  strain	  (67).	   lp54	  encodes	  many	  genes	   that	  are	  
differentially	  regulated	  in	  response	  to	  environmental	  cues	  like	  temperature	  and	  pH,	  
suggesting	   a	   role	   for	   lp54	   during	   the	   B.	   burgdorferi	   infectious	   cycle.	   The	   ospAB	  
operon	   is	   located	  on	   lp54.	  The	   inverse	   relationship	  of	  OspA	  and	  OspC	  during	   tick	  
colonization	   and	   transmission	  was	   the	   first	   observation	  of	   differentially	   regulated	  
genes	   in	  B.	   burgdorferi	   (see	   below)	   (14).	  Other	   genes	   encoded	  on	   lp54	   that	   likely	  
contribute	  to	  the	  B.	  burgdorferi	  enzootic	  cycle	  include	  bba52	  ((68),	  lp6.6	  (69),	  bba64	  
(70),	  cspA	  (71-­‐73),	  and	  the	  dbpAB	  operon	  (74,	  75).	  	  
The	   presence	   of	   lp25,	   lp28-­‐1,	   and	   lp36	   in	  B.	   burgdorferi	   has	   been	   directly	  
correlated	   with	   infectivity	   in	   mice	   (57,	   60,	   76).	   Through	   molecular	   genetic	  
approaches,	   the	   genes	   encoded	   on	   each	   of	   these	   plasmids	   that	   contribute	   to	   B.	  
burgdorferi	   infectivity	  have	  been	   identified.	   Infectivity	  of	  mice	  was	   restored	  when	  
spirochetes	  lacking	  lp25	  were	  complemented	  with	  the	  pncA	  gene,	  which	  encodes	  a	  
nicotinamidase,	  suggesting	  pncA	  is	  the	  only	  gene	  carried	  on	  lp25	  that	  is	  required	  for	  
mouse	   infectivity	   (59).	   An	   additional	   gene	   on	   lp25,	   bbe02,	   encodes	   a	   restriction-­‐
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modification	  system	  and	  is	  responsible	  for	  decreased	  transformation	  efficiency	  (77).	  
Inactivating	   bbe02	   in	   low	   passage	   clones	   results	   in	   increased	   transformation	  
frequency	  with	  shuttle	  vectors	  and	   the	  resulting	  clones	  are	   infectious	   in	  mice	   (78,	  
79).	   An	   additional	   restriction-­‐modification	   system	   is	   located	   on	   lp56,	   and	  
spirochetes	  lacking	  lp56	  exhibit	  increased	  transformation	  efficiency	  but	  retain	  their	  
infectivity	   in	  mice	  (77,	  79).	   	  One	  gene	  encoded	  on	  lp25,	  bbe16	  or	  bptA,	   is	  essential	  
for	   persistence	   in	   the	   tick	   vector	   and	   presumably	   encodes	   a	   surface-­‐exposed	  
lipoprotein	  that	  helps	  anchor	  spirochetes	  to	  the	  tick	  midgut	  (80).	  	  
The	  correlation	  of	  lp28-­‐1	  and	  infectivity	  in	  mice	  is	  attributed	  to	  the	  presence	  
of	   a	  mechanism	  of	   antigenic	   variation	   similar	   to	   the	   variable	  major	  protein	   (vmp)	  
system	   in	  B.	   hermsii,	   which	   causes	   relapsing	   fever.	   In	  B.	   burgdorferi,	   this	   locus	   is	  
designated	   as	   the	   Vmp-­‐like	   sequence	   or	   vls	   locus,	  which	   consists	   of	   an	   expressed	  
vlsE	  region	  and	  15	  upstream	  silent	  vls	  cassettes	  (81).	  	  The	  antigenically	  variable	  VlsE	  
protein	  allows	  B.	  burgdorferi	   to	  maintain	  persistent	   infection	   in	  spite	  of	   the	  host’s	  
adaptive	  immune	  response	  to	  the	  spirochete	  (82).	  	  	  
Spirochetes	  lacking	  lp36	  are	  non-­‐infectious	  in	  mice	  by	  needle	  inoculation	  and	  
exhibit	   low	   infectivity	   by	   tick	   bite,	   with	   limited	   dissemination	   to	   internal	   organs.	  
Infectivity	   was	   partially	   restored	   when	   bbk17,	   which	   encodes	   a	   putative	   adenine	  
deaminase,	   was	   expressed	   on	   a	   shuttle	   vector	   in	   lp36-­‐deficient	   spirochetes	   (76).	  
Seshu	   and	   colleagues	   reported	   that	   inactivating	   bbk32,	   encoding	   a	   fibronectin-­‐
binding	  adhesin,	  attenuated	  the	  infectivity	  of	  spirochetes	  in	  mice	  (83).	  It	  is	  unclear	  
whether	  additional	  lp36-­‐encoded	  genes	  also	  contribute	  to	  mammalian	  infectivity	  or	  




The	   environmental	   changes	   that	   accompany	   the	   tick	   blood	   meal	   trigger	   a	  
dramatic	  change	  in	  gene	  expression	  and	  the	  protein	  profile	  of	  B.	  burgdorferi	  within	  
the	  tick	  midgut.	  In	  vitro	  changes	  in	  pH,	  temperature,	  and	  cell	  density	  have	  been	  used	  
to	  induce	  changes	  in	  gene	  expression,	  which	  are	  thought	  to	  parallel	  the	  adaptation	  
of	  B.	  burgdorferi	  in	  vivo.	  Direct	  analysis	  of	  in	  vivo	  gene	  expression	  or	  protein	  profiles	  
in	  B.	  burgdorferi	   is	  not	  easily	  achieved	  due	  to	  the	  low	  numbers	  of	  spirochetes	  than	  
can	  be	  isolated	  from	  infected	  animals.	  However,	  Akins	  et	  al.	  developed	  a	  technique	  
in	  which	  spirochetes	  are	  grown	  to	  a	  high	  density	  in	  culture	  medium	  within	  a	  dialysis	  
membrane	  chamber	   (DMC)	   implanted	   in	   the	  peritoneal	   cavity	  of	  a	   rat	   (84),	  which	  
allows	  direct	  analysis	  of	  spirochete	  proteins	  and	  RNA	  (30,	  34,	  85,	  86).	  Studies	  using	  
this	  technique	  have	  determined	  that	  host-­‐specific	  factors	  invoke	  additional	  changes	  
in	   gene	   expression	   that	   are	   not	   evident	   when	   B.	   burgdorferi	   are	   grown	   under	  
varying	   culture	   conditions	   in	   vitro	   that	  mimic	   tick	   feeding	   (30,	   34).	   Using	   both	   in	  
vitro-­‐grown	  and	  host-­‐adapted	  spirochetes	  grown	  within	  DMCs,	  the	  mechanisms	  that	  
B.	   burgdorferi	   utilizes	   to	   adapt	   throughout	   the	   enzootic	   cycle	   have	   begun	   to	   be	  
elucidated.	  
Differential	  Regulation	  of	  the	  B.	  burgdorferi	  Osps	  	  
	   The	  dramatic	  alteration	   in	  B.	  burgdorferi	  gene	  expression	   that	  accompanies	  
tick	   feeding	  was	  first	  recognized	  with	  the	  reciprocal	  synthesis	  of	   the	  outer	  surface	  
(lipo)	   proteins	   A	   and	   C	   (OspA	   and	   OspC,	   respectively)	   (87).	   In	   unfed	   nymphal	   I.	  
scapularis	   ticks	   infected	  with	  B.	  burgdorferi,	   spirochetes	   located	   in	   the	   tick	  midgut	  
express	   OspA,	   but	   not	   OspC.	   During	   tick	   feeding,	   the	   proportion	   of	   OspA-­‐positive	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spirochetes	   decreases	   as	   spirochetes	   begin	   to	   upregulate	   OspC,	   preparing	   for	  
transmission	  to	  the	  mammalian	  host	  (14,	  87).	  	  
It	   has	   been	   reported	   that	   OspA	   is	   required	   for	   the	   colonization	   of	   the	   tick	  
midgut	   (88),	   presumably	   through	   its	   binding	   to	   a	   tick	   midgut	   receptor	   termed	  
TROSPA	  (89).	  However,	  Battisti	  et	  al.	  subsequently	  demonstrated	  that	  the	  defect	  in	  
tick	   colonization	   of	   spirochetes	   lacking	   the	   ospAB	   operon	  was	  more	   likely	   due	   to	  
immune	  clearance	  by	  antibodies	  in	  the	  incoming	  blood	  meal,	  suggesting	  a	  primary	  
function	  of	  OspA	  as	  a	  shield	  for	  conserved	  outer	  surface	  proteins	  (90).	  This	   is	  also	  
the	  premise	  behind	   the	  OspA	  vaccine	   for	  Lyme	  disease,	   in	  which	  antibodies	  made	  
against	   recombinant	   OspA,	   a	   protein	   not	   normally	   produced	   during	   natural	  
infection,	  prevent	  the	  transmission	  of	  B.	  burgdorferi	  from	  the	  tick	  to	  the	  vaccinated	  
host	  (91).	  
The	   role	   of	   OspC	   during	   early	   mammalian	   infection	   has	   been	   less	  
straightforward.	   It	   is	   well	   documented	   that	   OspC	   is	   required	   for	   transmission	   to,	  
and	   establishing	   infection	   within,	   the	   mammalian	   host	   (92-­‐97).	   However,	   the	  
specific	  functions	  of	  OspC	  are	  not	  fully	  understood.	  	  
Early	   studies	   reported	   that	   OspC	   is	   involved	   in	   the	   dissemination	   of	  
spirochetes	   from	   the	   tick	  midgut	   to	   the	   salivary	  glands	   (93,	  98).	  However,	  Grimm	  
and	  colleagues	  reported	  that	  spirochetes	  lacking	  OspC	  migrated	  to	  the	  tick	  salivary	  
glands	   efficiently	   but	   were	   unable	   to	   infect	   mice,	   suggesting	   that	   OspC	   is	   not	  
essential	   for	   the	  dissemination	  to	  the	  salivary	  glands	  but	  rather	  provides	  a	  critical	  
function	  during	   early	   infection	   in	  mammals	   (94-­‐97).	   In	   addition,	   patients	   infected	  
with	  B.	   burgdorferi	   often	   develop	   an	   early	   antibody	   response	   to	   OspC,	   indicating	  
that	   spirochetes	   expressing	   OspC	   are	   transmitted	   from	   vector	   to	   host	   (99).	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However,	  OspC	  on	  the	  surface	  of	  B.	  burgdorferi	  is	  transient,	  as	  it	  represents	  a	  target	  
for	  neutralizing	  antibodies,	  and	  thus,	  spirochetes	  downregulate	  ospC	  to	  avoid	  being	  
cleared	  by	  the	  host’s	  adaptive	  immune	  response	  (82,	  100,	  101).	  	  	  
The	  strict	  timing	  of	  ospC	  expression	  coincides	  with	  the	  host’s	  innate	  immune	  
response	  and	  suggests	  that	  OspC	  may	  play	  a	  role	  in	  avoiding	  clearance	  by	  the	  innate	  
immune	   system.	   There	   have	   been	   several	   reports	   implicating	   myeloid	  
differentiation	  marker	  88	  (MyD88)	  in	  mammalian	  innate	  immunity	  to	  B.	  burgdorferi	  
(102-­‐104).	  MyD88	  is	  a	  common	  adapter	  molecule	  required	  by	  many	  receptors	  and	  
pathways	   that	   trigger	   the	   innate	   immune	   response	   to	  microbial	   invasion.	   Stewart	  
and	   colleagues	   hypothesized	   that	   OspC	  might	   be	   important	   in	   evasion	   of	  MyD88-­‐
dependent	   innate	   immunity,	   but	   spirochetes	   lacking	   ospC	   were	   unable	   to	   infect	  
MyD88-­‐deficient	   mice,	   suggesting	   that	   the	   role	   of	   OspC	   is	   not	   solely	   to	   avoid	  
clearance	   by	   MyD88-­‐dependent	   immunity	   (95).	   Sarkar	   et	   al.	   also	   showed	   that	   B.	  
burgdorferi	  resistance	  to	  antimicrobial	  peptides	  was	  not	  dependent	  on	  the	  presence	  
of	  OspC.	  Although	   the	  primary	   function	  of	  OspC	   remains	  mysterious,	   the	  essential	  
nature	  of	  OspC	  is	  quite	  clear.	  	  	  
It	   has	   been	   shown	   that	   variation	   in	   culture	   conditions	   to	  which	  mimic	   the	  
environmental	   changes	   experienced	   within	   a	   feeding	   tick,	   such	   as	   an	   increase	   in	  
temperature	   and/or	   a	   decrease	   in	   pH,	   induce	   the	   expression	  of	  OspC.	   In	   contrast,	  
the	  downregulation	  of	  OspA	  has	  only	  been	  seen	  in	  spirochetes	  within	  feeding	  ticks	  
or	   grown	  within	  DMCs	  and	   is	  not	   evident	   in	   vitro.	  Regardless,	   the	  upregulation	  of	  
OspC	  and	  the	  downregulation	  of	  OspA	  are	  both	  dependent	  on	  the	  alternative	  sigma	  
factor	   RpoS	   (34,	   105-­‐108),	   which	   acts	   as	   a	   central	   ‘gatekeeper,’	   regulating	   the	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inverse	  relationship	  of	  B.	  burgdorferi	  genes	  involved	  in	  mammalian	  infection	  and	  in	  
persistence	  of	  spirochetes	  in	  the	  tick	  vector	  (34).	  
The	  RpoN/RpoS	  regulon	  
Considering	   the	   extensive	   transcriptional	   changes	   that	   the	   spirochete	  
undergoes	   throughout	   the	   infectious	   cycle,	   the	   B.	   burgdorferi	   genome	   does	   not	  
encode	  many	   commonly	   known	   genetic	   regulators,	   but	   genes	   for	   two	   alternative	  
sigma	  factors	  RpoN	  and	  RpoS	  are	  located	  on	  the	  chromosome	  (2).	  In	  many	  bacteria,	  
alternative	   sigma	   factors	   function	   as	   master	   regulators	   by	   coordinating	   the	   RNA	  
polymerase	   holoenzyme	   to	   specific	   genes	   required	   for	   the	   adaptation	   to	  
environmental	   or	   physiological	   stress.	   In	   E.	   coli,	   RpoS	   is	   required	   for	   the	   global	  
response	   to	   such	   stresses	   as	   nutrient	   deprivation,	   high	   osmolarity,	   and	   acidic	   pH	  
(109).	   However,	   Caimano	   et	   al.	   demonstrated	   that	   the	  B.	   burgdorferi	   RpoS	   is	   not	  
involved	   in	   the	   stress	   response	   but	   controls	   virulence	   expression	   during	   the	  
enzootic	  cycle	  (85).	  	  
E.	  coli	  RpoS	  levels	  are	  under	  strict	  control	  through	  multiple	  mechanisms	  that	  
regulate	  rpoS	   transcription,	   translation,	  and	  protein	  degradation.	   In	  B.	  burgdorferi,	  
RpoS,	  which	  is	  necessary	  for	  mammalian	  infection	  (85)	  and	  transmission	  during	  tick	  
feeding	  (110),	  is	  also	  tightly	  regulated.	  Yang	  et	  al.	  first	  demonstrated	  that	  RpoS	  was	  
OspC-­‐like	  in	  that	   it	   is	   induced	  by	  conditions	  that	  mimic	  those	  within	  a	  feeding	  tick	  
(see	   above),	   suggesting	   that	   ospC	   might	   be	   controlled	   through	   RpoS	   (105).	   This	  
hypothesis	   was	   later	   confirmed	   (106-­‐108).	   In	   a	   seminal	   study,	   Hübner	   and	  
colleagues	   demonstrated	   that	   B.	   burgdorferi	   RpoN	   regulates	   rpoS	   transcription	  
through	  the	  distinct	  -­‐24/-­‐12	  promoter	  (106).	  These	  data	  established	  the	  novel	  dual	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sigma	  factor	  cascade	   in	   the	  regulation	  of	   important	  virulence	   factors	  during	   the	  B.	  
burgdorferi	  enzootic	  cycle.	  
RpoN-­‐dependent	   transcription	   requires	   the	   activity	   of	   an	   enhancer	  binding	  
protein,	   adding	  another	   level	  of	   regulation.	   In	  B.	  burgdorferi,	   a	   response	   regulator	  
Rrp2	   coordinates	   with	   RpoN	   to	   induce	   rpoS	   transcription	   (111).	   However,	   Rrp2	  
must	  be	  phosphorylated	  to	  activate	  RpoN-­‐dependent	  rpoS	  gene	  expression.	  The	  hk2	  
gene,	   which	   encodes	   a	   sensor	   kinase,	   is	   located	   just	   upstream	   of	   rrp2	   and	   was	  
implicated	  in	  activating	  Rrp2	  and	  thus	  the	  RpoN/RpoS	  cascade.	  However,	  disruption	  
of	  hk2	  had	  no	  effect	  on	  RpoN/RpoS	  or	   infectivity	   in	  mice,	   suggesting	  Hk2	  was	  not	  
responsible	   for	   activation	   of	   Rrp2	   (112).	   Subsequent	   studies	   demonstrated	   that	  
acetyl	   phosphate	   could	   bypass	   the	   need	   for	   sensor	   kinases	   and	   directly	  
phosphorylate	  Rrp2	  to	  induce	  the	  RpoN/RpoS	  cascade	  (86).	  	  
Levels	   of	   acetyl	   phosphate	   within	   B.	   burgdorferi	   are	   controlled	   by	   two	  
enzymes,	  AckA	  and	  Pta,	  where	  AckA	   forms	  acetyl-­‐phosphate	   from	  acetate	  and	  Pta	  
degrades	  it	  in	  the	  process	  of	  making	  acetyl-­‐CoA.	  Recently,	  it	  was	  shown	  that	  bb0184,	  
which	  encodes	  carbon	  storage	  regulator	  A	  (CsrA),	  can	  affect	  the	  RpoN/RpoS	  regulon	  
through	   its	   effect	   on	   acetyl	   phosphate	   levels,	   presumably	   by	   repressing	   Pta.	   In	  E.	  
coli,	   CsrA	   is	   an	   RNA	   binding	   protein	   that	   regulates	   gene	   expression	   post-­‐
transcriptionally.	   CsrA	   induction	   in	  B.	   burgdorferi	   is	   correlated	  with	   activation	   of	  
Rrp2	  and	  upregulation	  of	  RpoS-­‐dependent	  genes,	  further	  suggesting	  a	  role	  for	  CsrA	  
in	   the	   complicated	   regulatory	   cascade	   during	   the	   transmission	   of	   B.	   burgdorferi	  
from	   tick	   to	   mammal	   (113,	   114).	   However,	   the	   mechanisms	   by	   which	   CsrA	   is	  
activated	   remain	   unclear.	   In	   addition,	   multiple	   other	   B.	   burgdorferi	   factors	   have	  
been	  implicated	  in	  regulating	  the	  Rrp2/RpoN/RpoS	  pathway.	  	  
 22 
BB0647,	  originally	  annotated	  as	  a	  homolog	  of	  Ferric	  uptake	  regulator	  (Fur)	  
(2),	  was	  renamed	  Borrelia	  oxidative	  stress	  regulator	  (BosR)	  after	  it	  was	  shown	  that	  
B.	   burgdorferi	   does	   not	   use	   iron	   (115)	   and	   that	   BB0647	   activated	   the	   oxidative	  
stress	  response	  in	  B.	  burgdorferi	  (116).	  Two	  parallel	  studies	  determined	  that	  BosR	  
was	   required	   for	   efficient	  RpoS	  production	  and	   thus	   the	  upregulation	  of	  ospC	   and	  
other	  genes	  necessary	  for	  mammalian	  infectivity	  (37,	  117).	  This	  is	  presumably	  the	  
reason	   the	   bosR	   mutant	   is	   not	   infectious	   in	   mice	   (37,	   117,	   118),	   as	   spirochetes	  
lacking	   RpoS	   or	   OspC	   are	   non-­‐infectious	   in	   mice	   (85,	   94-­‐97).	   BosR	   affects	   the	  
transcription	  of	  rpoS,	  but	  levels	  of	  rrp2	  and	  rpoN	  levels	  were	  not	  altered	  in	  the	  BosR	  
mutant,	   indicating	   that	   BosR	   specifically	   targets	   rpoS	   and	   not	   the	   entire	  
Rrp2/RpoN/RpoS	  cascade	  (37,	  117,	  118).	  It	  has	  been	  reported	  that	  there	  are	  three	  
putative	  BosR	  binding	  sites	  that	  could	  potentially	  affect	  rpoS	  transcription;	  two	  sites	  
are	   located	   upstream	   of	   the	   RpoN-­‐dependent	   -­‐24/-­‐12	   rpoS	   promoter,	   and	   one	   is	  
located	   within	   the	   rpoS	   ORF	   (118).	   However,	   Ouyang	   et	   al.	   only	   explored	   BosR	  
binding	  to	  synthetic	  probes	  and	  not	  activation	  of	  rpoS	  transcription	  in	  B.	  burgdorferi	  
(118).	   In	   addition,	   a	   previous	   study	   restored	   mouse	   infectivity	   to	   spirochetes	  
lacking	   rpoS	   using	   rpoS	   expressed	   from	   a	   minimal	   rpoS	   promoter	   that	   only	  
contained	  the	  -­‐24/-­‐12	  regions	  (119)	  and	  lacked	  the	  two	  sites	  to	  which	  BosR	  bound	  
with	  greater	  affinity	  (118),	  suggesting	  that	  the	  putative	  BosR	  binding	  sites	  were	  not	  
necessary	   for	   mammalian	   infection.	   Still,	   these	   mice	   were	   infected	   by	   needle	  
inoculation,	  and	  it	  is	  unclear	  if	  rpoS	  expressed	  from	  this	  minimal	  promoter	  would	  be	  
infectious	  in	  mice	  through	  natural	  transmission	  by	  tick	  bite.	  	  
In	  E.	  coli,	  several	  small	  non-­‐coding	  RNAs	  (sRNAs)	  bind	  to	  the	  rpoS	  transcript	  
and	   regulate	   its	   translation.	   Lybecker	   and	   Samuels	   identified	   an	   sRNA	   in	   B.	  
 23 
burgdorferi	  that	  is	  complementary	  to	  the	  upstream	  region	  of	  rpoS	  mRNA,	  which	  they	  
named	  DsrA	  after	  its	  similarity	  to	  the	  sRNA	  of	  the	  same	  name	  in	  E.	  coli	  (120).	  In	  the	  
canonical	  RpoN-­‐dependent	  pathway,	  rpoS	   is	   induced	   in	  response	   to	  an	   increase	   in	  
temperature,	  decrease	  in	  pH	  and/or	  an	  increase	  in	  cell	  density.	  However,	  Lybecker	  
and	   Samuels	   identified	   a	   longer	   rpoS	   transcript	   transcribed	   at	   low	   cell	   density,	  
which	   is	   not	   dependent	   on	   RpoN.	   Furthermore,	   only	   this	   longer	   rpoS	   transcript	  
contains	  the	  sequence	  to	  which	  DsrA	  is	  complementary	  (120).	  In	  E.	  coli,	  DsrA	  base	  
pairs	   with	   the	   upstream	   region	   of	   the	   rpoS	   transcript,	   which	   leads	   to	   a	  
conformational	  change	  that	  frees	  the	  Shine-­‐Dalgarno	  sequence,	  allowing	  translation	  
to	   occur,	   and	   it	   is	   thought	   that	   DsrA	   in	   B.	   burgdorferi	   functions	   by	   a	   similar	  
mechanism	  to	  regulate	  rpoS	  translation	  (120).	  	  
The	   activity	   of	   sRNAs	   in	   E.	   coli	   requires	   the	   RNA	   chaperone	   Hfq.	   B.	  
burgdorferi	  seems	  similar	   in	   this	  regard	  as	  Lybecker	  and	  colleagues	   identified	  a	  B.	  
burgdorferi	  homolog	  of	  the	  E.	  coli	  Hfq.	  They	  determined	  that	  the	  B.	  burgdorferi	  Hfq	  
bound	   DsrA	   and	   the	   rpoS	   transcript	   (121).	   Interestingly,	   neither	   the	   long	   rpoS	  
transcript	  nor	  DsrA	  are	  required	  for	  infectivity	  in	  mice	  by	  needle	  inoculation	  (119,	  
122),	  but	  the	  hfq	  mutant	  is	  non-­‐infectious	  in	  mice	  (121).	  These	  data	  suggest	  that	  Hfq	  
likely	  has	  other	  roles	  in	  the	  cell	  besides	  its	  interaction	  with	  DsrA	  and	  the	  long	  rpoS	  
transcript.	   In	   addition,	   the	   infectivity	   of	   the	   DsrA	   mutant	   by	   needle	   inoculation	  
suggests	  that	  DsrA	  and	  the	  long	  rpoS	  transcript	  might	  function	  exclusively	  in	  the	  tick	  
vector	  as	  spirochetes	  prepare	  for	  transmission	  to	  the	  mammalian	  host	  (122).	  	  
	   Lastly,	   there	   have	   been	   some	   conflicting	   results	   as	   to	   whether	   Rrp2	   and	  
RpoN	  have	  functions	  other	  than	  their	  requirements	  for	  expression	  of	  RpoS.	  Whereas	  
Fisher	  et	  al.	  described	  groups	  of	  genes	  that	  were	  dependent	  on	  RpoN,	  RpoS,	  or	  both	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(110),	  Ouyang	  et	  al.	  reported	  considerable	  overlap	  in	  genes	  that	  were	  regulated	  by	  
these	   two	   alternative	   sigma	   factors	   (35).	   However,	   Ouyang	   and	   colleagues	   also	  
reported	   that	  a	  subset	  of	  genes	  regulated	  by	  Rrp2	  were	   independent	  of	  RpoN	  and	  
RpoS	   (35).	   Both	   of	   these	   studies	   used	   microarray	   analysis	   as	   their	   primary	  
technique	   to	   identify	  differentially	   regulated	  genes	  and	   it	   is	  well	  documented	   that	  
changes	   in	   culture	   conditions	   affect	   B.	   burgdorferi	   gene	   expression,	   which	   could	  
account	  for	  the	  discrepancies	  between	  the	  studies.	  
Since	  Lyme	  disease	  was	  first	  recognized	  in	  the	  U.S.	  three	  decades	  ago,	  there	  
has	   been	   an	   impressive	   gain	   of	   knowledge	   on	   the	   pathogens	   that	   cause	   Lyme	  
disease,	   but	   many	   aspects	   of	   the	   biology	   of	   B.	   burgdorferi	   remain	   mysterious.	  
Undoubtedly,	   future	   studies	   will	   further	   elucidate	   how	   B.	   burgdorferi	   adapts	   to	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Regulation	  of	  gene	  expression	  is	  critical	  for	  the	  ability	  of	  Borrelia	  burgdorferi	  
to	   adapt	   to	   different	   environments	   during	   its	   natural	   infectious	   cycle.	   Reporter	  
genes	  have	  been	  used	  successfully	   to	  study	  gene	  regulation	   in	  multiple	  organisms.	  
Here,	   I	   have	   introduced	   a	   lacZ	   gene	   into	   B.	   burgdorferi	   and	   demonstrate	   that	   B.	  
burgdorferi	   produces	   a	   protein	   with	   detectable	   β-­‐galactosidase	   activity	   in	   both	  
liquid	   and	   solid	   media	   when	   lacZ	   is	   expressed	   from	   a	   constitutive	   promoter.	  
Furthermore,	   when	   lacZ	   is	   expressed	   from	   the	   ospC	   promoter,	   β-­‐galactosidase	  
activity	   is	  detected	  only	   in	  B.	  burgdorferi	   clones	   that	  express	  ospC.	  Using	   this	  ospC	  
promoter-­‐lacZ	  fusion,	  I	  show	  that	  ospC	  promoter	  activity	  varies	  on	  a	  colony	  level	  in	  
B.	   burgdorferi,	   which	   has	   not	   been	   previously	   demonstrated.	   These	   data	  
demonstrate	   that	   lacZ	   can	   be	   used	   to	   accurately	   monitor	   endogenous	   gene	  
expression	   in	  B.	  burgdorferi.	  The	  addition	  of	   lacZ	   to	   the	  repertoire	  of	  genetic	   tools	  
available	  for	  use	  in	  B.	  burgdorferi	  has	  contributed	  to	  a	  better	  understanding	  of	  how	  
B.	  burgdorferi	  gene	  expression	  is	  regulated	  during	  the	  infectious	  cycle.	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Introduction	  
Borrelia	  burgdorferi	  sensu	   lato,	   the	  pathogens	   that	   cause	  Lyme	  disease	   (1),	  
alternate	  between	  two	  distinct	  environments,	  an	  arthropod	  vector	  and	  a	  vertebrate	  
host.	  As	  B.	  burgdorferi	  moves	  from	  one	  milieu	  to	  the	  other,	   its	  ability	  to	  adapt	  and	  
survive	   requires	   dramatic	   changes	   in	   gene	   expression.	   Many	   studies	   have	   shown	  
that	   different	   B.	   burgdorferi	   gene	   products	   are	   upregulated	   or	   downregulated	   at	  
specific	   times	   throughout	   the	   infectious	   cycle	   (2,	   3)	   and	   in	   response	   to	   host	   and	  
environmental	   signals	   (4-­‐8).	   Although	   it	   is	   clear	   that	   B.	   burgdorferi	   alters	   gene	  
expression	   to	  adapt	   to	  different	  environments,	   the	  genetic	   tools	   for	   studying	  gene	  
regulation	  in	  B.	  burgdorferi	  are	  limited.	  	  
Within	  the	  last	  two	  decades,	  the	  complete	  genomic	  sequence	  of	  B.	  burgdorferi	  
strain	  B31	  was	  published	  (9,	  10),	  and	  techniques	  for	  basic	  genetic	  manipulation	  of	  B.	  
burgdorferi	   became	   available	   (11-­‐17).	   A	   chloramphenicol	   acetyltransferase	   (CAT)	  
gene	  was	   the	   first	   reporter	   gene	   fused	   to	  B.	   burgdorferi	   promoters	   for	   analysis	   of	  
promoter	   strength	   (18).	   The	   development	   of	   luciferase	   (19)	   and	   multiple	  
fluorescent	   proteins	   (15,	   20,	   21)	   as	   reporter	   systems	   in	   B.	   burgdorferi	   followed.	  
Although	  these	  systems	  have	  value,	  there	  are	  limitations	  with	  each	  (see	  discussion).	  
β-­‐galactosidase,	   encoded	   by	   lacZ,	   has	   been	   used	   extensively	   as	   a	   convenient	  
reporter	  gene	  in	  Escherichia	  coli	  and	  is	  still	  applicable	  to	  a	  broad	  range	  of	  organisms,	  
both	   prokaryotic	   and	   eukaryotic,	   but	   has	   not	   yet	   been	   used	   in	   B.	   burgdorferi.	   β-­‐
galactosidase	   activity	   can	   be	  monitored	   easily	   and	   quickly	   by	   simple	   colorimetric	  
assays	   in	   both	   liquid	   and	   solid	   media,	   neither	   of	   which	   require	   expensive	   or	  
specialized	  equipment.	  Additionally,	  a	  wide	  variety	  of	  substrates	  for	  β-­‐galactosidase	  
allow	  for	  different	  levels	  of	  sensitivity	  in	  either	  in	  vitro	  or	  in	  vivo	  detection	  formats	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(22).	   Having	   lacZ	   available	   as	   a	   genetic	   tool	   for	   B.	   burgdorferi	   would	   enhance	  
investigation	  of	   the	  complex	  regulatory	  events	  that	  are	   integral	   to	  the	  spirochete’s	  
infectious	   cycle.	  To	   this	   end,	   I	   developed	   lacZ	  as	   a	   reporter	   gene	   in	  B.	   burgdorferi	  
and	  demonstrated	  its	  utility.	  	  
	  
Materials	  and	  Methods	  
All	   chemicals	   and	   materials	   were	   purchased	   from	   Sigma	   (St.	   Louis,	   MO)	  
unless	  otherwise	  specified.	  	  
Bacterial	  Strains	  and	  Growth	  Conditions.	  
Plasmids	  (Table	  2-­‐1)	  for	  cloning	  were	  transformed	  into	  electrocompetent	  or	  
chemically	  competent	  Top10	  E.	  coli	   (Invitrogen,	  Carlsbad,	  CA)	  and	   final	  constructs	  
transformed	  into	  a	  Δlac	  E.	  coli	  strain,	  MC4100	   lamB-­‐	  zjb::Tn10	  (kindly	  provided	  by	  
John	  Carlson,	  Rocky	  Mountain	  Laboratories,	  Hamilton,	  MT).	  E.	  coli	  was	  plated	  on	  LB	  
agar	   (10	  g/L	  Tryptone,	  5	  g/L	  NaCl,	  5	  g/L	  Yeast	  extract,	  and	  15	  g/L	  agar)	  with	   the	  
appropriate	   antibiotic	   (spectinomycin	   at	   300	  µg/mL,	   kanamycin	   at	   30	  µg/mL	   ,	   or	  
gentamicin	   at	   5	  µg	   /mL).	   	   Liquid	   cultures	  were	   grown	   in	   LB	   broth	   supplemented	  
with	   the	   appropriate	   antibiotics	   (spectinomycin	   or	   kanamycin	   at	   100µg/mL	   or	  
gentamicin	  at	  10	  µg/mL).	  	  
BSKII	  medium	  (23)	  for	  culture	  of	  B.	  burgdorferi	  was	  made	  with	  CMRL	  1060	  
lacking	   phenol	   red	   (US	   Biologicals,	   Swampscott,	   MA).	   B.	   burgdorferi	   strain	   B31	  
clones	   A34	   (24)	   or	   B312	   (25)	   were	   grown	   to	   mid	   log	   phase	   (~5	   x	   107cell/ml).	  
Spirochetes	   were	   enumerated	   using	   dark-­‐field	   microscopy	   and	   a	   Petroff-­‐Hausser	  
counting	   chamber	   and	   prepared	   for	   electroporation	   as	   described	   previously	   (11).	  
Transformed	  A34	  and	  B312	  were	  selected	  using	  gentamicin	  at	  a	  concentration	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Table	  2-­‐1:	  Plasmids	  used	  in	  Chapter	  Two	  
Plasmid	   Resistance	   Comments;	  source	  or	  reference	  
pPBMB101	   kanR	   plasmid	  with	  an	  E.	  coli	  lacZ	  gene,	  used	  as	  template	  to	  amplify	  lacZEc;	  (26)	  
pCR8/GW/TOPO	   specR	   Gateway	  PCR	  entry	  vector;	  Invitrogen	  
pCR2.1/TOPO	   kanR,	  ampR	   PCR	  cloning	  vector;	  Invitrogen	  
pBSV2G	   gentR	   B.	  burgdorferi	  shuttle	  vector;	  (13)	  
pBSV2G_dvB2	   gentR	   altered	  pBSV2G,	  Gateway	  destination	  vector;	  James	  A.	  Carroll	  (unpublished)	  
pBH-­‐lacZEc	   gentR	   E.	  coli	  lacZ	  gene	  (lacZEc)	  cloned	  into	  pBSV2G_dvB2;	  this	  work	  
pBHflaBp-­‐lacZEc	   gentR	   pBH-­‐lacZEc	  with	  the	  flaB	  promoter	  cloned	  upstream	  of	  lacZEc;	  this	  work	  
pBH-­‐lacZBb	   gentR	   B.	  burgdorferi	  codon-­‐optimized	  lacZ	  gene	  (lacZBb)	  cloned	  into	  pBSV2G;	  this	  work	  
pBHflaBp-­‐lacZBb	   gentR	   pBH-­‐lacZBb	  with	  the	  flaB	  promoter	  cloned	  upstream	  of	  lacZBb;	  this	  work	  
pBHospCp-­‐lacZBb	   gentR	   pBH-­‐lacZBb	  with	  the	  ospC	  promoter	  cloned	  upstream	  of	  lacZBb;	  this	  work	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of	   40µg/mL.	   All	   B.	   burgdorferi	   cultures	   were	   grown	   at	   35°C	   and	   plates	   were	  
incubated	  under	  2.5%	  CO2.	  	  	  
Plasmid	  construction.	  
The	   E.	   coli	   lacZ	   gene	   (lacZEc),	   the	   multiple	   cloning	   site	   (MCS),	   and	   the	  
transcriptional	   terminator	  were	  amplified	   from	  pPBMB101	   (Table	  2-­‐1)	   (26)	  using	  
primers	   1	   and	   2	   (Table	   2-­‐2).	   The	   PCR	   product	   was	   cloned	   into	   the	   Gateway®	  
entrance	  vector	  pCR8/GW/TOPO	  (Table	  2-­‐1)	  (Invitrogen)	  and	  confirmed	  by	  direct	  
sequencing	   with	   primers	   1-­‐10	   (Table	   2-­‐2).	   pBSV2G_dvB2	   (Table	   2-­‐1),	   kindly	  
provided	   by	   James	  A.	   Carroll	   (Rocky	  Mountain	   Laboratories,	   Hamilton,	  MT),	   is	   an	  
altered	  form	  of	  the	  B.	  burgdorferi	  shuttle	  vector	  pBSV2G,	  which	  has	  attR1	  and	  attR2	  
sequences	   surrounding	   a	   chloramphenicol	   resistance	   cassette	   and	   the	   counter-­‐
selectable	  gene,	  ccdB	  ,	  making	  it	  a	  suitable	  destination	  vector	  for	  Gateway®	  cloning.	  
The	   insert	   containing	   lacZEc,	   the	   MCS,	   and	   the	   transcriptional	   terminator	   was	  
transferred	   from	  pCR8	   to	  pBSV2G_dvB2	  using	   the	  Clonase	   II	   enzyme	   (Invitrogen),	  
creating	  pBH-­‐lacZEc	  (Table	  2-­‐1	  and	  Figure	  2-­‐1A).	  	  
The	   flaB	   promoter	   was	   amplified	   from	   B.	   burgdorferi	   genomic	   DNA	   using	  
primers	   13	   and	   14	   (Table	   2-­‐2).	   The	   PCR	   fragment	  was	   cloned	   into	   pCR2.1-­‐TOPO	  
(Invitrogen)	   and	   sequenced	   to	   confirm	   the	   insert.	   The	   flaB	   promoter	  was	   excised	  
with	  BamHI	  and	  XhoI	  and	   ligated	   into	  appropriately	  digested	  pBH-­‐lacZEc,	  creating	  
pBHflaBp-­‐lacZEc	   (Table	   2-­‐1	   and	   Figure	   2-­‐1A).	   BamHI	   and	   XhoI	   were	   used	   for	  
creating	   promoter-­‐lacZ	   fusions	   in	   pPBMB101,	   which	   has	   a	   ribosome	   binding	   site	  
(RBS)	  between	  the	  XhoI	  site	  and	  the	  lacZ	  start	  site	  (26).	  	  
pBH-­‐lacZEc	  and	  pBHflaBp-­‐lacZEc	  were	  transformed	  into	  electrocompetent	  B.	  
burgdorferi	  (11).	  Spirochetes	  were	  allowed	  to	  recover	  overnight	  in	  BSK	  II	  medium	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Table	  2-­‐2:	  Primers	  and	  Probes	  used	  in	  Chapter	  Two	  
	   Name	   Sequence	  (5’-­‐3’)
a	  
1	   Long	  lacZ	  5'	  (NotI)	   AAGGAAAAAAGCGGCCGCTCTAGAGGATCCCGGGTCGACTAGTCTGCAGCTCGAGT	  
2	   Long	  lacZ	  3'	  (NotI)	   AAGGAAAAAAGCGGCCGCAGATCTTACTCAGGAGAGCGTTCACCGACAAACAACAG	  
3	   lacZ	  430	   TGATGAAAGCTGGCTACAGGAAGG	  
4	   lacZ	  908	   GTCACACTACGTCTGAACGTCGAA	  
5	   lacZ	  1525	   GGCCACCGATATTATTTGCCCGAT	  
6	   lacZ	  2053	   GGATGTCGCTCCACAAGGTAAACA	  
7	   lacZ	  2593	   TATCAGCCGGAAAACCTACCGGAT	  
8	   lacZ	  3121	   GCTGTTTTGGCGGATGAGAGAAGA	  
9	   lacZ	  1533	  5'	   ATATTATTTGCCCGATGTACGCGCGCGTGGATGAA	  
10	   lacZ	  1538	  3'	   TTCATCCACGCGCGCGTACATCGGGCAAAT	  
11	   lacZBb	  Int-­‐1	  Forward	   TGGTGTAATGGAAGATGGGTTGG	  
12	   lacZBb	  Mid	  Reverse	   GATAGACCATTTAGGAACAGCAGG	  
13	   flaB	  promoter	  5’	  (BamHI)	   CCCGCGGATCCCTGTCGCCTCTTGTGGCTTC	  
14	   flaB	  promoter	  3’	  (XhoI)	   CCCCGCTCGAGCATATATCATTCCTCCATGA	  
15	   ospC	  promoter	  5’	  (BamHI)	   CCCGCGGATCCAATTAAAACTTTTTTTATTAAAGTA	  
16	   ospC	  promoter	  3'	  (XhoI)	   CCCCGCTCGAGTAATTTGTGCCTCCTTTTTATTTAT	  	  
Taqman	  primers/probesb	  
17	   flaB	  forward	   TCTTTTCTCTGGTGAGGGAGCT	  
18	   flaB	  reverse	   TCCTTCCTGTTGAACACCCTCT	  
19	   flaB	  probe	   AAACTGCTCAGGCTGCACCGGTTC	  
20	   lacZBb	  forward	   TTCTCTTGGAGGATTTGCTAAAT	  
21	   lacZBb	  reverse	   ATCCCAAACAAATCCACCTT	  
22	   lacZBb	  probe	   TGGCAAGCATTCAGACAATATCCAAG	  
23	   ospC	  forward	   ACGGATTCTAATGCGGTTTTACTT	  
24	   ospC	  reverse	   CAATAGCTTTAGCAGCAATTTCATCT	  
25	   ospC	  probe	   CTGTGAAAGAGGTTGAAGCGTTGCTGTCAT	  
a	  underlined	  bases	  denote	  restriction	  sites	  
b	  Taqman	  probes	  were	  labeled	  with	  6-­‐carboxyfluorescein	  (FAM)	  and	  6-­‐
carboxytetramethylrhodamine	  (TAMRA)	  at	  the	  5'	  and	  3'	  ends,	  respectively	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without	   antibiotic	   selection	   and	   then	   plated	   in	   solid	   BSK	   medium	   supplemented	  
with	   gentamicin.	   Individual	   colonies	   were	   screened	   by	   PCR	   for	   lacZEc	   and	   the	  
gentamicin	  cassette.	  	  
lacZ	  optimization.	  
E.	   coli	   lacZ	   codon	  usage	   in	  B.	   burgdorferi	  was	   analyzed	  using	   the	  Graphical	  
Codon	  Usage	  Analyzer	   version	  2.0	   (www.gcua.schoedl.de).	  More	   than	  one-­‐third	  of	  
the	  codons	  in	  the	  E.	  coli	  lacZ	  gene,	  lacZEc,	  are	  considered	  rare	  (used	  less	  than	  20%	  
of	  the	  time)	  in	  B.	  burgdorferi.	  A	  codon-­‐optimized	  version	  of	  lacZ,	  lacZBb,	  which	  uses	  
less	   than	   1%	   of	   B.	   burgdorferi	   rare	   codons,	   was	   synthesized	   by	   GenScript	  
Corporation	  (Piscataway,	  NJ).	  A	  sequence	  alignment	  of	  the	  codon	  optimized	  lacZBb	  
gene	  with	  the	  original	   lacZEc	  gene	  is	  provided	  in	  Figure	  2-­‐2.	  The	  synthesized	  gene	  
was	  preceded	  by	   the	  same	  MCS	  and	  RBS	  as	   the	  original	   lacZEc.	   lacZBb	  was	  cloned	  
into	  pBSV2G	  (13)	  with	  XbaI	  and	  KpnI,	  producing	  pBH-­‐lacZBb	  (Table	  2-­‐1	  and	  
Figure	  2-­‐1B).	  The	  flaB	  promoter	  was	  added	  as	  described	  above	  to	  create	  pBHflaBp–
lacZBb	  (Table	  2-­‐1	  and	  Figure	  2-­‐1B).	  The	  intergenic	  region	  between	  guaA	  and	  ospC,	  
which	  includes	  the	  ospC	  promoter	  and	  regulatory	  operator	  sequences	  (27-­‐30),	  was	  
amplified	   from	  B.	   burgdorferi	   genomic	   DNA	  with	   primers	   15	   and	   16	   (Table	   2-­‐2),	  
cloned	   into	   pCR2.1,	   sequenced,	   and	   digested	   with	   BamHI	   and	   XhoI	   to	   ligate	   into	  
pBH-­‐lacZBb,	   creating	   pBHospCp-­‐lacZBb	   (Table	   2-­‐1).	   Constructs	  were	   transformed	  
into	  electrocompetent	  B.	  burgdorferi	  (11)	  and	  Δlac	  E.	  coli.	  	  
SDS-­‐PAGE	  and	  Immunoblotting	  
β-­‐galactosidase	   expression	   in	  E.	   coli	   and	  B.	   burgdorferi	  was	   assessed	   using	  
SDS-­‐PAGE	   as	   previously	   described	   (31).	   Briefly,	   E.	   coli	   and	   B.	   burgdorferi	   were	  
harvested	  and	  washed	  twice	  in	  Hepes-­‐NaCl	  (HN)	  buffer	  (50mM	  each,	  pH	  7.6).	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Figure	  2-­‐1:	  Schematic	  diagram	  of	  the	  lacZ	  shuttle	  vectors	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Figure	  2-­‐1	  legend:	  The	  E.	  coli	  lacZ	  gene	  was	  cloned	  into	  pBSV2G_dvB2,	  creating	  pBH-­‐
lacZEc	   (A,	   top).	   A	   B.	   burgdorferi	   codon-­‐optimized	   lacZ	   gene,	   lacZBb,	   was	   cloned	  
directly	   into	   pBSV2G,	   creating	   pBH-­‐lacZBb	   (B,	   top).	   The	   flaB	   promoter	   from	   B.	  
burgdorferi	   (flaBp)	   was	   added	   to	   each	   construct,	   yielding	   pBHflaBp-­‐lacZEc	   (A,	  
bottom)	  and	  pBHflaBp-­‐lacZBb	  (B,	  bottom),	  respectively.	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Figure	  2-­‐2:	  Nucleotide	  alignment	  of	  lacZBb	  and	  lacZEc	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Figure	   2-­‐2	   legend:	   Nucleotide	   sequences	   of	   the	   Borrelia	   burgdorferi	   codon-­‐
optimized	   lacZBb	   gene	   (top)	   aligned	  with	   the	   original	   lacZEc	   gene	   (bottom)	   from	  
Escherichia	   coli.	   Red	   letters	   indicate	   that	   the	   codon	   was	   changed	   in	   lacZBb.	  
Parenthetic	  numbers	  represent	  the	  position	  within	  the	  gene.	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Protein	   lysate	   from	   approximately	   107	   bacteria	   was	   loaded	   per	   lane	   in	   a	   10%	  
acrylamide	  gel.	  Protein	  gels	  were	  stained	  with	  Coomassie	  Brilliant	  Blue	  (Bio-­‐Rad)	  or	  
prepared	  for	  immunoblotting.	  
For	   Western	   Blots,	   proteins	   were	   electrophoretically	   transferred	   to	  
nitrocellulose	  membranes	  (Bio	  Rad	  Trans	  blot	  Transfer	  Medium).	  Membranes	  were	  
blocked	  with	  5%	  non-­‐fat	  milk	   in	  TBST	  (Tris-­‐buffered	  saline	  with	  0.1%	  Tween	  20)	  
Monoclonal	   mouse	   anti-­‐β-­‐galactosidase	   (Santa	   Cruz	   Biotechnology	   Inc.)	   at	   1:100,	  
monoclonal	  mouse	  anti-­‐FlaB	  (H9724)	  (32)	  at	  1:250,	  and	  polyclonal	  rabbit	  anti-­‐OspC	  
(33)	  at	  1:1500	  were	  used	  to	  probe	  membranes.	  Primary	  antibodies	  were	  diluted	  in	  
5%	   milk	   in	   TBST.	   Horseradish	   peroxidase-­‐conjugated	   secondary	   antibodies	   that	  
recognize	  mouse	  and	  rabbit	  immunoglobulins	  were	  diluted	  1:10,000	  and	  1:50,000,	  
respectively,	   in	   TBST	   with	   5%	   milk.	   Immunoreactivity	   was	   visualized	   using	   the	  
Supersignal	  West	   Pico	   Chemiluminescent	   substrate	   (Thermo	   Scientific)	   and	   x-­‐ray	  
film	  (Labscientific	  Inc.,	  NJ).	  	  
Screening	  for	  β-­‐galactosidase	  activity.	  
For	  β-­‐galactosidase	  assays,	  1mL	  of	  overnight	  E.	  coli	  cultures	  and	  5-­‐10mL	  of	  
mid-­‐log	  B.	   burgdorferi	   cultures	  were	  washed	   twice	   in	   HN	   buffer.	   Bacterial	   pellets	  
were	  resuspended	  in	  Z-­‐buffer	  (36mM	  NaH2PO4,	  67mM	  NaHPO4,	  0.1mM	  MgCl2,	  2mM	  
MgSO4,	   2.7ml/L	   β-­‐mercaptoethanol)	   at	   approximately	   5x108	   bacteria/mL	   before	  
lysis	   with	   chloroform	   and	   SDS.	   β-­‐galactosidase	   assays	   were	   performed	   using	   a	  
modified	  version	  of	   the	  Miller	  protocol	   (34).	  Briefly,	  aliquots	   (5-­‐20μL)	  of	  bacterial	  
lysates	  were	  added	  to	  96-­‐well	  plates	  (Costar,	  Corning,	  NY)	  in	  triplicate.	  Z-­‐buffer	  was	  
added,	  increasing	  the	  volume	  to	  160µL.	  50µL	  ONPG	  dissolved	  in	  Z-­‐buffer	  (4mg/mL)	  
was	   added	   and	   the	   plate	   incubated	   at	   room	   temperature	   (RT)	   for	   10-­‐15	  minutes.	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This	  incubation	  time	  was	  chosen	  because	  it	  was	  in	  the	  linear	  range	  of	  activity	  when	  
a	   kinetic	   assay	  was	  used	   (Figure	  2-­‐3A).	  After	   incubation,	   90µL	  of	   stop	  buffer	   (1M	  
Na2CO3)	  was	  added	  and	  the	  absorbance	  measured	  at	  405nm	  (Labsystems	  Multiskan	  
Plus,	   Fisher	   Scientific,	   Pittsburg,	   PA).	   Although	   the	   standard	   Miller	   protocol	   (34)	  
uses	   the	  absorbance	  at	  420nm	  to	  quantitate	  β-­‐galactosidase	  hydrolysis	  of	  ONPG,	   I	  
used	  a	  plate	  reader	  with	  a	  filter	  at	  405nm.	  When	  compared,	  however,	  there	  was	  not	  
a	   significant	   difference	   in	   activity	   when	   the	   absorbance	   was	  measured	   at	   420	   or	  
405nm	  (Figure	  2-­‐3B).	  
β-­‐galactosidase	   activity	   units,	   or	   Miller	   units	   (nmoles/minute),	   were	  
calculated	   as	   described	   before	   and	   reported	   as	   units	   per	   mg	   protein	   (35).	  
Background	   activity	   (units/mg	   protein)	   of	   bacteria	   lacking	   a	   shuttle	   vector	   was	  
subtracted	  from	  reported	  values.	  
Both	  E.	  coli	  and	  B.	  burgdorferi	  were	  grown	  on	  plates	  containing	  5-­‐bromo-­‐4-­‐
chloro-­‐3-­‐indolyl-­‐β-­‐D-­‐galactopyranoside	  (X-­‐gal,	  Roche	  Diagnostics,	   Indianapolis,	   IN)	  
at	   0.08	   g/L	   and	   gentamicin.	   Alternatively,	   ~0.5mL	   X-­‐gal	   dissolved	   in	   dimethyl	  
sulfoxide	   (DMSO)	   (20mg/ml)	   was	   spread	   on	   B.	   burgdorferi	   plates	   after	   colony	  
formation.	  	  
Protein	  Assay.	  
The	  concentration	  of	  protein	  in	  the	  bacterial	  lysates	  used	  for	  β-­‐galactosidase	  
assays	   was	   determined	   using	   the	   Bio-­‐Rad	   Protein	   Assay	   (Bio-­‐Rad	   Laboratories,	  
Hercules,	   CA)	   according	   to	   the	   manufacturer’s	   protocol.	   Dilutions	   of	   BSA	   (New	  
England	  Biolabs,	  NEB,	  Ipswich,	  MA)	  were	  used	  as	  standards.	  10µL	  of	  the	  standards	  
and	  5-­‐10µL	  bacterial	   lysates	  were	  added	  to	  96	  well	  plates	   in	  triplicate.	  A	  standard	  
curve	  was	  generated	  and	  used	  to	  determine	  protein	  concentrations	  of	  the	  lysates	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Figure	  2-­‐3	  legend:	  A.	  Kinetic	  β-­‐galactosidase	  assays.	  5,	  10,	  15,	  and	  20μL	  of	  whole	  cell	  
lysates	   from	  Δlac	  E.	   coli	  with	   (bottom	   left)	  and	  without	  pBHflaBp-­‐lacZEc	  (top	   left)	  
and	  B.	  burgdorferi	  A34	  with	  (bottom	  right)	  and	  without	  pBHflaBp-­‐lacZBb	  (top	  right)	  
were	   used	   in	   a	   modified	   version	   of	   the	   Miller	   protocol	   (34)	   to	   measure	   β-­‐
galactosidase	   activity.	   The	   absorbance	   at	   420	  was	  measured	   approximately	   every	  
minute	   for	   35	   minutes.	   Buffer	   alone	   was	   used	   as	   a	   baseline	   and	   the	   protein	  
concentration	   for	   each	   lysate	   is	   designated	   below	   each	   X-­‐axis.	  B.	   β-­‐galactosidase	  
activity	  measured	   at	   405nm	   and	   420nm.	  Modified	  Miller	   ONPG	   assays	   (34)	  were	  
performed	  on	  Δlac	  E.	  coli	  and	  A34	  without	  a	  shuttle	  vector	  or	  harboring	  a	  lacZ	  gene	  
expressed	   from	   the	   flaB	   promoter	   on	   a	   shuttle	   vector,	   as	   indicated.	   Absorbances	  
were	   taken	   at	   420nm	   (black	   bars)	   or	   405nm	   (white	   bars)	   to	   determine	   β-­‐
galactosidase	   units	   (Miller	   units),	   which	   are	   reported	   per	   mg	   protein	   and	   levels	  
represent	  mean	  +/-­‐	  SD	  (n=6).	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Quantitative	  reverse	  transcriptase	  polymerase	  chain	  reaction	  (qRT-­‐PCR).	  
	  	   RNA	  was	  harvested	  from	  ~30mL	  of	  a	  mid	  log	  B.	  burgdorferi	  culture	  using	  a	  
Masterpure	   RNA	   Preparation	   Kit	   (Epicentre	   Biotechnologies,	   Madison,	   WI)	  
according	   to	   the	   manufacturer’s	   protocol.	   	   The	   integrity	   of	   extracted	   RNA	   was	  
confirmed	  on	  an	  Agilent	  2100	  Bioanalyzer	  using	  an	  RNA	  6000	  Pico	  Total	  RNA	  chip	  
(Agilent	  Technologies,	  Foster	  City,	  CA)	  and/or	  by	  electrophoresis	  in	  an	  agarose	  gel.	  	  
2-­‐5µg	  of	  RNA	  was	  used	  as	  a	   template	   to	  synthesize	  cDNA	  using	   the	  High	  Capacity	  
cDNA	   Reverse	   Transcriptase	   (RT)	   Kit	   (Applied	   Biosystems,	   Life	   Technologies,	  
Carlsbad,	  CA).	  Quantitative-­‐PCR	  (qPCR)	  was	  performed	  in	  triplicate	  on	  100ng	  cDNA	  
using	   the	   Taqman	   Universal	   PCR	   Mastermix	   	   (Applied	   Biosystems)	   and	   primer-­‐
probe	   combinations	   for	   lacZBb,	   flaB,	   and	   ospC	   (Table	   2-­‐2).	   Real	   time	   qPCR	   was	  
performed	  using	  the	  ABI	  Prism	  7900	  HT	  Sequence	  Detection	  System.	  	  
	  
Results	  
lacZ	  gene	  constructs.	  
To	   investigate	  whether	   lacZ	   could	   be	   used	   as	   a	   simple	   reporter	   gene	   in	  B.	  
burgdorferi,	   I	   constructed	   four	   shuttle	  vectors,	  pBH-­‐lacZEc,	  pBHflaBp-­‐lacZEc,	  pBH-­‐
lacZBb,	  and	  pBHflaBp-­‐lacZBb	  (Table	  2-­‐1	  and	  Figure	  2-­‐1).	  These	  constructs	  carry	  an	  
E.	   coli	   lacZ	   gene	   (lacZEc)	   or	   a	  B.	   burgdorferi	   codon-­‐optimized	   lacZ	   gene	   (lacZBb),	  
with	  and	  without	  the	  constitutive	  B.	  burgdorferi	  flaB	  promoter.	  The	  lacZEc	  gene	  has	  
56%	  G+C	  base	  content,	  while	  the	  B.	  burgdorferi	  genome	  has	  only	  28%	  G+C	  content	  
(10).	   In	   order	   to	   enhance	  β-­‐galactosidase	   synthesis	   in	  B.	   burgdorferi,	   I	   designed	   a	  
synthetic	   lacZ	   gene,	   lacZBb,	   that	   reduced	   the	   G+C	   content	   to	   better	   reflect	   B.	  
burgdorferi	  codon	  preference.	  The	  flaB	  promoter	  was	  chosen	  for	  initial	  experiments	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because	  it	  is	  constitutively	  expressed	  in	  B.	  burgdorferi	  and	  E.	  coli	  and	  has	  been	  used	  
to	   drive	   expression	   of	   antibiotic	   resistance	   markers	   in	   B.	   burgdorferi	   (13).	   All	  
constructs	  were	  transformed	  into	  electrocompetent	  B.	  burgdorferi	  A34	  and	  a	  Δlac	  E.	  
coli	  strain	  and	  assessed	  for	  β-­‐galactosidase	  activity	  in	  liquid	  and	  solid	  media.	  	  
β-­‐galactosidase	  activity	  in	  bacterial	  cultures.	  
In	   order	   to	   assess	   the	   β-­‐galactosidase	   activity	   in	  B.	   burgdorferi	   and	  E.	   coli	  
transformants	   carrying	   the	   lacZ	   constructs,	   I	   adapted	   the	   well-­‐established	   Miller	  
ONPG	  assay	  (34)	  and	  normalized	  β-­‐galactosidase	  activity	   to	   the	  protein	  content	  of	  
the	   bacterial	   lysates	   as	   described	   by	   Nielsen	   et	   al.	   (35).	   Both	   E.	   coli	   and	   B.	  
burgdorferi	   harboring	   pBHflaBp-­‐lacZEc	   or	   pBHflaBp-­‐lacZBb	   displayed	   significant	  
activity	   when	   compared	   to	   bacteria	   containing	   the	   promoterless	   lacZ	   constructs	  
(Figure	   2-­‐4A).	   β-­‐galactosidase	   activity	   was	   significantly	   higher	   in	   B.	   burgdorferi	  
lysates	   containing	   pBHflaBp-­‐lacZBb	   compared	   to	   lysates	   with	   pBHflaBp-­‐lacZEc,	  
indicating	   that	   codon-­‐optimization	   of	   lacZ	   improved	   activity	   in	   B.	   burgdorferi	  
(Figure	  2-­‐4A).	  B.	  burgdorferi	  harboring	  pBHflaBp-­‐lacZBb	  and	  pBHflaBp-­‐lacZEc	  both	  
produced	   detectable	   amounts	   of	   β-­‐galactosidase	   protein	   when	   assayed	   by	  
immunoblot	   (Figure	   2-­‐4B).	   These	   results	   demonstrate	   that	   lacZ	   produces	   a	  
functional	   β-­‐galactosidase	   enzyme	   in	   B.	   burgdorferi	   when	   expressed	   using	   the	  
constitutive	  flaB	  promoter.	  	  
β-­‐galactosidase	  activity	  on	  B.	  burgdorferi	  plates.	  
Since	   β-­‐galactosidase	   activity	   could	   be	   detected	   in	  B.	   burgdorferi	   lysates,	   I	  
wanted	   to	   determine	   if	   lacZ	   could	   be	   used	   as	   a	   reporter	   gene	   for	   B.	   burgdorferi	  
colonies	  in	  solid	  medium.	  Typically,	  addition	  of	  X-­‐gal	  to	  solid	  medium	  allows	  for	  the	  
detection	  of	  bacterial	  colonies	  that	  possess	  an	  active	  β-­‐galactosidase	  enzyme,	  which	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Figure	  2-­‐4:	  β-­‐galactosidase	  in	  E.	  coli	  and	  B.	  burgdorferi	  lysates	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Figure	  2-­‐4	  legend:	  A.	  Modified	  Miller	  ONPG	  assays	  (34)	  were	  performed	  on	  Δlac	  E.	  
coli	  (white	  bars)	  and	  B.	  burgdorferi	  (black	  bars)	  harboring	  pBH-­‐lacZEc,	  pBHflaBp-­‐
lacZEc,	  pBH-­‐lacZBb,	  and	  pBHflaBp-­‐lacZBb,	  as	  indicated.	  β-­‐galactosidase	  activity	  
units	  (Miller	  units)	  are	  reported	  per	  mg	  protein	  and	  levels	  represent	  mean	  +/-­‐	  SD	  
(n=3).	  Background	  activity	  of	  bacteria	  without	  the	  shuttle	  vector	  was	  subtracted	  
from	  reported	  values.	  ***	  p<0.001	  and	  **	  p<0.01	  compared	  to	  respective	  
promoterless	  constructs	  or	  as	  indicated	  based	  on	  a	  Student’s	  two-­‐tailed	  t-­‐test.	  B.	  β-­‐
galactosidase	  (β-­‐gal)	  Immunoblot.	  Δlac	  E	  coli	  containing	  pBHflaBp-­‐lacZEc,	  	  B31-­‐A34	  
(without	  plasmid),	  and	  A34	  clones	  harboring	  pBH-­‐lacZEc,	  pBHflaBp-­‐LacZEc,	  pBH-­‐
lacZBb,	  and	  pBHflaBp-­‐lacZBb,	  as	  indicated,	  were	  probed	  with	  antibodies	  specific	  for	  
β-­‐gal.	  Flagellin	  protein	  (FlaB)	  levels	  were	  used	  as	  a	  control	  to	  normalize	  for	  protein	  
loading.	  Numbers	  on	  the	  left	  refer	  to	  protein	  size	  in	  kDa	  determined	  by	  the	  mobility	  
of	  protein	  standards.	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cleaves	   X-­‐gal	   into	   a	   blue-­‐colored	   product.	   Therefore,	   I	   used	   BSK	   solid	   medium	  
without	   phenol	   red	   supplemented	   with	   X-­‐gal	   (0.08	   g/L)	   to	   grow	   B.	   burgdorferi	  
clones	   harboring	   the	   lacZ	   constructs.	   	   Blue	   color	   development	   was	   observed	   2-­‐5	  
days	  after	  colony	   formation	   for	  B.	  burgdorferi	   colonies	  harboring	  either	  pBHflaBp-­‐
lacZEc	   or	   pBHflaBp-­‐lacZBb,	   but	   the	   incorporation	   of	   X-­‐gal	   into	   the	   solid	   plating	  
medium	  considerably	  slowed	  B.	  burgdorferi	  colony	  growth.	  However,	  when	  2%	  X-­‐
gal	   in	   DMSO	   was	   spread	   on	   B.	   burgdorferi	   plates	   after	   colony	   formation,	   color	  
development	   in	  colonies	  harboring	   the	   lacZ	  gene	  driven	  by	   the	   flaB	  promoter	  was	  
evident	   within	   15	   minutes	   and	   continued	   to	   increase	   overnight	   as	   the	   substrate	  
diffused	   throughout	   the	   plates	   (Figure	   2-­‐5).	   Importantly,	   colonies	   without	   a	  
promoter	   to	   drive	   lacZ	   expression	   remained	   unchanged	   (white)	   even	   after	  
overnight	   incubation	   (Figure	   2-­‐5).	   Furthermore,	   live	   spirochetes	   were	   recovered	  
from	   colonies	   48	   hours	   post	   X-­‐gal	   treatment,	   indicating	   X-­‐gal	   treatment	   did	   not	  
hinder	   bacterial	   viability.	   Colonies	   of	  B.	   burgdorferi	   harboring	   the	   optimized	   lacZ	  
gene,	  lacZBb,	  when	  expressed	  by	  the	  flaB	  promoter,	  developed	  a	  more	  uniform	  and	  
greater	   color	   intensity	   than	   B.	   burgdorferi	   containing	   pBHflaBp-­‐lacZEc,	   again	  
suggesting	   that	   the	  optimized	  gene	   is	  better	   suited	   for	  B.	  burgdorferi	   (Figure	  2-­‐5).	  
These	   results	  demonstrate	   that	   lacZ	   can	  be	  used	   to	  monitor	  gene	  expression	  of	  B.	  
burgdorferi	   colonies	   on	   plates.	   Furthermore,	   results	   from	   both	   liquid	   and	   plate	  
assays	   showed	   that	   codon-­‐optimization	   of	   the	   lacZ	   gene	   (lacZBb)	   improved	   β-­‐
galactosidase	   activity	   in	   B.	   burgdorferi,	   presumably	   through	   increased	   protein	  




Figure	  2-­‐5:	  lacZ	  for	  blue-­‐white	  selection	  of	  B.	  burgdorferi	  colonies	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Figure	  2-­‐5	  legend:	  BSK	  solid	  medium	  without	  phenol	  red	  was	  used	  to	  grow	  B31-­‐A34	  
clones	   harboring	   pBH-­‐lacZEc	   (top	   left),	   pBHflaBp-­‐lacZEc	   (top	   right),	   pBH-­‐lacZBb	  
(bottom	  left),	  and	  pBHflaBp-­‐lacZBb	  (bottom	  right).	   	  Approximately	  0.5ml	  of	  X-­‐gal	  in	  
DMSO	   (20mg/ml)	   was	   added	   to	   plates	   after	   colony	   formation	   and	   incubated	  
overnight	  before	  photographs	  were	  taken.	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β-­‐galactosidase	  activity	  as	  a	  reporter	  for	  ospC	  expression.	  
I	  demonstrated	  that	  β-­‐galactosidase	  protein	  is	  produced	  and	  shows	  
detectable	  activity	  in	  B.	  burgdorferi	  by	  expressing	  lacZ	  from	  a	  constitutive	  promoter	  
but	  wanted	  to	  confirm	  that	  lacZ	  expression	  reflects	  the	  expression	  of	  genes	  that	  are	  
differentially	  regulated	  in	  B.	  burgdorferi	  and	  therefore	  can	  be	  used	  as	  a	  reporter	  
gene	  for	  transcriptional	  activity.	  For	  this	  objective,	  I	  utilized	  two	  strains	  of	  B.	  
burgdorferi	  that	  differ	  in	  their	  expression	  of	  the	  ospC	  gene:	  B.	  burgdorferi	  clone	  B31-­‐
A34	  and	  B312.	  B31-­‐A34	  is	  derived	  from	  non-­‐infectious	  clone	  B31-­‐A	  (36)	  and	  does	  
not	  produce	  OspC	  in	  vitro	  (Figure	  2-­‐6A	  and	  ref	  (25)),	  while	  B312,	  a	  highly	  
attenuated	  clone	  of	  B31	  that	  lacks	  many	  plasmids,	  produces	  abundant	  amounts	  of	  
OspC	  in	  vitro	  (Figure	  2-­‐6	  and	  ref	  (25)).	  In	  order	  to	  determine	  lacZ	  expression	  driven	  
by	  the	  ospC	  promoter	  in	  these	  two	  B.	  burgdorferi	  genetic	  backgrounds,	  I	  cloned	  the	  
intergenic	  region	  between	  guaA	  and	  ospC,	  which	  includes	  the	  ospC	  promoter	  and	  all	  
ospC	  regulatory	  regions	  (27-­‐30),	  upstream	  of	  lacZBb	  in	  pBH-­‐lacZBb,	  creating	  
pBHospCp-­‐lacZBb.	  I	  then	  transformed	  A34	  and	  B312	  with	  pBHospCp-­‐lacZBb	  and	  
also	  introduced	  pBH-­‐lacZBb	  and	  pBHflaBp-­‐lacZBb	  into	  B312.	  	  
I	  immediately	  noticed	  that	  transformants	  of	  B312	  had	  variable	  OspC	  protein	  
levels,	   and	   significant	   variation	   in	   OspC	   protein	   was	   detected	   between	   different	  
B312	  clones	  (Figure	  2-­‐6A)	  and	  between	  independent	  cultures	  from	  the	  same	  clone	  
(Figure	  2-­‐6B).	  This	  observation	  has	  not	  been	  previously	   reported.	   In	  order	   to	  use	  
B312,	   I	   first	   confirmed	  OspC	   production	   in	   B312	   transformants	  with	   immunoblot	  
before	   proceeding	   with	   further	   experiments	   on	   those	   clones.	   Significant	   β-­‐
galactosidase	   activity	   was	   detected	   in	   B312	   harboring	   the	   pBHospCp-­‐lacZBb	  
plasmid	  compared	  to	  clones	  with	  the	  promoterless	  construct	  (Figure	  2-­‐7A).	  In	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Figure	  2-­‐6:	  Analysis	  of	  A34	  and	  B312	  protein	  lysates	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Figure	   2-­‐6	   legend:	  A.	   and	  B.	  Whole	   cell	   lysates	   of	   A34	   and	   B312	  without	   shuttle	  
vectors	   and	   harboring	   lacZ	   constructs,	   as	   indicated,	   were	   analyzed	   by	   antisera	  
recognizing	   β-­‐galactosidase	   (β-­‐gal),	   FlaB,	   and	   OspC.	   Numbers	   on	   the	   left	   refer	   to	  
protein	  size	  in	  kDa	  determined	  by	  the	  mobility	  of	  protein	  standards.	  Lysates	  of	  B312	  
with	  or	  without	  shuttle	  vectors	  in	  B	  are	  biological	  replicates	  of	  those	  shown	  in	  A	  and	  
demonstrate	  the	  variability	  in	  OspC	  production	  between	  samples	  C.	  B312	  whole	  cell	  
lysate	   analyzed	   by	   SDS-­‐PAGE	   and	   Coomassie	   blue	   staining.	   Protein	   bands	  
corresponding	  to	  FlaB	  and	  OspC	  are	  indicated.	  Numbers	  on	  the	  left	  refer	  to	  protein	  
size	  in	  kDa	  determined	  by	  the	  mobility	  of	  protein	  standards.	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Figure	  2-­‐7	   legend:	  A.	  β-­‐galactosidase	  activity	   in	  B.	  burgdorferi	  B31-­‐A34	  (red	  bars)	  
and	   B312	   (blue	   bars)	   harboring	   pBH-­‐lacZBb,	   pBHospCp-­‐lacZBb,	   and	   pBHflaBp-­‐
lacZBb,	  as	   indicated.	  Units	  are	  reported	  per	  mg	  protein	  and	   levels	  represent	  mean	  
+/-­‐	   SD	   (n=3).	   The	   background	   activity	   of	   bacteria	   lacking	   a	   shuttle	   vector	   was	  
subtracted	   from	   reported	   values.	   ND	   indicates	   that	   no	   significant	   activity	   was	  
detected	   above	   background	   (without	   plasmid)	   levels.	   ***	   p<0.001	   and	   **	   p<0.01	  
compared	   to	   respective	   promoterless	   constructs	   or	   as	   indicated	   based	   on	   a	  
Student’s	   two-­‐tailed	   t-­‐test.	   B.	   Transcript	   levels	   of	   ospC	   (solid	   bars)	   and	   lacZBb	  
(hatched	  bars)	  in	  A34	  (red)	  and	  B312	  (blue)	  clones	  harboring	  lacZBb,	  as	  indicated,	  
were	  measured	   by	   qRT-­‐PCR	  with	   primer/probe	   sets	   specific	   for	  ospC	  and	   lacZBb,	  
respectively,	   and	   normalized	   to	   the	   chromosomal	   flaB	   gene	   transcript.	   ospC	   and	  
lacZBb	  transcript	  levels	  are	  reported	  per	  100	  flaB	  copies	  and	  values	  represent	  mean	  
+/-­‐	  SD	  (n=3).	  cDNA	  from	  a	  RT-­‐PCR	  reaction	  without	  reverse	  transciptase	  was	  used	  
to	  control	  for	  background	  detection	  and	  was	  subtracted	  from	  reported	  values.	  C-­‐E.	  
BSK	   solid	   medium	   without	   phenol	   red	   was	   used	   to	   grow	   B31-­‐A34	   harboring	  
pBHospCp-­‐lacZBb	   (C),	   B312	   harboring	   pBHospCp-­‐lacZBb	   (D),	   or	   B312	   harboring	  
pBHflaBp-­‐lacZBb	  (E).	  Approximately	  0.5ml	  of	  X-­‐gal	  in	  DMSO	  (20mg/ml)	  was	  added	  
to	   plates	   after	   colony	   formation	   and	   allowed	   to	   incubate	   overnight	   before	  
photographs	  were	  taken.	  Magnified	  insets	  have	  been	  added	  to	  D	  and	  E	  to	  highlight	  
differences	   between	   B312	   colonies	   harboring	   pBHospCp-­‐lacZBb	   or	   pBHflaBp-­‐
lacZBb.	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contrast,	   β-­‐galactosidase	   activity	   was	   not	   detected	   in	   B31-­‐A34	   when	   the	   ospC	  
promoter	  was	  used	  to	  express	  lacZBb	  (Figure	  2-­‐7A),	  consistent	  with	  the	  lack	  of	  OspC	  
protein	   production	   in	   this	   strain	   (Figure	   2-­‐6A).	   	   Notably	   in	   B312,	   β-­‐galactosidase	  
activity	   controlled	  by	   the	   flaB	   promoter	  was	  40-­‐fold	  higher	   than	  activity	   from	   the	  
ospC	  promoter	  (Figure	  2-­‐7A).	  This	  significant	  difference	   in	  β-­‐galactosidase	  activity	  
driven	  by	   the	   flaB	   and	  ospC	  promoters	   in	  B312	  was	  somewhat	  surprising	  because	  
similar	  levels	  of	  FlaB	  and	  OspC	  proteins	  were	  detected	  by	  immunoblot	  or	  Coomassie	  
blue	  staining	  (Figure	  2-­‐6B	  and	  C,	  respectively	  and	  ref	  (25)).	  Thus,	  I	  investigated	  the	  
transcript	   levels	  of	  ospC	  and	   lacZBb	   in	  B312,	  normalizing	   to	   flaB	   transcript	   levels.	  
Endogenous	   ospC	   transcript	   levels	   in	   B312	   lacking	   a	   shuttle	   vector	   and	   B312	  
transformants	   was	   roughly	   half	   of	   flaB	   transcript	   levels	   (56	   ospC	   transcripts	   for	  
every	  100	  flaB	  transcripts)	  (Figure	  2-­‐7B,	  solid	  blue	  bar).	  	  Similarly,	  lacZBb	  transcript	  
levels	   in	   B312	   were	   dramatically	   lower	   when	   controlled	   by	   the	   ospC	   promoter	  
compared	   to	   the	   flaB	   promoter	   (Figure	   2-­‐7B,	   hatched	   blue	   bars).	   As	   expected,	   no	  
ospC	   transcript	  or	   lacZBb	   transcript	  controlled	  by	  the	  ospC	  promoter	  was	  detected	  
in	   A34.	   Notably,	   the	   lacZBb	   transcript	   levels	   driven	   by	   either	   the	   flaB	   or	   ospC	  
promoters	  were	  5-­‐10	  fold	  higher	  than	  the	  endogenous	  gene	  transcripts,	  presumably	  
reflecting	   the	   difference	   in	   copy	   number	   between	   the	   shuttle	   vector	   (lacZBb)	   and	  
genome	  (flaB	  or	  ospC)	  (37).	  This	  increase	  in	  gene	  expression	  from	  the	  shuttle	  vector	  
may	   be	   beneficial	   when	   analyzing	   lacZ	   expression	   from	   weak	   B.	   burgdorferi	  
promoters.	  	  
I	  also	  assessed	  β-­‐galactosidase	  activity	  controlled	  from	  the	  ospC	  promoter	  in	  
B.	   burgdorferi	   colonies	   grown	   on	   BSK	   solid	   medium	   without	   phenol	   red.	   As	  
expected,	   colonies	   of	   A34	   harboring	   pBHospCp-­‐lacZBb	   remained	   white	   after	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overnight	  treatment	  with	  X-­‐gal	  (Figure	  2-­‐7C),	  indicating	  these	  clones	  do	  not	  express	  
ospC	  or	  lacZBb	  under	  control	  of	  the	  ospC	  promoter	  and	  thus	  did	  not	  synthesize	  the	  
β-­‐galactosidase	   protein.	   Even	  when	  OspC	   production	  was	   verified	   by	   immunoblot	  
and	  Coomassie	  blue	  staining	  (see	  Figure	  2-­‐6),	  not	  all	  of	  the	  B312	  colonies	  harboring	  
pBHospCp-­‐lacZBb	   turned	   blue	   after	   X-­‐gal	   treatment,	   suggesting	   that	   ospC	  
expression	   varied	   at	   the	   individual	   colony	   level	   (Figure	   2-­‐7D).	   This	   variation	   in	  
expression	   of	   β-­‐galactosidase	   appeared	   to	   be	   due	   to	   stochastic	   differences	   in	  
expression	  of	  the	  ospC	  promoter	  in	  this	  genetic	  background	  rather	  than	  an	  intrinsic	  
property	   of	   the	   B312	   strain,	   as	   B312	   colonies	   harboring	   the	   pBHflaBp-­‐lacZBb	  
plasmid	  did	  not	  vary	   in	   intensity	  (Figure	  2-­‐7E).	  Additionally,	  plasmid	   loss	  was	  not	  
responsible	   for	   the	   variation	   seen	   with	   pBHospCp-­‐lacZBb,	   since	   at	   least	   96%	   of	  
colonies	  grown	  without	  antibiotic	  selection	  still	  contained	  the	  shuttle	  vector	  (Figure	  
2-­‐8).	   Together,	   these	   results	   demonstrate	   that	   β-­‐galactosidase	   activity	   and	   lacZBb	  
gene	   expression	   accurately	   reflect	   promoter	   strength	   and	   regulation	   of	   gene	  
expression	  in	  B.	  burgdorferi	  (Figure	  2-­‐7).	  Results	  from	  the	  plate	  assays	  also	  indicate	  
variation	   in	  ospC	   expression	   in	  B312,	  with	  only	  some	  colonies	   transcribing	   lacZBb	  
from	  the	  ospC	  promoter.	  This	  clonal	  variation	  in	  ospC	  regulation	  in	  B312	  could	  not	  
have	   been	   observed	  with	   immunoblots	   and	   Coomassie	   blue	   staining	   alone,	  which	  
reflect	  the	  protein	  production	  by	  the	  bulk	  population	  in	  culture,	  and	  illustrates	  the	  
utility	  of	  having	  lacZ	  as	  a	  reporter	  gene	  in	  B.	  burgdorferi.	  
	  
Discussion	  
B.	   burgdorferi	   has	   a	   complicated	   genetic	   system	   encompassing	   at	   least	   20	  
plasmids	  in	  addition	  to	  the	  linear	  chromosome.	  	  Furthermore,	  the	  infectious	  cycle	  of	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Figure	  2-­‐8:	  pBHospCp-­‐lacZBb	  stability	  in	  B312	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Figure	  2-­‐8	   legend:	  PCR	  amplification	  of	   lacZBb	   from	  B312	  colonies	  grown	  without	  
selection.	   B312/pBHospCp-­‐lacZBb	   was	   grown	   in	   solid	  medium	  without	   antibiotic	  
selection.	  26	  colonies	  were	  screen	  by	  PCR	  for	  lacZBb	  using	  primers	  lacZBb	  Int-­‐1	  and	  
lacZBb	  Mid	  Reverse	  (Table	  2-­‐2).	  The	  pBHflaBp-­‐lacZBb	  plasmid	  (1st	   lane)	  was	  used	  
as	   a	   positive	   control,	   as	   was	   a	   colony	   of	   B312/pBHospCp-­‐lacZBb	   grown	   under	  
gentamicin	  selection	  (2nd	  lane).	  Water	  served	  as	  a	  negative	  control	  (NC,	  last	  lane)	  in	  
the	  PCR	  reaction.	  Numbers	  on	  the	  left	  refer	  to	  the	  size	  in	  base	  pairs	  (bp)	  based	  on	  
the	  mobility	  of	  standards.	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B.	   burgdorferi	   requires	   dramatic	   changes	   in	   gene	   expression	   as	   the	   spirochete	  
moves	   from	   the	   vector	   to	   the	   host	   and	   vice	   versa.	   In	   order	   to	   understand	   gene	  
regulation	   in	  B.	  burgdorferi,	   genetic	   tools,	   including	   reporter	  genes,	   are	  necessary.	  
However,	  the	  existing	  reporter	  genes	  developed	  for	  use	  in	  B.	  burgdorferi	  have	  some	  
limitations.	  CAT	  assays	  are	  often	  time	  consuming	  and	  require	  expensive	  radioactive	  
substrates.	   Furthermore,	   CAT	   assays	   lack	   the	   sensitivity	   shown	   by	   other	   reporter	  
genes	   (22),	   and	   CAT	   has	   only	   been	   used	   as	   a	   transient	   reporter	   gene	   in	   B.	  
burgdorferi	   (18,	   38).	   Firefly	   luciferase	   requires	   luciferin	   as	   a	   substrate,	   as	  well	   as	  
ATP,	  magnesium,	  and	  oxygen.	  	  Additionally,	  a	  luminometer	  or	  scintillation	  counter	  is	  
required	   for	   quantification,	   and	   the	   luciferase	   assay	   can	   lack	   sensitivity	   and	  
reproducibility	   unless	   used	   in	   conjunction	  with	   inducible	   systems.	   Of	   the	   current	  
reporter	   genes	   used	   in	   B.	   burgdorferi,	   GFP	   has	   the	   broadest	   utility.	   GFP	   emits	  
fluorescence	  without	   the	   requirement	   for	   a	   substrate	   and	   can	   be	   used	   in	   both	   in	  
vitro	  and	  in	  vivo	  formats.	  Still,	  a	  spectrofluorometer	  or	  flow	  cytometer	  is	  necessary	  
for	   GFP	   quantification,	   making	   GFP	   a	   costly	   reporter	   gene.	   Additionally,	   GFP	   is	   a	  
stable	   protein	   and	   often	   does	   not	   reflect	   transient	   or	   dynamic	   promoter	   activity	  
(22).	  
My	  goal	  in	  these	  studies	  was	  to	  determine	  whether	  lacZ,	  one	  of	  the	  oldest	  and	  
most	   widely	   used	   reporter	   genes,	   could	   be	   adapted	   to	   monitor	   transcriptional	  
activity	  in	  B.	  burgdorferi.	  β-­‐galactosidase	  activity,	  encoded	  by	  lacZ,	  can	  be	  measured	  
using	  simple	  colorimetric	  substrates,	  and	  thus	  does	  not	  require	  expensive	  materials	  
or	   equipment.	   Furthermore,	   β-­‐galactosidase	   activity	   can	   be	   detected	   in	   liquid	   or	  
solid	   media	   and	   some	   substrates	   allow	   in	   vivo	   detection	   as	   well	   (39).	   I	   used	   the	  
constitutive	   B.	   burgdorferi	   flaB	   promoter	   to	   express	   either	   an	   E.	   coli	   lacZ	   gene	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(lacZEc)	  or	  a	  B.	  burgdorferi	  codon-­‐optimized	   lacZ	  gene	  (lacZBb).	  Results	  show	  that	  
the	  β-­‐galactosidase	  protein	  is	  produced	  in	  B.	  burgdorferi	  and	  activity	  is	  detected	  in	  
both	  liquid	  (Figure	  2-­‐4)	  and	  solid	  media	  (Figure	  2-­‐5).	  As	  anticipated,	  β-­‐galactosidase	  
activity	  with	  the	  codon-­‐optimized	  lacZBb	  was	  considerably	  higher	  in	  B.	  burgdorferi	  
than	  that	  of	  the	  original	  E.	  coli	  lacZ	  gene	  (Figure	  2-­‐4).	  The	  greater	  activity	  of	  lacZBb	  
likely	  reflects	  more	  efficient	  translation	  of	  the	  mRNA	  when	  the	  gene	  is	  optimized	  for	  
the	  codon-­‐preference	  of	  B.	  burgdorferi.	  	  
	  To	   determine	   whether	   lacZ	   expression	   and	   β-­‐galactosidase	   activity	  
appropriately	   reflect	   endogenous	   gene	   activity	   in	   B.	   burgdorferi,	   I	   introduced	   an	  
ospC	  promoter-­‐lacZBb	  gene	  fusion	  into	  two	  B.	  burgdorferi	  clones	  that	  differ	  in	  their	  
OspC	  protein	  production.	  When	  B312	  colonies	  harboring	  lacZBb	  driven	  by	  the	  ospC	  
promoter	  were	   assayed	  with	   X-­‐gal,	   β-­‐galactosidase	   activity,	   and	   presumably	   ospC	  
promoter	   activity,	   varied	   from	   colony	   to	   colony	   (Figure	   2-­‐7D),	   suggesting	   clonal	  
regulation	  of	  ospC	  expression	  in	  B312.	  Furthermore,	  the	  β-­‐galactosidase	  activity	  and	  
lacZBb	   transcript	   reflected	   endogenous	   ospC	   promoter	   activity	   in	   B.	   burgdorferi	  
(Figure	  2-­‐7A	  and	  B).	  Although	  the	  FlaB	  and	  OspC	  protein	  levels	  were	  not	  markedly	  
different	   from	   each	   other	   in	   B312	   when	   assessed	   by	   Coomassie	   blue	   staining	   or	  
immunoblot	  (Figure	  2-­‐6),	  I	  noticed	  a	  dramatic	  difference	  in	  β-­‐galactosidase	  activity	  
between	   the	   flaB	   and	   ospC	   promoters	   when	   they	   were	   used	   to	   express	   lacZBb	  
(Figure	  2-­‐7).	  In	  B312,	  β-­‐galactosidase	  activity	  produced	  from	  pBHflaBp-­‐lacZBb	  was	  
40-­‐fold	  higher	  than	  from	  pBHospCp-­‐lacZBb.	  Similarly,	   lacZBb	   transcript	  was	  6-­‐fold	  
higher	   when	   driven	   by	   the	   flaB	   promoter	   compared	   to	   the	   ospC	   promoter.	  
Moreover,	  the	  endogenous	  ospC	  transcript	  level	  in	  B312	  was	  approximately	  half	  of	  
the	  endogenous	   flaB	   transcript	   level	   (Figure	  2-­‐7),	  and	  β-­‐galactosidase	  protein	  was	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only	  detected	  when	  the	  flaB	  promoter	  was	  used	  to	  drive	  expression	  of	  lacZ	  (Figure	  
2-­‐6).	  Since	  ospC	  transcript	  was	  detected	  at	  a	  lower	  level	  than	  the	  flaB	  transcript	  and	  
β-­‐galactosidase	   activity	  was	  much	   lower	  when	   lacZBb	  was	   controlled	   by	   the	  ospC	  
promoter,	  the	  amount	  of	  β-­‐galactosidase	  protein	  produced	  with	  the	  ospC	  promoter	  
in	   B312	   could	   be	   below	   the	   levels	   of	   detection	   for	   immunoblot.	   These	   results	  
demonstrate	  different	   strengths	  of	   the	   flaB	   and	  ospC	  promoters	   and	   suggest	  post-­‐
transcriptional	   regulation	   occurs	   in	   B.	   burgdorferi;	   further	   studies	   are	   needed	   to	  
investigate	  this	  possibility.	  	  
One	   advantage	   of	   using	   reporter	   gene	   fusions	   to	   assess	   the	   transcriptional	  
activity	  of	  various	  promoters	  is	  that	  it	  eliminates	  differences	  in	  post-­‐transcriptional	  
regulation	  that	  may	  affect	  endogenous	  protein	   levels.	  The	  reporter	  gene	  transcript	  
and	  encoded	  protein	  are	  the	  same	  irrespective	  of	  which	  promoter	  is	  used	  to	  express	  
it.	   The	   reporter	   genes	   previously	   used	   in	   B.	   burgdorferi	   all	   require	   expensive	  
substrates	   and/or	   specialized	   equipment	   for	   detection	   and	   quantification.	   In	  
contrast,	   β-­‐galactosidase	   activity	   can	   be	   detected	   with	   simple	   colorimetric	  
substrates	   and	   quantified	   with	   a	   spectrometer.	   In	   fact,	   B.	   burgdorferi	   promoters	  
have	  previously	  been	   fused	   to	   lacZ,	  but	  β-­‐galactosidase	  activity	  was	  assessed	   in	  E.	  
coli,	   not	   B.	   burgdorferi	   (26,	   40).	   However,	   since	   many	   studies	   have	   detected	  
significant	  differences	  in	  the	  expression	  profiles	  of	  B.	  burgdorferi	  genes	  in	  E.	  coli	  (18,	  
38,	  41,	  42),	  using	  lacZ	  as	  a	  reporter	  gene	  directly	  in	  B.	  burgdorferi	  will	  allow	  a	  more	  
accurate	   analysis	   of	   native	   promoter	   activity.	   Additionally,	   there	   are	   many	  
substrates	  for	  β-­‐galactosidase,	  which	  allow	  lacZ	  to	  be	  used	  in	  multiple	  applications,	  
including	  simple	  in	  vitro	  assays	  to	  assess	  promoter	  activity	  and	  rapid	  screening	  for	  
 76 
transformants	  on	  solid	  media.	  Thus,	  adding	  lacZ	  to	  the	  repertoire	  of	  genetic	  tools	  for	  
B.	  burgdorferi	  should	  facilitate	  investigation	  of	  the	  regulatory	  mechanisms	  that	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Abstract	  
Persistent	   infection	   of	   a	   mammalian	   host	   by	   Borrelia	   burgdorferi,	   the	  
spirochete	   that	   causes	   Lyme	   disease,	   requires	   specific	   down-­‐regulation	   of	   an	  
immunogenic	  outer	  surface	  protein,	  OspC.	  Although	  OspC	   is	  an	  essential	  virulence	  
factor	  needed	  by	  the	  spirochete	  to	  establish	  infection	  in	  the	  mammal,	  it	  represents	  a	  
potent	  target	  for	  the	  host’s	  acquired	  immune	  response	  and	  constitutive	  expression	  
of	  OspC	  results	  in	  spirochete	  clearance.	  In	  this	  study,	  we	  demonstrate	  that	  a	  factor	  
encoded	   on	   a	   linear	   plasmid	   of	  B.	   burgdorferi,	   lp17,	   can	   negatively	   regulate	   ospC	  
transcription	  from	  the	  endogenous	  gene	  on	  the	  circular	  plasmid	  cp26	  and	  from	  an	  
ospC	   promoter-­‐lacZ	   fusion	   on	   a	   shuttle	   vector.	   Furthermore,	   we	   have	   identified	  
bbd18	   as	   the	  gene	  on	   lp17	   that	   is	   responsible	   for	   this	  effect.	  These	  data	   identify	  a	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novel	   component	   of	   ospC	   regulation	   and	   provide	   the	   basis	   for	   determining	   the	  
molecular	  mechanisms	  of	  ospC	  repression	  in	  vivo.	  
	  
Introduction	  
Borrelia	  burgdorferi,	  the	  causal	  organism	  of	  Lyme	  disease	  (1-­‐3),	  maintains	  its	  
complex	  enzootic	   life	  cycle	   in	   two	  different	  environmental	  niches,	   Ixodes	   ticks	  and	  
mammalian	   hosts	   (4).	   To	   achieve	   this,	   B.	   burgdorferi	   senses	   key	   changes	   in	   its	  
surroundings	  and	  undergoes	  dramatic	  adaptive	  changes	  in	  gene	  expression.	  As	  part	  
of	   this	   adaptive	   response,	   spirochetes	   in	   the	   midguts	   of	   infected	   ticks	   initiate	  
synthesis	  of	  an	  abundant	  outer	  surface	  protein,	  OspC,	  when	  the	  ticks	  take	  in	  a	  blood	  
meal	   (5-­‐7).	   The	   incorporation	   of	   OspC	   on	   its	   outer	   membrane	   prepares	   B.	  
burgdorferi	   for	   transmission	   to	   a	  mammalian	  host,	  where	   it	   establishes	  persistent	  
infection.	   We	   have	   previously	   demonstrated	   that	   B.	   burgdorferi	   mutants	   lacking	  
functional	   OspC	   cannot	   initiate	   mammalian	   infection	   following	   transmission	   by	  
infected	   ticks	  (8-­‐11).	  However,	  since	  OspC	  represents	  a	  potent	  neutralizing	   target,	  
ospC	   expression	   must	   be	   downregulated	   after	   initiation	   of	   infection	   to	   avoid	  
clearance	  of	  the	  spirochete	  by	  the	  host’s	  acquired	  immune	  response	  (12-­‐15).	  	  
As	   an	   infected	   nymphal	   tick	   attaches	   to	   a	   mammalian	   host	   and	   feeds,	  
spirochetes	  residing	  in	  the	  tick	  midgut	  experience	  changes	  in	  temperature,	  pH	  and	  
nutrients,	   which	   signal	   a	   global	   adaptive	   response	   in	   gene	   expression	   through	   a	  
novel	  regulatory	  cascade	  involving	  the	  response	  regulator	  Rrp2	  and	  the	  alternative	  
sigma	   factors	   RpoN	   (σN,	   σ54)	   and	   RpoS	   (σS,	   σ38)	   (16-­‐19).	   In	   addition	   to	   ospC,	   a	  
number	  of	  other	  B.	  burgdorferi	  genes	  are	   induced	  during	   tick	   feeding	   through	  this	  
RpoN/RpoS	   signaling	   pathway	   (17,	   20-­‐25).	   However,	   unlike	   ospC,	   many	   of	   these	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genes	   continue	   to	   be	   expressed	   during	   mammalian	   infection	   (26).	   Hence,	  
subsequent	   repression	   of	   ospC	   is	   a	   gene-­‐specific	   mechanism	   required	   to	   avoid	  
immune	  clearance.	  
Xu	   and	   colleagues	   have	   recently	   described	   a	   palindromic	   sequence	  
immediately	   upstream	   of	   the	   ospC	   promoter	   that	   represents	   a	   potential	   operator	  
site	   to	   which	   a	   repressor	   could	   bind	   (27,	   28).	   Although	   B.	   burgdorferi	   mutants	  
lacking	   this	   palindromic	   sequence	   can	   initiate	   mammalian	   infection,	   ospC	  
expression	   is	  not	  downregulated	   in	   these	  mutants	  and	  thus	   they	  are	  subsequently	  
recognized	  and	  cleared	  by	  neutralizing	  antibodies	  of	  the	  acquired	  immune	  response	  
(27).	   However,	   the	   invoked	   repressor	   that	   binds	   to	   the	   operator	   site	   and	   down-­‐
regulates	  ospC	  expression	  in	  vivo	  has	  not	  been	  identified.	  	  
In	   an	   earlier	   study,	   Sadziene	   and	   colleagues	   described	   several	   highly	  
attenuated	  B.	  burgdorferi	  clones	  that	  constitutively	  synthesize	  OspC	  during	   in	  vitro	  
growth,	  in	  contrast	  to	  the	  parental	  B31	  strain	  from	  which	  these	  clones	  were	  derived	  
(29).	   These	   B.	   burgdorferi	   clones	   had	   lost	   many	   or	   all	   linear	   plasmids	   during	  
extended	   in	   vitro	   passage	   but	   retained	   the	   26	   kilobase	   (kb)	   circular	   plasmid	   (cp),	  
cp26,	  which	  carries	  the	  ospC	  gene	  (29).	  Synthesis	  of	  OspC	  correlated	  with	  loss	  of	  a	  
particular	   linear	   plasmid	   (lp),	   lp17,	   and	   ospC	   expression	   was	   highest	   in	   clones	  
lacking	   both	   lp17	   and	   another	   plasmid,	   lp54.	   These	   authors	   proposed	   that	   lp17	  
encodes	  a	  putative	  repressor	  that	  typically	  silences	  ospC	  in	  strain	  B31	  during	  in	  vitro	  
growth;	   they	   also	   suggested	   that	   further	   evidence	   for	   this	   repressor	   could	   be	  
provided	  by	  restoration	  of	  lp17	  to	  clones	  from	  which	  it	  had	  been	  lost	  (29).	  Although	  
this	   was	   technically	   infeasible	   when	   proposed	   in	   1993,	   the	   genetic	   system	   of	   B.	  
burgdorferi	   has	   developed	   to	   a	   stage	   where	   displacement	   and	   restoration	   of	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individual	  plasmids	  are	  now	  possible	  (30-­‐32).	  In	  this	  report,	  we	  describe	  a	  series	  of	  
experiments	   in	  which	  we	   investigate	   the	   ability	   of	   both	   full-­‐length	   and	   truncated	  
forms	   of	   lp17,	   as	   well	   as	   lp17	   gene	   sequences	   introduced	   on	   a	   shuttle	   vector,	   to	  
repress	  ospC	  gene	  expression.	  	  
	  
Materials	  and	  Methods	  
Bacterial	  strains	  and	  culture	  conditions.	  
	  All	   B.	   burgdorferi	   strains	   were	   inoculated	   from	   frozen	   stocks	   into	   liquid	  
Barbour-­‐Stoenner-­‐Kelly	   (BSKII)	   medium	   supplemented	   with	   6%	   rabbit	   serum	  
(PelFreez	   Biologicals,	   Rogers,	   AR)	   and	   grown	   at	   35°C	   under	   2.5%	   CO2	   (33).	   B.	  
burgdorferi	   strains,	   Escherichia	   coli	   strains	   and	   plasmids	   used	   in	   this	   study	   are	  
described	  in	  Table	  3-­‐1.	  	  
Transformation	  of	  B.	  burgdorferi.	  
B.	   burgdorferi	   was	   transformed	   by	   electroporation	   as	   previously	   described	  
(34,	   35).	   Briefly,	   10–15	   μg	   of	   plasmid	   DNA	   or	   genomic	   DNA	   was	   introduced	   by	  
electroporation	   into	   competent	   B.	   burgdorferi	   cells,	   freshly	   prepared	   from	   an	  
exponential	  phase	  culture.	  Following	  electroporation,	  the	  cells	  were	  resuspended	  in	  
5	  ml	  of	  BSKII	  and	  allowed	  to	  recover	  for	  18–24	  h	  at	  35°C.	  The	  spirochetes	  were	  then	  
diluted	  to	  20	  ml	  of	  BSKII	  supplemented	  with	  kanamycin	  (200	  mg/ml),	  distributed	  at	  
200	  μl/well	  in	  96	  well	  flat	  bottom	  Costar	  plates	  (Corning,	  Lowell,	  MA)	  and	  incubated	  
at	   35°C	   with	   2.5%	   CO2.	   Alternatively,	   recovered	   cells	   were	   plated	   in	   solid	   BSKII	  
medium	  with	  kanamycin	  (200mg/ml)	  and/or	  gentamicin	  (40μg/ml)	  and	  incubated	  
at	  35°C	  with	  2.5%	  CO2.	  	  
Screening	  of	  transformants.	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Table	  3-­‐1:	  Strains	  and	  Plasmids	  used	  in	  Chapter	  Three	  
Strain	  or	  plasmid	   Description	   Reference	  
B.	  burgdorferi	  strains	  
B31-­‐A3	   Infectious	  derivative	  of	  wild-­‐type	  B31-­‐MI,	  lacks	  cp9	   (36)	  
ospCK1	  
ospC	  mutant;	  isogenic	  derivative	  of	  B31-­‐A3;	  




ospCK1	  derivative	  that	  constitutively	  expresses	  ospC	  
(ospCK1/pBSV2G-­‐flaBp-­‐ospC);	  containing	  all	  B31	  




high	  passage,	  non-­‐infectious	  clone	  containing	  lp54,	  
cp26,	  cp32-­‐1,	  cp32-­‐3,	  cp32-­‐4,	  cp32-­‐7,	  cp32-­‐8;	  
synthesizes	  OspA/B	  and	  OspC	  in	  vitro	  
(29);	  this	  
study	  
B31-­‐A	   non-­‐infectious	  clone	  of	  the	  prototype	  B.	  burgdorferi	  sensu	  stricto	  isolate	  B31	   (38)	  
B31-­‐A,	  lp17::kan	   B31-­‐A	  derivative	  carrying	  pKK81	  integration	  on	  lp17;	  kanamycin	  resistant	   (39)	  
B312_lp17.8	   B312	  derivative	  harboring	  lp17::kan;	  kanamycin-­‐	  resistant	   This	  study	  
B312	  +pGCB409	   B312	  derivative	  harboring	  pGCB409;	  kanamycin-­‐resistant	  
(40);	  this	  
study	  
B312+pGCB413	   B312	  derivative	  harboring	  pGCB413;	  kanamycin-­‐resistant	  
(40);	  this	  
study	  
B312+pGCB426	   B312	  derivative	  harboring	  pGCB426;	  kanamycin-­‐resistant	  
(40);	  this	  
study	  
B312+pGCB473	   B312	  derivative	  harboring	  pGCB473;	  kanamycin-­‐resistant	  
(40);	  this	  
study	  
B312+pBSV2*-­‐7’	   B312	  derivative	  harboring	  bbd15-­‐bbd18	  region	  of	  lp17	  on	  a	  shuttle	  vector;	  kanamycin-­‐resistant	   this	  study	  
B312	  +	  pBSV2*-­‐
NP-­‐bbd18	  
B312	  derivative	  harboring	  bbd18	  gene	  under	  the	  





B312	  derivative	  harboring	  bbd18	  under	  the	  control	  





B312	  derivative	  harboring	  bbd18	  without	  a	  
promoter	  on	  a	  shuttle	  vector;	  kanamycin-­‐resistant	   this	  study	  
B312	  +	  pBHospCp-­‐
lacZBb*	  
B312	  derivative	  harboring	  lacZBb*	  under	  the	  control	  





lacZBb*	  +	  lp17::kan	  
B312	  derivative	  harboring	  lacZBb*	  under	  the	  control	  
of	  the	  ospC	  promoter	  on	  a	  shuttle	  vector	  and	  
lp17::kan;	  gentamicin-­‐	  and	  kanamycin-­‐resistant	  
(41);	  this	  
study	  
E.	  coli	  strains	  
Top10	  +	  pOKflaBp-­‐
bbd18	  













Top10	  with	  lacZBb	  under	  the	  control	  of	  the	  ospC	  






Top10	  with	  both	  the	  constitutive	  bbd18	  gene	  on	  
pOK12	  and	  the	  promoter-­‐less	  lacZBb	  gene	  on	  






Top10	  with	  both	  the	  constitutive	  bbd18	  gene	  on	  
pOK12	  and	  lacZBb	  under	  the	  control	  of	  the	  ospC	  





pBSV2*	   pBSV2	  derivative	  created	  by	  disrupting	  the	  EcoRI	  site	  at	  nt.	  1852	   (43)	  
pBSV2*-­‐7’	   pBSV2*	  with	  a	  2721bp	  insert	  spanning	  bbd15-­‐18	  (nt.	  9360-­‐12081)	  of	  lp17	   this	  study	  
pBSV2*-­‐NP-­‐bbd18	  
pBSV2*	  with	  an	  insert	  encompassing	  bbd18	  and	  





pBSV2*	  with	  the	  constitutive	  flaB	  promoter	  driving	  
expression	  of	  bbd18	  (nt.	  11648-­‐10881	  of	  lp17).	   this	  study	  
pBSV2*-­‐bbd18	   pBSV2*	  carrying	  a	  promoter-­‐less	  bbd18	  gene	  (nt.	  11648-­‐10881	  of	  lp17).	   this	  study	  
pGCB409	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB409	  carrying	  bbd1	  through	  bbd23	   (40)	  
pGCB413	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB413	  carrying	  bbd7	  through	  bbd25	   (40)	  
pGCB426	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB426	  carrying	  bbd1	  through	  5’	  of	  bbd20	   (40)	  
pGCB473	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB473	  carrying	  bbd1	  through	  bbd14	   (40)	  
pBH-­‐lacZBb*	  
Promoter-­‐less	  Borrelia	  codon-­‐optimized	  lacZBb	  gene	  
on	  the	  shuttle	  vector	  pBSV2G	  with	  BspHI	  restriction	  
site	  added	  upstream	  of	  lacZBb	  
(41);	  this	  
study	  




flaBp-­‐bbd18	  cassette	  from	  pBSV2*-­‐flaBp-­‐bbd18	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After	  7-­‐8	  days,	  20	  ml	  of	  bacterial	  cultures	  from	  positive	  wells	  (identified	  by	  
phenol	   red	   indicator	   color	   change	   and	   confirmed	   by	   dark	   field	  microscopy)	  were	  
inoculated	  into	  5	  ml	  of	  BSKII	  supplemented	  with	  kanamycin	  and	  incubated	  at	  35°C.	  
Typically,	   approximately	   10	   of	   96	   wells	   were	   positive	   for	   growth	   and	   hence	  
transformants	   could	   be	   considered	   clonal	   (44).	   Total	   genomic	   DNA	   was	   isolated	  
from	   outgrowth	   cultures	   with	   a	   Wizard	   genomic	   DNA	   purification	   kit	   (Promega,	  
Madison,	   WI).	   Transformants	   were	   distinguished	   from	   spontaneous	   resistance	  
mutants	   by	   polymerase	   chain	   reaction	   (PCR)	   with	   total	   genomic	   DNA,	   using	  
appropriate	   primers	   (Table	   3-­‐2).	   Alternatively,	   colonies	   in	   solid	   media	   were	  
screened	  directly	  by	  PCR	  to	  confirm	  the	  stable	  presence	  of	  introduced	  DNA.	  	  
B312	  transformants	  carrying	  full	  length	  and	  truncated	  forms	  of	  lp17.	  
Genomic	  DNA	  isolated	  from	  B31-­‐A,	  lp17::kan	  (39)	  and	  plasmid	  DNA	  isolated	  
from	   four	  different	  B.	   burgdorferi	   clones	   (GCB409,	  GCB413,	  GCB426	  and	  GCB473)	  
harboring	  truncated	  forms	  of	  lp17	  (40)	  were	  used	  to	  generate	  B312	  transformants	  
carrying	  either	  full	  length	  or	  the	  respective	  lp17	  deletion	  variant	  (Table	  3-­‐1).	  B312	  
clones	  carrying	   the	   full-­‐length	   lp17	  were	  confirmed	  by	  PCR	  using	  primers	  specific	  
for	  kanamycin	  and	  several	   lp17	  genes	   (Table	  3-­‐2).	  The	  deletions	   in	   lp17	   from	   the	  
donor	   GCB	   strains	   were	   confirmed	   by	   PCR	   and	   Southern	   blot	   analysis	   (Dr.	   Amit	  
Sarkar,	  personal	  communication).	  The	  deleted	  forms	  of	  lp17	  were	  designated	  by	  the	  
respective	   GCB	   strain	   from	   which	   they	   were	   derived	   (e.g.,	   pGCB409	   is	   the	   lp17	  
variant	  carried	  by	  GCB409).	  B312	  transformants	  were	  initially	  screened	  by	  PCR	  for	  
the	   kanamycin-­‐resistance	   cassette	   present	   on	   lp17	   and	   then	   checked	   by	   PCR	   for	  
additional	   lp17	   sequences	   to	   confirm	   introduction	   of	   the	   desired	   lp17	   deletion	  
variant	  from	  GCB	  clones.	  The	  complete	  plasmid	  content	  of	  each	  B312	  transformant	  
 89 
Table	  3-­‐2:	  Primers	  and	  probes	  used	  in	  Chapter	  Three	  
	  	   Name	   Sequence	  (5’-­‐3’)a	   Reference	  
1	   flaB	  qPCR	  forward	   TCCTTCCTGTTGAACACCCTCT	   (45)	  
2	   flaB	  qPCR	  reverse	   TCTTTTCTCTGGTGAGGGAGCT	  	   (45)	  
3	   flaB	  	  qPCR	  probe	   AAACTGCTCAGGCTGCACCGGTTC	   (45)	  
4	   ospC	  qPCR	  forward	   ACGGATTCTAATGCGGTTTTACTT	   (46)	  
5	   ospC	  qPCR	  reverse	   CAATAGCTTTAGCAGCAATTTCATCT	  	   (46)	  
6	   ospC	  qPCR	  probe	   CTGTGAAAGAGGTTGAAGCGTTGCTGTCAT	   (46)	  
7	   guaA	  forward	   TGACTCATGATAATTTGAAATT	   This	  study	  
8	   ospC	  reverse	   CACCTTCTTTACCAAGATCTGT	   This	  study	  
9	   bbd11	  forward	   GTGTATACTGACCCAAGGTCAA	   (23)	  
10	   bbd11	  reverse	   AGAAATGGGGTTACATTTGAAGCTTGG	   (23)	  
11	   bbd14	  forward	   AACGCTCAAGGCTAAAATCA	   (23)	  
12	   bbd14	  reverse	   CTGTCAGTTTTTCCATTCATCATCC	   (23)	  
13	   bbd21	  forward	   GCATTTCATATTCAAAAAGGTGGTGTTGGG	   (23)	  
14	   bbd21	  reverse	   TAGGCATAAAGCATCTCCCA	   (23)	  
15	  
kan	  5’	  NdeI	  
forward	   CATATGAGCCATATTCAACGGGAAACG	   (38)	  
16	   kan	  reverse	   TTAATTAATGAGCTAGCGCCGT	   This	  study	  
17	   bbd14	  end	  forward	   GCTCTAGAAATTAAAATTAATCAAAATTAATTGb	   This	  study	  
18	  
bbd19	  start	  
reverse	   GCTCTAGAGATAAAAATAAAATTCATTTATCb	   This	  study	  
19	  
lacZBb	  Int-­‐1	  
forward	   TGGTGTAATGGAAGATGGGTTGG	   This	  study	  
20	   lacZBb	  Mid	  reverse	   GATAGACCATTTAGGAACAGCAGG	   This	  study	  
21	  
ospC	  promoter-­‐
BamHI	  forward	   CCCGCGGATCCAATTAAAACTTTTTTTATTAAAGTA	   (41)	  
22	  
ospC	  promoter-­‐
BspHI	  reverse	   CCCCGTCATGATTTGTGCCTCCTTTTTATTTAT	   This	  study	  
23	   bbd18_NP	  forward	   CCGGAATTCCAGAATTTACTTACAATATTTAACCTTC	   This	  study	  
24	   bbd18	  forward	   CCGGAATTCATGCAAAAAGAAATAACAATAAAC	   This	  study	  
25	   bbd18	  +reverse	   CCGGAATTCGTAAGGTAGAAAACGATCTACCAAT	   This	  study	  
a	  qPCR	  probes	  were	  labeled	  with	  6-­‐carboxyfluorescein	  (FAM)	  and	  6-­‐
carboxytetramethylrhodamine	  (TAMRA)	  at	  the	  5'	  and	  3'	  ends,	  respectively.	  Restriction	  sites	  are	  
underlined	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was	  also	  determined	  by	  PCR	  (36)	  to	  confirm	  that	  no	  plasmids	  other	  than	  lp17	  had	  
been	  introduced.	  	  	  
Shuttle	  vector	  constructs	  harboring	  lp17	  sequences	  and	  B312	  transformants.	  
A	  2721	  bp	  fragment	  of	  lp17	  extending	  from	  the	  3’	  end	  of	  bbd14	  (nt.	  9360)	  to	  
the	  5’	  end	  of	  bbd19	  (nt.	  12081)	  was	  amplified	  from	  B31-­‐A3	  genomic	  DNA	  (primers	  
17	  and	  18,	  Table	  3-­‐2)	  and	  cloned	  into	  the	  pCR2.1	  TOPO	  vector	  (Invitrogen).	  Clones	  
harboring	   the	   desired	   lp17	   fragment	   were	   identified	   by	   PCR	   amplification	   and	  
restriction	   digest,	   and	   confirmed	   by	   sequencing.	   The	  ~2.7kb	   insert	   fragment	  was	  
excised	   with	   XbaI	   (New	   England	   Biolabs,	   Beverly,	   MA)	   and	   ligated	   into	   XbaI-­‐
digested	  pBSV2*	  vector	  (43),	  yielding	  pBSV2*-­‐7’	  (Table	  3-­‐1).	  
A	  767	  bp	  fragment	  of	  lp17	  (nt.	  11648-­‐10881)	  comprising	  the	  BBD18	  coding	  
sequence	   and	   downstream	   sequences	   (no	   promoter)	   was	   amplified	   from	   B31-­‐A3	  
genomic	  DNA	  (primers	  24	  and	  25,	  Table	  3-­‐2)	  and	  cloned	  into	  pCR2.1	  TOPO	  vector	  
(Invitrogen).	  Clones	  harboring	   the	  desired	   fragment	  were	   identified	  by	   restriction	  
digest	   and	   confirmed	   by	   sequencing.	   The	   insert	   fragment	  was	   excised	  with	  EcoRI	  
(New	  England	  Biolabs,	   Beverly,	  MA)	   and	   ligated	   into	  EcoRI-­‐digested	   pBSV2*	   (43),	  
yielding	  pBSV2*-­‐bbd18	   (Table	  3-­‐1).	  The	  same	  bbd18	   fragment	  was	  also	  cloned	  on	  
the	   shuttle	   vector	   under	   the	   control	   of	   the	   constitutive	   flaB	   promoter,	   yielding	  
pBSV2*-­‐flaBp-­‐bbd18.	  Finally,	  a	  1176	  bp	   fragment	  of	   lp17	  encompassing	  the	  bbd18	  
gene	  with	  5’	  and	  3’	  flanking	  sequences	  (nt.	  12056-­‐10881)	  was	  amplified	  from	  B31-­‐
A3	  genomic	  DNA	  (primers	  23	  and	  25,	  Table	  3-­‐2)	  and	  cloned	  into	  pBSV2*	  in	  a	  similar	  
fashion,	  yielding	  pBSV2*-­‐NP-­‐bbd18	  (native	  promoter)	  (Table	  3-­‐1).	  
Plasmid	   DNA	   isolated	   from	   E.	   coli	   harboring	   pBSV2*,	   pBSV2*-­‐7’,	   pBSV2*-­‐
bbd18	   (promoter-­‐less),	   pBSV2*-­‐NP_bbd18	   (native	   promoter)	   or	   pBSV2*-­‐flaBp-­‐
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bbd18	   (constitutive	   flaB	   promoter)	   (Table	   3-­‐1)	   was	   used	   to	   transform	   B312.	  
Transformants	  were	  selected	  in	  liquid	  BSK	  II	  medium	  in	  the	  presence	  of	  kanamycin	  
(200µg/ml)	  and	  screened	  by	  PCR	  with	  specific	  primers	  for	  the	  kanamycin	  cassette	  
(38)	  and	  bbd18	  (Table	  3-­‐2).	  Shuttle	  vectors	  from	  B.	  burgdorferi	  transformants	  were	  
rescued	  in	  E.	  coli	  and	  characterized	  by	  restriction	  digest	  to	  confirm	  insert.	  
lacZBb	  reporter	  constructs	  and	  expression	  in	  B312.	  	  	  
The	  ospC	  promoter	  was	  amplified	  from	  B31-­‐A3	  genomic	  DNA	  (primers	  21	  
and	  22,	  Table	  3-­‐2),	  cloned	  into	  pCR2.1	  (Invitrogen),	  and	  sequenced	  to	  confirm	  the	  
insert.	  The	  ospC	  promoter	  fragment	  was	  excised	  with	  BamHI	  and	  BspHI	  and	  ligated	  
into	  appropriately	  digested	  pBH_lacZBb*	  (a	  derivative	  of	  pBH_lacZBb	  with	  a	  BspHI	  
restriction	  site	  immediately	  upstream	  of	  lacZBb)	  (41),	  creating	  pBHospCp-­‐lacZBb*	  
(Table	  3-­‐1).	  
Plasmid	  DNA	  from	  E.	  coli	  harboring	  pBHospCp-­‐lacZBb*	  (Table	  3-­‐1)	  was	  used	  
to	   transform	   B312	   and	   B312_lp17.8	   (Table	   3-­‐1).	   Transformants	   were	   selected	   in	  
solid	  media	   containing	   gentamicin	   (40μg/ml)	   and	   individual	   colonies	   screened	  by	  
PCR	  for	  lacZBb	  and	  retention	  of	  the	  kanamycin	  cassette	  in	  B312_lp17.8	  	  (Table	  3-­‐2).	  
B312	  derivatives	  harboring	  pBHospCp-­‐lacZBb*,	  with	  or	  without	  lp17	  marked	  
with	  a	  kanamycin	  cassette	  (Table	  3-­‐1),	  were	  grown	  in	  BSKII	  solid	  medium	  lacking	  
phenol	   red,	   supplemented	   with	   the	   appropriate	   antibiotic(s).	   After	   colony	  
formation,	   approximately	   0.5ml	   X-­‐gal	   (5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl-­‐beta-­‐D-­‐
galactopyranoside,	   20mg/ml	   in	   dimethylformamide)	   was	   added	   to	   detect	   β-­‐
galactosidase	   activity,	   as	   described	   previously	   (Chapter	   1	   and	   ref	   (41)).	   Colonies	  
were	   screened	   for	   maintenance	   of	   the	   kanamycin	   cassette	   and	   lacZBb	   with	   the	  
appropriate	  primers	  (Table	  3-­‐2).	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BBD18	  construct	  for	  co-­‐expression	  in	  E.	  coli.	  	  
The	  flaB	  promoter-­‐bbd18	  insert	  fragment	  was	  cut	  out	  of	  pBSV2*flaBp-­‐bbd18	  
(Table	  3-­‐1)	  with	  NotI	  and	  ligated	  into	  appropriately	  digested	  pOK12	  (42),	  creating	  
pOKflaBp-­‐bbd18	   (Table	   3-­‐1).	   E.	   coli	   (Top	   10)	   was	   transformed	   with	   pOKflaBp-­‐
bbd18,	  pBH_lacZBb*,	  or	  pBHospCp-­‐lacZBb*,	  or	  both	  pOKflaBp-­‐bbd18	  and	  one	  of	  the	  
lacZBb*	  plasmids.	  Resulting	  colonies	  were	  screened	  for	  the	  presence	  of	  flaBp::bbd18	  
and/or	   lacZBb	   as	   appropriate	   and	   streaked	   on	   LB	   agar	   plates	   containing	   the	  
appropriate	  antibiotic(s)	  and	  X-­‐gal.	  	  
Quantitative	  reverse	  transcriptase	  PCR	  (qRT-­‐PCR).	  
Total	   RNA	   was	   extracted	   from	   exponential	   phase	   B.	   burgdorferi	   cultures	  
using	   the	  Nucleospin	  RNA	  II	  kit	   (Fisher	  Scientific,	  Pittsburgh,	  PA)	  according	   to	   the	  
manufacturer’s	   specifications	   and	   treated	   with	   RNase-­‐free	   DNase	   I.	   Synthesis	   of	  
cDNA	  was	   carried	   out	   using	   random	   hexamer	   primers	   and	   a	   high-­‐capacity	   cDNA	  
reverse	   transcriptase	   kit	   (Applied	   Biosystems,	   Branchburg,	   NJ).	   These	   reactions	  
were	  also	  carried	  out	  in	  the	  absence	  of	  reverse	  transcriptase	  to	  serve	  as	  a	  control	  for	  
residual	   DNA	   contamination.	   Newly	   synthesized	   cDNA	  was	   treated	  with	   RNase	   H	  
(Ambion,	   Applied	   Biosystems)	   for	   1	   h	   at	   37°C	   to	   remove	   RNA-­‐DNA	   hybrids	   and	  
samples	  were	  then	  cleaned	  and	  concentrated	  using	  a	  MinElute	  PCR	  purification	  kit	  
(Qiagen,	  Valencia,	  CA).	  Concentrated	  cDNA	  samples	  were	  quantified	  by	  absorbance	  
at	   260	   nm	   and	   diluted	   to	   50	   ng/µl	   in	   DNase-­‐	   and	   RNase-­‐free	   water	   (Applied	  
Biosystems).	   Quantitative	   PCR	  was	   performed	  with	   100ng	   cDNA	   using	   a	   TaqMan	  
Universal	   PCR	   Master	   Mix	   (Applied	   Biosystems)	   and	   primer-­‐probe	   combinations	  
(Table	   3-­‐2)	   for	   B.	   burgdorferi	   flaB	   (flagellin)	   (45)	   and	   ospC	   (46)	   genes,	   using	   an	  
Applied	  Biosystems	  7900HT	  instrument.	  The	  relative	  copy	  numbers	  of	  flaB	  and	  ospC	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transcripts	  were	  determined	  using	  a	  standard	  curve	   for	  each	  gene	   target	   that	  was	  
generated	  with	  purified	  genomic	  DNA	  from	  105,	  104,	  103,	  102	  and	  101	  spirochetes.	  
Samples	  were	  analyzed	  in	  triplicate	  and	  gene	  expression	  reported	  as	  the	  number	  of	  
ospC	   per	   flaB	   mRNA	   copies.	   The	   amplification	   of	   samples	   without	   reverse	  
transcriptase	   was	   similar	   to	   that	   for	   the	   no-­‐template	   control.	   Data	   sets	   were	  
compared	  using	  the	  GraphPad	  Prism	  version	  4.0	  for	  Windows	  (GraphPad	  Software,	  
San	  Diego	  CA).	  
SDS-­‐PAGE	  and	  immunobloting.	  	  
B.	  burgdorferi	  protein	  lysate	  preparation	  and	  their	  separation	  by	  12.5%	  SDS-­‐
PAGE	   were	   as	   previously	   described	   (47).	   Gels	   were	   run	   in	   duplicate	   and	   either	  
stained	   with	   Coomassie	   Brilliant	   Blue	   (Sigma,	   St.	   Louis,	   MO)	   or	   blotted	   to	  
nitrocellulose	   membranes	   (BioRad,	   Hercules,	   CA).	   Membranes	   were	   blocked	  
overnight	  with	  5%	  nonfat	  milk	   (BD	  Diagnostics,	  Franklin	  Lakes,	  NJ)	   in	  TBS-­‐Tween	  
20	   (20mM	  TRIS	   pH	   7.5,	   150mM	  NaCl,	   0.05%	  Tween	   20),	   and	   probed	  with	   rabbit	  
anti-­‐OspC	  polyclonal	  antiserum	  (1:1000	  dilution)	  (10),	  anti-­‐FlaB	  mouse	  monoclonal	  
antibody	   H9724	   (1:25	   dilution)	   (48)	   and	   rabbit	   anti-­‐BBD18	   antiserum	   (1:500	  
dilution)	   (described	   below).	   Next,	   membranes	   were	   incubated	   with	   peroxidase-­‐
conjugated	   anti-­‐rabbit	   or	   anti-­‐mouse	   serum	   (Sigma).	   Finally,	   peroxidase	   activity	  
was	  detected	  using	  Super	  Signal	   reagents	   (Thermo	  Scientific,	  Rockford,	   IL)	   and	  X-­‐
ray	  film	  (LabScientific	  Inc,	  Livingston,	  New	  Jersey).	  
BBD18	  peptide	  antiserum.	  	  
A	  synthetic	  15	  amino	  acid	  peptide	  (CRHFDEQNKTNFNES),	  matching	  residues	  
120-­‐133	  of	   the	  annotated	  BBD18	  protein	  and	  the	  addition	  of	  a	  cysteine	  residue	  at	  
the	   N-­‐terminus	   for	   conjugation,	   was	   used	   to	   generate	   BBD18-­‐specific	   antisera	   in	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rabbits	   (Genscript,	   Piscataway,	   NJ).	   Affinity-­‐purified	   antibodies	   (Genscript)	   were	  
used	  in	  immunoblot	  analyses	  (1:500	  dilution)	  to	  detect	  BBD18.	  
Sequencing	  the	  ospC	  promoter	  region.	  	  
An	  approximately	  1	  kb	  fragment	  extending	  through	  the	  guaA-­‐ospC	  intergenic	  
region	  was	   amplified	   from	   both	   B31-­‐A3	   and	   B312	   total	   genomic	   DNA	   (primers	   7	  
and	  8,	  Table	  3-­‐2)	  and	  cloned	  into	  the	  pCR2.1	  TOPO	  vector	  (Invitrogen,	  Carlsbad,	  CA)	  
in	   E.	   coli	   Top	   10	   (Invitrogen).	   Inserts	   were	   sequenced	   using	   the	   ABI	   Big	   Dye	  
Terminator	  Cycle	  sequencing	  Ready	  Reaction	  Kit	  with	  an	  ABI	  3700	  DNA	  sequencer	  
(Applied	   Biosystems)	   and	   the	   sequences	   of	   the	   guaA-­‐ospC	   intergenic	   region	   from	  
B31-­‐A3	   and	   B312	   were	   compared	   using	   DNA-­‐Star	   software	   (DNASTAR,	   Inc.	  
Madison,	  WI).	  	  
	  
Results	  
Characterization	  of	  strain	  B312.	  
Specific	   down-­‐regulation	   of	   immunogenic	   OspC	   during	   the	   early	   phase	   of	  
mammalian	  infection	  is	  a	  key	  strategy	  adopted	  by	  B.	  burgdorferi	   for	  persistence	  in	  
the	  mammalian	  host	   (11,	   12,	   15,	   37).	   Sadziene	  et	   al.	   previously	  observed	   that	   the	  
highly	   attenuated	   B.	   burgdorferi	   clone	   B312	   expresses	   an	   otherwise	   cryptic	   ospC	  
gene	  when	   lp17	   is	   lost	   (29),	  prompting	   the	  hypothesis	   that	  an	   lp17-­‐encoded	  gene	  
product	   might	   be	   responsible	   for	   the	   specific	   and	   timely	   repression	   of	   ospC	  
expression	  in	  vivo.	  
In	   order	   to	   address	   the	   influence	   of	   lp17	   on	   ospC	   expression,	   we	   first	  
determined	  the	  plasmid	  content	  of	  strain	  B312	  by	  PCR,	  using	  specific	  primer	  pairs	  
for	  each	  of	  the	  21	  plasmids	  of	  strain	  B31	  (36,	  49,	  50).	  This	  analysis	  confirmed	  that	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B312	   lacks	   all	   B31	   plasmids	   except	   cp26,	   lp54	   and	   several	   cp32s	   (Dr.	   Sarkar,	  
personal	   communication	   and	   ref	   (29)).	   We	   also	   analyzed	   the	   protein	   content	   of	  
B312	  and	  confirmed	  that	  OspC	  was	  synthesized	  (Figure	  3-­‐1A,	  lane	  2),	  in	  contrast	  to	  
wild-­‐type	   (wt)	  B31,	  which	  does	  not	   synthesize	  OspC	  under	   typical	   in	  vitro	   growth	  
conditions	  (Figure	  3-­‐1A,	   lane	  1)	  (29,	  51).	  Finally,	  we	  analyzed	  the	  sequence	  of	   the	  
ospC	  promoter	  and	  upstream	  flanking	  region	  (187	  bp)	  of	  clone	  B312	  and	  found	  that	  
it	  was	  identical	  to	  the	  wt	  B31	  sequence	  (Dr.	  Sarkar,	  personal	  communication	  and	  ref	  
(50,	  52)).	  Thus,	  although	  clone	  B312	  constitutively	  synthesizes	  OspC	  during	  in	  vitro	  
growth,	   there	  are	  no	  changes	   in	   the	  5’	   flanking	  region	  of	   the	  ospC	  gene	  that	  might	  
account	  for	  this	  phenotypic	  switch.	  
Restoration	  of	  lp17	  into	  B312	  
To	  investigate	  the	  hypothesis	  that	  lp17	  negatively	  regulates	  ospC	  expression,	  
the	  entire	  lp17	  plasmid	  was	  introduced	  into	  B312	  by	  transformation	  with	  genomic	  
DNA	   from	   a	   B.	   burgdorferi	   strain	   in	   which	   a	   selectable	   marker,	   the	   kanamycin	  
resistance	  cassette	  (38),	  had	  been	  inserted	  near	  the	  left	  telomere	  of	  lp17	  (lp17::kan)	  
(39).	  The	  complete	  plasmid	  content	  of	  the	  resulting	  transformant,	  B312_lp17.8,	  was	  
determined	   by	   PCR	   (36)	   to	   confirm	   that	   no	   plasmids	   other	   than	   lp17	   had	   been	  
introduced	   (Dr.	   Sarkar,	   personal	   communication).	   As	   predicted,	   B312_lp17.8	   no	  
longer	  synthesizes	  OspC	  (Figure	  3-­‐1A,	  lane	  3),	  consistent	  with	  a	  role	  for	  one	  or	  more	  
lp17	  genes	  in	  negative	  regulation	  of	  ospC.	  	  
The	   influence	   of	   lp17	   on	   ospC	   expression	   was	   analyzed	   by	   quantitative	  
reverse	   transcription	  (qRT)	  PCR	  of	  RNA	   from	  B312	  clones	  with	  and	  without	   lp17;	  
ospC	   transcript	  was	  normalized	   to	   flaB	  mRNA	  copies	   for	  each	  strain.	  This	  analysis	  
demonstrated	  approximately	  10-­‐fold	  less	  ospC	  transcript	  in	  the	  B312	  derivative	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Figure	  3-­‐1:	  Negative	  regulation	  of	  ospC	  by	  lp17	  in	  B312.	  	  	  
	   	  
	  
 97 
Figure	  3-­‐1	   legend:	  A.	  Total	  B.	  burgdorferi	  protein	   lysates	  analyzed	  by	   immunoblot	  
with	  OspC	   and	  FlaB	   antisera,	   as	   indicated:	  wild	   type	   clone	  B31-­‐A3	   (lane	  1);	  B312	  
(lane	   2);	   B312_lp17.8	   (lane	   3);	  mutant	  ospCK1	   (lane	   4);	  ospCK1+ospC	   (lane	   5).	  B.	  
ospC	  transcript	  level	  in	  total	  RNA	  from	  B312	  and	  B312_lp17.8	  (+lp17)	  as	  measured	  
by	   quantitative	   RT-­‐PCR	   and	   normalized	   to	   the	   chromosomal	   flaB	   gene	   transcript.	  
(***)	   indicates	   P<0.002	   based	   on	   Student’s	   two-­‐tailed	   t-­‐test.	   C.	   ospC	   promoter	  
activity	  in	  B.	  burgdorferi	  B312	  (-­‐lp17)	  and	  B312_lp17.8	  (+lp17)	  monitored	  by	  a	  lacZ	  
reporter	   gene.	   	   Beta-­‐galactosidase	   activity	   in	   B.	   burgdorferi	   transformed	   with	   a	  
shuttle	  vector	  carrying	  a	  lacZ	  reporter	  gene	  fused	  to	  the	  ospC	  promoter	  (pBHospCp-­‐
lacZBb*)	   was	   detected	   by	   the	   addition	   of	   X-­‐Gal	   to	   solid	   BSKII	   medium	   without	  
phenol	   red,	   resulting	   in	   blue	   B312	   colonies	   (left),	   whereas	   B312_lp17.8	   colonies	  
remained	  white	  (right).	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harboring	  lp17	  relative	  to	  the	  original	  B312	  clone	  lacking	  lp17	  (Figure	  3-­‐1B).	  These	  
data	  suggest	   that	   lp17	  negatively	   regulates	  OspC	  production	  at	   the	   transcriptional	  
level.	  	  	  
ospC	  transcription	  in	  B312	  as	  monitored	  with	  a	  lacZ	  reporter	  gene	  
We	  recently	  developed	  a	   lacZ	  reporter	  system	  for	  B.	  burgdorferi	  and	  used	  it	  
to	  analyze	  ospC	   gene	  expression	   in	  various	  B31	  clones,	   including	  B312	   (Chapter	  1	  
and	  (41)).	  To	  confirm	  that	  introduction	  of	  lp17	  uniformly	  inhibited	  ospC	  expression	  
in	  the	  B312	  background,	  we	  monitored	  ospC	  promoter	  activity	  with	  a	  lacZ	  reporter	  
construct,	   pBHospCp-­‐lacZBb*,	   using	   a	   blue/white	   colony	   screen	   to	   assay	   β-­‐
galactosidase	  activity	  in	  a	  large	  numbers	  of	  transformants.	  B312	  colonies	  harboring	  
pBHospCp-­‐lacZBb*	  turned	  blue	  after	  treatment	  with	  X-­‐gal	  (Figure	  3-­‐1C),	  indicating	  
expression	   from	   the	   ospC	   promoter	   and	   production	   of	   an	   active	   β-­‐galactosidase	  
enzyme,	  as	  reported	  previously	  (Chapter	  1	  and	  ref	  (41)).	  However,	   introduction	  of	  
pBHospCp-­‐lacZBb	   into	  B312_17.8	   resulted	   in	  most	   colonies	   remaining	  white	   after	  
incubation	   with	   X-­‐gal	   (Figure	   3-­‐1C).	   We	   confirmed	   the	   presence	   of	   pBHospCp-­‐
lacZBb*	  in	  these	  colonies	  by	  PCR,	  suggesting	  that	  a	  factor	  encoded	  by	  lp17	  repressed	  
lacZBb	  expression	  from	  the	  ospC	  promoter	  in	  B312_17.8.	  Although	  we	  did	  detect	  a	  
few	  blue	  colonies	  in	  B312_17.8	  harboring	  pBHospCp-­‐lacZBb	  (Figure	  3-­‐1C),	  this	  was	  
a	  rare	  occurrence	  (~1	   in	  250).	  These	  blue	  colonies	  retained	   lp17,	  as	  confirmed	  by	  
PCR,	   and	   had	   the	   same	   ospC	   promoter	   sequence	   as	   the	   lacZ	   reporter	   construct	  
present	   in	   white	   colonies,	   potentially	   indicating	   a	   mutation	   in	   the	   putative	   ospC	  
repressor	  or	  variation	  in	  some	  other	  component	  of	  ospC	  regulation	  (see	  Discussion).	  	  
Effect	  of	  truncated	  lp17	  upon	  OspC	  production	  by	  B312	  in	  vitro.	  
These	  initial	  observations	  support	  the	  hypothesis	  that	  sequences	  carried	  by	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Figure	  3-­‐2:	  Introduction	  of	  truncated	  and	  cloned	  segments	  of	  lp17	  into	  B312	  and	  the	  
resulting	  OspC	  phenotype.	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Figure	   3-­‐2	   legend:	   A.	   Schematic	   diagram	   of	   truncated	   forms	   of	   lp17	   created	   by	  
insertion	  of	  replicated	  telomeres	  (40).	  lp17	  sequences	  are	  deleted	  to	  the	  left	  of	  the	  
insertion	  point	  for	  pGCB413	  (red	  arrowhead	  above	  diagram)	  and	  to	  the	  right	  of	  the	  
insertion	  points	  for	  pGCB409,	  pGCB426	  and	  pGCB473	  (yellow	  arrowheads	  beneath	  
diagram).	   Light	   shading	   indicates	   lp17	   sequences	   that	   are	   not	   present	   in	   the	  
respective	   lp17	   truncated	  variants.	  Gene	  designations	  are	  as	  previously	  annotated	  
(49,	   50).	   The	   presence	   (+)	   or	   absence	   (-­‐)	   of	   OspC	   in	   protein	   lysates	   of	   B312	  
transformants	  carrying	  different	  truncated	  forms	  of	  lp17	  is	  indicated	  to	  the	  right	  of	  
each	   plasmid	   diagram.	  B.	   OspC	   immunoblots	   of	   B312	   and	   transformants	   carrying	  
truncated	  forms	  of	  lp17,	  and	  the	  ospCK1	  mutant.	  	  Whole	  cell	  lysates	  of	  B.	  burgdorferi	  
strains,	   as	   identified	   at	   the	   top	   of	   each	   lane,	   were	   separated	   by	   SDS-­‐PAGE	   and	  
analyzed	   by	   immunoblot	  with	   anti-­‐OspC	   antiserum.	  C.	   Schematic	   diagram	   of	   lp17	  
sequences	  introduced	  on	  the	  shuttle	  vector	  pBSV2*.	  The	  presence	  (+)	  or	  absence	  (-­‐)	  
of	  OspC	   in	  protein	   lysates	  of	  B312	   transformants	   carrying	   these	   shuttle	  vectors	   is	  
indicated	   to	   the	   right	  of	   each	  plasmid	  diagram.	  The	  number	   in	  parentheses	   to	   the	  
left	   of	   each	   diagram	   corresponds	   with	   the	   lane	   designation	   in	   the	   immunoblot	  
panels	   shown	   below.	   NP,	   native	   promoter;	   flaBp,	   constitutive	   promoter.	  D.	   OspC,	  
BBD18	  and	  FlaB	  immunoblots	  of	  B.	  burgdorferi.	  Whole	  cell	  lysates	  of	  B.	  burgdorferi	  
wild	  type	  clone	  B31-­‐A3	  (lane	  1),	  high	  passage	  clone	  B312	  (lane	  2),	  B312+pBSV2*-­‐7’	  
(lane	   3),	   B312+pBSV2*-­‐NP-­‐bbd18	   (lane	   4),	   B312+pBSV2*flaB-­‐bbd18	   (lane	   5)	   and	  
B312+pBSV2*bbd18	   (lane	   6)	   were	   analyzed	   by	   immunoblot	   with	   antisera	  
recognizing	  OspC,	  BBD18	  and	  FlaB,	  as	  indicated.	  The	  estimated	  sizes	  of	  the	  proteins	  
recognized	  in	  each	  immunoblot,	  relative	  to	  the	  mobilities	  of	  standards,	  are	  indicated	  
to	  the	  right	  of	  each	  panel.	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lp17	  repress	  ospC	  transcription.	  In	  order	  to	  narrow	  down	  the	  putative	  lp17	  gene(s)	  
responsible	   for	   this	   effect,	   we	   utilized	   several	   lp17	   deletion	   variants	   previously	  
generated	   by	   Beaurepaire	   and	   Chaconas	   (Figure	   3-­‐2A)	   (40).	   These	   terminally	  
truncated	   forms	   of	   lp17	   were	   constructed	   by	   insertion	   of	   a	   synthetic	   replicated	  
telomere	   at	   various	   points	   along	   the	   plasmid	   and	   subsequent	   cleavage	   by	   the	  
endogenous	   telomere	   resolvase,	   with	   recovery	   of	   the	   lp17	   fragment	   that	   retains	  
essential	  replication	   functions	  and	  the	  selectable	  marker	  (40).	  We	  anticipated	  that	  
transformation	   of	   B312	   with	   a	   segment	   of	   lp17	   harboring	   the	   putative	   ospC	  
repressor	  gene	  would	  result	  in	  reduced	  OspC	  production,	  similar	  to	  what	  was	  found	  
with	   the	   full-­‐length	   plasmid.	   Conversely,	   introduction	   of	   an	   lp17	   deletion	   variant	  
that	   lacks	   the	   ospC	   repressor	  would	   not	   diminish	   ospC	   expression	   in	   B312.	   Thus,	  
comparing	  the	  OspC	  phenotype	  of	  B312	  transformants	  carrying	  different	  segments	  
of	   lp17	   would	   highlight	   the	   region	   of	   lp17	   sufficient	   for	   repression	   of	   ospC	   and	  
thereby	   facilitate	   subsequent	   identification	   of	   the	   sequences	   responsible	   for	   this	  
effect.	  	  
	   We	  confirmed	   the	   structures	  of	   the	   lp17	  variants	   in	   four	   clones,	  GCB409,	  
GCB413,	  GCB426	  and	  GCB473,	  whose	  deletions	   extend	   in	   from	  either	   the	   right	  or	  
left	   telomeres	   of	   the	   plasmid	   (Figure	   3-­‐2A)	   (40).	   Results	   obtained	   by	   PCR	  
amplification	   with	   primers	   targeting	   different	   regions	   of	   lp17,	   and	   Southern	   blot	  
hybridization	  with	  probes	  for	  the	  left	  and	  right	  halves	  of	  lp17,	  were	  consistent	  with	  
the	  predicted	  sizes	  and	  structures	  of	  the	  deleted	  forms	  of	  these	  plasmids	  (Dr.	  Sarkar	  
personal	  communication	  and	  see	  Figure	  4-­‐4).	  
	   Transformation	   of	   B312	   with	   these	   truncated	   forms	   of	   lp17	   had	   varying	  
effects	  on	  OspC	  synthesis	  depending	  upon	  which	   lp17	  sequences	  were	   introduced	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(Figure	  3-­‐2B).	  The	   complete	  plasmid	   content	  of	   each	  B312	   transformant	  was	  also	  
determined	   by	   PCR	   (36)	   to	   confirm	   that	   no	   plasmids	   other	   than	   lp17	   had	   been	  
introduced.	   Taken	   together,	   these	   data	   are	   consistent	  with	   negative	   regulation	   of	  
ospC	   by	   an	   internal	   segment	   of	   lp17.	   Particularly	   informative	   were	   truncations	  
extending	   in	   from	   the	   right	   telomere	   of	   lp17,	   which	   resulted	   in	   the	   complete	  
absence	  of	  OspC	  in	  B312	  harboring	  bbd1-­‐23	  (pGCB409)	  or	  bbd1-­‐19	  (pGCB426),	  yet	  
abundant	   OspC	   production	   in	   B312	   containing	  bbd1-­‐14	   (pGCB473)	   (Figure	   3-­‐2B).	  
These	   results	   suggest	   that	   the	   bbd15-­‐19	   segment	   of	   lp17	   can	   repress	   ospC	  
expression.	  
Effect	  of	  BBD18	  on	  ospC	  expression	  
	   To	   test	   this	   hypothesis	   directly,	   the	   implicated	   ~2.7kb	   fragment	   of	   lp17	  
was	  cloned	  into	  the	  shuttle	  vector	  pBSV2*	  and	  introduced	  into	  B312,	  in	  the	  absence	  
of	  other	  lp17	  sequences.	  As	  predicted,	  B312	  transformants	  harboring	  the	  bbd15-­‐19	  
segment	  of	  lp17	  (pBSV2*-­‐7’)	  no	  longer	  synthesize	  OspC	  (Figure	  3-­‐2C	  and	  D).	  These	  
data	   indicate	   that	   gene(s)	   or	   sequences	   in	   this	   region	   of	   lp17	   either	   directly	   or	  
indirectly	  lead	  to	  repression	  of	  ospC.	  The	  lp17	  sequences	  introduced	  on	  the	  shuttle	  
vector	   were	   further	   limited	   to	   those	   encompassing	   only	   bbd18,	   the	   largest	   open	  
reading	  frame	  in	  this	  region,	  with	  or	  without	  a	  promoter	  (Figure	  3-­‐2C).	  As	  shown	  by	  
immunoblot	   analysis	   in	   Figure	   3-­‐2D,	   expression	   of	   bbd18,	   from	   either	   its	   native	  
promoter	   or	   the	   constitutive	   flaB	   promoter,	   inversely	   correlated	   with	   ospC	  
expression	   in	   clone	   B312.	   Introduction	   of	   the	   promoterless	   bbd18	   gene	   did	   not	  
diminish	  ospC	  expression.	  These	  data	  demonstrate	  that	  expression	  of	  bbd18	  in	  clone	  
B312	  results	  in	  repression	  of	  ospC.	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   We	  have	  demonstrated	  that	  the	  ospC	  promoter-­‐lacZBb	  reporter	  accurately	  
reflects	  expression	  of	  the	  native	  ospC	  gene	  in	  B312	  (Chapter	  2,	  Figures	  2-­‐6,	  2-­‐7,	  and	  
3-­‐1C	  and	  ref	  (41)).	  To	  investigate	  whether	  repression	  of	  ospC	  by	  BBD18	  is	  direct	  or	  
mediated	   through	   another	   B.	   burgdorferi	   factor,	   we	   utilized	   the	   ospC	   promoter-­‐
lacZBb	   reporter	   in	   E.	   coli	   and	   introduced	   constitutively	   expressed	   bbd18	   on	   a	  
compatible	   plasmid.	   Conducting	   this	   experiment	   in	   a	   heterologous	   host	   in	   the	  
absence	  of	  other	  Borrelia	  factors	  permits	  a	  clearer	  assessment	  of	  the	  mechanism	  of	  
ospC	  repression	  by	  BBD18.	  Surprisingly,	  synthesis	  of	  BBD18	  did	  not	  diminish	  ospC	  
promoter	   activity	   in	   E.	   coli,	   as	   monitored	   by	   colony	   color	   (Figure	   3-­‐3A).	   In	   a	  
quantitative	   assay	   for	   β-­‐galactosidase	   activity	   in	   liquid	   cultures	   (Figure	  3-­‐3C),	   the	  
expression	   of	   BBD18	   led	   to	   lower	   overall	   activity	   units	   per	  mg	   protein.	  However,	  
this	  was	  not	  specific	  to	  the	  ospC	  promoter,	  as	  lacZ	  expressed	  from	  the	  flaB	  promoter	  
was	   also	   affected.	   This	   is	   likely	   just	   an	   artifact	   of	   how	  we	   report	   β-­‐galcatosidase	  
activity	   since	   we	   normalize	   to	   total	   mg	   protein	   in	   the	   lysate.	   Regardless,	   lacZBb	  
expression	  and	  corresponding	  β-­‐galactosidase	  activity	  from	  the	  ospC	  promoter	  was	  
significantly	  above	  activity	  from	  the	  promoter-­‐less	  lacZBb	  (pBH-­‐lacZBb)	  even	  when	  
BBD18	  was	  produced	   (Figure	  3-­‐3C),	   indicating	  BBD18	   is	  unable	   to	   repress	   lacZBb	  
expression	  from	  the	  ospC	  promoter	  in	  E.	  coli.	  While	  preliminary,	  these	  data	  suggest	  
an	  indirect	  mechanism	  of	  repression	  of	  ospC	  by	  BBD18	  in	  B.	  burgdorferi.	  	  
	  
Discussion	  
In	   this	   study,	  we	   have	   confirmed	   the	   hypothesis	   that	   the	   presence	   of	   lp17	  
negatively	  influences	  expression	  of	  ospC	  in	  a	  highly	  attenuated	  B.	  burgdorferi	  clone,	  
B312.	  By	  restoring	  all	  or	  part	  of	  the	  lp17	  plasmid,	  we	  have	  shown	  that	  a	  ~2.7	  kb	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Figure	  3-­‐3:	  Assessing	  BBD18-­‐mediated	  repression	  of	  the	  ospC	  promoter	  in	  E.	  coli.	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Figure	  3-­‐3	   legend:	  A.	  ospC	  promoter-­‐lacZBb*	  expression	   in	  E.	  coli	  as	  monitored	  by	  
colony	   color.	   Reporter	   constructs	   carrying	   lacZBb*,	   with	   or	   without	   the	   ospC	  
promoter	   (as	   identified	   at	   the	   left	   side	   of	   the	   figure),	  were	   introduced	   into	  E.	   coli	  
that	   harbored	   or	   lacked	   a	   second	   plasmid	   with	   a	   constitutively	   expressed	   bbd18	  
gene	  (as	  designated	  at	  the	  top	  of	  the	  figure)	  and	  streaked	  on	  plates	  containing	  X-­‐gal.	  
Expression	  of	  lacZBb*	  from	  the	  ospC	  promoter	  in	  the	  presence	  or	  absence	  of	  BBD18	  
resulted	   in	   blue	  bacterial	   colonies	   (bottom	  panels),	  whereas	  bacteria	   carrying	   the	  
promoter-­‐less	   lacZBb*	   formed	  white	   colonies	   in	  both	   conditions	   (top	  panels).	  The	  
number	   of	   each	   panel	   corresponds	   with	   the	   lane	   designation	   in	   the	   following	  
immunoblot.	  B.	  BBD18	  immunoblot	  of	  E.	  coli	  harboring	  plasmids	  with	  the	  following	  
genes:	   constitutively	   expressed	   flaBp::bbd18	   (lane	  1);	   promoter-­‐less	   lacZBb*	   (lane	  
2);	   ospC	   promoter-­‐lacZBb*	   (lane	   3);	   promoter-­‐less	   lacZBb*	   plus	   constitutively	  
expressed	   flaBp::bbd18	   (lane	   4);	   ospC	   promoter-­‐lacZBb*	   plus	   constitutively	  
expressed	   flaBp::bbd18	   (lane	   5).	   The	   estimated	   size	   of	   BBD18	   relative	   to	   the	  
mobilities	   of	   standards	   is	   indicated	   to	   the	   right	   of	   the	   immunoblot.	   C.	   Modified	  
Miller	   ONPG	   assays	   (53)	  were	   performed	   on	  E.	   coli	  harboring	   plasmids	   encoding	  
bbd18	   expressed	   from	   the	   flaB	   promoter	   and/or	   lacZBb	   without	   a	   promoter	   or	  
expressed	   from	   the	   flaB	   or	   ospC	   promoters,	   as	   indicated.	   β-­‐galactosidase	   activity	  
units	  (Miller	  units)	  are	  reported	  per	  mg	  protein	  and	   levels	  represent	  mean	  +/-­‐	  SD	  
(n=3).	   Background	   activity	   of	   bacteria	   without	   a	   plasmid	   was	   subtracted	   from	  
reported	  values.	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region	  of	  lp17	  is	  sufficient	  to	  repress	  ospC	  expression	  in	  clone	  B312,	  where	  all	  other	  
linear	  plasmids	  but	  lp54	  are	  missing.	  Furthermore,	  by	  introducing	  a	  subset	  of	  lp17	  
sequences	   from	   this	   region	   on	   a	   shuttle	   vector,	   we	   have	   demonstrated	   that	  
expression	  of	  the	  bbd18	  gene	  alone	  is	  sufficient	  to	  mediate	  ospC	  repression	  in	  clone	  
B312	  of	  B.	  burgdorferi.	  The	  protein	  or	  RNA	  product(s)	  encoded	  by	  bbd18	   exerts	  a	  
negative	   effect	   on	   ospC	   expression,	   and	   could	   act	   directly,	   by	   binding	   to	   the	  ospC	  
promoter	   and	   blocking	   transcription,	   or	   indirectly,	   by	   altering	   the	   expression	   of	  
other	  genes	  that	  regulate	  ospC	  expression.	  	  If	  working	  indirectly,	  BBD18	  could	  either	  
repress	   an	   activator	   or	   induce	   a	   repressor	   of	   ospC	   expression.	   All	   of	   these	  
possibilities	  would	   result	   in	   an	  OspC-­‐negative	  phenotype	   of	  B312	  when	  BBD18	   is	  
present,	  whereas	  OspC	  synthesis	  would	  continue	  in	  its	  absence.	  
Initial	   results	   obtained	   with	   an	   ospC	   promoter-­‐	   lacZBb	   reporter	   in	   a	  
heterologous	  host	  support	  an	  indirect	  role	  for	  BBD18	  in	  regulating	  ospC	  expression	  
(Figure	  3-­‐3).	  E.	  coli	   carrying	  both	   the	  ospC	   promoter	  driving	   expression	  of	   lacZBb	  
and	   a	   constitutively	   expressed	  bbd18	  gene	   form	   blue	   colonies,	   indicating	   that	   the	  
lacZBb	  gene	  continues	  to	  be	  expressed	  from	  the	  ospC	  promoter	  even	  in	  the	  presence	  
of	  BBD18	  protein.	  A	  caveat	  to	  this	  experiment	  is	  the	  possibility	  that	  a	  B.	  burgdorferi	  
co-­‐factor	  or	  modification	  not	  present	  in	  E.	  coli	  could	  be	  required	  for	  BBD18	  to	  bind	  
the	   ospC	   promoter	   and	   block	   transcription.	   Alternatively,	   the	   amount	   of	   BBD18	  
protein	  made	  by	  E.	  coli	  (Figure	  3-­‐3B)	  may	  be	  insufficient	  or	  unavailable	  for	  efficient	  
repression	  of	  the	  ospC	  promoter	  on	  a	  multi-­‐copy	  plasmid.	  As	  a	  working	  model	  that	  
accommodates	   the	   available	   data,	   however,	   we	   propose	   that	   BBD18	   indirectly	  
regulates	  ospC	  through	  induction	  of	  a	  repressor	  that	  binds	  to	  the	  ospC	  promoter	  and	  
blocks	  transcription	  (Figure	  3-­‐4).	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Figure	  3-­‐4:	  Proposed	  model	  of	  ospC	   regulation	   in	  wild	   type	  and	  B312	  strains	  of	  B.	  
burgdorferi	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Figure	   3-­‐4	   legend:	   Activation	   of	   the	   response	   regulator	   Rrp2	   in	   wild	   type	   B.	  
burgdorferi	   by	   environmental	   signals	   present	   during	   tick	   feeding	   leads	   to	   rpoS	  
transcription	  through	  the	  alternative	  sigma	  factor	  RpoN	  (σ54),	  which	  interacts	  with	  
RNA	   polymerase	   (RNAP)	   (18,	   19).	   	   RpoS	   in	   turn	   positively	   regulates	   ospC	  
transcription,	  resulting	  in	  OspC	  on	  the	  spirochete’s	  outer	  membrane	  during	  a	  critical	  
initial	  stage	  of	  mammalian	  infection	  (8,	  18).	  Persistent	  infection	  of	  mammals	  by	  wild	  
type	   B.	   burgdorferi	   requires	   specific	   repression	   of	   ospC	   to	   evade	   host	   acquired	  
immunity	  (15).	  Clone	  B312	  constitutively	  synthesizes	  OspC	  in	  the	  absence	  of	  stimuli	  
typically	   required	   for	   induction	   in	   wild	   type	   B.	   burgdorferi.	   Likewise,	   bbd18	   is	  
constitutively	   expressed	   when	   lp17	   is	   restored	   to	   B312,	   resulting	   in	   ospC	  
repression.	  Inverted	  arrowheads	   	  ( )	   indicate	  putative	  operator	  site	  upstream	  
of	  ospC.	  Parts	  of	  this	  figure	  are	  closely	  modeled	  after	  a	  figure	  by	  Burtnick	  et	  al.	  (54).	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   During	   the	   in	  vivo	   infectious	  cycle,	   synthesis	  of	  OspC	   is	   induced	  during	   tick	  
feeding	  and	  present	  at	  the	  initiation	  of	  mammalian	  infection	  (6),	  but	  subsequently	  	  
downregulated	  to	  avoid	  immune	  clearance,	  presumably	  through	  a	  repressor	  (11-­‐13,	  
15,	  26,	  27,	  55-­‐57).	  During	   in	  vitro	  growth,	  most	  B.	  burgdorferi	  sensu	  strictu	   strains	  
do	  not	  synthesize	  OspC	  unless	  culture	  conditions	  are	  altered	  to	  simulate	  tick	  feeding	  
and	   the	   early	   stage	   of	   mammalian	   infection	   (6),	   resulting	   in	   induction	   of	   the	  
Rrp2/RpoN/RpoS	   regulatory	   cascade	   (18,	   19,	   58).	   However,	   clone	   B312,	   which	  
lacks	   many	   plasmids,	   constitutively	   synthesizes	   OspC	   without	   manipulation	   of	  
culture	  conditions,	  yet	  has	  an	  ospC	  promoter	  identical	  to	  that	  of	  wt	  B31.	  Two	  unique	  
features	  of	  B312	  can	  be	  invoked	  to	  place	  the	  role	  of	  BBD18	  within	  the	  context	  of	  our	  
current	  understanding	  of	  ospC	  regulation	  in	  wt	  B.	  burgdorferi.	  First,	  RpoS	  should	  be	  
induced	  in	  B312.	  Second,	  the	  putative	  ospC	  repressor	  should	  be	  made	  or	  activated	  in	  
B312	   when	   lp17	   (bbd18)	   is	   present.	   Typically,	   transient	   induction	   of	   RpoS	   by	  
shifting	  the	  temperature,	  pH	  or	  growth	  phase	  of	  cultures	   is	  needed	  to	   induce	  ospC	  
expression	   in	   infectious	  B31	  clones	  carrying	   lp17	  (Figure	  3-­‐4),	   indicating	   that	   in	  a	  
wt	   background,	   RpoS	   is	  made	   only	   under	   certain	   culture	   conditions	   and	   that	   the	  
repressor	   is	   not	   made	   (28,	   58).	   However,	   a	   constitutively	   activated	   RpoN-­‐RpoS	  
pathway	   also	   has	   been	   observed	   in	   some	   ospA/B	   mutants	   (59).	   We	   suggest	   that	  
regulation	   of	   ospC	   in	   wt	   B.	   burgdorferi	   reflects	   a	   multi-­‐layered	   network	   of	   both	  
conditionally	   regulated	   and	   stochastic	   elements,	   as	   illustrated	   by	   the	   mixed	  
phenotypic	   response	   of	   individual	   spirochetes	   in	   an	   isogenic	   B.	   burgdorferi	  
population	  exposed	   to	   the	   same	  environmental	   stimuli	   (7).	  Plasmids	   lost	  by	  B312	  
presumably	   encode	   factors	   that	   contribute	   to	   other	   levels	   of	   ospC	   and	   bbd18	  
regulation,	  both	  global	  and	  gene-­‐specific.	  The	  rpoS-­‐induced,	  ospC-­‐repressed	  state	  of	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B312	   carrying	   lp17	   fortuitously	   mimics	   the	   phenotypic	   state	   of	   wild-­‐type	   B.	  
burgdorferi	   during	   persistent	   mammalian	   infection,	   which	   presents	   a	   unique	  
opportunity	  to	  investigate	  ospC	  repression	  in	  vitro.	   	  
The	  bbd18	  locus	  on	  lp17	  implicated	  in	  ospC	  regulation	  encodes	  a	  single	  open	  
reading	  frame	  in	  the	  annotated	  B31	  sequence	  (49,	  50).	  Database	  searches	   indicate	  
that	  bbd18	   is	  well	   conserved	   among	   diverse	  B.	   burgdorferi	   sensu	   lato	   strains	   and	  
that	  related	  sequences	  are	  present	  in	  at	  least	  some	  relapsing	  fever	  Borrelia,	  but	  do	  
not	   identify	  any	  homologs	  of	  known	  or	  unknown	  function	  in	  other	  organisms.	  The	  
predicted	   BBD18	   protein	   has	   a	   fairly	   high	   percentage	   of	   charged	   (29%)	   and	  
aromatic	   (11%)	  amino	  acid	   residues,	   comprising	  a	  basic	  protein	  with	  a	  molecular	  
mass	  of	  25,729	  daltons	  and	  an	   isoelectric	  point	  (pI)	  of	  9.39.	  Structural	  predictions	  
suggest	  a	  predominantly	  alpha-­‐helical	  protein	  with	  a	  few	  beta-­‐sheets,	  connected	  by	  
a	   number	   of	   coiled	   regions.	   	   Although	   the	   general	   characteristics	   and	   predicted	  
structure	   of	   BBD18	   are	   compatible	   with	   DNA	   interaction,	   analyses	   of	   the	   BBD18	  
sequence	  using	  Pfam	  and	  InterPro	  databases	  (60,	  61)	  do	  not	  reveal	  homology	  with	  
known	  DNA-­‐binding	   proteins,	  DNA-­‐binding	   domains	   or	   transcriptional	   regulators.	  
Ongoing	  studies	  will	  determine	   if	   the	  entire	  BBD18	  open	  reading	   frame	   is	  needed	  
for	   ospC	   repression	   in	   B.	   burgdorferi	   and	   whether	   BBD18	   can	   bind	   DNA	   in	   a	  
sequence-­‐specific	  manner.	  
	  In	   this	   study,	  we	   utilized	   a	   recently	   developed	   lacZ	   reporter	   system	   for	  B.	  
burgdorferi	   (Chapter	  1	   and	   (41))	   to	  demonstrate	   that	  bbd18	   regulates	  ospC	   at	   the	  
transcriptional	   level,	   perhaps	   indirectly.	   We	   are	   currently	   using	   this	   tool	   in	  
conjunction	   with	   other	   approaches	   to	   delineate	   which	   promoter	   sequences	   are	  
responsible	   for	   BBD18-­‐mediated	   repression	   of	   ospC	   in	   B312.	   	   Subsequent	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experiments	  will	  determine	  whether	  deletion	  of	  bbd18	   in	  wt	  B31	  clones	  results	   in	  
continued	   ospC	   expression	   in	   vivo	   and	   abrogation	   of	   persistent	   B.	   burgdorferi	  
infection,	   as	   predicted.	   Ultimately,	   this	   combined	   in	   vitro	   and	   in	   vivo	   approach	  
should	  elucidate	  the	  molecular	  mechanisms	  by	  which	  the	  essential	  virulence	  factor	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The	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   presented	   in	   this	   chapter	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  conducting	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  tick	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Abstract	  
In	  order	   to	  cause	   infection	   in	  mammals,	  B.	  burgdorferi	   spirochetes	  within	  a	  
feeding	   tick	   sense	   environmental	   changes	   and	   subsequently	   alter	   their	   gene	  
expression	   and	   protein	   profiles.	   The	   induction	   of	   the	   Rrp2-­‐RpoN-­‐RpoS	   cascade	   is	  
central	   to	   this	   adaptive	   response	   and	   is	   required	   for	   the	   upregulation	   of	   genes	  
important	  for	  mammalian	  infection,	  including	  outer	  surface	  protein	  (Osp)	  C.	  OspC	  is	  
required	   for	   early	   infection	   but	   is	   also	   a	   target	   of	   the	   host’s	   adaptive	   immune	  
system,	  and	   thus	  OspC	   is	   repressed	  soon	  after	  B.	  burgdorferi	   establishes	   infection.	  
Previously,	  we	  identified	  BBD18	  as	  a	  repressor	  of	  OspC	  in	  a	  non-­‐infectious	  clone	  of	  
B.	   burgdorgeri.	  Here,	  we	  have	   investigated	   the	   role	  of	  bbd18	  during	   the	   infectious	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cycle	  by	  constitutively	  expressing	  or	   inactivating	  bbd18	   in	  an	  infectious	  clone	  of	  B.	  
burgdorferi.	  We	  show	   that	   spirochetes	  harboring	  a	   constitutively	  expressed	  bbd18	  
are	  non-­‐infectious	  in	  mice	  by	  needle	  inoculation	  and	  tick	  bite,	  presumably	  because	  
they	  do	  not	  induce	  OspC.	  In	  contrast,	  B.	  burgdorferi	  lacking	  bbd18	  (and	  other	  genes	  
on	  the	  right	  end	  of	  lp17)	  can	  establish	  infection	  and	  persist	  in	  the	  mouse	  model	  but	  
show	   a	   defect	   in	   tissue	   colonization.	   Using	   in	   vitro	   approaches,	  we	   show	   that	   the	  
putative	   ospC	   operator	   is	   not	   required	   for	   ospC	   repression	   by	   BBD18	   and	   that	  
production	  of	  BBD18	  affects	  expression	  of	  other	  RpoS-­‐dependent	  genes	  in	  addition	  
to	  OspC.	  Site-­‐directed	  mutagenesis	  within	  a	  proposed	  nucleic	  acid-­‐binding	  domain	  
in	  BBD18	  abrogates	  its	  ability	  to	  repress	  OspC	  and	  prevent	  infection	  in	  mice	  when	  
constitutively	  expressed.	  Together	  these	  data	  demonstrate	  that	  irregular	  regulation	  
of	  BBD18	  alters	  the	  infectivity	  of	  B.	  burgdorferi	  and	  suggest	  that	  regulation	  of	  RpoS-­‐
dependent	   genes	   by	   BBD18	   might	   occur	   through	   putative	   BBD18-­‐nucleic	   acid	  
interactions.	   We	   propose	   that	   BBD18	   is	   a	   novel	   plasmid-­‐encoded	   player	   in	   the	  
control	  of	  the	  RpoS	  regulon,	  which	  is	  critical	  for	  B.	  burgdorferi	  to	  establish	  infection	  
in	  mammals.	  	  
	  
Introduction	  
The	   causative	   agent	   of	   Lyme	   disease,	   Borrelia	   burgdorferi	   (1-­‐3),	   is	  
maintained	  in	  an	  enzoonotic	  cycle	  involving	  Ixodes	  ticks	  and	  mammalian	  hosts	  (4).	  	  
Persistence	  in	  this	  cycle	  requires	  B.	  burgdorferi	  to	  sense	  environmental	  changes	  and	  
alter	   its	   gene	   expression	   and	   protein	   profiles.	   	   A	   key	   example	   of	   this	   adaptation	  
occurs	  when	  infected	  ticks	  take	  in	  a	  blood	  meal	  and	  spirochetes	  in	  the	  tick	  midgut	  
upregulate	   Outer	   surface	   protein	   (Osp)	   C,	   which	   prepares	   B.	   burgdorferi	   for	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transmission	  to	  the	  mammalian	  host	  (5-­‐7).	  Our	   laboratory	  previously	  showed	  that	  
B.	  burgdorferi	  mutants	  lacking	  a	  functional	  OspC	  are	  non-­‐infectious	  by	  tick	  bite	  (8-­‐
11).	  However,	  OspC	  is	  also	  a	  target	  for	  neutralizing	  antibodies	  and	  ospC	  expression	  
is	   downregulated	   after	   B.	   burgdorferi	   establishes	   infection	   in	   order	   to	   avoid	  
clearance	  by	  the	  host’s	  adaptive	  immune	  response	  (12-­‐15).	  	  
	   Spirochetes	   within	   a	   feeding	   tick	   experience	   a	   change	   in	   temperature,	   pH,	  
and	   other	   host	   factors,	   which	   leads	   to	   induction	   of	   the	   RpoN-­‐RpoS	   regulatory	  
pathway	   (16-­‐19).	   This	   cascade	   is	   responsible	   for	   the	   upregulation	   of	   genes	  
associated	  with	  mammalian	  infection,	  including	  ospC	  (20-­‐25).	  However,	  while	  ospC	  
is	   repressed	   to	   avoid	   immune	  pressure,	   other	  RpoS-­‐induced	   genes	   continue	   to	   be	  
expressed	  throughout	  infection	  (26,	  27).	  These	  observations	  lead	  to	  the	  hypothesis	  
that	  a	  specific	  mechanism	  is	  required	  to	  repress	  ospC	  (12).	  
Previous	   work	   by	   Xu	   et	   al.	   showed	   that	   an	   inverted	   repeat	   sequence	   or	  
putative	   operator,	   upstream	   of	   the	   ospC	   promoter,	   was	   necessary	   for	   in	   vivo	  
repression	   of	   ospC.	   B.	   burgdorferi	   mutants	   lacking	   this	   palindromic	   sequence	  
successfully	   established	   infection	   in	  mice	   but	   subsequently	   were	   cleared	   by	   anti-­‐
OspC	   neutralizing	   antibodies,	   presumably	   because	   the	   spirochetes	   could	   not	  
downregulate	   ospC	   expression	   (28,	   29).	   More	   recently,	   our	   lab	   described	   a	   novel	  
gene	  on	  lp17,	  bbd18,	  that	  when	  expressed	  led	  to	  the	  downregulation	  of	  ospC	  at	  the	  
transcriptional	  level	  (30).	  Because	  our	  previous	  work	  with	  BBD18	  was	  conducted	  in	  
the	  non-­‐infectious	  B.	  burgdorferi	  clone	  B312,	  we	  wanted	  to	  confirm	  that	  BBD18	  can	  
repress	   OspC	   in	   a	   wild-­‐type	   (wt)	   clone	   and	   investigate	   the	   role	   of	   BBD18	   in	   the	  
infectious	   cycle.	   More	   specifically,	   we	   were	   interested	   in	   whether	   BBD18	   is	   the	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invoked	  in	  vivo	  repressor	  that	  binds	  to	  the	  palindromic	  sequence	  described	  by	  Xu	  et	  
al.	  (28).	  
During	   the	   course	   of	   these	   studies,	   Casselli	   et	   al.	   demonstrated	   that	   B.	  
burgdorferi	  clones	  carrying	  a	  truncated	  version	  of	  lp17	  lacking	  a	  6.7kB	  segment	  that	  
encompasses	  bbd18	  were	  able	  to	  establish	  infection	  in	  mice,	  but	  had	  delayed	  tissue	  
colonization.	  They	  also	  reported	  that	  these	  clones,	  which	  lack	  bbd18,	  had	  increased	  
OspC	  production	  and	  that	  restoration	  of	  bbd18	  reversed	  this	  in	  vitro	  phenotype	  (31).	  
These	   results	   are	   not	   wholly	   inconsistent	   with	   our	   hypothesis	   that	   BBD18	   is	  
responsible	  for	  repression	  of	  ospC	  during	  the	  infectious	  cycle.	  Here,	  we	  have	  taken	  a	  
different	  approach	  and	  determined	  the	  effect	  of	  a	  constitutively	  expressed	  bbd18	  on	  
mammalian	  infectivity	  and	  tick	  transmission.	  We	  have	  also	  used	  the	  lacZ	  expression	  
system	   in	   B.	   burgdorferi	   (32),	   as	   well	   as	   other	   direct	   and	   indirect	   techniques,	   to	  
further	  investigate	  the	  mechanism	  of	  ospC	  repression	  by	  BBD18.	  	  
	  
Material	  and	  Methods	  
All	   chemicals	   and	   materials	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   MO)	  
unless	  otherwise	  specified.	  
Bacterial	  Strains	  and	  Growth	  Conditions.	  	  
B.	   burgdorferi	   strains	   (Table	   4-­‐1)	   were	   inoculated	   from	   frozen	   stocks	   into	  
Barbour-­‐Stoenner-­‐Kelly	   (BSK	   II)	  medium	  (33)	  with	  or	  without	  phenol	   red	   (32).	  B.	  
burgdorferi	  cultures	  were	  generally	  grown	  at	  35°C	  and	  plates	  were	  incubated	  under	  
2.5%	  CO2.	  Spirochetes	  were	  enumerated	  using	  dark-­‐field	  microscopy	  and	  a	  Petroff-­‐
Hausser	   counting	   chamber	   and	   prepared	   for	   electroporation	   as	   described	  
previously	  (34).	  Competent	  B.	  burgdorferi	  was	  transformed	  with	  ~10μg	  plasmid	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Table	  4-­‐1	  Strains	  and	  Plasmids	  Used	  in	  Chapter	  Four	  
strain	  or	  plasmid	   Description	   Reference	  
B.	  burgdorferi	  strains	  
B31-­‐S9	  (S9)	   infectious,	  bbe02	  mutant;	  derivative	  of	  B31-­‐A3-­‐68;	  streptomycin	  resistant	   (35)	  
S9/pBSV2*-­‐flaBp-­‐bbd18-­‐A	  
B31-­‐S9	  with	  bbd18	  under	  control	  of	  flaB	  promoter	  
on	  shuttle	  vector,	  lacks	  cp32-­‐1	  and	  lp28-­‐4;	  
kanamycin	  and	  streptomycin	  resistant	  
this	  study	  
S9/chase-­‐pBSV2G	  
derivative	  of	  B31-­‐S9/pBSV2*-­‐flaBp-­‐bbd18-­‐A	  in	  
which	  pBSV2G	  was	  used	  to	  displace	  pBSV2*-­‐flaBp-­‐
bbd18;	  gentamicin	  and	  streptomycin	  resistant	  
this	  study	  
S9/pBSV2*-­‐flaBp-­‐bbd18-­‐B	  
independent	  clone	  of	  B31-­‐S9	  with	  bbd18	  under	  
control	  of	  flaB	  promoter	  on	  	  shuttle	  vector,	  retains	  
full	  plasmid	  content	  of	  B31-­‐S9;	  kanamycin	  and	  
streptomycin	  resistant	  
this	  study	  
B31-­‐A/lp17::kan	   B31-­‐A	  derivative	  carrying	  pKK81	  integration	  on	  lp17;	  kanamycin	  resistant	   (36)	  
S9Δbbd18	  
S9	  derivative	  in	  which	  the	  bbd18	  ORF	  is	  disrupted	  
with	  flgBp-­‐aacC1	  through	  allelic	  exchange	  with	  
pOK12-­‐bbd18-­‐KO;	  streptomycin	  and	  gentamicin	  
resistant	  
this	  study	  
S9Δbbd18/lp17::kan	   S9Δbbd18	  complemented	  with	  lp17::kan;	  streptomycin	  and	  kanamycin	  resistant	   this	  study	  
S9Δbbd18/pBSV2*NP-­‐
bbd18	  
S9Δbbd18	  complemented	  with	  bbd18	  expressed	  
from	  its	  native	  promoter	  on	  a	  shuttle	  vector;	  
streptomycin,	  gentamicin,	  and	  kanamycin	  resistant	  
this	  study	  
S9/pGCB426	   S9	  derivative	  harboring	  the	  lp17	  truncation,	  pGCB426	  (bbd1-­‐20);	  kanamycin	  resistant	   this	  study	  
S9/pGCB473	   S9	  derivative	  harboring	  the	  lp17	  truncation,	  pGCB473	  (bbd1-­‐14);	  kanamycin	  resistant	   this	  study	  
B31-­‐A3	  (A3)	   Infectious	  clonal	  derivative	  of	  wild-­‐type	  B31-­‐MI,	  lacks	  cp9	   (37)	  
A3ΔrpoS	   rpoS	  mutant,	  derivative	  of	  B31-­‐A3;	  kanamycin	  resistant	   (37)	  
B312	   high-­‐passage	  non-­‐infectious	  B31	  clone,	  synthesizes	  OspC	  in	  vitro	  without	  manipulation	   (30,	  38)	  
B312/pBHospCp-­‐lacZBb*	  
B312	  derivative	  harboring	  lacZBb*	  on	  shuttle	  vector	  





B312	  derivative	  harboring	  lacZBb*	  on	  shuttle	  vector	  
under	  control	  of	  a	  minimal	  ospC	  promoter	  lacking	  





B312	  derivative	  harboring	  lacZBb*	  under	  the	  
control	  of	  an	  ospC-­‐flaB	  fusion	  promoter	  (-­‐35	  up	  to	  
+1	  of	  ospC	  promoter	  fused	  with	  +1	  to	  ATG	  of	  flaB	  




B312	  derivative	  harboring	  bbd18	  under	  control	  of	  






B312	  derivative	  with	  lacZBb*	  under	  control	  of	  ospC	  
promoter	  and	  bbd18	  under	  control	  of	  flaB	  promoter	  






B312	  derivative	  with	  lacZBb*	  under	  control	  of	  
minimal	  ospC	  promoter	  that	  lacks	  the	  palindromic	  
operator	  sequence	  and	  bbd18	  under	  control	  of	  flaB	  
promoter	  on	  compatible	  	  shuttle	  vectors;	  






B312	  derivative	  harboring	  lacZBb*	  under	  the	  
control	  of	  an	  ospC-­‐flaB	  fusion	  promoter	  (-­‐35	  up	  to	  
+1	  of	  ospC	  promoter	  fused	  with	  +1	  to	  ATG	  of	  flaB	  
promoter)	  and	  bbd18	  under	  control	  of	  flaB	  
promoter	  on	  compatible	  shuttle	  vectors;	  kanamycin	  
and	  gentamicin	  resistant	  
this	  study	  
B312/pBSV2G-­‐flaBp-­‐recA	  
B312	  derivative	  with	  recA	  under	  the	  control	  of	  the	  
flaB	  promoter	  on	  a	  shuttle	  vector;	  gentamicin	  
resistant	  
this	  study	  




B312	  derivative	  harboring	  wt	  bbd18	  under	  the	  
control	  of	  the	  constitutive	  flaB	  promoter	  on	  a	  




B312	  derivative	  harboring	  a	  bbd18	  variant	  (K58A,	  
S67A,	  C74A,	  K79A,	  D94A,	  and	  D96A)	  under	  the	  
control	  of	  the	  constitutive	  flaB	  promoter	  on	  a	  





B312	  derivative	  harboring	  a	  bbd18	  variant	  (N56A,	  
I57A,	  K58A,	  S66A,	  S67A,	  N69A,	  I70A,	  and	  M72A)	  
under	  the	  control	  of	  the	  constitutive	  flaB	  promoter	  




B312	  derivative	  harboring	  a	  bbd18	  variant	  (K58E,	  
K79E,	  D94R,	  and	  D96R)	  under	  the	  control	  of	  the	  





B312	  derivative	  harboring	  a	  bbd18	  variant	  (S67A	  
and	  V85A)	  under	  the	  control	  of	  the	  constitutive	  flaB	  
promoter	  on	  a	  shuttle	  vector;	  kanamycin-­‐resistant	  
this	  study	  
S9/pBSV2*-­‐flaBp-­‐bbd18Δ3	  
S9	  derivative	  harboring	  a	  bbd18	  variant	  (K58E,	  
K79E,	  D94R,	  and	  D96R)	  under	  the	  control	  of	  the	  
constitutive	  flaB	  promoter	  on	  a	  shuttle	  vector;	  
streptomycin	  and	  kanamycin-­‐resistant	  
this	  study	  
S9/pBSV2*-­‐flaBp-­‐bbd18Δ4	  
S9	  derivative	  harboring	  a	  bbd18	  variant	  (S67A	  and	  
V85A)	  under	  the	  control	  of	  the	  constitutive	  flaB	  





derivative	  of	  the	  cp9-­‐based	  shuttle	  vector,	  pBSV2,	  	  




derivative	  of	  the	  cp9-­‐based	  shuttle	  vector,	  pBSV2,	  	  
gentamicin-­‐resistance	  cassette,	  incompatible	  with	  
pBSV2*	  
(40)	  
pBSV2*flaBp-­‐bbd18	   pBSV2*	  with	  bbd18	  under	  control	  of	  constitutive	  flaB	  promoter	   (30)	  
pBHospCp-­‐lacZBb*	   pBH-­‐lacZBb*	  with	  ospC	  promoter	  driving	  expression	  of	  lacZBb	   (30)	  
pBHP7F-­‐lacZBb*	  
pBH-­‐lacZBb*	  with	  minimal	  ospC	  promoter	  that	  
lacks	  the	  palindromic	  operator	  sequence	  driving	  




pBH-­‐lacZBb*	  with	  an	  ospC-­‐flaB	  fusion	  promoter	  	  
(-­‐35	  up	  to	  +1	  of	  ospC	  transcript	  fused	  with	  +1	  to	  
ATG	  of	  flaB)	  driving	  expression	  of	  lacZBb*	  
this	  study	  
pBSV28-­‐1-­‐flaBp-­‐bbd18	   pBSV28-­‐1	  with	  bbd18	  under	  control	  of	  the	  constitutive	  flaB	  promoter	  
(41);	  this	  
study	  







pBSV2*	  with	  an	  insert	  encompassing	  bbd18	  and	  




pBSV2*	  with	  a	  synthetic	  bbd18	  gene	  containing	  
amino	  acid	  changes	  K58A,	  S67A,	  C74A,	  K79A,	  




pBSV2*	  with	  a	  synthetic	  bbd18	  gene	  containing	  
amino	  acid	  changes	  N56A,	  I57A,	  K58A,	  S66A,	  S67A,	  
N69A,	  I70A,	  and	  M72A;	  expressed	  from	  the	  
constitutive	  flaB	  promoter	  
this	  study	  
pBSV2*flaBp-­‐bbd18Δ3	  
pBSV2*	  with	  a	  synthetic	  bbd18	  gene	  containing	  
amino	  acid	  changes	  K58E,	  K79E,	  D94R,	  and	  D96R;	  
expressed	  from	  the	  constitutive	  flaB	  promoter	  
this	  study	  
pBSV2*flaBp-­‐bbd18Δ4	  
pBSV2*	  with	  a	  synthetic	  bbd18	  gene	  containing	  
amino	  acid	  changes	  S67A	  and	  V85A;	  expressed	  
from	  the	  constitutive	  flaB	  promoter	  
this	  study	  
pOK12-­‐bbd18-­‐KO	  
suicide	  vector	  for	  allelic	  exchange	  with	  the	  bbd18	  
ORF;	  bbd18	  and	  flanking	  region	  in	  pOK12;	  flgBp-­‐
aacC1	  inserted	  into	  the	  bbd18	  ORF	  
(42);	  this	  
study	  
pGCB426	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB426	  carrying	  bbd1	  through	  5’	  end	  of	  bbd20	   (30,	  43)	  
pGCB473	   lp17	  deletion	  variant	  from	  B.	  burgdorferi	  strain	  GCB473	  carrying	  bbd1	  through	  bbd14	   (30,	  43)	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DNA	  (see	  below	  and	  Table	  4-­‐1)	  purified	  from	  E.	  coli.	  Transformations	  of	  B312	  and	  
B31-­‐S9	  (subsequently	  referred	  to	  as	  S9)	  were	  selected	  in	  solid	  BSK	  II	  medium	  with	  
the	  appropriate	  antibiotics:	  gentamicin	  (40µg/mL),	  kanamycin	  (200µg/mL),	  and/or	  
streptomycin	  	  (50	  μg/ml).	  Colonies	  arising	  in	  selective	  media	  were	  screened	  by	  PCR	  
for	   lacZBb,	   bbd18,	   the	   gentamicin	   marker	   or	   the	   kanamycin	   marker	   with	  
appropriate	  primers	  (Table	  4-­‐2)	  to	  confirm	  the	  stable	  introduction	  of	  plasmid	  DNA.	  	  
Routine	   cloning	   was	   performed	   using	   chemically	   competent	   Top10	  
Escherichia	   coli	   (Invitrogen,	   Carlsbad,	   CA).	   E.	   coli	  was	   plated	   on	   LB	   agar	   (10g/L	  
Tryptone,	   5g/L	   NaCl,	   5g/L	   yeast	   extract,	   and	   15g/L	   agar)	   with	   the	   appropriate	  
antibiotic	   (kanamycin	   at	   30µg	  mL-­‐1	   or	   gentamicin	   at	   5	  µg	  mL-­‐1).	   	   Liquid	   cultures	  
were	  grown	  in	  LB	  broth	  supplemented	  with	  the	  appropriate	  antibiotics	  (kanamycin	  
at	  100µg	  mL-­‐1	  or	  gentamicin	  at	  10	  µg	  mL-­‐1)	  
Plasmid	  construction.	  
	   A	   minimal	   ospC	   promoter,	   lacking	   the	   inverted	   repeat	   (putative	   operator)	  
sequence,	  was	  amplified	  from	  B31-­‐A3	  (A3)	  genomic	  DNA	  (gDNA)	  using	  primers	  P7F	  
(28)	  and	  ospC	  promoter-­‐BspHI	  Reverse	  (Table	  4-­‐2),	  cloned	  into	  pCR2.1	  (Invitrogen),	  
and	   sequenced	   to	   confirm	   insert.	   This	   promoter	   was	   excised	  with	   the	   restriction	  
enzymes	  BamHI	   and	  BspHI	   (New	  England	  Biolabs,	  NEB,	   Ipswich,	  MA)	   and	   ligated	  
into	   appropriately	   digested	   pBH-­‐lacZBb*	   (30),	   creating	   pBHP7F-­‐lacZBb*	   (Table	   4-­‐
1).	  An	  ospC-­‐flaB	  fusion	  promoter	  was	  amplified	  from	  A3	  gDNA	  using	  primers	  ospC-­‐
35region	  Forward	  and	  ospCp-­‐flaBp-­‐RBS	  Reverse,	  which	  encodes	  the	  5’	  untranslated	  
region	  of	  flaB	  in	  the	  primer	  sequence	  (Table	  4-­‐2).	  	  This	  fusion	  promoter	  was	  cloned	  
into	   pCR2.1	   (Invitrogen),	   sequenced,	   and	   recloned	   into	   pBH-­‐lacZBb*	   as	   described	  
above,	  creating	  pBHospCp-­‐flaBpRBS-­‐lacZBb*	  (Table	  4-­‐1).	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Table	  4-­‐2:	  Primers	  used	  in	  Chapter	  Four	  
Name	   Sequence	  (5'-­‐3')a	   Reference	  
ospCp	  Forward	   CCCGCGGATCCAATTAAAACTTTTTTTATTAAAGTA	   (30,	  32)	  
P7F	   CACTGGATCCTTATTTTTTCAAATAAAAAATTGA	   (28)	  
ospC	  promoter-­‐BspHI	  
Reverse	   CCCCGTCATGATTTGTGCCTCCTTTTTATTTAT	   (30)	  
ospC-­‐35region	  







lacZBb	  Int-­‐1	   TGGTGTAATGGAAGATGGGTTGG	   (30)	  
lacZBb	  Mid	  Reverse	   GATAGACCATTTAGGAACAGCAGG	   (30)	  
kan	  5'	  NdeI	  Forward	   CATATGAGCCATATTCAACGGGAAACG	   (30)	  
kan	  Reverse	   TTAATTAATGAGCTAGCGCCGT	   (30)	  
gent	  Forward	   TCTCGGCTTGAACGAATTGTTACGT	   (35)	  
gent	  Reverse	   GGCAGTCGCCCTAAAACAAAGTT	   (35)	  
bbd13	  Forward	   ACGGTGTAAGACTTTATTCTTTAAAAGAATTCC	   (44)	  
bbd13	  reverse	   AAAATATGACCCATCTTTTTTGAAGC	   (44)	  
bbd18-­‐NdeI-­‐For	   GGGAATTCCATATGCAAAAAGAAATAACAATAAACTATAATG	   this	  study	  
bbd18-­‐XmaI-­‐Rev	   TCCCCCCGGGCATTTTACTTAAAAGCGTTTAATTTT	   this	  study	  
bbd18-­‐promoter	  




GTTAAAATTTTATATTC	  	   this	  study	  
a	  underlined	  bases	  denote	  restriction	  sites	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The	   flaBp-­‐bbd18	   cassette	  was	  excised	   from	  pBSV2*flaBp-­‐bbd18	   (30)	  with	  NotI-­‐HF	  
(NEB)	   and	   ligated	   into	   appropriately	   digested	   and	   de-­‐phosphorylated	   pBSV28-­‐1	  
(41)	  to	  create	  pBSV28-­‐1-­‐flaBp-­‐bbd18	  (Table	  4-­‐1).	  	   	  
Suicide	  vector	  construction	  	  
To	   inactivate	   bbd18,	   an	   allelic	   exchange	   vector	  was	   constructed	   as	   follows.	  
The	  region	  of	  lp17	  containing	  bbd18	  and	  its	  flanking	  regions	  (lp17	  nt	  12053-­‐10684)	  
was	   amplified	   by	   PCR	   using	   primers	   bbd18-­‐promoter	   Forward	   and	   bbd18	  
terminator	   Reverse	   (Table	   4-­‐2)	   and	   cloned	   into	   pCR2.1.	   This	   region	   was	  
subsequently	   recloned	   into	   pOK12	   to	   avoid	   introducing	   the	   ampicillin-­‐resistance	  
gene	   into	  B.	   burgdorferi.	   The	   flgB	   promoter	   driving	   expression	   of	   the	  aacC1	   gene	  
(conferring	   gentamicin	   resistance)	   was	   amplified	   from	   pBSV2G	   and	   cloned	   into	  
pCR2.1.	   The	   flgBp-­‐aacC1	   cassette	   was	   excised	   out	   of	   pCR2.1	   using	   HindIII,	   ends	  
blunted	  with	  T4	  DNA	  polymerase	  (NEB)	  and	  ligated	  into	  the	  unique	  MfeI	  site	  that	  is	  
32bp	  downstream	  of	  the	  ATG-­‐start	  site	  of	  the	  bbd18	  open	  reading	  frame	  in	  pOK12.	  
One	  clone,	  named	  pOK12-­‐bbd18-­‐KO	  (Table	  4-­‐1),	   in	  which	  the	   flgBp-­‐aacC1	  cassette	  
was	   inserted	   in	   the	   opposite	   orientation	   of	   the	   native	  bbd18	   gene,	  was	   chosen	   to	  
inactivate	  bbd18	  in	  B.	  burgdorferi.	  	  
β-­‐galactosidase	  assays.	  
To	  assess	  β-­‐galactosidase	  activity	  of	  colonies	  grown	  in	  solid	  media,	  ~0.3mL	  
5-­‐bromo-­‐4-­‐chloro-­‐indolyl-­‐β-­‐D-­‐	   galactopyranoside	   (X-­‐gal)	   dissolved	   in	  
dimethylformamide	   (DMF)	   (10mg/ml)	   was	   spread	   on	   B.	   burgdorferi	   plates	   after	  
colony	  formation.	  	  
SDS-­‐PAGE	  and	  immunoblotting	  
Lysates	  from	  high	  density	  or	  temperature-­‐shifted	  cultures,	  to	  enhance	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induction	   of	   the	   RpoN/RroS	   regulon,	   were	   analyzed	   for	   protein	   content.	   For	  
temperature	  shifts,	  duplicate	  50mL	  B.	  burgdorferi	  cultures	  were	  first	  grown	  at	  35°C.	  
When	   the	   concentration	   reached	   approximately	   5x105-­‐1x106	   spirochetes/mL,	  
cultures	  were	   shifted	   to	   25°C	   (i.e.	   room-­‐temperature).	   7-­‐10	   days	   later,	   one	   of	   the	  
duplicate	  cultures	  was	  returned	  to	  35°C	  for	  48	  hours.	  Equal	  numbers	  of	  spirochetes	  
were	   harvested	   from	   both	   culture	   conditions.	   All	   samples	   were	   washed	   twice	   in	  
HEPES-­‐NaCl	  (HN)	  buffer	  (50mM	  each,	  pH	  7.6)	  and	  resuspended	  in	  Laemmli	  loading	  
buffer	   to	   be	   separated	   on	   12.5%	   SDS-­‐PAGE	   gels.	   Gels	   were	   run	   in	   duplicate	   and	  
either	   stained	   with	   Coomassie	   blue	   or	   electrophoretically	   transferred	   to	  
nitrocellulose	   membranes	   (Bio-­‐Rad).	   Membranes	   were	   blocked	   in	   TBS-­‐Tween	   20	  
(20mM	  TRIS	  pH	  7.5,	   150mM	  NaCl,	   0.01%	  Tween	  20)	  with	  or	  without	  nonfat	  milk	  
(BD	  Diagnostics,	  Franklin	  Lakes,	  NJ)	  and	  probed	  with	  mouse	  monoclonal	  anti-­‐FlaB	  
H9724	  (1:200)	   (45),	   rabbit	  polyclonal	  anti-­‐OspC	  antiserum	  (1:1000	  dilution)	  (10),	  
rabbit	   anti-­‐BBD18	   antiserum	   (30),	   chicken	   polyclonal	   anti-­‐BBA66	   antibody	  
(1:6,000)(46),	   rabbit	   polyclonal	   anti-­‐DbpA	   antibody	   200-­‐401-­‐B98S	   (1:1000	  
dilution;	  Rockland	  Immunochemicals,	  Gilbertsville,	  PA),	  or	  UGA-­‐17	  rabbit	  polyclonal	  
anti-­‐RpoS	  antibody	  (1:500)(a	  kind	  gift	  from	  F.	  Gherardini).	  Horseradish	  peroxidase-­‐
conjugated	   secondary	   antibodies	   that	   recognize	   mouse,	   rabbit,	   or	   chicken	  
immunoglobulins	   were	   diluted	   1:10,000,	   1:50,000,	   or	   1:10,000,	   respectively,	   in	  
TBST	   with	   non-­‐fat	   milk.	   Immunoreactivity	   was	   visualized	   using	   the	   Supersignal	  
West	  Pico	  Chemiluminescence	  substrate	  (Thermo	  Scientific,	  Rockford,	  IL)	  and	  X-­‐ray	  
film	  (Labscientific	  Inc.,	  Livingston	  NJ).	  	  
Mouse	  Infection	  
All	  mouse	  studies	  were	  done	  in	  accordance	  with	  guidelines	  of	  the	  National	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Institutes	   of	   Health	   and	   protocols	   were	   approved	   by	   the	   Rocky	   Mountain	  
Laboratories	  Animal	  Care	  and	  Use	  Committee.	  The	  Rocky	  Mountain	  Laboratories	  are	  
accredited	   by	   the	   International	   Association	   for	   Assessment	   and	   Accreditation	   of	  
Laboratory	  Animal	  Care	  (AAALAC).	   Infection	  studies	  were	  conducted	  with	  6-­‐	   to	  8-­‐
week-­‐old	  female	  RML	  mice,	  an	  outbred	  strain	  of	  Swiss-­‐Webster	  mice	  reared	  at	  the	  
Rocky	  Mountain	  Laboratories	  breeding	  facility.	  Mice	  were	  retro-­‐orbitally	  bled	  prior	  
to	   injection	   and	   then	   needle-­‐inoculated	   with	   a	   target	   dose	   of	   104	   B.	   burgdorferi	  
spirochetes	   (8x103	   spirochetes	   intraperitoneally	   and	   2x103	   spirochetes	  
subcutaneously).	   After	   3	   weeks,	   mice	   were	   bled	   to	   assess	   seroconversion	   to	   B.	  
burgdorferi	  proteins,	   and	   ear	  punch	  biopsies	  placed	   into	  BSK	   II	  medium	   to	   assess	  
the	   presence	   of	   spirochetes	   in	   these	   tissues.	   At	   4-­‐8	   weeks	   post-­‐inoculation,	   mice	  
were	  euthanized	  and	  ear,	  bladder,	  and	  joint	  tissues	  were	  cultured	  in	  BSK	  II	  medium	  
for	  final	  assessment	  of	  infection.	  
Tick	  Transmission	  Studies	  
Ixodes	   scapularis	   larvae	   were	   artificially	   infected	   as	   previously	   described	  
(47)	  Briefly,	  larval	  I.	  scapularis	  were	  partially	  dehydrated	  for	  48	  hours	  at	  a	  relative	  
humidity	   of	   85%	   before	   an	   aliquot	   of	   B.	   burgdorferi	   culture	   (~1x108	  
spirochetes/mL)	   was	   added.	   The	   ticks	   were	   incubated	  with	  B.	   burgdorferi	   for	   45	  
min	   at	   35°C,	   washed	   twice	   with	   PBS,	   and	   then	   allowed	   to	   recover	   for	   48	   hours	  
before	  feeding	  on	  naïve	  mice	  to	  repletion	  (~100/mouse).	  	  To	  assess	  colonization	  by	  
B.	  burgdorferi,	  a	  subset	  of	  fed	  larvae	  were	  crushed	  at	  7	  days	  post-­‐feeding	  and	  either	  
plated	   in	   solid	   BSK	   medium	   or	   placed	   in	   liquid	   BSK	   medium.	   Remaining	   fed	   I.	  
scapularis	   larvae	  were	   allowed	   to	  molt	   to	  nymphs	  and	   recover	   (approximately	  12	  
weeks	  post-­‐larval	  feeding)	  before	  feeding	  on	  naïve	  mice	  (2-­‐4	  nymphs/mouse)	  .	  Two	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or	   three	   I.	   scapularis	   nymphs	   were	   removed	   at	   48	   hours	   post-­‐attachment	   and	  
prepared	   for	   immunofluorescence	   (see	   below).	   Remaining	   attached	   nymphs	   (1-­‐
2/mouse)	   were	   allowed	   to	   feed	   to	   repletion	   and	   at	   7	   days	   post-­‐feeding	   were	  
crushed	  and	  plated	  in	  BSK	  solid	  medium	  to	  enumerate	  spirochetes.	  Mice	  that	  were	  
fed	   on	   by	   infected	   I.	   scapularis	   were	   euthanized	   at	   3	   weeks	   post-­‐feeding	   and	  
processed	  as	  described	  above	  to	  assess	  B.	  burgdorferi	  transmission	  via	  tick	  bite	  and	  
ensuing	  infection.	  	  
Fluorescence	  Microscopy	  
Manually	   detached	   I.	   scapularis	   nymphs	   were	   dissected	   in	   phosphate	  
buffered	   saline	   (PBS)	  on	  glass	  microscope	   slides.	  Tick	   smears	  were	  allowed	   to	  air	  
dry	  before	  being	  passed	  over	  a	  flame	  to	  heat-­‐fix.	  Samples	  were	  then	  permeabilized	  
in	   acetone	   for	  30	  minutes.	  Mouse	  monoclonal	   antibody	  B5	   recognizing	  OspC	  of	  B.	  
burgdorferi	  B31	  (kindly	  provided	  by	  Dr.	  Robert	  Gilmore	  and	  originally	  produced	  by	  
Dr.	  Lamine	  MBow,	  (48))	  was	  used	  to	  determine	  if	  spirochetes	  were	  producing	  OspC,	  
and	  a	  hyperimmune	  convalescent	  rabbit	  anti-­‐B.	  burgdorferi	  antiserum	  (Drs.	  Robert	  
Karstens	   and	   Tom	   Schwan,	   RML,	   NIAID,	   NIH)	   was	   used	   to	   detect	   all	   spirochetes	  
regardless	   of	   their	   OspC	   phenotype.	   Primary	   antibodies	   were	   detected	   using	  
rhodamine-­‐conjugated	  goat	  anti-­‐rabbit	  (B.	  burgdorferi)	  and	  Alexa-­‐488	  labeled	  goat	  
anti-­‐mouse	  (OspC)	  sera.	  All	  antibodies	  were	  diluted	  1:100	  in	  PBS	  with	  0.75%	  Bovine	  
Serum	  Albumin	  (BSA)	  and	  incubated	  at	  35°C	  for	  30	  minutes.	  Vectashield	  mounting	  
medium	   (Vector	   Laboratories,	   Burlingame,	   CA)	   was	   used	   to	   prevent	   the	  
photobleaching	   of	   fluorochromes.	   Images	   were	   taken	   with	   a	   Nikon	   Eclipse	   80i	  
microscope	  and	  a	  Nikon	  Digital	  Sight	  Qi1Mc	  camera.	  	  
Southern	  Blotting	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Genomic	  DNA	  was	   isolated	   from	  B.	   burgdorferi	   cultures	  using	   the	  Promega	  
Wizard	   Genomic	   DNA	   purification	   kit	   (Promega,	   Madison,	   WI).	   Approximately	  
275ng	   of	   uncut	   gDNA	   was	   separated	   on	   a	   0.5	   %	   agarose	   gel	   by	   field-­‐inversion	  
electrophoresis	   with	   program	   2	   on	   the	   PPI-­‐200	   Pulse-­‐Field	   Gel	   Controller	   (MJ	  
Research,	   Watertown,	   MA)	   The	   gel	   was	   depurinated,	   denatured,	   neutralized,	   and	  
blotted	  onto	  a	  Magnagraph	  nylon	  transfer	  membrane	  (GE,	  Boulder,	  CO).	  gDNA	  was	  
cross-­‐linked	  to	  the	  membrane	  with	  a	  UV	  Stratalinker	  1800	  (Stratagene,	  Los	  Angles,	  
CA).	   Probes	  were	   generated	   by	   PCR	   amplification	   of	  B.	   burgdorferi	   B31-­‐A3	   gDNA	  
with	  bbd13,	  aacC1,	  or	  the	  kanamycin-­‐resistant	  gene	  primers	  (Table	  4-­‐2)	  and	  a	  DIG	  
probe	   synthesis	   kit	   (Roche,	   Indianapolis,	   IN),	   according	   to	   the	   manufacturer’s	  
instructions.	  Hybridization	  of	  the	  labeled	  probe	  with	  the	  membrane-­‐bound	  DNA	  and	  
signal	  development	  were	  done	  as	  described	  before	  (Chapter	  2,	  (30)).	  	  
Site-­‐directed	  Mutagenesis	  of	  BBD18	  
	   Based	   on	   structural	   predictions	   (see	   below)	   and	   amino	   acid	   conservation	  
within	  both	  Lyme	  disease	  spirochetes	  and	  relapsing	  fever	  spirochetes	  (unpublished	  
sequences,	   Dr.	   Tom	   Schwan,	   RML,	   NIAID,	   NIH),	  we	   designed	   four	  bbd18	   variants,	  
each	  with	  multiple	  amino	  acid	  substitutions.	  The	  changes	  are	  as	  follows:	  bbd18-­‐Δ1	  
has	   lysine	   58	   changed	   to	   alanine	   (K58A),	   S67A,	   C74A,	   K79A,	   D94A,	   and	   D96A;	  
bbd18-­‐Δ2	  has	  N56A,	  I57A,	  K58A,	  S66A,	  S67A,	  N69A,	  I70A,	  and	  M72A;	  bbd18-­‐Δ3	  has	  
K58E,	  K79E,	  D94R,	  and	  D96R;	  bbd18-­‐Δ4	  has	  S67A,	  and	  V85A.	  These	  BBD18	  variants	  
had	   similar	   predicted	   secondary	   structures	   as	   wt	   BBD18	   (PSIPRED	   Protein	  
Structure	   Prediction	   Server;	   available	   at	   http://bioinf.cs.ucl.ac.uk/psipred/).	  
Synthetic	  genes	  with	  the	  specific	  nucleotide	  changes	  were	  synthesized	  by	  GenScript	  
Corporation	   (Piscataway,	   NJ)	   with	   EcoRI	   recognition	   sites	   at	   both	   ends.	   These	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synthetic	   genes	   were	   excised	   from	   pUC57	   with	   EcoRI-­‐HF	   (NEB)	   and	   ligated	   into	  
appropriately	   digested	   and	   de-­‐phosphorylated	   pBSV2*flaBp	   (39)	   in	   a	   manner	  
following	  the	  construction	  of	  pBSV2*flaBp-­‐bbd18,	  which	  contains	  the	  wt	  bbd18	  gene	  
under	   expression	   of	   the	   constitutive	   flaB	   promoter	   (30).	   Resulting	   clones	   were	  
screened	   by	   PCR	   to	   confirm	   orientation	   and	   presence	   of	   the	   insert	   and	   then	  
sequenced	   to	   confirm	   that	   no	   other	   mutations	   had	   arisen	   during	   cloning.	   These	  
shuttle	  vectors	  were	  transformed	  into	  B312	  and	  assessed	  for	  their	  ability	  to	  repress	  
OspC	  by	   immunoblot.	  pBSV2*flaBp-­‐bbd18Δ3	  and	  pBSV2*flaBp-­‐bbd18Δ4	  were	  also	  
transformed	  into	  S9.	  
	   Single	   (or	   double)	   amino	   acid	   bbd18	   variants	   were	   created	   using	   the	  
Quikchange	  Lightning	  Single	  or	  Multi	  Site-­‐directed	  mutagenesis	  kits	  (Agilent,	  Santa	  
Clara,	   CA)	   and	   pBSV2*flaBp-­‐bbd18,	   according	   to	   the	   manufacturer’s	   instructions.	  
Primers	   were	   designed	   with	   the	   primer	   design	   tool	   available	   on	   their	   website	  
(https://www.genomics.agilent.com).	   We	   created	   the	   following	   single	   residue	  
variants:	   K58E,	   K79E,	   D94R,	   D96R;	   and	   the	   following	   double	   residue	   variants:	  
K58E/D94R,	   K79E/D96R,	   and	   D103R/K113E	   (control).	   Resulting	   clones	   were	  
sequenced	   to	   confirm	   that	   only	   the	   specified	  mutations	  had	  been	   introduced.	   The	  
shuttle	   vectors	   were	   subsequently	   transformed	   into	   B312	   and	   assessed	   for	   the	  
ability	  to	  repress	  OspC	  by	  immunoblotting	  as	  above.	  	  
Complementation	  of	  the	  bbd18	  mutant	  
	   To	  complement	  the	  bbd18	  mutant,	  lp17	  harboring	  the	  flgBp-­‐aacC1	   insertion	  
in	  the	  bbd18	  open	  reading	  frame	  was	  displaced	  with	  an	  lp17	  that	  was	  marked	  with	  a	  
kanamycin-­‐resistance	   cassette.	   This	   lp17::kan	   (Table	   4-­‐1)	   was	   created	   by	   the	  
intergration	   of	   pKK81	   into	   lp17	   in	   B31-­‐A	   (36)	   (30).	   pBSV2*NP-­‐bbd18	   (Table	   4-­‐
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1)(30),	  which	  harbors	  a	  wt	  bbd18	  gene	  expressed	  from	  its	  native	  promoter,	  was	  also	  
used	  to	  transform	  the	  bbd18	  mutant.	  Both	  complemented	  clones	  retained	  the	  same	  
plasmid	  content	  as	  S9-­‐Δbbd18	  and	  the	  parental	  S9.	  	  	  
	  
Results	  
B.	  burgdorferi	  constitutively	  expressing	  bbd18	   is	  non-­‐infectious	  in	  the	  mouse	  
model.	  
	   The	   presence	   of	   OspC	   on	   the	   surface	   of	   B.	   burgdorferi	   not	   only	   prepares	  
spirochetes	  for	  mammalian	  infection	  but	  is	  also	  a	  target	  for	  the	  mammalian	  immune	  
system.	  Thus,	  OspC	  must	  be	  specifically	  downregulated	  during	  infection	  to	  prevent	  
clearance	  of	  the	  spirochete	  (12).	  As	  described	  in	  chapter	  3,	  we	  found	  that	  BBD18,	  a	  
novel	  protein	  encoded	  on	  lp17,	  caused	  repression	  of	  ospC	  at	  the	  transcriptional	  level	  
in	  the	  non-­‐infectious	  high-­‐passage	  B.	  burgdorferi	  strain	  B312	  (30).	  
To	   address	   whether	   BBD18	   is	   important	   during	   the	   infectious	   cycle,	   we	  
wanted	   to	   constitutively	   express	   bbd18	   in	   an	   infectious	   B.	   burgdorferi	   clone	   and	  
determine	  whether	  that	  interferes	  with	  infection	  or	  transmission.	  We	  hypothesized	  
that	   if	   bbd18	   expressed	   by	   a	   constitutive	   promoter	   represses	   ospC,	   which	   is	   an	  
essential	   virulence	   factor	   for	   infection	   in	  mice,	   a	   low-­‐passage	  B.	   burgdorferi	   clone	  
constitutively	  expressing	  bbd18	  would	  be	  unable	  to	  upregulate	  OspC	  and	  therefore	  
would	   be	   non-­‐infectious	   in	   the	   mouse	   model.	   To	   achieve	   this,	   we	   utilized	   low-­‐
passage	  S9,	  a	  virulent	  clone	  of	  B.	  burgdorferi	  that	  lacks	  two	  restriction	  modification	  
systems	   that	   have	   been	   shown	   to	   hinder	   efficient	   shuttle	   vector	   transformations	  
into	  B.	  burgdorferi	  (35,	  49,	  50).	  S9	  was	  transformed	  with	  pBSV2*flaBp-­‐bbd18	  (30),	  a	  
shuttle	   vector	   harboring	   bbd18	   expressed	   from	   the	   constitutive	   flaB	   promoter.	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Independent	   transformations	   yielded	   in	   two	   transformants,	   S9/pBSV2*flaBp-­‐
bbd18-­‐A	   and	   S9/pBSV2*flaBp-­‐bbd18-­‐B.	   When	   the	   complete	   plasmid	   profile	   was	  
analyzed,	   we	   found	   that	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   retained	   all	   parental	   plasmids,	  
while	   S9/pBSV2*flaBp-­‐bbd18-­‐A	   had	   lost	   lp28-­‐4	   and	   cp32-­‐1;	   the	   loss	   of	   either	   of	  
these	   plasmids	   has	   not	   been	   associated	  with	   a	   loss	   of	   virulence	   (a	   representative	  
image	   of	   the	   B.	   burgdorferi	   plasmid	   profile	   is	   available	   in	   Figure	   4-­‐4C).	   	   To	   our	  
knowledge,	  however,	  infectivity	  of	  B.	  burgdorferi	  lacking	  both	  cp32-­‐1	  and	  lp28-­‐4	  has	  
not	  been	  tested.	  To	  confirm	  that	  any	  observed	  differences	  from	  wt	  S9	  were	  caused	  
by	   constitutive	   expression	   of	   bbd18,	   we	   displaced	   pBSV2*flaBp-­‐bbd18	   from	  
S9/pBSV2*flaBp-­‐bbd18-­‐A	   with	   the	   incompatible	   plasmid	   pBSV2G.	   Southern	   blot	  
analysis	   with	   probes	   specific	   for	   the	   gentamicin-­‐	   (pBSV2G)	   or	   kanamycin-­‐	  
(pBSV2*flaBp-­‐bbd18)	  resistance	  genes	  was	  used	  to	  confirm	  the	  presence	  of	  pBSV2G	  
and	  absence	  of	  pBSV2*flaBp-­‐bbd18	  (Figure	  4-­‐1).	  This	  clone,	  referred	  to	  as	  S9/chase-­‐
pBSV2G,	   retained	   the	   same	  plasmid	  profile	   as	   the	  parent	   strain	   (S9/pBSV2*flaBp-­‐
bbd18-­‐A)	  yet	  lacked	  constitutive	  bbd18.	  
Groups	  of	  5	  mice	  were	  injected	  with	  S9,	  S9/pBSV2*flaBp-­‐bbd18-­‐A,	  S9/chase-­‐
pBSV2G,	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B.	   After	   3	   weeks,	   mice	   inoculated	   with	   S9	   or	  
S9/chase-­‐pBSV2G	  were	  seropositive	  for	  B.	  burgdorferi	  proteins,	  but	  mice	  inoculated	  
with	   S9/pBSV2*flaBp-­‐bbd18-­‐A	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   did	   not	   seroconvert	  
(Table	   4-­‐3).	   In	   addition,	   spirochetes	  were	   isolated	   from	   tissues	   (ear,	   bladder,	   and	  
ankle	   joint)	   of	   mice	   inoculated	   with	   S9	   or	   S9/chase-­‐pBSV2G	   but	   not	   from	   mice	  
inoculated	   with	   S9/pBSV2*flaBp-­‐bbd18-­‐A	   or	   -­‐B	   (Table	   4-­‐3).	   These	   results	  
demonstrate	   that	   constitutively	   expressed	   bbd18	   renders	   B.	   burgdorferi	   non-­‐
infectious	  by	  needle	  inoculation.	  Restoration	  of	  infectivity	  in	  S9/chase-­‐pBSV2G	  also	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Figure	   4-­‐1	   legend:	   A.	   gDNA	   from	   spirochetes	   harboring	   a	   constitutive	   bbd18	  
separated	  by	  phase-­‐inversion	  gel	  electrophoresis.	  Uncut	  gDNA,	  isolated	  from	  wt	  S9,	  
S9/pBSV2*flaBp-­‐bbd18-­‐A,	   S9/chase-­‐pBSV2G,	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B,	   as	  
indicated,	   was	   analyzed	   by	   gel	   electrophoresis	   and	   visualized	   using	   Gel	   Red	   and	  
ultra	  violet	  light.	  The	  size	  in	  base	  pairs	  (bp)	  based	  on	  the	  migration	  of	  standards	  is	  
listed	   in	   between	   the	   panels.	  B.	   gDNA	   hybridization	   with	   probes	   recognizing	   the	  
gentamicin-­‐	   (gent,	   left)	   or	   kanamycin-­‐	   (kan,	   right)	   resistance	   genes.	   Nylon	  
membrane-­‐bound	   gDNA	   transferred	   from	   gels	   shown	   in	   A	   was	   incubated	   with	   a	  
DIG-­‐labeled	   probe	   corresponding	   to	   gent	   or	   kan	   resistance	   cassettes,	   which	   are	  
carried	   by	   pBSV2G	   or	   pBSV2*flaBp-­‐bbd18,	   respectively.	   Probe	   hybridization	   was	  
visualized	  using	  an	  anti-­‐DIG	  antibody,	  chemiluminescent	  substrates,	  and	  X-­‐ray	  film.	  
The	  size	  in	  base	  pairs	  (bp)	  based	  on	  the	  migration	  of	  standards	  is	  listed	  between	  the	  
two	  panels.	  
	   	  
 141 
Table	   4-­‐3:	   Constitutive	   expression	   of	   BBD18	   prevents	  B.	   burgdorferi	   infectivity	   in	  
mice	  by	  needle	  inoculation	  	  
strain	  
No.	  of	  sero-­‐positive	  
mice	  /no.	  of	  injected	  
micea	  
No.	  of	  tissue	  reisolates/no.	  of	  
injected	  mice	  (ear,	  bladder,	  joint)b	  
S9	   5/5	   5/5,	  5/5,	  5/5	  
S9/pBSV2*flaBp-­‐bbd18-­‐A	   0/5	   0/5,	  0/5,	  0/5	  
S9/chase-­‐pBSV2G	   4/5	   4/5,	  4/5,	  4/5	  
S9/pBSV2*flaBp-­‐bbd18-­‐B	   0/5	   0/5,	  0/5,	  0/5	  
a	  seroconversion	  to	  B.	  burgdorferi	  proteins	  was	  assessed	  at	  3	  weeks	  post-­‐inoculation	  
b	  mice	  were	  euthanized	  at	  5	  weeks	  post-­‐inoculation	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corroborated	   these	   findings	   and	   indicated	   that	   the	   inappropriate	   expression	   of	  
bbd18	  was	  the	  sole	  cause	  of	  the	  loss	  of	  infectivity	  from	  S9/pBSV2*flaBp-­‐bbd18-­‐A.	  In	  
addition,	   the	   fact	   that	  S9/chase-­‐pBSV2G	  was	   infectious	  (Table	  4-­‐3)	  despite	   lacking	  
both	  cp32-­‐1	  and	   lp28-­‐4,	  verified	   that	   these	  plasmids,	  alone	  or	   in	  combination,	  are	  
not	  critical	  for	  the	  infectivity	  of	  B.	  burgdorferi	  by	  needle	  inoculation.	  	  
Constitutively	   expressed	   bbd18	   prevents	   the	   upregulation	   of	   OspC	   by	   B.	  
burgdorferi	  within	  feeding	  ticks.	  	  
B.	   burgdorferi	   overexpressing	   bbd18	   were	   non-­‐infectious	   by	   needle	  
inoculation,	  but	  in	  nature	  B.	  burgdorferi	  	  spirochetes	  are	  transmitted	  by	  Ixodes	  ticks	  
(4).	   We	   wanted	   to	   investigate	   the	   potential	   impact	   on	   B.	   burgdorferi	   of	  
overexpressing	   bbd18	   within	   ticks	   and	   during	   natural	   transmission	   to	   the	  
mammalian	  host.	  We	  would	  typically	  do	  this	  by	  feeding	  larval	  I.	  scapularis	  ticks	  on	  
infected	  mice	   and	   assess	   acquisition	   of	  B.	   burgdorferi	   before	   allowing	   the	   ticks	   to	  
molt	   into	   nymphs.	   However,	   mice	   inoculated	   with	   S9/pBSV2*flaBp-­‐bbd18-­‐A	   or	  
S9/pBSV2*flaBp-­‐bbd18-­‐B	   were	   not	   infected.	   Thus,	   we	   followed	   a	   well-­‐establish	  
protocol	   (47)	   to	   artificially	   infect	   I.	   scapularis	   larvae	   with	   S9,	   S9/pBSV2*flaBp-­‐
bbd18-­‐A,	   S9/chase-­‐pBSV2G,	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B.	   The	   majority	   of	   ticks	  
analyzed	  seven	  days	  after	  larval	  feeding	  contained	  viable	  spirochetes	  (Figure	  4-­‐2A),	  
indicating	   that	   the	   artificial	   infection	   was	   successful.	   The	   remaining	   fed	   larval	   I.	  
scapularis	  were	  allowed	  to	  molt	  and	  recover	  (~12	  weeks	  after	  larval	  feeding)	  before	  
groups	  fed	  on	  naïve	  mice	  (~5	  ticks/mouse).	  	  
Infected	  nymphs	  either	   fed	   to	  repletion	  (1-­‐4/mouse)	   to	  determine	  whether	  
B.	   burgdorferi	   overexpressing	  bbd18	  were	   infectious	   in	  mice	   via	   tick	   transmission	  
(Table	  4-­‐4)	  or	  were	  manually	  detached	  at	  48	  hours	  post-­‐attachment	  to	  assess	  the	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Figure	   4-­‐2:	   Constitutive	   expression	   of	   bbd18	   does	   not	   affect	   tick	   colonization	   or	  
persistence	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Figure	  4-­‐2	  legend:	  A.	  Spirochete	  burden	  in	  fed	  artificially	  infected	  larval	  I.	  scapularis.	  
Larvae	  were	  artificially	   infected	  (47)	  with	  S9,	  S9/pBSV2*flaBp-­‐bbd18-­‐A,	  S9/chase-­‐
pBSV2G,	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B,	   as	   indicated,	   and	   fed	   on	   naïve	   mice.	   Each	  
point	  denotes	  the	  number	  of	  viable	  spirochetes	  per	  tick	  as	  determined	  by	  the	  CFU	  
on	   solid	  media	  when	   fed	   larval	   ticks	  were	   individually	   crushed	   and	   plated	   seven	  
days	   after	   drop	   off,	   and	   bars	   represent	  mean	   +	   SD.	   The	   fraction	   below	   the	   X-­‐axis	  
indicates	   the	   number	   of	   infected	   ticks	   over	   the	   total	   analyzed	   (four/strain).	   B.	  
Spirochete	   burden	   in	   fed	   nymphs,	   which	   were	   artificially	   infected	   as	   larvae.	  
Remaining	   fed	   artificially	   infected	   larvae	   (other	   than	   the	   subset	   analyzed	   for	  
infection	  in	  A)	  were	  allowed	  to	  molt	  before	  being	  fed	  on	  naïve	  mice	  as	  nymphs.	  Each	  
point	   denotes	   the	   number	   of	   viable	   spirochetes	   per	   nymph	   as	   determined	   by	   the	  
CFU	  on	  solid	  media	  when	  fed	  ticks	  were	  individually	  crushed	  and	  plated	  seven	  days	  
after	  drop	  off,	  and	  bars	  represent	  mean	  +	  SD.	  Black	  points	  indicate	  nymphs	  that	  fed	  
to	  repletion,	  whereas	  red	  points	   indicate	  nymphs	  that	  were	  only	  partially	   fed.	  The	  
fraction	   below	   the	   X-­‐axis	   indicates	   the	   number	   of	   infected	   ticks	   over	   the	   total	  
analyzed	  (4-­‐7/strain).	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Table	  4-­‐4:	  Transmission	  of	  B.	  burgdorferi	  by	  infected	  ticks	  
strain	   No.	  of	  infected	  mice/mice	  fed	  on	  by	  
infected	  larvaea	  
No.	  of	  seropositive	  mice	  
/mice	  fed	  on	  by	  infected	  
nymphsb	  
No.	  of	  mouse	  
reisolates/mice	  fed	  on	  by	  
infected	  nymphs	  (ear,	  
bladder,	  joint)c	  
S9	   1/1	   2/2	   2/2	  
S9/pBSV2*flaBp-­‐
bbd18-­‐A	   0/1	   0/4d	   0/4d	  
S9/chase-­‐pBSV2G	   1/1	   1/1	   0/1	  
S9/pBSV2*flaBp-­‐
bbd18-­‐B	   0/1	   0/1	   0/1	  
a	  results	  from	  serology	  confirmed	  with	  reisolation	  from	  ear,	  bladder	  and	  joint	  tissues	  when	  mice	  
were	  euthanized	  at	  3	  weeks	  post	  larvae	  drop-­‐off	  
b	  seroconversion	  to	  B.	  burgdorferi	  proteins	  assessed	  when	  mice	  were	  euthanized	  3	  weeks	  after	  
nymph	  drop-­‐off	  
c	  mice	  were	  euthanized	  at	  3	  weeks	  after	  nymph	  drop-­‐off	  
	  
d	  includes	  data	  from	  independent	  experiments	  by	  Dr.	  Amit	  Sarkar	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upregulation	  of	  OspC	  on	  the	  surface	  of	  B.	  burgdorferi	  in	  feeding	  ticks	  (see	  below).	  S9	  
and	   S9/chase-­‐pBSV2G	   were	   transmitted	   by	   infected	   nymphs	   to	   mice	   where	   they	  
established	   infection,	  as	  measured	  by	  seroconversion	  and	  tissue	  reisolation	  (Table	  
4-­‐4).	   In	   contrast,	   mice	   fed	   on	   by	   ticks	   infected	   with	   S9/pBSV2*flaBp-­‐bbd18-­‐A	   or	  
S9/pBSV2*flaBp-­‐bbd18-­‐B	  neither	  seroconverted	  to	  B.	  burgdorferi	  proteins	  nor	  were	  
spirochetes	  reisolated	  from	  tissues	  when	  mice	  were	  euthanized	  at	  3	  weeks	  (Table	  4-­‐
4).	   Although	   B.	   burgdorferi	   containing	   pBSV2*flaBp-­‐bbd18	   were	   not	   able	   to	  
establish	   infection	   in	  mice	   by	   needle	   inoculation	   (Table	   4-­‐3)	   or	   tick	   transmission	  
(Table	   4-­‐4),	   the	   overexpression	   of	   bbd18	   did	   not	   affect	   the	   persistence	   of	  
spirochetes	   within	   ticks,	   and	   spirochete	   numbers	   within	   nymphs	   were	   not	  
significantly	   different	   between	   strains	   when	   assessed	   seven	   days	   after	   drop	   off	  
(Figure	  4-­‐2B).	  Additionally,	  since	  S9/chase-­‐pBSV2g	  persisted	  through	  the	  tick	  molt	  
and	  was	   transmitted	   to	  naïve	  mice	   (Table	  4-­‐4	  and	  Figure	  4-­‐2),	   cp32-­‐1	  and	   lp28-­‐4	  
are	  not	  required	  for	  B.	  burgdorferi	   survival	   in	   its	  natural	   infectious	  cycle.	  We	  have	  
shown	   that	  B.	   burgdorferi	   that	   constitutively	   express	  bbd18	   are	   non-­‐infectious	   by	  
needle-­‐inoculation	   (Table	   4-­‐3)	   and	   tick	   bite	   (Table	   4-­‐4),	   but	   we	   wanted	   to	  
investigate	   the	   mechanism	   by	   which	   this	   occurs.	   Since	   BBD18	   represses	   OspC	  
synthesis	   in	   vitro,	   we	   hypothesized	   that	   the	   observed	   loss	   of	   infectivity	   of	  
S9/pBSV2*flaBp-­‐bbd18-­‐A	   and	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   resulted	   because	   BBD18	  
repressed	   OspC	   within	   feeding	   ticks	   and	   during	   early	   infection	   where	   wt	   B.	  
burgdorferi	  normally	  produce	  OspC.	  Thus,	  we	  determined	  the	  OspC	  phenotype	  of	  S9,	  
S9/pBSV2*flaBp-­‐bbd18-­‐A,	   and	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   within	   feeding	   nymphs	  
that	  were	   forcibly	   removed	  at	  48	  hours	  post-­‐attachment.	  We	  used	   this	   time	  point	  
because	   Piesman	   and	   Schwan	   reported	   the	   highest	   proportion	   of	   OspC-­‐positive	  
 147 
spirochetes	   at	  day	  2	   after	   attachment	   (6).	  We	  used	  a	  monoclonal	  mouse	  antibody	  
recognizing	  OspC	  to	  analyze	  B.	  burgdorferi	   that	  had	   induced	  OspC	  (Figure	  4-­‐3,	   left	  
panels)	   and	   a	   convalescent	   rabbit	   serum	   to	   visualize	   the	   entire	   B.	   burgdorferi	  
population	  (Figure	  4-­‐3,	  right	  panels)	  within	  dissected	  ticks.	  We	  only	  detected	  OspC	  
on	  spirochetes	   in	   ticks	   infected	  with	  the	  wt	  S9	  strain,	  which	  did	  not	  constitutively	  
express	   bbd18,	   as	   shown	   by	   green	   spirochetes	   in	   Figure	   4-­‐3	   (top	   left).	   Although	  
there	   were	   no	   OspC-­‐positive	   spirochetes	   in	   ticks	   containing	   S9/pBSV2*-­‐flaBp-­‐
bbd18-­‐A	  or	  S9/pBSV2*-­‐flaBp-­‐bbd18-­‐B,	  spirochetes	  were	  evident	  within	  these	  ticks	  
when	   analyzed	   using	   the	   anti-­‐B.	   burgdorferi	   rabbit	   serum	   (Figure	   4-­‐3,	   red	  
spirochetes,	  right	  panels).	  These	  data	  demonstrate	  that	  constitutive	  bbd18	  prevents	  
the	   upregulation	   of	   OspC	   by	   B.	   burgdorferi,	   even	   in	   the	   natural	   environment	   of	   a	  
feeding	   tick,	   where	   OspC	   is	   normally	   induced.	   Presumably	   this	   lack	   of	   OspC	   in	  
S9/pBSV2*flaBp-­‐bbd18-­‐A	   and	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   is	   central	   to	   why	   these	  
strains	   were	   non-­‐infectious	   in	   mice	   (Tables	   4-­‐3	   and	   4-­‐4),	   as	   OspC	   is	   critical	   for	  
establishing	  infection	  in	  mammals	  (8-­‐11).	  
B.	  burgdorferi	  lacking	  bbd18	  are	  infectious	  in	  mice	  	  
Previous	  in	  vitro	  results	  using	  a	  high	  passage	  clone	  of	  B.	  burgdorferi	  showed	  
that	   expression	   of	   bbd18	   represses	   the	   critical	   virulence	   factor	   ospC,	   and	   in	   the	  
absence	   of	   BBD18,	   ospC	   is	   expressed	   (Chapter	   3,	   (30)).	   Our	   current	   data	  
demonstrate	   that	   overexpression	   of	   bbd18	   in	   an	   infectious	   clone	   represses	   the	  
upregulation	   of	   ospC	   in	   feeding	   ticks	   and	   prevents	   infection	   in	   mice.	   Thus,	   we	  
hypothesized	   that	   an	   infectious	   clone	   of	  B.	   burgdorferi	   that	   lacks	  bbd18	  would	   be	  
infectious	  in	  mice	  since	  OspC	  would	  not	  be	  repressed.	  However,	   if	  BBD18	  is	  the	   in	  
vivo	  ospC	  repressor	  required	  to	  downregulate	  ospC	  in	  response	  to	  immune	  pressure,	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Figure	  4-­‐3:	  B.	  burgdorferi	   constitutively	  expressing	  bbd18	   do	  not	  upregulate	  OspC	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Figure	  4-­‐3	  legend:	  Immunofluorescence	  microscopy	  of	  spirochetes	  within	  feeding	  I.	  
scapularis	   nymphs.	   Nymphs	   infected	   with	   S9	   (top),	   S9/pBSV2*flaBp-­‐bbd18-­‐A	  
(middle),	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B	   (bottom)	   were	   manually	   detached	   after	   2	  
days	  of	  attachment	  and	  assessed	   for	   the	  presence	  of	  OspC.	  Spirochetes	  within	   tick	  
smears	  were	  co-­‐stained	  with	  a	  mouse	  monoclonal	  antibody	  recognizing	  OspC	  (left	  
panels)	  and	  polyclonal	  rabbit	  serum	  that	  detects	  all	  B.	  burgdorferi	  regardless	  of	  the	  
OspC	  phenotype	  (right	  panels).	  Spirochetes	  were	  detected	  in	  each	  tick	  with	  the	  anti-­‐
B.	  burgdorferi	  rabbit	  serum	  (right	  panels,	  red	  spirochetes).	  However,	  OspC	  was	  only	  
detected	  on	   the	   surface	  of	  wt	  S9	   spirochetes	   (top	   left)	   and	  not	  on	   the	   spirochetes	  
overexpressing	   bbd18	   (S9/pBSV2*flaBp-­‐bbd18-­‐A	   or	   S9/pBSV2*flaBp-­‐bbd18-­‐B,	  
middle	  and	  bottom	  left,	   respectively).	   Images	  were	  taken	  with	  a	  Nikon	  Eclipse	  80i	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then	  B.	   burgdorferi	   lacking	   bbd18	   should	   not	   persist,	   as	   the	   mammalian	   immune	  
system	   would	   target	   spirochetes	   that	   continue	   to	   express	   ospC.	   A	   recent	   study	  
investigating	   the	   role	   of	   genes	   encoded	   on	   lp17	   used	   truncations	   of	   lp17	   in	   an	  
infectious	  B.	  burgdorferi	  clone	  (31).	  Casselli	  et	  al.	   injected	  mice	  with	  B.	  burgdorferi	  
harboring	   a	   truncated	   version	  of	   lp17,	   in	  which	   the	   region	   encoding	  bbd16-­‐bbd25	  
(including	   bbd18)	   was	   deleted	   by	   the	   insertion	   of	   a	   synthetic	   telomere.	   This	   B.	  
burgdorferi	  strain	  was	  able	  to	  establish	  infection	  and	  even	  persist	  up	  to	  8	  weeks	  but	  
had	  a	  defect	   in	  colonizing	   the	  murine	  bladder	  (31).	  While	  attempting	   to	   inactivate	  
bbd18	   (which	   proved	   to	   be	   not	   straightforward),	   we	   decided	   to	   repeat	   the	  
experiments	  by	  Casselli	  et	  al.,	  and	  utilize	  lp17	  truncations	  in	  the	  infectious	  clone	  S9	  
to	   further	   investigate	   the	  role	  of	  bbd18	  during	  the	   infectious	  cycle.	  We	  used	  gDNA	  
from	  B.	  burgdorferi	   containing	  pGCB473	  (30,	  51),	   a	   truncated	  version	  of	   lp17	   that	  
only	  harbors	  bbd1-­‐bbd14	  (lacking	  bbd18),	   to	   transform	  S9	  and	  displace	   full-­‐length	  
lp17.	  We	  also	  used	  pGCB426	  (30,	  51),	  a	  truncated	  version	  of	  lp17	  containing	  bbd1-­‐
bbd20	  	  (retaining	  bbd18)	  as	  a	  more	  appropriate	  control	  for	  S9/pGCB473.	  	  Southern	  
blot	  analysis	  confirmed	  that	  full-­‐length	  lp17	  had	  been	  displaced	  from	  S9	  using	  both	  
pGCB473	   and	   pGCB426	   (Figure	   4-­‐4B),	   and	   the	   resulting	   strains	   S9/pGCB473	  
(Figure	  4-­‐4C)	  and	  S9/pGCB426	  	  (data	  not	  shown)	  retained	  the	  full	  plasmid	  content	  
as	  wt	  S9.	  
	   Groups	   of	   5	   mice	   were	   inoculated	   with	   S9,	   S9/pGCB473,	   or	   S9/pGCB426.	  
After	  3	  weeks,	  all	  mice	  from	  groups	  infected	  with	  S9/pGCB426	  or	  S9/pGCB473	  had	  
seroconverted	  to	  B.	  burgdorferi	  proteins	  (Table	  4-­‐5).	   	  These	  data	  demonstrate	  that	  
spirochetes	   lacking	   the	   right	   end	   of	   lp17,	   and	   importantly	   bbd18,	   are	   able	   to	  
establish	  infection	  in	  mice	  by	  needle	  inoculation.	  	  After	  euthanizing	  the	  mice	  at	  8	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Figure	  4-­‐4:	  Full-­‐length	  lp17	  displaced	  by	  pGCB426	  and	  pGCB473	  in	  S9	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Figure	  4-­‐4	   legend:	  A.	  Genomic	  DNA	  from	  S9	  or	  S9	  containing	   the	   lp17	  truncations	  
pGCB426	  or	  pGCB473	  separated	  by	  field-­‐inversion	  gel	  electrophoresis.	  Uncut	  gDNA	  
isolated	   from	   wt	   S9,	   B312,	   four	   transformants	   of	   S9/pGCB426,	   and	   11	  
transformants	   of	   S9/pGCB473,	   as	   indicated,	   was	   analyzed	   by	   gel	   electrophoresis	  
and	  visualized	  with	  Gel	  Red	  and	  ultraviolet	  light.	  The	  size	  in	  base	  pairs	  (bp)	  relative	  
to	   the	  migration	   of	   standards	   is	   shown	   to	   the	   left.	  B.	   gDNA	  hybridization	  with	   an	  
lp17	   gene	   (bbd13)	   probe.	   Nylon-­‐membrane-­‐bound	   gDNA	   transferred	   from	   gels	  
shown	  in	  A	  was	  incubated	  with	  a	  DIG-­‐labeled	  probe	  corresponding	  to	  bbd13,	  which	  
recognizes	  lp17	  (full-­‐length	  or	  smaller	  truncated	  forms).	  Hybridization	  of	  the	  probe	  
was	  visualized	  using	  an	  anti-­‐DIG	  antibody,	  chemiluminescent	  substrates,	  and	  X-­‐ray	  
film.	  C.	  Representative	   image	  of	   the	  plasmid	  profile	  of	  B.	  burgdorferi.	  One	  clone	  of	  
S9/pGCB473	  (A	  and	  B)	  had	  the	  same	  plasmid	  profile	  as	  parental	  S9,	  which	  lacks	  cp9	  
and	   lp56,	   when	   gDNA	   was	   analyzed	   using	   primers	   specific	   to	   individual	   B.	  
burgdorferi	  plasmids	  (52)	  The	  plasmids	  corresponding	  to	  the	  specific	  amplicons	  are	  
indicated	  above	  and	  gene	  numbers	  are	  specified	  when	  plasmids	  have	  more	  than	  one	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Table	  4-­‐5:	  B.	  burgdorferi	  harboring	  lp17-­‐truncations	  are	  infectious	  in	  mice	  by	  needle	  
inoculation	  
strain	  
No.	  of	  sero-­‐positive	  
mice/no.	  of	  injected	  
micea	  
No.	  of	  ear	  biopsy	  
reisolates/no.	  of	  injected	  
miceb	  
No.	  of	  mouse	  reisolates/no.	  
of	  injected	  mice	  (ear,	  
bladder,	  joint)c	  
S9	   4/5	   4/5	   4/5,	  4/5,	  4/5	  
S9/pGCB426	  
(+bbd18)	   5/5	   3/5	   4/5,	  0/5*,	  1/5	  
S9/pGCB473	  	  
(-­‐bbd18)	   5/5	   3/5	   5/5,	  2/5,	  3/5	  
a	  seroconversion	  to	  B.	  burgdorferi	  proteins	  was	  assessed	  at	  3	  weeks	  post-­‐inoculation	  
b	  ear	  biopsies	  were	  taken	  at	  3	  weeks	  post-­‐inoculation	   	  
c	  mice	  were	  euthanized	  at	  8	  weeks	  post-­‐inoculation	   	  
*	  P-­‐value	  <0.05	  compared	  to	  S9	  using	  the	  Fisher's	  exact	  test	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weeks	   post-­‐inoculation,	   spirochetes	   were	   reisolated	   from	   ear	   tissues	   of	   all	  
S9/pGCB473-­‐infected	  mice	  (lacks	  bbd18)	  and	  four	  out	  of	  five	  S9-­‐	  and	  S9/pGCB426	  
infected	  mice	  (retains	  bbd18)	  (Table	  4-­‐5).	  However,	  we	  observed	  lower	  colonization	  
of	  bladder	  and	  joint	  tissue	  for	  mice	  inoculated	  with	  B.	  burgdorferi	  harboring	  either	  
of	  the	  lp17	  truncations	  (Table	  4-­‐5).	  These	  results	  are	  in	  accord	  with	  the	  data	  from	  
Casselli	  et	  al.	  in	  which	  they	  reported	  a	  complete	  loss	  in	  bladder	  colonization	  in	  mice	  
infected	   with	   B.	   burgdorferi	   lacking	   bbd16-­‐25	   at	   8	   weeks	   post-­‐inoculation.	  
Surprisingly,	   only	   the	   bladder	   colonization	   defect	   observed	   in	  mice	   infected	   with	  
S9/pGCB426	  was	  significantly	  different	  from	  colonization	  results	  with	  S9	  (P-­‐value	  =	  
0.0476	  compared	  to	  S9	  using	  Fisher’s	  exact	   test)	   (Table	  4-­‐5),	   indicating	  that	  some	  
factor	   encoded	   by	   bbd20-­‐25	   (and	   not	   bbd18)	   contributes	   to	   the	   dissemination	  
and/or	  colonization	  of	  peripheral	  tissue	  by	  B.	  burgdorferi.	  	  
Nonetheless,	  these	  data	  confirm	  that	  spirochetes	  lacking	  bbd18	  are	  infectious	  
in	   the	   mouse	   model,	   but	   also	   suggest	   that	   bbd18	   is	   not	   the	   in	   vivo	   repressor	  
necessary	   for	   the	  downregulation	  of	  ospC	   after	  B.	  burgdorferi	   establishes	   infection	  
(12).	  To	  further	  investigate	  the	  role	  of	  bbd18	  during	  the	  infectious	  cycle,	  we	  wanted	  
to	  investigate	  whether	  the	  lack	  of	  bbd18	  would	  have	  any	  effect	  on	  tick	  acquisition	  or	  
transmission,	   which	   was	   not	   addressed	   by	   Casselli	   et	   al.	   (31).	   Therefore,	   we	   fed	  
uninfected	   I.	   scapularis	   larvae	   on	   the	   mice	   infected	   with	   S9,	   S9/pGCB426	   and	  
S9/pGCB473.	  Although	  results	  from	  ear	  biopsies	  taken	  at	  3	  weeks	  post-­‐inoculation	  
confirmed	  that	  the	  mice	  on	  which	  ticks	  were	  fed	  contained	  viable	  spirochetes	  within	  
skin	  tissues	  (Table	  4-­‐5),	  most	  larval	  ticks	  did	  not	  acquire	  spirochetes	  when	  they	  fed	  
on	  infected	  mice	  at	  4	  weeks	  post-­‐inoculation	  (Table	  4-­‐6),	  even	  from	  wt	  S9-­‐	  infected	  
mice,	  presumably	  reflecting	  some	  technical	  problem,	  but	  this	  experiment	  was	  not	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Table	  4-­‐6:	  Larval	  ticks	  did	  not	  acquire	  B.	  burgdorferi	  from	  infected	  mice	  
mouse	  infection	  strain	   no.	  infected	  larval	  ticks/no.	  analyzed	  
S9	   3/10	  
S9/pGCB426	  (+bbd18)	   0/10	  
S9/pGCB473	  (-­‐bbd18)	   1/10	  
a	  larval	  tick	  infection	  was	  determine	  by	  CFU	  on	  solid	  media	  or	  reisolation	  of	  spirochetes	  in	  liquid	  
media	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repeated	   because	   we	   had	   finally	   succeeded	   in	   inactivating	   the	   bbd18	   ORF	   in	   an	  
infectious	  B.	  burgdorferi	   clone.	  Thus,	  we	  decided	   to	  use	   this	   “clean”	  bbd18	  mutant	  
(S9Δbbd18,	   Table	  4-­‐1	  and	  below)	   in	   subsequent	   studies	   to	  avoid	  any	   confounding	  
results	   due	   to	   the	   deletion	   of	   the	   additional	   lp17-­‐encoded	   genes	   missing	   from	  
S9/pGCB426	  and	  S9/pGCB473.	  	  
Interrupting	  the	  bbd18	  ORF	  in	  S9	  
We	   have	   shown	   that	   constitutive	   expression	   of	   bbd18	   abrogates	   B.	  
burgdorferi	   infection	   in	   mice	   but	   wanted	   to	   investigate	   whether	   bbd18	   was	  
necessary	  during	  the	  infectious	  cycle	  by	  interrupting	  the	  bbd18	  ORF	  in	  an	  otherwise	  
infectious	  B.	   burgdorferi	   clone.	  We	   created	   an	   allelic	   exchange	   construct,	   pOK12-­‐
bbd18-­‐KO,	   in	   which	   the	   flgBp-­‐aacC1	   cassette,	   conferring	   gentamicin	   resistance,	  
interrupts	   the	  bbd18	  ORF	  near	   the	  5’	  end.	  After	  multiple	  attempts	  at	   transforming	  
S9	   with	   linearized	   pOK12-­‐bbd18-­‐KO,	   we	   identified	   a	   few	   colonies	   that	   amplified	  
both	  a	  wt	  and	  mutant	   size	  bbd18	   fragment	  by	  PCR;	   the	  mutant	  band	   is	  about	  1kb	  
larger	  is	  size	  due	  to	  the	  insertion	  of	  the	  flgBp-­‐aacC1	  cassette	  in	  the	  bbd18	  ORF	  (see	  
Figure	  4-­‐5C).	   Since	  we	  had	   linearized	   the	  allelic	   exchange	  vector,	  we	   thought	   that	  
the	  presence	  of	  both	  bands	  implied	  merodiploid	  lp17	  plasmid	  content	  as	  opposed	  to	  
the	  integration	  of	  the	  entire	  pOK12-­‐bbd18-­‐KO	  plasmid	  into	  lp17.	  After	  several	  serial	  
passages	  under	  gentamicin	  selection	  and	  screening	  colonies	  by	  PCR,	  we	  identified	  a	  
clone,	   referred	   to	   as	   S9Δbbd18,	   that	   only	   yielded	   a	  mutant-­‐size	  bbd18	   band	  when	  
screened	   by	   PCR	   (Figure	   4-­‐5C).	   Southern	   blotting	   confirmed	   that	   the	   flgBp-­‐aacC1	  
cassette	  had	  integrated	  on	  lp17	  and	  a	  wt	  bbd18	  gene	  copy	  was	  not	  present	  (Figure	  
4-­‐5).	   S9Δbbd18	   also	   retained	   the	   entire	   plasmid	   content	   as	   parental	   S9	   (a	  
representative	  image	  of	  the	  B.	  burgdorferi	  plasmid	  profile	  as	  determined	  by	  PCR	  is	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Figure	  4-­‐5:	  Inactivation	  of	  bbd18	  in	  S9	  
	  
	   	  
 158 
Figure	  4-­‐5	  legend:	  A.	  Genomic	  DNA	  from	  S9,	  A34Δbbd18,	  or	  S9Δbbd18	  separated	  by	  
field-­‐inversion	  gel	  electrophoresis.	  Uncut	  gDNA,	  isolated	  from	  wt	  S9,	  A34Δbbd18,	  or	  
S9Δbbd18,	   as	   indicated,	  was	   analyzed	   by	   gel	   electrophoresis	   and	   visualized	   using	  
Gel	  Red	  and	  ultraviolet	  light.	  The	  size	  in	  base	  pairs	  (bp)	  relative	  to	  the	  migration	  of	  
standards	   is	   listed	   between	   duplicate	   panels	   B.	   gDNA	   hybridization	   with	   probes	  
recognizing	  aacC1,	   the	   gentamicin-­‐resistance	  gene	   (gent,	   left	   blot)	  or	  bbd13	   (right	  
blot).	   Nylon	   membrane-­‐bound	   gDNA	   transferred	   from	   gels	   shown	   in	   A	   was	  
incubated	   with	   a	   DIG-­‐labeled	   probes	   corresponding	   to	   gent	   to	   localize	   the	   flgBp-­‐
aacC1	   insertion	   in	   the	  B.	  burgdorferi	   genome	  or	  bbd13,	  which	   is	   encoded	  on	   lp17.	  
Probe	   hybridization	  was	   visualized	   using	   an	   anti-­‐DIG	   antibody,	   chemiluminescent	  
substrates,	   and	   X-­‐ray	   film.	   The	   size	   in	   base	   pairs	   (bp)	   based	   on	   the	  migration	   of	  
standards	   is	   listed	   in	   between	   the	   two	   panels.	   C.	   Agarose	   gel	   analysis	   of	   PCR	  
amplification	  of	  the	  bbd18	  ORF.	  bbd18	  specific	  primers	  (Table	  4-­‐2)	  were	  used	  with	  
the	  bbd18	   inactivation	  plasmid,	  pOK12-­‐bbd18-­‐KO,	  wt	  S9	  gDNA,	  or	  a	  colony	  for	  the	  
S9Δbbd18	   clone,	   as	   indicated,	   	   to	   amplify	   the	   corresponding	  bbd18	   fragment.	   The	  
inactivation	   of	   bbd18	   leads	   to	   a	   larger	   product	   because	   of	   the	   insertion	   of	   flgBp-­‐
aacC1	   into	   the	  bbd18	  ORF.	  The	  size	   in	  base	  pairs	   (bp)	   relative	   to	   the	  migration	  of	  
standards	  is	  listed	  on	  the	  left.	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displayed	  in	  Figure	  4-­‐4C).	  	  
In	  order	  to	  confirm	  that	  any	  observed	  differences	  from	  wt	  S9	  were	  due	  to	  the	  
inactivation	  of	  bbd18,	  we	  wanted	   to	  complement	  S9Δbbd18	  with	  a	  wt	  bbd18	  gene.	  
However,	  we	  were	  concerned	  that	  expression	  of	  bbd18	  from	  a	  shuttle	  vector	  would	  
not	  complement	  the	  phenotype	  of	  S9Δbbd18,	  since	  overexpression	  of	  bbd18	  alone	  in	  
S9	   also	   abrogated	   infection	   in	   mice	   (Table	   4-­‐3).	   To	   address	   this	   possible	  
complication,	  we	  first	  utilized	  lp17::kan	  from	  the	  B31-­‐A	  derivative	  carrying	  pKK81	  
integration	  on	  lp17	  (30,	  36)	  to	  displace	  lp17	  harboring	  the	  flgBp-­‐aacC1	  insertion	  in	  
the	  bbd18	  open	  reading	  frame.	  Although	  this	  strategy	  would	  indicate	  that	  the	  	  
phenotype	  of	  the	  bbd18	  mutant	  was	  due	  to	  a	  change	  in	  lp17,	  it	  would	  not	  necessarily	  
specify	  bbd18	  as	  the	  culprit.	  Thus,	  we	  also	  used	  pBSV2*NP-­‐bbd18	  (Table	  4-­‐1,	  (30)),	  
which	  harbors	   a	  wt	  bbd18	   gene	   expressed	   from	   its	  native	  promoter,	   to	   transform	  
S9Δbbd18.	  We	  hypothesized	  that	  by	  using	  the	  native	  bbd18	  promoter,	  we	  could	  limit	  
the	   amount	   of	  bbd18	   expressed	   and	   control	   for	   the	  proper	   regulation	  of	  bbd18.	   If	  
this	   latter	  strategy	  worked,	  we	  would	  be	  able	   to	  demonstrate	   that	  any	  phenotypic	  
defect	  of	  S9Δbbd18	  was	  strictly	  due	  to	  the	  interruption	  of	  the	  native	  bbd18	  gene	  on	  
lp17.	   Both	   complemented	   clones,	   S9Δbbd18/lp17::kan	   and	   S9Δbbd18/pBSV2*NP-­‐	  
bbd18	  (Table	  4-­‐1),	  retained	  the	  full	  plasmid	  content	  as	  S9Δbbd18	  and	  the	  parental	  
S9	  (see	  Figure	  4-­‐4C	  for	  an	  example	  of	  the	  S9	  plasmid	  profile).	  	  	  
	   Groups	  of	  5	  mice	  were	  inoculated	  with	  S9,	  S9Δbbd18,	  S9Δbbd18/lp17::kan	  or	  
S9Δbbd18/pBSV2*NP-­‐bbd18.	   After	   3	   weeks,	   we	   assessed	   the	   seroconversion	   of	  
inoculated	  mice	   to	  B.	   burgdorferi	   proteins	   and	   attempted	   to	   reisolate	   spirochetes	  
from	  ear	  biopsy	  tissue.	  We	  found	  that	  none	  of	  the	  mice	  inoculated	  with	  S9Δbbd18,	  
S9Δbbd18/lp17::kan,	   or	   S9Δbbd18/pBSV2*NP-­‐bbd18	   seroconverted	   and	   that	   no	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spirochetes	   were	   reisolated	   from	   ear	   biopsy	   cultures,	   whereas	   wt	   S9	   resulted	   in	  
infection	  by	  both	  measures,	  as	  expected	  (Table	  4-­‐7).	  The	  lack	  of	  infectivity	  in	  mice	  
inoculated	   with	   S9Δbbd18	   was	   surprising	   since	   mice	   infected	   with	   S9/pGCB473,	  
which	  lacks	  bbd18,	  had	  seroconverted	  to	  B.	  burgdorferi	  by	  3	  weeks	  and	  spirochetes	  
were	  isolated	  from	  all	  ear	  tissues	  from	  these	  mice	  at	  8	  weeks	  (Table	  4-­‐5).	  The	  fact	  
that	  mice	  inoculated	  with	  S9Δbbd18/lp17::kan	  or	  S9Δbbd18/pBSV2*NP-­‐bbd18	  were	  
also	  not	  seropositive	  and	  no	  spirochetes	  were	  reisolated	  from	  ear	  tissues	  (Table	  4-­‐
7)	  indicated	  that	  neither	  complementing	  strategy	  restored	  the	  ability	  to	  infect	  mice.	  
This	  inability	  to	  complement	  the	  infectivity	  defect	  of	  S9Δbbd18	  suggests	  that	  other	  
mutations	  occurred	  in	  S9Δbbd18	  in	  addition	  to	  the	  insertion	  of	  flgBp-­‐aacC1	  into	  the	  
bbd18	  ORF.	  We	  did	  not	  detect	  any	  obvious	  changes	  in	  S9Δbbd18	  that	  would	  account	  
for	   its	   lack	  of	   infectivity,	  as	   it	  retained	  the	  full	  plasmid	  content	  of	  wt	  S9	  and	  had	  a	  
similar	   protein	   profile	   as	   analyzed	   by	   Coomassie	   staining	   (Figure	   4-­‐6).	   We	   have	  
attempted	  to	  reconstruct	  another	  bbd18	  mutant	   in	  an	   infectious	  background	  using	  
both	  the	  linearized	  allelic	  exchange	  construct	  (pOK12-­‐bbd18-­‐KO)	  and	  genomic	  DNA	  
from	  S9Δbbd18,	  but	  so	  far	  have	  been	  unsuccessful.	  	  	  
	   The	   secondary	   mutations	   that	   occurred	   in	   S9Δbbd18	   and	   the	   fact	   that	   we	  
have	  been	  unable	  to	   isolate	  a	  second	  bbd18	  mutant	  are	  not	  surprising	  considering	  
the	  difficulty	  in	  obtaining	  the	  first	  bbd18	  mutant	  in	  S9.	  It	  is	  noteworthy,	  though,	  that	  
using	  the	  same	  allelic	  exchange	  construct,	  pOK12-­‐bbd18-­‐KO,	  we	  readily	  generated	  a	  
bbd18	  mutant	   in	   the	   non-­‐infectious	  B.	   burgdorferi	   clone	  A34	   (53)	   during	   the	   first	  
round	  of	  transformations	  and	  this	  was	  easily	  repeated.	  Additionally,	  displacing	  full-­‐
length	  lp17	  from	  S9	  with	  pGCB473,	  the	  lp17	  truncation	  that	   is	  missing	  bbd18,	  was	  
relatively	  easy	  compared	  to	  the	  allelic	  exchange	  that	  resulted	  in	  S9Δbbd18.	  These	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Table	   4-­‐7:	   The	   bbd18	   mutant	   and	   its	   complemented	   clones	   are	   non-­‐infectious	   in	  
mice	  by	  needle	  inoculation	  	  
strain	  
No.	  of	  sero-­‐positive	  
mice/no.	  of	  injected	  
micea	  
No.	  of	  mouse	  
reisolates/no.	  of	  injected	  
mice	  
S9	   5/5	   5/5b	  
S9Δbbd18	   0/10	   0/10c	  
S9Δbbd18/lp17::kan	   0/10	   0/10d	  
S9Δbbd18/pBSV2*NP-­‐bbd18	   0/5	   0/5d	  
a	  seroconversion	  to	  B.	  burgdorferi	  proteins	  was	  assessed	  at	  3	  weeks	  post-­‐inoculation	  
b	  reisolation	  from	  ear,	  bladder,	  and	  joint	  for	  each	  mouse,	  mice	  were	  euthanized	  at	  6	  weeks	  post-­‐
inoculation	  
c	  total	  of	  reisolation	  from	  ear,	  bladder,	  and	  joint	  for	  5	  mice	  euthanized	  at	  6	  weeks	  post-­‐inoculation	  
and	  reisolation	  from	  ear	  tissues	  only	  from	  5	  mice	  euthanized	  at	  5	  weeks	  post-­‐inoculation	  
d	  reisolation	  from	  ear	  only,	  mice	  were	  eithanized	  at	  4-­‐5	  weeks	  post-­‐inoculation	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Figure	   4-­‐6:	   Coomassie	   staining	   does	   not	   reveal	   any	   differences	   in	   total	   protein	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Figure	  4-­‐6	  legend:	  Coomassie	  blue	  stained	  gel	  of	  S9	  clones.	  Whole	  cell	  lysates	  of	  S9	  
and	   S9	   derivatives,	   as	   indicated,	  were	   separated	   on	   a	   12.5%	   acrylamide	   gel	   	   and	  
then	  stained	  with	  Coomassie	  blue	  to	  visualize	  protein.	  Numbers	  on	  the	  left	  refer	  to	  
protein	  size	  in	  kDa	  determined	  by	  the	  mobility	  of	  protein	  standards.	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data	  suggest	  that	  there	  is	  some	  undefined	  but	  critical	  aspect	  of	  the	  retention	  of	  the	  
bbd18	   locus	   and/or	   the	   BBD18	   protein	  within	   the	   context	   of	   an	   infectious	   strain,	  
which	  carries	  other	  lp17	  genes.	  	  
	   We	   have	   shown	   that	   bbd18	   likely	   plays	   a	   role	   during	   the	   B.	   burgdorferi	  
infectious	  cycle,	  as	  spirochetes	  that	  constitutively	  express	  bbd18	  are	  non-­‐infectious	  
and	   do	   not	   upregulate	   OspC	   within	   feeding	   ticks.	   Spirochetes	   lacking	   a	   large	  
segment	   of	   lp17,	   including	   bbd18,	   were	   able	   to	   establish	   infection	   but	   were	  
attenuated	  for	  colonization	  of	  the	  mice	  bladder	  and	  joint.	  However,	  we	  were	  unable	  
to	   identify	   a	   specific	   contribution	   of	   bbd18	   to	   this	   phenotype,	   as	   B.	   burgdorferi	  
containing	  pGCB426,	  which	  retains	  a	  wt	  bbd18	  gene,	  had	  a	  similar	  phenotype,	  and	  
secondary	  mutations	  in	  S9Δbbd18	  prevented	  mouse	  infection	  even	  when	  the	  bbd18	  
mutation	  was	   complemented	  with	   a	  wt	  bbd18	   gene.	   The	   fact	   that	   the	   only	  bbd18	  
mutant	   that	   we	   recovered	   in	   an	   infectious	   background	   had	   additional	   mutations	  
might	   intrinsically	   suggest	   the	   importance	  of	  bbd18	   during	   the	   infectious	   cycle,	   as	  
these	   additional	   changes	  may	   be	   required	   in	   order	   for	  bbd18	   to	   be	   disrupted.	   To	  
further	  understand	  what	   role	  BBD18	  might	  be	  playing	  during	   the	   infectious	  cycle,	  
we	  also	  used	  in	  vitro	  assays	  to	  investigate	  the	  mechanism	  of	  how	  BBD18	  represses	  
OspC.	  	  
The	  putative	  ospC	  operator	  is	  not	  necessary	  for	  repression	  by	  BBD18.	  
	   Previous	   work	   by	   Xu	   and	   colleagues	   (28)	   identified	   a	   putative	   operator	  
upstream	  of	  the	  ospC	  promoter	  that	  was	  necessary	  for	  the	  downregulation	  of	  ospC	  in	  
response	  to	  immune	  pressure.	  Thus,	  the	  simplest	  mechanism	  we	  imagined	  for	  how	  
BBD18	   might	   repress	   ospC	   would	   be	   BBD18	   binding	   to	   this	   putative	   operator	  
sequence.	  To	  test	  this,	  we	  wanted	  to	  determine	  whether	  the	  operator	  sequence	  was	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required	  for	  repression	  of	  ospC	  by	  BBD18.	  Typically,	  wt	  B.	  burgdorferi	  clones	  do	  not	  
produce	  OspC	   in	  vitro	  unless	  grown	   to	  high	  density	  or	  otherwise	  manipulated.	  On	  
the	  other	  hand,	  the	  high	  passage	  B.	  burgdorferi	  clone	  B312	  (Table	  4-­‐1	  and	  (30,	  32,	  
38))	  produces	  abundant	  OspC	  protein	  in	  vitro	  without	  manipulation,	  which	  makes	  it	  
an	  ideal	  clone	  with	  which	  to	  investigate	  the	  ospC	  promoter	  sequences	  required	  for	  
repression	  by	  BBD18.	  We	  also	  utilized	  the	  lacZ	  reporter	  system	  that	  was	  developed	  
for	  B.	  burgdorferi	  (32)	   to	  aid	   in	   these	  experiments.	  We	  expressed	   lacZBb*	   in	  B312	  
using	   either	   a	   full-­‐length	   ospC	   promoter	   that	   includes	   the	   entire	   inverted	   repeat	  
(putative	   operator	   sequence)	   or	   a	   minimal	   ospC	   promoter,	   P7F,	   which	   lacks	   the	  
putative	  operator	  sequence	  (Figure	  4-­‐7A).	  Xu	  et	  al.	  demonstrated	  that	  this	  minimal	  
ospC	   promoter	   was	   sufficient	   for	   inducing	   OspC	   in	   B.	   burgdorferi,	   but	   that	   these	  
spirochetes	  were	  unable	  to	  downregulate	  ospC	  in	  vivo	  (28).	  In	  B312,	  both	  versions	  
of	  the	  OspC	  promoter	   led	  to	  expression	  of	   lacZ	  as	  detected	  by	  X-­‐gal	   in	  solid	  media	  
(Figure	   4-­‐7B,	   top	   panels).	   We	   then	   co-­‐expressed	   bbd18	   in	   these	   clones	   using	   a	  
constitutive	   promoter	   on	   a	   compatible	   shuttle	   vector.	   BBD18	  was	   able	   to	   repress	  
lacZ	   expression	   from	   either	   ospC	   promoter	   regardless	   of	   whether	   the	   putative	  
operator	   sequence	   was	   present	   or	   not	   (Figure	   4-­‐7B,	   bottom	   panels).	   These	   data	  
indicate	  that	  BBD18	  does	  not	  require	  the	  putative	  operator	  sequence	  for	  repression	  
of	  ospC.	  Furthermore,	  similar	   experiments	  using	   lacZ	   expressed	   from	  an	  ospC-­‐flaB	  
fusion	  promoter,	  which	  was	  created	  by	  created	  by	  fusing	  the	  core	  ospC	  promoter	  (-­‐
35	  region	  up	  to	  the	  +1)	  and	  the	  flaB	  promoter	  5’	  untranslated	  region	  (+1	  to	  the	  ATG	  
translation	  start,	  including	  the	  RBS)	  demonstrated	  that	  only	  the	  core	  ospC	  promoter	  
(-­‐35	  and	  -­‐10	  regions)	  was	  required	  for	  repression	  of	  ospC	  by	  BBD18	  (Figure	  4-­‐7B,	  
right	  panels).	  These	  findings	  indicate	  that	  BBD18	  in	  an	  operator-­‐independent	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Figure	   4-­‐7	   legend:	   A.	   The	   ospC	   promoter	   and	   upstream	   regulatory	   regions.	   Two	  
large	  inverted	  repeat	  sequences	  (putative	  operator,	  indicated	  by	  a	  pair	  of	  divergent	  
arrows),	   the	   -­‐35	   and	   -­‐10	   regions,	   the	   ribosome-­‐binding	   site	   (RBS)	   and	   the	   start	  
codon	  ATG	  (in	  bold)	  of	  ospC	  are	  all	   indicated.	  The	  transcriptional	  start	  site	  (54)	   is	  
designated	   as	   +1.	   The	   5’	   ends	   of	   primers	   use	   to	   construct	   the	   ospC-­‐lacZ	   reporter	  
genes	  with	  or	  without	  the	  putative	  operator	  (ospCp	  forward	  and	  P7F,	  respectively;	  
Table	   4-­‐2)	   are	   indicated	  with	   arrows	   above	   the	   sequence.	   This	   diagram	   is	   closely	  
modeled	  after	  a	  figure	  by	  Xu	  et	  al.	  (28).	  B.	  lacZBb	  expression	  in	  B.	  burgdorferi	  from	  a	  
variety	   of	   ospC	   promoters	   assessed	   by	   X-­‐gal	   in	   solid	   media.	   BSK	   solid	   medium	  
without	   phenol	   red	   was	   used	   to	   grow	   B312/pBHospCp-­‐lacZBb*	   (left),	  
B312/pBHP7F-­‐lacZBb*	  (middle),	  or	  B312/pBHospCp-­‐flaBpRBS-­‐lacZBb*	  (right)	  with	  
(bottom)	   or	   without	   (top)	   pBSV28-­‐1-­‐flaBp-­‐bbd18,	   as	   indicated.	   After	   colony	  
formation,	  X-­‐gal	  was	  added.	  β-­‐galactosidase	  activity	  (blue	  color)	  was	  only	  detected	  
in	  colonies	  without	  BBD18	  (top),	  indicating	  that	  BBD18	  was	  able	  to	  repress	  lacZBb	  
expression	   from	   the	   ospC	   promoter	   whether	   or	   not	   the	   operator	   sequence	   was	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manner,	  suggesting	  that	  BBD18	  is	  not	  the	  ospC-­‐specific	  in	  vivo	  repressor	  (28).	  Since	  
our	  previous	  experiments	  in	  E.	  coli	  (Figure	  3-­‐3)	  indicated	  an	  indirect	  mode	  of	  ospC	  
repression	  by	  BBD18,	  we	  questioned	  whether	  BBD18	  might	  be	  working	  upstream	  of	  
ospC	  possibly	  through	  the	  alternative	  sigma	  factor,	  RpoS,	  which	  is	  required	  for	  ospC	  
expression	  in	  B.	  burgdorferi	  (20,	  25).	  	  
Inactivation	  of	  RpoS	  in	  B312	  abrogates	  OspC	  production	  
	   Since	   B312	   is	   a	   high	   passage	   strain	   and	   produces	   OspC	   in	   vitro	   without	  
manipulation	   unlike	   wt	   virulent	   B.	   burgdorferi,	   we	   wanted	   to	   confirm	   that	   OspC	  
expression	   in	   B312	   is	   indeed	   dependent	   on	   RpoS	   as	   described	   for	   low-­‐passage	  
virulent	  B.	  burgdorferi	  (20,	  25).	   In	  order	  to	  accomplish	  this,	  we	  inactivated	  rpoS	   in	  
clone	  B312	  by	  the	  same	  allelic	  exchange	  construct	  used	  to	   inactivate	  rpoS	   in	  wt	  B.	  
burgdorferi	   (37).	   Although	   we	   had	   tried	   to	   obtain	   transformants	   in	   B312	   with	  
various	   allelic	   exchange	   constructs	   in	   the	   past,	   we	   had	   not	   succeeded.	   In	   this	  
attempt,	  we	  first	  transformed	  B312	  with	  a	  shuttle	  vector	  harboring	  a	  constitutively	  
expressed	  recA	  gene,	  as	  Dr.	  Frank	  Gherardini	  (RML,	  NIAID,	  NIH)	  had	  suggested	  that	  
this	  might	  increase	  the	  frequency	  of	  homologous	  recombination	  (and	  consequently	  
allelic	   exchange)	   in	   B.	   burgdorferi	   (personal	   communication	   with	   Dr.	   Frank	  
Gherardini).	   To	   this	   end,	   we	   transformed	   the	   B312	   derivative	   containing	   recA	  
(B312/pBSV2G-­‐flaBp-­‐recA,	   Table	   4-­‐1)	   with	   the	   rpoS::kan	   inactivation	   construct	  
(37).	  This	  strategy	  was	  successful	  and	  we	  were	  able	  to	  isolate	  a	  B312	  transformant	  
in	  which	  rpoS	  had	  been	  inactivated.	  We	  then	  analyzed	  the	  B312ΔrpoS	  clone	  for	  the	  
presence	   of	   OspC	   by	   immunoblot	   (Figure	   4-­‐8).	  We	   detected	   OspC	   in	  wt	   B312,	   as	  
expected,	   and	   in	   B312/pBSV2G-­‐flaBp-­‐recA,	   but	   not	   in	   the	   B312	   rpoS	   mutant	   in.	  
These	  data	  confirm	  that	  OspC	  expression	  in	  B312	  is	  RpoS-­‐dependent	  (Figure	  4-­‐8)	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Figure	  4-­‐8	  legend:	  OspC	  and	  FlaB	  Immunoblots	  of	  B.	  burgdorferi.	  Whole	  cell	  lysates	  
of	   B312,	   A34	   (negative	   control),	   B312/pBSV2G-­‐flaBp-­‐recA	   (parent	   of	   B312Δrpos),	  
and	  B312Δrpos	  were	  analyzed	  with	  antisera	  recognizing	  OspC	  and	  FlaB,	  which	  was	  
used	  as	  an	  internal	  control	  for	  protein	  loading.	  Numbers	  at	  the	  left	  refer	  to	  protein	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and	  validate	  the	  utility	  of	  B312	  in	  the	  analysis	  of	  ospC	  regulation	  by	  BBD18.	  	  
BBD18	  affects	  other	  RpoS-­‐dependent	  genes.	  	  
	   During	  the	  infectious	  cycle,	  spirochetes	  within	  feeding	  ticks	  induce	  the	  Rrp2-­‐
RpoN-­‐RpoS	   cascade	   and	  RpoS	   is	   directly	   responsible	   for	   the	   upregulation	   of	  ospC	  
(20,	   25)	   and	   numerous	   other	   genes,	   including	   dbpA	   (20,	   25)	   and	   bba66	   (46)	  We	  
hypothesized	   that	   if	   BBD18	  were	   acting	  upstream	  of	  ospC,	   perhaps	  on	  RpoS,	   then	  
BBD18	  would	  also	  affect	   the	  production	  of	  other	  RpoS-­‐regulated	  proteins,	   such	  as	  
DbpA	  and	  BBA66.	  Thus,	  we	  wanted	   to	  determine	   if	  BBD18	  has	   an	   effect	   on	   these	  
other	  RpoS-­‐dependent	  genes	  by	  constitutively	  expressing	  BBD18	  in	  an	  infectious	  B.	  
burgdorferi	  clone	  and	  analyzing	  the	  protein	  content	  by	  immunoblot.	  Unlike	  the	  high-­‐
passage	   non-­‐infectious	   clone	   B312	   that	   produces	   OspC	   in	   vitro	   without	  
manipulation,	   the	   production	   of	   RpoS	   and	   thus	   OspC,	   DbpA,	   and	   BBA66	   in	   an	  
infectious	  B.	   burgodorferi	   clone	   like	   S9	  must	   be	   induced.	   This	   can	   be	   achieved	   by	  
mimicking	  some	  of	  the	  environmental	  changes	  that	  are	   found	  within	  feeding	  ticks,	  
such	  as	  the	  change	  in	  temperature	  (7,	  17,	  55)	  and	  pH	  (17,	  56).	  Since	  we	  wanted	  to	  
assess	  the	  ability	  of	  BBD18	  to	  repress	  the	  production	  of	  OspC,	  DbpA,	  and	  BBA66,	  we	  
used	   temperature-­‐shifted	   B.	   burgdorferi	   cultures	   to	   ensure	   that	   the	   necessary	  
signals	  for	  RpoS	  induction	  were	  present.	  Spirochetes	  were	  harvested	  from	  cultures	  
grown	   at	   25°	   or	   from	   cultures	   that	   were	   shifted	   to	   35°.	   Whole	   cell	   lysates	   were	  
assessed	  for	  the	  production	  of	  OspC,	  DbpA,	  BBA66,	  or	  RpoS	  using	  specific	  antisera	  
for	   each	   (Figure	  4-­‐9A).	  Of	  note,	  multiple	   antibodies	   against	  RpoS	  were	   tested,	  but	  
only	  the	  one	  used	  in	  Figure	  4-­‐9A	  (a	  gift	  from	  Dr.	  Frank	  Gherardini,	  RML,	  NIAID,	  NIH)	  
detected	  a	  protein	  that	  migrated	  at	  the	  estimated	  size	  of	  RpoS,	  31	  kDa.	  Because	  this	  
antibody	  also	  reacted	  with	  proteins	  of	  other	  sizes,	  a	  larger	  portion	  of	  the	  RpoS	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Figure	  4-­‐9:	  BBD18	  represses	  additional	  RpoS-­‐dependent	  genes	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Figure	   4-­‐9	   legend:	   A.	   OspC,	   DbpA,	   BBA66,	   and	   RpoS	   immunoblots	   of	   whole-­‐cell	  
lysates	   from	   A3,	   A3ΔrpoS,	   S9,	   or	   S9/pBSV2*flaBp-­‐bbd18	   that	   were	   temperature-­‐
shifted	   from	   25°	   to	   35°C	   to	   induce	   the	   Rrp2-­‐RpoN-­‐RpoS	   regulon,	   as	   indicated.	  B.	  
burgdorferi	  were	  harvested	  in	  equal	  number	  from	  cultures	  growing	  at	  25°	  or	  35°C	  
and	   analyzed	   on	   immunoblots	   with	   antisera	   recognizing	   OspC,	   DbpA,	   BBA66,	   or	  
RpoS.	   Numbers	   at	   the	   left	   refer	   to	   protein	   size	   in	   kDa	   relative	   to	   the	  mobility	   of	  
protein	  standards.	  RpoS	  and	  the	  RpoS-­‐dependent	  proteins	  OspC,	  DbpA,	  and	  BBA66	  
were	  induced	  in	  A3	  and	  S9	  when	  cultures	  were	  harvested	  at	  35°C,	  but	  are	  not	  found	  
in	   the	  rpoS	  mutant	   (A3ΔrpoS)	  or	  S9/pBSV2*flaBp-­‐bbd18	  at	  either	   temperature.	  B.	  
Coomassie	  blue	  stain	  gel	  of	  samples	  from	  A.	  A	  duplicate	  gel	  of	  samples	  from	  A	  was	  
stained	  with	  Coomassie	  blue	   to	   illustrate	   comparable	  protein	   loading.	  Numbers	  at	  
the	   left	   refer	   to	   protein	   size	   in	   kDa	   relative	   to	   the	  mobility	   of	   protein	   standards.	  
These	  experiments	  were	  conducted	  by	  Dr.	  Daniel	  Dulebohn.	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immunoblot	  is	  shown.	  While	  A3	  and	  S9	  both	  produced	  RpoS	  and	  subsequently	  OspC,	  
DbpA,	   and	  BBA66	  when	   grown	   at	   35°,	   these	   proteins	  were	   not	   detected	   at	   either	  
temperature	   in	   lysates	   from	  the	  rpoS	  mutant	  (A3ΔrpoS,	   (37))	  or	   in	  S9	  harboring	  a	  
constitutively	   expressed	  bbd18	   (S9/pBSV2*flaBp-­‐bbd18,	   Figure	   4-­‐9A).	   A	   duplicate	  
gel	   of	   the	   samples	   shown	   in	   Figure	   4-­‐9A	   was	   stained	   with	   Coomassie	   blue	   to	  
illustrate	   protein	   loading	   (Figure	   4-­‐9B).	   The	   absence	   of	   OspC,	   DbpA,	   and	   BBD18	  
from	   S9/pBSV2*flaBp-­‐bbd18	   indicates	   that	   BBD18	   repression	   affects	   multiple	  
RpoS-­‐dependent	   genes	   and	   not	   just	   OspC.	   The	   lack	   of	   detectable	   RpoS	   protein	   in	  
S9/pBSV2*flaBp-­‐bbd18	   also	   supports	   the	   interpretation	   that	   BBD18	   affects	   RpoS,	  
which	   is	   the	  mechanism	  through	  which	  BBD18	  represses	  OspC,	  DbpA,	  and	  BBA66.	  
Ongoing	   experiments	   are	   directed	   at	   identifying	   the	   mechanism	   of	   BBD18	  
repression	  of	  RpoS	  (Dr.	  Daniel	  Dulebohn)	  
BBD18	  structural	  prediction	  and	  site-­‐directed	  mutagenesis	  	  
Although	  BBD18	  is	  highly	  conserved	  in	  Lyme	  disease	  and	  relapsing	  fever	  
spirochetes,	  we	  were	  unable	  to	  find	  any	  appreciable	  homologs	  or	  analogs	  outside	  of	  
the	   Borrelia	   genus.	   The	   predicted	   BBD18	   protein	   is	   a	   basic	   protein	   with	   many	  
charged	   and	   aromatic	   residues,	   and	   structural	   predictions	   suggest	   a	   primarily	  
alpha-­‐helical	  structure,	  not	  incompatible	  with	  nucleic	  acid	  interaction.	  With	  limited	  
information	   as	   to	   the	   function	   of	   BBD18,	   we	   contacted	   the	   Office	   of	  
Cyberinfrastructure	   and	   Computational	   Biology	   (OCCB),	   NIAID,	   NIH	   for	   their	  
expertise.	  Xavier	  Ambroggio,	  a	  Computational	  Structural	  Biologist	  at	  OCCB,	  used	  the	  
primary	  amino	  acid	  sequence	  of	  BBD18	  in	  a	  Position-­‐Specific	  Iterated	  BLAST	  (PSI-­‐
BLAST,	  NCBI)	  search	  to	  create	  a	  limited	  structural	  model	  of	  BBD18	  based	  on	  weak	  
similarity	  with	   the	  DNA-­‐binding	  motif	   of	   the	  plasmid	  partitioning	   genes	  ParB	   and	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SopB	  (Figure	  4-­‐10A).	   	  The	  alignment	  of	  the	  BBD18,	  ParB,	  and	  SopB	  primary	  amino	  
acid	   sequences	  within	   this	   structural	  motif	   is	   provided	   in	   Figure	   4-­‐10B.	   Although	  
this	  is	  a	  limited	  model	  and	  the	  structural	  prediction	  only	  accounts	  for	  34	  of	  the	  220	  
residues	   in	   the	  predicted	  BBD18	  protein,	   it	   is	   the	  only	   structural	  model	   available.	  
Thus,	   we	   hypothesized	   that	   if	   BBD18	   were	   indeed	   interacting	   with	   nucleic	   acids	  
through	  this	  putative	  motif,	  we	  might	  be	  able	  to	  abrogate	  repressor	  function	  by	  site-­‐	  
directed	  mutagenesis	  within	  this	  region.	  Using	  this	  structural	  prediction	  (Figure	  4-­‐
10A	  and	  B)	  and	  an	  alignment	  of	  the	  primary	  amino	  acid	  sequence	  of	  BBD18	  in	  Lyme	  
disease	  spirochetes	  and	  its	  counterpart	  in	  relapsing	  fever	  spirochetes	  (unpublished	  
sequences,	  Dr.	  Tom	  Schwan,	  RML,	  NIAID,	  NIH),	  we	  designed	   four	  BBD18	  variants.	  
Each	  variant	  had	  multiple	  amino	  acid	  substitutions	  (see	  Materials	  and	  Methods	  and	  
Figure	  4-­‐10C),	  most	  within	  the	  putative	  nucleic	  acid	  binding	  domain	  (Figure	  4-­‐10A	  
and	   B),	   although	   2	   aspartic	   acids	   residues	   outside	   of	   this	   region,	   which	   were	  
absolutely	  conserved	  in	  all	  sequences	  analyzed,	  were	  also	  changed.	  A	  partial	  amino	  
acid	  alignment	  of	  wt	  BBD18	  and	  these	  4	  site-­‐directed	  mutants	  is	  provided	  in	  Figure	  
4-­‐10C.	   Synthetic	   genes	   encoding	   these	   BBD18	   variants	   were	   obtained	   from	  
GenScript	   and	   cloned	   into	   a	   shuttle	   vector,	   creating	   pBSV2*flaBp-­‐bbd18Δ1-­‐4,	  
respectively	  (Table	  4-­‐1).	  	  
We	   then	   wanted	   to	   test	   whether	   these	   bbd18	   variants	   were	   similar	   to	   wt	  
bbd18	   in	  their	  ability	  to	  repress	  ospC	   in	  B.	  burgdorferi.	   	  We	  again	  utilized	  the	  high-­‐
passage	  B.	  burgdorferi	  clone	  B312,	  which	  produces	  substantial	  OspC	   in	  vitro.	  After	  
stably	   introducing	   each	   of	   the	   bbd18	   variants	   into	   B312,	   we	   analyzed	   whole	   cell	  
lysates	   for	   the	   presence	   of	   OspC.	   As	   expected,	   B312	   (which	   lacks	   lp17	   and	   thus	  
bbd18)	  produces	  significant	  OspC	  (Figure	  4-­‐10D,	  lane	  1)	  while	  there	  is	  no	  detectable	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Figure	  4-­‐10:	  Putative	  DNA-­‐binding	  motif	  of	  BBD18	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Figure	  4-­‐10	  legend:	  A.	  The	  structural	  alignment	  of	  BBD18	  (magenta)	  and	  the	  DNA-­‐
binding	  motif	  of	  SopB	  (green)	  and	  ParB	  (cyan)	  created	  by	  Xavier	  Ambroggio	  (OCCB,	  
NIAID,	   NIH).	   Image	   created	   in	   Pymol	   and	   includes	   the	   DNA	   double	   helix	   as	  
reference.	  The	  circled	  residues,	  serine	  (top	  circle,	  position	  67	  in	  BBD18)	  and	  valine	  
(bottom	  circle,	  position	  85	  in	  BBD18)	  are	  conserved	  in	  all	  three	  proteins	  (see	  B).	  B.	  
The	   primary	   amino	   acid	   alignment	   of	   the	   residues	   included	   in	   the	   structural	  
mapping	   in	   A.	   The	   protein	   text	   colors	   correspond	   to	   the	   ribbon	   colors	   in	   A.	   The	  
serine	  and	  valine	   residues	   conserved	   in	  BBD18,	   SopB,	   and	  ParB	  are	   shown	   in	   red	  
text.	  C.	  The	  amino	  acid	  alignment	  of	  wt	  BBD18	  (position	  56-­‐96)	  and	  the	  four	  BBD18	  
variants,	  which	  were	   created	  based	  on	   the	   structural	  model	   (A	   and	  B)	   and	   amino	  
acid	  conservation	  within	  Borrelia	  species.	  Residue	  changes	  compared	  to	  wt	  BBD18	  
are	  indicated	  in	  red	  text.	  Note	  these	  changes	  include	  residues	  that	  are	  seven	  amino	  
acids	  downstream	  of	  the	  carboxy	  terminal	  end	  of	  the	  structural	  model	  in	  A.	  Residues	  
not	   listed	   in	   this	   partial	   alignment	  were	   not	   altered	   from	   those	   in	  wt	   BBD18.	   	   D.	  
OspC	  (top),	  BBA66	  (middle),	  and	  BBD18	  (bottom)	  immunoblots	  of	  B312	  harboring	  
wt	   bbd18	   or	   bbd18	   variants	   (listed	   in	   C)	   expressed	   from	   the	   flaB	   promoter	   on	   a	  
shuttle	   vector.	   Whole	   cell	   lysates	   of	   B312	   without	   a	   shuttle	   vector	   (lane	   1),	  
B312/pBSV2*flaBp-­‐bbd18	   (wt,	   lane	   2),	   or	   B312	   harboring	   the	   bbd18	   variants,	   as	  
indicated	  (lanes	  3-­‐6)	  were	  analyzed	  by	  immunoblot	  with	  antisera	  recognizing	  OspC	  
(top),	  BBA66	  (middle),	  or	  BBD18	  (bottom).	  The	  size	  (kDa)	  based	  on	  the	  mobility	  of	  
protein	   standards	   is	   denoted	   on	   the	   left	   and	   lane	   numbers	   are	   indicated	   on	   the	  
bottom.	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OspC	   in	   B312	   harboring	   a	   shuttle	   vector	   carrying	   a	   constitutive	   wt	   bbd18	   gene	  
(Figure	  4-­‐10D,	  lane	  2).	  BBD18Δ2	  and	  BBD18Δ4	  were	  also	  able	  to	  fully	  repress	  OspC	  
production	  in	  B312	  (Figure	  4-­‐10D,	  lanes	  4	  and	  lane	  6,	  respectively),	  indicating	  that	  
the	  respective	  mutations	  in	  these	  bbd18	  variants	  did	  not	  abrogate	  BBD18	  repressor	  
activity.	   It	   was	   somewhat	   surprising	   that	   bbd18Δ4	  was	   still	   able	   to	   repress	   OspC	  
because	   bbd18Δ4	   encoded	   a	   change	   in	   S67	   and	   V85,	   the	   only	   two	   absolutely	  
conserved	   residues	   in	   the	  motif	   shared	   by	   BBD18,	   SopB	   and	   ParB	   (Figure	   4-­‐10A,	  
circled	   and	   Figure	   4-­‐10B	   in	   red).	   In	   contrast,	   BBD18Δ3	   had	   a	   striking	   loss	   in	  
repressor	  function	  compared	  to	  wt	  BBD18,	  as	  evident	  by	  the	  abundant	  synthesis	  of	  
OspC	   protein	  when	   this	   BBD18	   variant	   was	   introduced	   into	   B312	   (Figure	   4-­‐10D,	  
lane	  5).	  OspC	  was	  also	  detected	  in	  B312	  harboring	  pBSV2*flaBp-­‐bbd18Δ1	  (Figure	  4-­‐
10D,	   lane	  3),	  although	  to	  a	   lesser	  extent	  than	  with	  BBD18Δ3.	  We	  also	   investigated	  
the	  effect	  of	  the	  bbd18	  variants	  on	  the	  production	  of	  another	  RpoS-­‐dependent	  gene,	  
bba66.	  Although	  BBA66	  production	  was	  less	  than	  that	  of	  OspC	  in	  B312,	  it	  followed	  a	  
similar	  pattern	  as	  OspC,	  where	  BBA66	  was	  detected	  in	  wt	  B312	  and	  when	  bbd18Δ3	  
was	   expressed	   (Figure	   4-­‐10D,	   lanes	   1	   and	   5,	   respectively).	   There	   is	   a	   faint	   band	  
corresponding	  to	  BBA66	  in	  B312/pBSV2*flaBp-­‐bbd18Δ1	  (Figure	  4-­‐10D,	  lane	  3),	  but	  
BBA66	   is	  not	  detected	   in	  clones	  harboring	   the	  wt	  BBD18	  or	  other	  bbd18	   variants.	  
Using	   the	   BBD18-­‐antibody,	   we	  were	   able	   to	   detect	   a	   BBD18	   protein	   in	   all	   of	   the	  
B312	  clones	  harboring	  a	  bbd18	   gene	  expressed	  on	  a	   shuttle	  vector	   (Figure	  4-­‐10D,	  
lanes	  2-­‐6).	  	  
Closer	   examination	   of	   the	   amino	   acid	   changes	   that	   resulted	   in	   loss	   of	  
repression	   by	   BBD18	   identified	   four	   residues	   that	   may	   be	   involved	   in	   BBD18	  
function;	   K58,	   K79,	   D94,	   and	   D96	   were	   changed	   in	   the	   bbd18	   variants	   that	   had	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reduced	   or	   absent	   repressor	   activity	   when	   expressed	   in	   B312	   (Figure	   4-­‐10D).	  
However,	  single	  mutations	  for	  each	  of	  these	  residues	  seem	  to	  have	  no	  effect,	  as	  each	  
of	   these	  single	   residue	  bbd18	   variants	  was	  still	   able	   to	   fully	   repress	  OspC	   in	  B312	  
(Figure	   4-­‐11	   and	   data	   not	   shown).	   A	   caveat	   to	   these	   studies	   is	   that	   since	  we	   are	  
expressing	   the	   variants	   from	   a	   strong	   constitutive	   promoter,	   a	   slight	   phenotype	  
might	   be	   masked	   in	   our	   qualitative	   OspC	   repressor	   assay.	   Regardless,	   the	  
identification	  of	  a	  bbd18	  variant	  (bbd18Δ3)	   that	  produces	  BBD18	  protein	  but	  does	  
not	   repress	   OspC	   or	   BBA66,	   provides	   us	   with	   a	   tool	   to	   further	   investigate	   the	  
function	  of	  BBD18.	  	  
B.	  burgdorferi	  that	  constitutively	  express	  bbd18Δ3	  remain	  infectious	  in	  mice	  	   	  
The	   difficulty	   in	   inactivating	   bbd18	   in	   an	   infectious	   background	   led	   us	   to	  
question	   whether	   bbd18	   might	   have	   a	   function	   other	   than	   regulating	   RpoS	   and	  
RpoS-­‐dependent	   genes,	   none	   of	   which	   are	   essential	   for	   in	   vitro	   growth.	   Since	  we	  
have	  identified	  a	  bbd18	  variant	  that	  does	  not	  repress	  OspC	  (bbd18Δ3),	  we	  wanted	  to	  
determine	   if	   constitutively	   expressing	   this	   repressor-­‐inactive	   form	   of	   BBD18	   in	  
virulent	  B.	  burgdorferi	  would	  render	  them	  non-­‐infectious,	  as	  we	  had	  observed	  with	  
wt	   bbd18.	   To	   this	   end,	   we	   transformed	   S9	   with	   both	   pBSV2*flaBp-­‐bbd18Δ3	   or	  
pBSV2*flaBp-­‐bbd18Δ4	   as	   a	   positive	   control,	   since	   BBD18Δ4	   retained	   repressor	  
activity	  	  (Figure	  4-­‐10C	  and	  D).	  
Groups	  of	  5	  mice	  were	  inoculated	  with	  wt	  S9,	  S9/pBSV2*flaBp-­‐bbd18Δ3,	  or	  
S9/pBSV2*flaBp-­‐bbd18Δ4.	   At	   3	  weeks,	   we	   found	   that	  mice	   infected	  with	   both	   S9	  
and	  S9/pBSV3*flaBp-­‐bbd18Δ3	  had	  seroconverted	   to	  B.	  burgdorferi	   proteins,	  while	  
mice	   infected	   with	   S9/pBSV2*flaBp-­‐bbd18Δ4	   were	   not	   infected	   (Table	   4-­‐8).	   The	  
infectivity	  of	  S9	  constitutively	  expressing	  bbd18	  variants	  was	  inversely	  correlated	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Figure	   4-­‐11:	   Single	   and	  double	   residue	   site-­‐directed	  mutants	   of	   BBD18	   retain	   the	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Figure	   4-­‐11	   legend:	   A.	   OspC	   immunoblot	   of	   B312	   containing	   single	   and	   double	  
residue	  variants	  of	  bbd18.	  Whole	  cell	   lysates	  of	  B312	  harboring	  bbd18	  variants,	  as	  
indicated,	  were	  analyzed	  with	  antisera	  recognizing	  OspC.	  The	  estimated	  size	  of	  OspC	  
relative	  to	   the	  mobilities	  of	  standards	   is	   indicated	  on	  the	   left.	  B.	  A	  duplicate	  gel	  of	  
the	  samples	  from	  A	  was	  strained	  with	  Coommassie	  blue	  to	  assess	  the	  total	  protein	  
in	  each	  sample.	  The	  size	  (kDa)	  based	  on	  the	  mobility	  of	  protein	  standards	  is	  denoted	  

















	   	  
 182 
Table	   4-­‐8	  B.	   burgdorferi	   that	   constitutively	   express	   bbd18Δ3	   remain	   infectious	   in	  
mice	  	  	  
strain	  
No.	  of	  sero-­‐positive	  
mice/no.	  of	  injected	  
micea	  
No.	  of	  ear	  biopsy	  
reisolates/no.	  of	  injected	  
miceb	  
No.	  of	  mouse	  
reisolates/no.	  of	  injected	  
mice	  (ear,	  bladder,	  joint)c	  
S9	   4/4	   4/4	   4/4,	  4/4,	  4/4	  
S9/pBSV2*flaBp-­‐
bbd18Δ3	   4/5	   1/5	   4/5,	  4/5,	  4/5	  
S9/pBSV2*flaBp-­‐
bbd18Δ4	   0/5	   0/5	   0/5,	  0/5,	  0/5	  
a	  seroconversion	  to	  B.	  burgdorferi	  proteins	  was	  assessed	  at	  3	  weeks	  post-­‐inoculation	  
b	  ear	  biopsies	  were	  taken	  at	  3	  weeks	  post-­‐inoculation	   	  
c	  mice	  were	  euthanized	  at	  32	  days	  post-­‐inoculation	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with	  their	  in	  vitro	  ability	  to	  repress	  OspC;	  BBD18Δ3	  does	  not	  repress	  OspC	  (Figure	  
4-­‐10D)	  and	  does	  not	  render	  S9	  non-­‐infectious	  when	  it	  is	  overexpressed	  (Table	  4-­‐8),	  
whereas	  the	  opposite	  is	  true	  for	  BBD18Δ4.	  This	  experiment	  served	  as	  an	  important	  
control	  for	  previous	  experiments	  with	  constitutively	  expressed	  wt	  BBD18	  (Table	  4-­‐
3)	  in	  that	  inappropriate	  expression	  of	  an	  irrelevant	  or	  non-­‐functional	  protein	  does	  
not	   intrinsically	  render	  B.	  burgdorferi	  non-­‐infectious,	  since	  constitutive	  expression	  
of	   only	   the	   BBD18	   proteins	   with	   repressor	   activity	   (i.e.	   wt	   bbd18	   or	   bbd18Δ4)	  
resulted	   in	   a	   non-­‐infectious	   phenotype.	   Although	   these	   data	   do	   not	   rule	   out	   the	  
possibility	   of	   a	   secondary	   function	   of	   BBD18,	   they	   do	   indicate	   that	   repression	   of	  
RpoS-­‐dependent	   genes	   is	   the	   reason	   that	   B.	   burgdorferi	   constitutively	   expressing	  
bbd18	   are	  non-­‐infectious	   in	   the	  mouse	  model.	   	   To	   our	   knowledge,	   this	   is	   the	   first	  
report	  of	  a	  plasmid-­‐encoded	  gene	  in	  B.	  burgdorferi	  that	  regulates	  RpoS,	  and	  thus,	  we	  
conclude	   that	  BBD18	   is	  a	  novel	  participant	   in	   the	  regulation	  of	   the	  complex	  Rrp2-­‐




	   The	   complex	   life	   cycle	   of	   B.	   burgdorferi	   requires	   the	   spirochete	   to	   sense	  
environmental	  changes	  and	  subsequently	  adjust	  gene	  expression	  and	  protein	  	  
profiles	  as	  it	  transits	  from	  the	  tick	  vector	  to	  the	  mammalian	  host	  and	  vice	  versa.	  The	  
best-­‐studied	   example	   of	   differential	   gene	   expression	   in	   B.	   burgdorferi	   is	   the	  
reciprocal	   expression	   of	   OspA	   and	   OspC	   during	   tick	   feeding	   (7).	   This	  
groundbreaking	  observation	  led	  to	  the	  identification	  of	  a	  global	  regulatory	  cascade	  
that	   includes	   a	   response	   regulatory	   protein,	   Rrp2	   (57-­‐59),	   and	   two	   alternative	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sigma	  factors,	  RpoN,	  and	  RpoS	  (19,	  20).	  It	  has	  been	  shown	  that	  the	  Rrp2-­‐RpoN-­‐RpoS	  
cascade	   is	   responsible	   for	   the	   upregulation	   of	   genes	   necessary	   during	   the	  
mammalian	  phase	  of	  the	  spirochete’s	  enzoontic	  cycle	  (20,	  24,	  25,	  46,	  60),	  including	  
OspC	  (20,	  23),	  a	  critical	  virulence	   factor	  during	  early	   infection	  (8,	  11).	  Spirochetes	  
lacking	   a	   functional	   OspC	   protein	   are	   non-­‐infectious	   in	   mice	   (9,	   10),	   but	   B.	  
burgdorferi	   that	   constitutively	   express	   OspC	   are	   recognized	   and	   subsequently	  
cleared	   by	   the	  mammalian	   adaptive	   immune	   response	   (12,	   14,	   15).	   Although	   the	  
strict	  regulation	  of	  OspC	  has	  been	  well	  documented,	  the	  underlying	  mechanisms	  are	  
still	  not	  entirely	  understood.	  	  
Previously	  we	   identified	   a	   plasmid-­‐encoded	   protein,	   BBD18	   that	   repressed	  
expression	   of	   OspC	   in	   the	   high-­‐passage	   non-­‐infectious	   B.	   burdorferi	   clone	   B312	  
(Chapter	   3,	   (30))	   Here,	   we	   have	   investigated	   the	   in	   vivo	   effect	   of	   constitutively	  
expressing	   bbd18	   or	   deleting	   bbd18	   in	   low-­‐passage,	   virulent	   B.	   burgdorferi.	   By	  
expressing	   bbd18	   with	   a	   constitutive	   promoter,	   we	   confirmed	   that	   BBD18	   can	  
suppress	   the	   induction	  of	  OspC	  during	  tick	   feeding	  (Figure	  4-­‐3).	  This	   is	  significant	  
since	   spirochetes	   within	   the	   tick	   midgut	   require	   OspC	   to	   be	   transmitted	   and	  
subsequently	  establish	  infection	  in	  the	  mammalian	  host	  (8).	  Taking	  into	  account	  this	  
essential	   role	   of	   OspC,	   it	   is	   not	   surprising	   that	   S9	   harboring	   a	   constitutively	  
expressed	  bbd18	  were	  not	  infectious	  by	  needle	  inoculation	  (Table	  4-­‐3)	  and	  tick	  bite	  
(Table	   4-­‐4).	   This	   outcome	   suggests	   that	   BBD18	   is	   important	   during	   infection,	   but	  
does	  not	  elucidate	  its	  in	  vivo	  function.	  To	  this	  end,	  we	  undertook	  to	  inactivate	  bbd18.	  
Based	   on	   the	   ability	   of	   BBD18	   to	   repress	   OspC,	   we	   expected	   a	   bbd18	   mutant	   to	  
establish	   infection	   in	  mammals	   but	   not	   persist	   if	   BBD18	  were	   the	   critical	   in	   vivo	  
ospC	   repressor	   for	   evasion	   of	   host	   immunity	   (12,	   14).	   After	   many	   attempts	   (~2	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years	  of	  effort	  by	  multiple	  people),	  we	  finally	  isolated	  a	  bbd18	  mutant	  in	  the	  virulent	  
clone	  S9	  (S9Δbbd18,	  see	  Figure	  4-­‐5).	  S9Δbbd18	  was	  non-­‐infectious	  when	  inoculated	  
into	  mice,	  but	  did	  not	  regain	  infectivity	  when	  bbd18	  was	  restored	  on	  full-­‐length	  lp17	  
or	   a	   shuttle	   vector;	   this	   indicated	   that	   other	   secondary	  mutations	  were	   probably	  
responsible	  for	  the	  non-­‐infectious	  phenotype	  of	  S9Δbbd18	  (Table	  4-­‐7).	  	  
During	  the	  course	  of	  our	  studies,	  a	  report	  by	  Casselli	  et	  al.	  demonstrated	  that	  
spirochetes	   containing	   a	   truncated	   version	   of	   lp17	   in	   which	   bbd16-­‐25	   had	   been	  
deleted	  (and	  importantly,	  bbd18)	  were	  infectious	  in	  mice	  by	  needle	  inoculation.	  We	  
repeated	   similar	   experiments	   using	   two	   different	   lp17	   truncations	   that	   retain	   or	  
lack	  bbd18.	  Similar	  to	  Casselli	  et	  al.,	  we	  found	  that	  B.	  burgdorferi	  lacking	  bbd18	  (and	  
a	  large	  portion	  of	  lp17)	  was	  infectious	  by	  needle	  inoculation	  (Table	  4-­‐5).	  Liang	  and	  
colleagues	  reported	   that	  downregulation	  of	  OspC	   in	  response	   to	   immune	  pressure	  
occurs	  from	  day	  17	  onward	  (12,	  14).	  However,	  both	  Casselli	  et	  al.	  and	  our	  lab	  found	  
that	  B.	   burgdorferi	   containing	   lp17	   truncations,	   which	   do	   not	   retain	   bbd18,	   were	  
able	  to	  persist	  at	  least	  8	  weeks	  (~56	  days)	  post-­‐inoculation	  (Table	  4-­‐5).	  The	  ability	  
of	   these	  BBD18	  mutants	   to	  persist	   in	  mice	  beyond	  the	  point	  at	  which	  OspC	  would	  
typically	   be	   downregulated	   indicates	   that	   bbd18	   is	   likely	   not	   the	   in	   vivo	   OspC	  
repressor.	   In	  addition,	  these	  data	  imply	  that	  bbd18	   is	  not	  critical	   for	  B.	  burgdorferi	  
survival	  or	  infection	  within	  mice.	  Thus,	  it	  remains	  unclear	  why	  inactivation	  of	  bbd18	  
in	  wt	  B.	  burgdorferi	  presented	  such	  a	  challenge	  and	  why,	  once	   isolated,	   the	  bbd18	  
mutant	   had	   accumulated	   secondary	   mutations	   that	   rendered	   it	   non-­‐infectious	   in	  
mice.	  Furthermore,	  the	  ease	  with	  which	  we	  were	  able	  to	  obtain	  a	  bbd18	  mutant	  in	  a	  
high-­‐passage,	  non-­‐infectious	  B.	  burgdorferi	   clone	  also	  suggests	   the	  complex	  role	  of	  
bbd18	  in	  a	  wt	  background.	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The	  ability	  of	   constitutively	   expressed	  BBD18	   to	   repress	  OspC	  and	   thereby	  
prevent	  infection	  in	  mice,	  the	  strict	  conservation	  of	  bbd18	  in	  both	  Lyme	  disease	  and	  
relapsing	  fever	  spirochetes,	  combined	  with	  the	  lack	  of	  an	  apparent	  role	  for	  BBD18	  
in	   mammalian	   infection,	   made	   us	   question	   the	   role	   of	   BBD18	   and	   where	   BBD18	  
might	   function	   during	   the	   infectious	   cycle.	   To	   address	   the	   first	   question,	   we	  
investigated	  the	  mechanism	  of	  BBD18	  repression	  of	  OspC.	  The	  simplest	  mechanism	  
to	   invoke	   is	   a	   direct	   interaction	   of	   BBD18	   with	   the	   ospC	   promoter,	   which	   would	  
prevent	  the	  transcription	  of	  ospC.	  Xu	  and	  colleagues	  described	  a	  putative	  operator	  
site	   upstream	   of	   the	   traditional	   ospC	   promoter	   that	   is	   necessary	   for	   the	  
downregulation	  of	  ospC	  in	  vivo.	  The	  persistence	  in	  mice	  of	  spirochetes	  of	  S9	  lacking	  
bbd18	   (S9/pGCB473)	   suggested	   that	   bbd18	   was	   not	   playing	   a	   role	   in	   the	  
downregulation	   of	   OspC	   in	   vivo,	   but	   we	   wanted	   to	   identify	   the	   requisite	   ospC	  
promoter	   elements	   for	   repression	   by	   BBD18.	   To	   this	   end,	   we	   utilized	   the	   B.	  
burgdorferi	  lacZ	  reporter	  system	  (Chapter	  2	  and	  (32))	  in	  combination	  with	  the	  high-­‐
passage	  B.	  burgdorferi	  clone	  B312,	  which	  produces	  abundant	  OspC	  in	  vitro	  (30,	  32,	  
38).	   When	   BBD18	   was	   introduced	   into	   B312	   carrying	   lacZBb*	   constructs	   with	  
different	  versions	  of	  the	  ospC	  promoter,	  we	  found	  that	  BBD18	  repression	  of	  ospC	  did	  
not	   require	   the	   putative	   operator	   sequence	   (Figure	   4-­‐7).	   Furthermore,	   we	  
determined	  that	  only	  the	  -­‐35	  and	  -­‐10	  regions	  of	  the	  opsC	  promoter	  were	  required	  	  
for	  repression	  by	  BBD18	  (Figure	  4-­‐7B).	  	  
It	  is	  well	  documented	  that	  the	  expression	  of	  ospC	  in	  vivo	  is	  dependent	  on	  the	  
alternative	  sigma	  factor	  RpoS	  (17,	  20,	  23,	  25)	  and	  we	  confirmed	  that	  this	  was	  also	  
the	   case	   in	   the	   high-­‐passage	   clone	   B312	   (Figure	   4-­‐8).	   Since	   only	   the	   -­‐35	   and	   -­‐10	  
regions	   of	   the	   ospC	   promoter	   (the	   region	   where	   RpoS	   and	   the	   RNA	   polymerase	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holoenzyme	   bind)	   were	   necessary	   for	   BBD18-­‐mediated	   repression	   of	   ospC,	   we	  
wished	   to	   determine	   if	   the	   regulatory	   activity	   of	   BBD18	   was	   through	   RpoS.	  
Therefore,	   Dr.	   Daniel	   Dulebohn	   analyzed	   lysates	   of	   S9	   carrying	   or	   lacking	   a	  
constitutively	   expressed	  bbd18	   gene.	   He	   found	   that	  while	   RpoS	   and	   subsequently	  
OspC,	  DbpA,	  and	  BBA66	  were	   induced	   in	   response	   to	  a	   temperature-­‐shift	   to	  35°C,	  
spirochetes	  harboring	  a	  constitutively	  expressed	  bbd18	  failed	  to	  make	  any	  of	  these	  
proteins	  (Figure	  4-­‐9).	  These	  data	  indicate	  that	  BBD18	  is	  likely	  repressing	  OspC	  (as	  
well	   as	   DbpA	   and	   BBA66)	   through	   its	   effect	   on	   RpoS.	   Preliminary	   data	   by	   Dr.	  
Dulebohn	   are	   most	   consistent	   with	   a	   post-­‐transcriptional	   mechanism,	   suggesting	  
that	  BBD18	  either	  prevents	  translation	  of	  the	  rpoS	  transcript	  or	  targets	  degradation	  
of	  RpoS	  protein.	  	  
The	  B.	  burgdorferi	  genome	  does	  not	  encode	  many	  commonly	  known	  genetic	  
regulators	   (61).	   However,	   in	   recent	   years	   a	   number	   of	   regulatory	   elements	   that	  
intersect	  with	  the	  central	  Rrp2-­‐RpoN-­‐RpoS	  pathway	  have	  been	  identified,	  including	  
DsrA	  (18),	  BosR	  (62-­‐64),	  and	  Hfq	  (65).	  DsrA	  is	  a	  small	  non-­‐coding	  RNA	  that	  binds	  to	  
a	   region	   upstream	  of	   the	   rpoS	   ORF,	  which	   leads	   to	   a	   conformational	   change.	   This	  
conformational	  change	  in	  the	  rpoS	  transcript	  frees	  the	  Shine-­‐Dalgarno	  site,	  allowing	  
translation	   to	  occur	   (18).	  Lybecker	  and	  colleagues	   later	   identified	  a	  B.	  burgdorferi	  
homolog	  of	   the	  RNA	   chaperone	  Hfq,	  which	   is	   typically	   required	   for	   the	   activity	   of	  
sRNAs.	   Indeed,	   they	   found	   that	   the	   B.	   burgdorferi	   Hfq	   bound	   DsrA	   and	   the	   rpoS	  
transcript	  (65).	  	  
BosR	  (BB0647)	  was	  originally	  annotated	  as	  a	  Fur	   (Ferric	  uptake	  regulator)	  
homolog	  in	  B.	  burgdorferi	  (61)	  but	  was	  renamed	  after	  Boylan	  et	  al.	  determined	  that	  
it	  activated	  the	  oxidative	  stress	  response	  in	  B.	  burgdorferi;	  BosR	  stands	  for	  Borrelia	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oxidative	   stress	   regulator	   (62).	   Two	   parallel	   studies	   using	   low-­‐passage	   B.	  
burgdorferi	  found	  that	  BosR	  was	  required	  for	  efficient	  RpoS	  production	  and	  thus	  the	  
upregulation	  of	  ospC	  and	  other	  genes	  necessary	  for	  mammalian	  infectivity	  (63,	  64).	  
The	   inactivation	   of	  dsrA	   or	  hfq	   had	   similar	   effects	   on	  RpoS,	   and	   the	  hfq	   and	  bosR	  
mutants	  were	  non-­‐infectious	  in	  mice	  by	  needle	  inoculation.	  	  
It	  is	  interesting	  that	  the	  phenotype	  of	  B.	  burgdorferi	  overexpressing	  bbd18	  is	  
similar	  to	  B.	  burgdorferi	  in	  which	  DsrA,	  BosR,	  or	  Hfq	  have	  been	  inactivated.	  Although	  
it	  has	  been	  shown	  that	  BosR	  is	  required	  for	  transcription	  of	  rpoS	  (63,	  66),	  DsrA	  and	  
Hfq	   are	   involved	   in	   translational	   regulation	   of	   rpoS	   (18,	   65).	   BBD18	   might	  
counteract	  the	  effects	  any	  of	  these	  factors,	  preventing	  production	  of	  RpoS	  protein.	  	  
To	  our	  knowledge,	  only	  the	  bosR	  mutant	  has	  been	  examined	  in	  ticks.	  Ouyang	  
et	   al.	   detected	   similar	   numbers	   of	   spirochetes	   in	   I.	   scapularis	   nymphs	   after	   they	  
were	  microinjected	  with	  wt	  B.	  burgdorferi	  or	  the	  bosR	  mutant	  and	  subsequently	  fed	  
on	   naïve	   mice	   (63).	   This	   is	   again	   similar	   to	   phenotype	   of	   S9	   harboring	   a	  
constitutively	   expressed	   bbd18,	   where	   there	   was	   not	   a	   significant	   difference	   in	  
spirochete	   load	   in	   larval	   or	   nymphal	   ticks	   (Figure	   4-­‐2).	   The	   lack	   of	   a	   detectable	  
phenotype	   in	   ticks	   infected	   with	   spirochetes	   that	   either	   lack	   bosR	   or	   that	  
inappropriately	   express	  bbd18	   is	   not	   surprising	   since	   rpoS	   is	   not	   expressed	   by	  B.	  
burgdorferi	   in	   flat	   ticks	   (22).	   In	   addition,	   neither	   RpoN,	   nor	   RpoS	   is	   required	   for	  
persistence	  within	  ticks	  (60)	  In	  fact,	  this	  lack	  of	  rpoS	  in	  flat	  ticks	  indirectly	  suggests	  
a	   possible	   role	   for	   BBD18	   in	   the	   transition	   from	  mammal	   to	   tick,	   in	   that	   BBD18	  
could	   repress	   the	   production	   of	   RpoS	   protein	   in	   feeding	   ticks	   as	   spirochetes	   are	  
acquired	  from	  an	  infected	  host	  before	  rpoS	  transcription	  is	  downregulated	  by	  other	  
mechanisms.	  Since	  RpoS	   is	  also	  required	   for	   the	  repression	  of	  ospA	   as	  spirochetes	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transmit	   to	   the	   mammalian	   host	   (22),	   the	   repression	   of	   RpoS	   by	   BBD18	   as	   B.	  
burgdorferi	  transition	  back	  to	  the	  tick	  vector	  would	  allow	  OspA	  to	  be	  de-­‐repressed,	  
resulting	  in	  the	  spirochetes’	  effective	  colonization	  of	  the	  tick	  midgut	  (67).	  The	  ability	  
of	   B.	   burgdorferi	   lacking	   bbd18	   to	   infect	   mice	   also	   indirectly	   supports	   a	   role	   for	  
BBD18	   in	   the	   tick	   vector	   rather	   than	   the	   mammalian	   host.	   However,	   we	   did	   not	  
succeed	  in	  an	  initial	  attempt	  to	  test	  this	  hypothesis	  due	  to	  a	  technical	  problem	  with	  
larval	  tick	  feeding.	  
Although	  B.	  burgdorferi	   lacking	  bbd18	  were	  infectious	  in	  mice,	  Casselli	  et	  al.	  
reported	  that	  their	  B.	  burgdorferi	  clone	  harboring	  a	  truncated	  form	  of	  lp17	  did	  not	  
colonize	  the	  mouse	  bladder.	  We	  found	  that	  spirochetes	  carrying	  two	  different	  lp17	  
truncations,	   one	   of	   which	   retained	   bbd18,	   did	   not	   efficiently	   colonize	   the	   mouse	  
bladder	   or	   joint	   tissue	   (Table	   4-­‐5),	   likely	   ruling	   out	   a	   role	   for	   BBD18	   in	  
dissemination	   and	   colonization	   of	   distal	   tissues.	   The	   number	   of	   differentially	  
regulated	  genes	  encoded	  on	   lp17	   (22,	  59,	  68),	   the	  high	  conservation	  of	  most	   lp17	  
genes	  among	  B.	  burgdorferi	  strains	  (69),	  and	  the	  fact	  that	  lp17	  is	  rarely	  lost,	  all	  point	  
to	  the	  importance	  of	  additional	  	  genes	  on	  lp17	  during	  the	  infectious	  cycle.	  
	   Our	  finding	  that	  BBD18	  represses	  the	  production	  of	  RpoS	  in	  wt	  B.	  burgdorferi	  
is	   interesting	   in	   that	   two	   groups	   previously	   implicated	   the	   Rrp2/RpoN/RpoS	   in	  
regulating	   bbd18.	   Caimano	   and	   colleagues	   reported	   that	   microarray	   analysis	   of	  
spirochetes	  grown	  in	  dialysis	  membrane	  chambers	  (DMCs)	  within	  a	  rat	  peritoneum	  
suggested	  that	  bbd18	  was	  repressed	  by	  RpoS,	  but	  this	  was	  not	  confirmed	  with	  qRT-­‐
PCR	   (22),	   and	   bbd18	   was	   not	   listed	   as	   being	   repressed	   by	   RpoS	   or	   RpoN	   in	   a	  
previous	  microarray	  report	  (60).	  In	  a	  separate	  study,	  microarray	  data	  indicated	  that	  
bbd18	  was	   repressed	  by	  Rrp2	  but	  not	  RpoS	   (68).	  Considering	   the	   inverse	   roles	  of	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BBD18	  and	  Rrp2	  on	  RpoS	  activity,	  it	  is	  possible	  to	  imagine	  a	  scenario	  in	  which	  Rrp2	  
represses	   BBD18	   in	   order	   to	   activate	   RpoS.	   rpoS	   is	   transcribed	   through	   the	  
coordinated	  roles	  of	  Rrp2	  and	  the	  alternative	  sigma	  factor	  RpoN.	  Since	  it	   is	  widely	  
accepted	   that	   phosphorylation	   of	   Rrp2	   serves	   as	   the	   trigger	   for	   spirochetes	  
transitioning	  into	  the	  mammalian-­‐phase	  of	  the	  life	  cycle	  (57),	   it	  would	  make	  sense	  
that	   Rrp2	   would	   also	   repress	   expression	   of	   bbd18,	   preventing	   BBD18	   from	  
repressing	   the	   translation	   of	   rpoS.	   However,	   if	  we	   entertain	   the	   initial	   suggestion	  
that	   RpoS	   is	   responsible	   for	   the	   repression	   of	   BBD18,	   the	   question	   becomes	   how	  
would	   B.	   burgdorferi	   produce	   enough	   RpoS	   protein	   in	   the	   presence	   of	   BBD18,	   if	  
BBD18	  can	  prevent	  the	  production	  or	  accumulation	  of	  RpoS.	  Additional	  studies	  are	  
necessary	   to	   investigate	   the	   regulation	   and	   timing	   of	   bbd18	   expression.	  
Undoubtedly,	  regulation	  in	  B.	  burgdorferi	  is	  complicated,	  but	  BBD18	  in	  concert	  with	  
BosR,	  DsrA,	  Hfq,	  Rrp2,	  and	  RpoN	  might	  help	  modulate	  specific	  levels	  of	  RpoS	  needed	  
throughout	  the	  B.	  burgdorferi	  life	  cycle.	  	  
	  In	  order	  to	  gain	  a	  better	  understanding	  of	  a	  possible	  role	  for	  BBD18	  during	  
the	  infectious	  cycle,	  we	  wanted	  to	  investigate	  how	  BBD18	  might	  function.	  Since	  we	  
were	   unable	   to	   find	   any	   homologs	   for	   BBD18	   outside	   of	   the	   Borrelia	   genus,	   we	  
collaborated	  with	  Xavier	  Ambroggio,	  a	  Computational	  Structural	  Biologist	  from	  the	  
Office	  of	  Cyberinfrastructure	  and	  Computational	  Biology	  (NIAID,	  NIH).	  He	  created	  a	  
partial	   model	   for	   BBD18	   through	   a	   structural	   alignment	   with	   the	   DNA-­‐binding	  
motifs	  of	  ParB	  and	  SopB	   from	  E.	  coli,	  with	  which	   they	  share	  weak	  similarity.	  ParB	  
and	   SopB	   are	   best	   known	   for	   their	   roles	   in	   the	   partitioning	   of	   plasmids	   and	  
chromosomes	   and	   are	  highly	   conserved	   in	  both	  Gram-­‐positive	   and	  Gram-­‐negative	  
bacteria	  (reviewed	  in	  (70)).	  In	  addition,	  it	  has	  been	  shown	  that	  ParB	  and	  SopB	  also	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function	   as	   autoregulators	   controlling	   their	   own	   transcription	   (71,	   72).	   Given	   the	  
data	  suggesting	  that	  BBD18	  represses	  rpoS	  post-­‐transcriptionally,	  we	  could	  imagine	  
a	  BBD18	  domain	  that	  interacts	  with	  nucleic	  acids.	  To	  test	  the	  hypothesis	  that	  BBD18	  
repression	  requires	  this	  putative	  DNA-­‐binding	  domain,	  we	  designed	  synthetic	  bbd18	  
variants	  with	  discrete	  amino	  acid	  substitutions	  within	  this	  region	  and	  determined	  if	  
the	   variants	   retained	   repressor	   activity	   of	  OspC.	  We	   found	  one	  variant,	  BBD18Δ3,	  
that	  was	  not	   able	   to	   repress	  OspC	   (Figure	  4-­‐10D).	   Four	   amino	  acids	   substitutions	  
distinguish	  BBD18Δ3	  from	  wt	  BBD18	  (Figure	  4-­‐9C).	  It	  seems	  unlikely	  that	  mutating	  
four	  random	  residues	  within	  the	  entire	  BBD18	  protein	  would	  have	  a	  similar	  effect	  
on	   OspC	   repression,	   which	   leads	   us	   to	   tentatively	   conclude	   that	   there	   is	   some	  
validity	  to	  this	  structural	  prediction	  of	  BBD18.	  We	  anticipated	  that	  we	  could	  further	  
delineate	  the	  amino	  acids	  that	  were	  critical	  for	  BBD18	  function	  by	  mutating	  each	  of	  
these	   four	   residues	   individually,	   but	   this	   experiment	   did	   not	   yield	   any	   additional	  
information,	   as	   individual	   or	   double	   amino	   acid	   substitutions	   did	   not	   abrogate	  
repressor	  activity	  (Figure	  4-­‐11	  and	  data	  not	  shown).	  One	  caveat	  is	  that	  these	  bbd18	  
variants	  were	  expressed	  from	  the	  constitutive	   flaB	  promoter	  and	  a	  slight	  defect	   in	  
BBD18	   function	   may	   be	   compensated	   by	   the	   amount	   of	   the	   variant	   protein	  
produced.	  	  
We	   also	   attempted	   to	   infect	   mice	   with	   spirochetes	   that	   overexpress	   the	  
BBD18	  variants.	  We	  predicted	   that	  B.	  burgdorferi	  overexpressing	  a	  BBD18	  variant	  
that	  could	  not	  repress	  OspC	  would	  be	  infectious	  in	  mammals.	  We	  also	  hypothesized	  
that	  we	  might	  be	  able	  to	  identify	  a	  secondary	  function	  of	  BBD18	  within	  the	  life	  cycle	  
of	  B.	  burgdorferi	  by	  using	  a	  bbd18	  variant	  that	  lacked	  the	  ability	  to	  repress	  ospC	  but	  
still	   attenuated	   infectivity	   in	  mice.	   However,	  we	   found	   that	   the	   ability	   to	   prevent	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infection	   of	   mice	   was	   strongly	   correlated	   with	   the	   in	   vitro	   repressor	   activity	   of	  
BBD18	   (Tables	  4-­‐3	  and	  4-­‐8).	  These	  data	  also	   suggest	   that	  BBD18	  does	  not	  have	  a	  
critical	   unrelated	   function	   in	   vivo.	   This	   experiment	   also	   served	   as	   an	   important	  
control	  for	  the	  possibility	  that	  overexpressing	  any	  protein	  in	  B.	  burgdorferi	  above	  its	  
normal	  levels	  might	  attenuate	  the	  infectivity	  of	  the	  spirochetes.	  However,	  these	  data	  
argue	   against	   that	   interpretation,	   as	   overexpressing	   a	   non-­‐repressing	   variant	  
(bbd18Δ3)	  did	  not	  intrinsically	  alter	  the	  infectivity	  of	  B.	  burgdorferi.	  	  
We	   have	   provided	   evidence	   that	   BBD18	   can	   alter	   the	   infectivity	   of	   B.	  
burgdorferi	  by	   repressing	   critical	   virulence	   factors	   like	  OspC	   through	   its	   affect	   on	  
RpoS.	  To	  our	  knowledge,	  BBD18	  is	  the	  first	  example	  of	  a	  plasmid-­‐encoded	  gene	  that	  
affects	   the	   central	   Rrp2-­‐RpoN-­‐RpoS	   regulon.	   Given	   this	   new	   information,	   it	   is	  
interesting	   that	   Lyme	   disease	   and	   relapsing	   fever	   spirochetes,	   which	   display	  
strikingly	  different	   life	  cycles	  and	   infect	  different	  vectors,	  both	  retain	  bbd18.	  Thus,	  
we	  propose	  that	  the	  conserved	  BBD18	  protein	  assists	  in	  the	  precise	  gene	  regulation	  
that	  is	  critical	  for	  the	  survival	  and	  infection	  of	  spirochetes	  within	  the	  Lyme	  disease	  
and	  relapsing	  fever	  families.	  Ongoing	  experiments	  will	  determine	  the	  specific	  target	  




1.	   Benach	   JL,	   Bosler	   EM,	   Hanrahan	   JP,	   Coleman	   JL,	   Bast	   TF,	   Habicht	   GS,	  
Cameron	  DJ,	  Ziegler	  JL,	  Burgdorfer	  W,	  Barbour	  AG,	  Edelman	  R,	  Kaslow	  
RA.	   1983.	   Spirochetes	   isolated	   from	   the	   blood	   of	   two	   patients	   with	   Lyme	  
disease.	  N.	  Engl.	  J.	  Med.	  308:740-­‐742.	  
2.	   Burgdorfer	  W,	  Barbour	  AG,	  Hayes	  SF,	  Benach	  JL,	  Grunwaldt	  E,	  Davis	  JP.	  
1982.	  Lyme	  disease	  -­‐	  a	  tick-­‐borne	  spirochetosis?	  Science	  216:1317-­‐1319.	  
 193 
3.	   Steere	  AC,	  Grodzicki	  RL,	  Kornblatt	  AN,	  Craft	  JE,	  Barbour	  AG,	  Burgdorfer	  
W,	  Schmid	  GP,	  Johnson	  E,	  Malawista	  SE.	  1983.	  The	  spirochetal	  etiology	  of	  
Lyme	  disease.	  N.	  Engl.	  J.	  Med.	  308:733-­‐740.	  
4.	   Lane	  RS,	  Piesman	  J,	  Burgdorfer	  W.	  1991.	  Lyme	  borreliosis:	   relation	  of	   its	  
causative	  agent	  to	  its	  vectors	  and	  hosts	  in	  North	  America	  and	  Europe.	  Annu.	  
Rev.	  Entomol.	  36:587-­‐609.	  
5.	   Ohnishi	   J,	   Piesman	   J,	   de	   Silva	   AM.	   2001.	   Antigenic	   and	   genetic	  
heterogeneity	  of	  Borrelia	  burgdorferi	  populations	  transmitted	  by	  ticks.	  Proc.	  
Natl.	  Acad.	  Sci.	  U	  S	  A	  98:670-­‐675.	  
6.	   Schwan	  TG,	  Piesman	  J.	  2000.	  Temporal	  changes	  in	  outer	  surface	  proteins	  A	  
and	  C	  of	  the	  Lyme	  disease-­‐associated	  spirochete,	  Borrelia	  burgdorferi,	  during	  
the	  chain	  of	  infection	  in	  ticks	  and	  mice.	  J.	  Clin.	  Microbiol.	  39:382-­‐388.	  
7.	   Schwan	  TG,	  Piesman	  J,	  Golde	  WT,	  Dolan	  MC,	  Rosa	  PA.	  1995.	  Induction	  of	  
an	   outer	   surface	   protein	   on	   Borrelia	   burgdorferi	   during	   tick	   feeding.	   Proc.	  
Natl.	  Acad.	  Sci.	  U	  S	  A	  92:2909-­‐2913.	  
8.	   Grimm	  D,	  Tilly	  K,	  Byram	  R,	  Stewart	  PE,	  Krum	  JG,	  Bueschel	  DM,	  Schwan	  
TG,	  Policastro	  PF,	  Elias	  AF,	  Rosa	  PA.	  2004.	  Outer-­‐surface	  protein	  C	  of	   the	  
Lyme	   disease	   spirochete:	   A	   protein	   induced	   in	   ticks	   for	   infection	   of	  
mammals.	  Proc.	  Natl.	  Acad.	  Sci.	  U	  S	  A	  101:3142-­‐3147.	  
9.	   Stewart	  PE,	  Wang	  X,	  Bueschel	  DM,	  Clifton	  DR,	  Grimm	  D,	  Tilly	  K,	  Carroll	  
JA,	   Weis	   JJ,	   Rosa	   PA.	   2006.	   Delineating	   the	   requirement	   for	   the	   Borrelia	  
burgdorferi	   virulence	   factor	   OspC	   in	   the	   mammalian	   host.	   Infect.	   Immun.	  
74:3547-­‐3553.	  
 194 
10.	   Tilly	   K,	   Bestor	   A,	   Jewett	   MW,	   Rosa	   P.	   2007.	   Rapid	   clearance	   of	   Lyme	  
disease	  spirochetes	  lacking	  OspC	  from	  skin.	  Infect.	  Immun.	  75:1517-­‐1519.	  
11.	   Tilly	  K,	  Krum	  JG,	  Bestor	  A,	  Jewett	  MW,	  Grimm	  D,	  Bueschel	  D,	  Byram	  R,	  
Dorward	   D,	   Stewart	   P,	   Rosa	   P.	   2006.	   Borrelia	   burgdorferi	   OspC	   protein	  
required	  exclusively	   in	  a	   crucial	   early	   stage	  of	  mammalian	   infection.	   Infect.	  
Immun.	  74:3554-­‐3564.	  
12.	   Liang	   FT,	   Jacobs	  MB,	   Bowers	   LC,	   Philipp	  MT.	   2002.	   An	   immune	   evasion	  
mechanism	   for	   spirochetal	   persistence	   in	   Lyme	   borreliosis.	   J.	   Exp.	   Med.	  
195:415-­‐422.	  
13.	   Liang	   FT,	   Nelson	   FK,	   Fikrig	   E.	   2002.	   Molecular	   adaptation	   of	   Borrelia	  
burgdorferi	  in	  the	  murine	  host.	  J.	  Exp.	  Med.	  196:275-­‐280.	  
14.	   Liang	   FT,	   Yan	   J,	   Mbow	  ML,	   Sviat	   SL,	   Gilmore	   RD,	  Mamula	  M,	   Fikrig	   E.	  
2004.	   Borrelia	   burgdorferi	   changes	   its	   surface	   antigenic	   expression	   in	  
response	  to	  host	  immune	  responses.	  Infect.	  Immun.	  72:5759-­‐5767.	  
15.	   Xu	  Q,	  Seemanapalli	  SV,	  McShan	  K,	  Liang	  FT.	  2006.	  Constitutive	  expression	  
of	   outer	   surface	   protein	   C	   diminishes	   the	   ability	   of	  Borrelia	   burgdorferi	   to	  
evade	  specific	  humoral	  immunity.	  Infect.	  Immun.	  74:5177-­‐5184.	  
16.	   Brooks	  CS,	  Hefty	  PS,	  Jolliff	  SE,	  Akins	  DR.	  2003.	  Global	  analysis	  of	  Borrelia	  
burgdorferi	   genes	   regulated	   by	   mammalian	   host-­‐specific	   signals.	   Infect.	  
Immun.	  71:3371-­‐3383.	  
17.	   Yang	   X,	   Goldberg	  MS,	   Popova	   TG,	   Schoeler	   GB,	  Wikel	   SK,	   Hagman	  KE,	  
Norgard	   MV.	   2000.	   Interdependence	   of	   environmental	   factors	   influencing	  
reciprocal	  patterns	  of	  gene	  expression	   in	  virulent	  Borrelia	  burgdorferi.	  Mol.	  
Microbiol.	  37:1470-­‐1479.	  
 195 
18.	   Lybecker	  MC,	  Samuels	  DS.	  2007.	  Temperature-­‐induced	  regulation	  of	  RpoS	  
by	  a	  small	  RNA	  in	  Borrelia	  burgdorferi.	  Mol.	  Microbiol.	  64:1075-­‐1089.	  
19.	   Smith	  AH,	  Blevins	  JS,	  Bachlani	  GN,	  Yang	  XF,	  Norgard	  MV.	  2007.	  Evidence	  
that	   RpoS	   (sigmaS)	   in	   Borrelia	   burgdorferi	   is	   controlled	   directly	   by	   RpoN	  
(sigma54/sigmaN).	  J.	  Bacteriol.	  189:2139-­‐2144.	  
20.	   Hübner	  A,	  Wang	  X,	  Nolen	  DM,	  Popova	  TG,	  Cabello	  FC,	  Norgard	  M.	  2001.	  
Expression	  of	  Borrelia	  burgdorferi	  OspC	  and	  DbpA	   is	  controlled	  by	  a	  RpoN-­‐
RpoS	  regulatory	  pathway.	  Proc.	  Natl.	  Acad.	  Sci.	  U	  S	  A	  98:12724-­‐12729.	  
21.	   Burtnick	   MN,	   Downey	   JS,	   Brett	   PJ,	   Boylan	   JA,	   Frye	   JG,	   Hoover	   TR,	  
Gherardini	  FC.	  2007.	  Insights	  into	  the	  complex	  regulation	  of	  rpoS	  in	  Borrelia	  
burgdorferi.	  Mol.	  Microbiol.	  65:277-­‐293.	  
22.	   Caimano	   MJ,	   Iyer	   R,	   Eggers	   CH,	   Gonzalez	   C,	   Morton	   EA,	   Gilbert	   MA,	  
Schwartz	   I,	   Radolf	   JD.	   2007.	   Analysis	   of	   the	   RpoS	   regulon	   in	   Borrelia	  
burgdorferi	   in	   response	   to	   mammalian	   host	   signals	   provides	   insight	   into	  
RpoS	  function	  during	  the	  enzootic	  cycle.	  Mol.	  Microbiol.	  65:1193-­‐1217.	  
23.	   Yang	  XF,	  Lybecker	  MC,	  Pal	  U,	  Alani	  SM,	  Blevins	  J,	  Revel	  AT,	  Samuels	  DS,	  
Norgard	  MV.	  2005.	  Analysis	  of	  the	  ospC	  regulatory	  element	  controlled	  by	  the	  
RpoN-­‐RpoS	   regulatory	   pathway	   in	   Borrelia	   burgdorferi.	   J.	   Bacteriol.	  
187:4822-­‐4829.	  
24.	   Caimano	  MJ,	  Eggers	  CH,	  Hazlett	  KR,	  Radolf	  JD.	  2004.	  RpoS	  is	  not	  central	  to	  
the	   general	   stress	   response	   in	   Borrelia	   burgdorferi	   but	   does	   control	  
expression	  of	  one	  or	  more	  essential	  virulence	  determinants.	   Infect.	   Immun.	  
72:6433-­‐6445.	  
 196 
25.	   Eggers	   CH,	   Caimano	  MJ,	   Radolf	   JD.	   2004.	   Analysis	   of	   promoter	   elements	  
involved	   in	   the	   transcriptional	   initiation	   of	   RpoS-­‐dependent	   Borrelia	  
burgdorferi	  genes.	  J.	  Bacteriol.	  186:7390-­‐7402.	  
26.	   Crother	  TR,	  Champion	  CI,	  Whitelegge	  JP,	  Aguilera	  R,	  Wu	  X-­‐Y,	  Blanco	  DR,	  
Miller	  JN,	  Lovett	  MA.	  2004.	  Temporal	  analysis	  of	  the	  antigenic	  composition	  
of	   Borrelia	   burgdorferi	   during	   infection	   in	   rabbit	   skin.	   Infect.	   Immun.	  
72:5063-­‐5072.	  
27.	   Ouyang	   Z,	   Narasimhan	   S,	   Neelakanta	   G,	   Kumar	   M,	   Pal	   U,	   Fikrig	   E,	  
Norgard	  MV.	  2012.	  Activation	  of	  the	  RpoN-­‐RpoS	  regulatory	  pathway	  during	  
the	  enzootic	  life	  cycle	  of	  Borrelia	  burgdorferi.	  BMC	  Microbiol.	  12:44.	  
28.	   Xu	  Q,	  McShan	  K,	  Liang	  FT.	  2007.	  Identification	  of	  an	  ospC	  operator	  critical	  
for	  immune	  evasion	  of	  Borrelia	  burgdorferi.	  Mol.	  Microbiol.	  64:220-­‐236.	  
29.	   Xu	   Q,	   McShan	   K,	   Liang	   FT.	   2008.	   Verification	   and	   dissection	   of	   the	   ospC	  
operator	  by	  using	  flaB	  promoter	  as	  a	  reporter	  in	  Borrelia	  burgdorferi.	  Microb.	  
Pathog.	  45:70-­‐78.	  
30.	   Sarkar	   A,	   Hayes	   BM,	   Dulebohn	   DP,	   Rosa	   PA.	   2011.	   Regulation	   of	   the	  
virulence	   determinant	   OspC	   by	   bbd18	   on	   linear	   plasmid	   lp17	   of	   Borrelia	  
burgdorferi.	  J.	  Bacteriol.	  193:5365-­‐5373.	  
31.	   Casselli	   T,	   Tourand	   Y,	   Bankhead	   T.	   2012.	   Altered	   murine	   tissue	  
colonization	   by	   Borrelia	   burgdorferi	   following	   targeted	   deletion	   of	   linear	  
plasmid	  17-­‐carried	  genes.	  Infect.	  Immun.	  80:1773-­‐1782.	  
32.	   Hayes	  B,	  Jewett	  M,	  Rosa	  P.	  2010.	  A	  lacZ	  reporter	  system	  for	  use	  in	  Borrelia	  
burgdorferi.	  Appl.	  Environ.	  Microbiol.	  76:7407-­‐7412.	  
 197 
33.	   Barbour	   AG.	   1984.	   Isolation	   and	   cultivation	   of	   Lyme	   disease	   spirochetes.	  
Yale	  J.	  Biol.	  Med.	  57:521-­‐525.	  
34.	   Samuels	   DS.	   1995.	   Electrotransformation	   of	   the	   spirochete	   Borrelia	  
burgdorferi,	  p.	  253-­‐259.	   In	  Nickoloff	   JA	  (ed.),	  Methods	   in	  Molecular	  Biology,	  
vol.	   47:	   Electroporation	   Protocols	   for	  Microorganisms.	   Humana	   Press,	   Inc.,	  
Totowa,	  NJ.	  
35.	   Rego	   RO,	   Bestor	   A,	   Rosa	   PA.	   2011.	   Defining	   the	   plasmid-­‐encoded	  
restriction-­‐modification	   systems	   of	   the	   Lyme	   disease	   spirochete	   Borrelia	  
burgdorferi.	  J.	  Bacteriol.	  193:1161-­‐1171.	  
36.	   Chaconas	   G,	   Stewart	   PE,	   Tilly	   K,	   Bono	   JL,	   Rosa	   P.	   2001.	   Telomere	  
resolution	  in	  the	  Lyme	  disease	  spirochete.	  EMBO	  J.	  20:3229-­‐3237.	  
37.	   Elias	  AF,	  Stewart	  PE,	  Grimm	  D,	  Caimano	  MJ,	  Eggers	  CH,	  Tilly	  K,	  Bono	  JL,	  
Akins	   DR,	   Radolf	   JD,	   Schwan	   TG,	   Rosa	   P.	   2002.	   Clonal	   polymorphism	   of	  
Borrelia	   burgdorferi	   strain	   B31	   MI:	   implications	   for	   mutagenesis	   in	   an	  
infectious	  strain	  background.	  Infect.	  Immun.	  70:2139-­‐2150.	  
38.	   Sadziene	  A,	  Wilske	  B,	   Ferdows	  MS,	   Barbour	  AG.	   1993.	   The	   cryptic	  ospC	  
gene	   of	   Borrelia	   burgdorferi	   B31	   is	   located	   on	   a	   circular	   plasmid.	   Infect.	  
Immun.	  61:2192-­‐2195.	  
39.	   Bestor	  A,	  Stewart	  PE,	  Jewett	  MW,	  Sarkar	  A,	  Tilly	  K,	  Rosa	  PA.	  2010.	  Using	  
the	   Cre-­‐lox	   recombination	   system	   to	   investigate	   lp54	   gene	   requirement	   in	  
the	  infectious	  cycle	  of	  Borrelia	  burgdorferi.	  Infect.	  Immun.	  78:2397-­‐2407.	  
40.	   Elias	   AF,	   Bono	   JL,	   Kupko	   JJ,	   Stewart	   PE,	   Krum	   JG,	   Rosa	   PA.	   2003.	   New	  
antibiotic	   resistance	   cassettes	   suitable	   for	   genetic	   studies	   in	   Borrelia	  
burgdorferi.	  J.	  Mol.	  Microbiol.	  Biotechnol.	  6:29-­‐40.	  
 198 
41.	   Stewart	   PE,	   Chaconas	   G,	   Rosa	   P.	   2003.	   Conservation	   of	   plasmid	  
maintenance	   functions	   between	   linear	   and	   circular	   plasmids	   in	   Borrelia	  
burgdorferi.	  J.	  Bacteriol.	  185:3202-­‐3209.	  
42.	   Vieira	   J,	  Messing	   J.	   1991.	  New	  pUC-­‐derived	   cloning	   vectors	  with	   different	  
selectable	  markers	  and	  DNA	  replication	  origins.	  Gene	  100:189-­‐194.	  
43.	   Beaurepaire	   C,	   Chaconas	   G.	   2005.	   Mapping	   of	   essential	   replication	  
functions	   of	   the	   linear	   plasmid	   lp17	   of	   Borrelia	   burgdorferi	   by	   targeted	  
deletion	  walking.	  Mol.	  Microbiol.	  57:132-­‐142.	  
44.	   Ojaimi	  C,	  Brooks	  C,	  Casjens	  S,	  Rosa	  P,	  Elias	  A,	  Barbour	  AG,	  Jasinskas	  A,	  
Benach	   J,	   Katona	   L,	   Radolf	   J,	   Caimano	  M,	   Skare	   J,	   Swingle	   K,	   Akins	   D,	  
Schwartz	   I.	   2003.	   Profiling	   temperature-­‐induced	   changes	   in	   Borrelia	  
burgdorferi	   gene	   expression	   using	   whole	   genome	   arrays.	   Infect.	   Immun.	  
71:1689-­‐1705.	  
45.	   Barbour	   AG,	   Hayes	   SF,	   Heiland	   RA,	   Schrumpf	   ME,	   Tessier	   SL.	   1986.	   A	  
Borrelia-­‐specific	   monoclonal	   antibody	   binds	   to	   a	   flagellar	   epitope.	   Infect.	  
Immun.	  52:549-­‐554.	  
46.	   Clifton	  DR,	  Nolder	  CL,	  Hughes	  JL,	  Nowalk	  AJ,	  Carroll	  JA.	  2006.	  Regulation	  
and	   expression	   of	   bba66	   encoding	   an	   immunogenic	   infection-­‐associated	  
lipoprotein	  in	  Borrelia	  burgdorferi.	  Mol.	  Microbiol.	  61:243-­‐258.	  
47.	   Policastro	  PF,	  Schwan	  TG.	  2003.	  Experimental	  infection	  of	  Ixodes	  scapularis	  
larvae	   (Acari:	   Ixodidae)	   by	   immersion	   in	   low	   passage	   cultures	   of	   Borrelia	  
burgdorferi.	  J.	  Med.	  Entomol.	  40:364-­‐370.	  
 199 
48.	   Mbow	  ML,	   Gilmore	  RD,	   Jr.,	   Titus	  RG.	   1999.	   An	  OspC-­‐specific	  monoclonal	  
antibody	  passively	  protects	  mice	  from	  tick-­‐transmitted	  infection	  by	  Borrelia	  
burgdorferi	  B31.	  Infect.	  Immun.	  67:5470-­‐5472.	  
49.	   Lawrenz	   MB,	   Kawabata	   H,	   Purser	   JE,	   Norris	   SJ.	   2002.	   Decreased	  
electroporation	  efficiency	   in	  Borrelia	  burgdorferi	   containing	   linear	  plasmids	  
lp25	   and	   lp56:	   impact	   on	   transformation	   of	   infectious	   Borrelia.	   Infect.	  
Immun.	  70:4851-­‐4858.	  
50.	   Kawabata	  H,	  Norris	   SJ,	  Watanabe	  H.	   2004.	   BBE02	   disruption	  mutants	   of	  
Borrelia	  burgdorferi	  B31	  have	  a	  highly	  transformable,	   infectious	  phenotype.	  
Infect.	  Immun.	  72:7147-­‐7154.	  
51.	   Beaurepaire	   C,	   Chaconas	   G.	   2007.	   Topology-­‐dependent	   transcription	   in	  
linear	   and	   circular	   plasmids	   of	   the	   segmented	   genome	   of	   Borrelia	  
burgdorferi.	  Mol.	  Microbiol.	  63:443-­‐453.	  
52.	   Purser	   JE,	   Norris	   SJ.	   2000.	   Correlation	   between	   plasmid	   content	   and	  
infectivity	   in	   Borrelia	   burgdorferi.	   Proc.	   Natl.	   Acad.	   Sci.	   U	   S	   A	   97:13865-­‐
13870.	  
53.	   Jewett	   MW,	   Byram	   R,	   Bestor	   A,	   Tilly	   K,	   Lawrence	   K,	   Burtnick	   MN,	  
Gherardini	   F,	   Rosa	   PA.	   2007.	   Genetic	   basis	   for	   retention	   of	   a	   critical	  
virulence	  plasmid	  of	  Borrelia	  burgdorferi.	  Mol.	  Microbiol.	  66:975-­‐990.	  
54.	   Marconi	   RT,	   Samuels	   DS,	   Garon	   CF.	   1993.	   Transcriptional	   analyses	   and	  
mapping	  of	  the	  ospC	  gene	  in	  Lyme	  disease	  spirochetes.	  J.	  Bacteriol.	  175:926-­‐
932.	  
55.	   Obonyo	  M,	  Munderloh	  UG,	  Fingerle	  V,	  Wilske	  B,	  Kurtti	  TJ.	  1999.	  Borrelia	  
burgdorferi	   in	   tick	   cell	   culture	   modulates	   expression	   of	   outer	   surface	  
 200 
proteins	   A	   and	   C	   in	   response	   to	   temperature.	   J.	   Clin.	   Microbiol.	   37:2137-­‐
2141.	  
56.	   Carroll	   JA,	   Garon	   CF,	   Schwan	   TG.	   1999.	   Effects	   of	   environmental	   pH	   on	  
membrane	  proteins	  in	  Borrelia	  burgdorferi.	  Infect.	  Immun.	  67:3181-­‐3187.	  
57.	   Yang	   XF,	   Alani	   SM,	   Norgard	   MV.	   2003.	   The	   response	   regulator	   Rrp2	   is	  
essential	   for	   the	   expression	   of	   major	   membrane	   lipoproteins	   in	   Borrelia	  
burgdorferi.	  Proc.	  Natl.	  Acad.	  Sci.	  U	  S	  A	  100:11001-­‐11006.	  
58.	   Blevins	   JS,	   Xu	   H,	   He	  M,	   Norgard	  MV,	   Reitzer	   L,	   Yang	   XF.	   2009.	   Rrp2,	   a	  
sigma54-­‐dependent	   transcriptional	   activator	   of	   Borrelia	   burgdorferi,	  
activates	   rpoS	   in	   an	   enhancer-­‐independent	  manner.	   J.	   Bacteriol.	  191:2902-­‐
2905.	  
59.	   Boardman	  BK,	  He	  M,	  Ouyang	   Z,	   Xu	  H,	   Pang	  X,	   Yang	  XF.	   2008.	   Essential	  
role	   of	   the	   response	   regulator	   Rrp2	   in	   the	   infectious	   cycle	   of	   Borrelia	  
burgdorferi.	  Infect.	  Immun.	  76:3844-­‐3853.	  
60.	   Fisher	   MA,	   Grimm	   D,	   Henion	   AK,	   Elias	   AF,	   Stewart	   PE,	   Rosa	   PA,	  
Gherardini	   FC.	   2005.	   Borrelia	   burgdorferi	   sigma54	   is	   required	   for	  
mammalian	   infection	   and	  vector	   transmission	  but	  not	   for	   tick	   colonization.	  
Proc.	  Natl.	  Acad.	  Sci.	  U	  S	  A	  102:5162-­‐5167.	  
61.	   Fraser	  CM,	  Casjens	  S,	  Huang	  WM,	  Sutton	  GG,	  Clayton	  R,	  Lathigra	  R,	  White	  
O,	  Ketchum	  KA,	  Dodson	  R,	  Hickey	  EK,	  Gwinn	  M,	  Dougherty	  B,	  Tomb	  J-­‐F,	  
Fleischmann	  RD,	  Richardson	  D,	  Peterson	  J,	  Kerlavage	  AR,	  Quackenbush	  
J,	   Salzberg	   S,	   Hanson	  M,	   van	   Vugt	   R,	   Palmer	  N,	   Adams	  MD,	   Gocayne	   J,	  
Weidmann	  J,	  Utterback	  T,	  Watthey	  L,	  McDonald	  L,	  Artiach	  P,	  Bowman	  C,	  
Garland	   S,	   Fujii	   C,	   Cotton	  MD,	  Horst	   K,	   Roberts	   K,	   Hatch	   B,	   Smith	  HO,	  
 201 
Venter	  JC.	  1997.	  Genomic	  sequence	  of	  a	  Lyme	  disease	  spirochaete,	  Borrelia	  
burgdorferi.	  Nature	  390:580-­‐586.	  
62.	   Boylan	   JA,	   Posey	   JE,	   Gherardini	   FC.	   2003.	   Borrelia	   oxidative	   stress	  
response	   regulator,	   BosR:	   a	   distinctive	   Zn-­‐dependent	   transcriptional	  
activator.	  Proc.	  Natl.	  Acad.	  Sci.	  U	  S	  A	  100:11684-­‐11689.	  
63.	   Ouyang	   Z,	   Kumar	  M,	   Kariu	   T,	   Haq	   S,	   Goldberg	  M,	   Pal	   U,	   Norgard	  MV.	  
2009.	  BosR	   (BB0647)	   governs	   virulence	   expression	   in	  Borrelia	   burgdorferi.	  
Mol.	  Microbiol.	  74:1331-­‐1343.	  
64.	   Hyde	   JA,	   Shaw	   DK,	   Smith	   Iii	   R,	   Trzeciakowski	   JP,	   Skare	   JT.	   2009.	   The	  
BosR	   regulatory	   protein	   of	   Borrelia	   burgdorferi	   interfaces	   with	   the	   RpoS	  
regulatory	   pathway	   and	  modulates	   both	   the	   oxidative	   stress	   response	   and	  
pathogenic	   properties	   of	   the	   Lyme	   disease	   spirochete.	   Mol.	   Microbiol.	  
74:1344-­‐1355.	  
65.	   Lybecker	   MC,	   Abel	   CA,	   Feig	   AL,	   Samuels	   DS.	   2010.	   Identification	   and	  
function	  of	   the	  RNA	  chaperone	  Hfq	   in	   the	  Lyme	  disease	  spirochete	  Borrelia	  
burgdorferi.	  Mol.	  Microbiol.	  78:622-­‐635.	  
66.	   Ouyang	  Z,	  Deka	  RK,	  Norgard	  MV.	  2011.	  BosR	  (BB0647)	  controls	  the	  RpoN-­‐
RpoS	  regulatory	  pathway	  and	  virulence	  expression	  in	  Borrelia	  burgdorferi	  by	  
a	  novel	  DNA-­‐binding	  mechanism.	  PLoS	  Pathog.	  7:e1001272.	  
67.	   Yang	  XF,	  Pal	  U,	  Alani	   SM,	   Fikrig	  E,	  Norgard	  MV.	   2004.	   Essential	   role	   for	  
OspA/B	  in	  the	  life	  cycle	  of	  the	  Lyme	  disease	  spirochete.	  J.	  Exp.	  Med.	  199:641-­‐
648.	  
 202 
68.	   Ouyang	  Z,	  Blevins	  JS,	  Norgard	  MV.	  2008.	  Transcriptional	   interplay	  among	  
the	   regulators	   Rrp2,	   RpoN	   and	   RpoS	   in	   Borrelia	   burgdorferi.	   Microbiology	  
154:2641-­‐2658.	  
69.	   Casjens	   SR,	   Mongodin	   EF,	   Qiu	  WG,	   Luft	   BJ,	   Schutzer	   SE,	   Gilcrease	   EB,	  
Huang	  WM,	   Vujadinovic	  M,	   Aron	   JK,	   Vargas	   LC,	   Freeman	   S,	   Radune	  D,	  
Weidman	  JF,	  Dimitrov	  GI,	  Khouri	  HM,	  Sosa	  JE,	  Halpin	  RA,	  Dunn	  JJ,	  Fraser	  
CM.	   2012.	   Genome	   stability	   of	   Lyme	   disease	   spirochetes:	   comparative	  
genomics	  of	  Borrelia	  burgdorferi	  plasmids.	  PLoS	  One	  7:e33280.	  
70.	   Gerdes	   K,	   Moller-­‐Jensen	   J,	   Bugge	   Jensen	   R.	   2000.	   Plasmid	   and	  
chromosome	  partitioning:	  surprises	  from	  phylogeny.	  Mol.	  Microbiol.	  37:455-­‐
466.	  
71.	   Hirano	  M,	  Mori	  H,	  Onogi	  T,	  Yamazoe	  M,	  Niki	  H,	  Ogura	  T,	  Hiraga	  S.	  1998.	  
Autoregulation	   of	   the	   partition	   genes	   of	   the	   mini-­‐F	   plasmid	   and	   the	  
intracellular	  localization	  of	  their	  products	  in	  Escherichia	  coli.	  Mol.	  Gen.	  Genet.	  
257:392-­‐403.	  
72.	   Kwong	   SM,	   Yeo	   CC,	   Poh	   CL.	   2001.	   Molecular	   analysis	   of	   the	   pRA2	  
partitioning	   region:	   ParB	   autoregulates	   parAB	   transcription	   and	   forms	   a	  




APPENDIX	  A:	  Library	  screen	  for	  the	  ospA	  repressor	  
	  
Introduction	  
While	  OspC	  is	  upregulated	  as	  Borrelia	  burgdorferi	  establishes	  infection	  in	  the	  
host	   (see	   introduction	   and	   chapters	   1-­‐3),	   OspA	   is	   produced	   when	   B.	   burgdorferi	  
colonizes	  the	  tick	  (1),	  where	  it	  is	  required	  for	  colonization	  and	  thus	  survival	  during	  
the	  infectious	  cycle	  (2).	  However,	  if	  present	  in	  the	  mammalian	  host,	  OspA	  is	  a	  potent	  
antigen	   and	   stimulates	   the	   production	   of	   bactericidal	   antibodies.	   In	   fact,	  
recombinant	   OspA	   is	   the	   only	   vaccine	   ever	   licensed	   to	   prevent	   Lyme	   disease	   in	  
humans	  by	  blocking	  transmission	  from	  the	  tick	  vector	  (3)	  
Although	  OspA	   is	   strictly	   repressed	  when	  spirochetes	  are	   transmitted	   from	  
the	   tick	   to	   the	  mammalian	  host,	   the	   specific	  mechanisms	  and	  B.	  burgdorferi	   genes	  
controlling	  ospA	  expression	  have	  not	  been	  identified.	  Others	  have	  shown	  that	  ospA	  
is	   regulated	   at	   the	   level	   of	   transcription	   (4),	   suggesting	   that	   the	   B.	   burgdorferi	  
genome	  encodes	  a	  specific	  ospA	  repressor.	  	  
In	  order	  to	  identify	  the	  genes	  necessary	  for	  repression	  of	  ospA,	  I	  designed	  an	  
expression	  library	  screen	  using	  an	  ospA	  promoter-­‐lacZ	  reporter	  construct.	  Although	  
most	  of	  the	  randomly	  cloned	  inserts	  would	  not	  affect	  lacZ	  expression	  from	  the	  ospA	  
promoter,	   those	   inserts	   encoding	   proteins	   that	   normally	   repress	   ospA	   during	   the	  
infectious	  cycle	  should	  repress	  the	  production	  of	  β-­‐galactosidase.	  
I	   created	   a	   complete	   B.	   burgdorferi	   genomic	   DNA	   library	   containing	   small	  
(100-­‐300bp)	   inserts	   under	   expression	   of	   the	   constitutive	   flaB	   promoter	   and	  
introduced	   this	   library	   into	   the	  B.	   burgdorferi	   clone	   that	   expresses	   lacZ	   from	   the	  
ospA	  promoter.	   Expression	   of	   these	   library	   clones	   failed	   to	   affect	   lacZ	   expression	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from	  the	  opsA	  promoter	  or	  endogenous	  OspA	  production	  in	  B.	  burgdorferi.	  Multiple	  
attempts	  were	  made	   to	   construct	   a	  middle-­‐sized	   insert	   (300-­‐850bp)	   and	   a	   large-­‐
sized	   insert	   (850bp-­‐2kb)	   library,	   but	   technical	   difficulties	   prevented	   successful	  
completion	  and	  the	  project	  was	  not	  continued.	  	  
	  
Materials	  and	  Methods	  
All	  enzymes	  were	  purchased	  from	  New	  England	  Biolabs	  (NEB,	  Ipswich,	  MA)	  
and	  all	   chemicals	   and	  other	  materials	  were	  purchased	   from	  Sigma	   (St.	   Louis,	  MO)	  
unless	  otherwise	  specified.	  
Bacterial	  Strains	  and	  Growth	  Conditions	  
BSKII	  medium	   (5)	   for	   culture	   of	   B.	   burgdorferi	  was	  made	  with	  CMRL	  1060	  
lacking	  phenol	  red	  (US	  Biologicals,	  Swampscott,	  MA).	  B.	  burgdorferi	  strain	  B31-­‐A34,	  
(Table	   A-­‐1,	   referred	   to	   as	   A34	   from	   now	   on)(6)	   was	   grown	   to	   mid	   log	   phase,	  
enumerated	  using	  dark-­‐field	  microscopy	  with	  a	  Petroff-­‐Hausser	  counting	  chamber	  
and	  prepared	  for	  electroporation	  as	  described	  previously	  (7).	  Transformants	  were	  
selected	   using	   gentamicin	   at	   a	   concentration	   of	   40µg/mL	   and/or	   kanamycin	   at	  
200µg/mL.	   All	   B.	   burgdorferi	   cultures	   were	   grown	   at	   35°C	   and	   plates	   were	  
incubated	  under	  2.5%	  CO2.	  
The	   Escherichia	   coli	   strain	   Top10	   (Invitrogen,	   Carlsbad,	   CA)	   was	   used	   for	  
routine	   cloning	   and	   propagation	   of	   the	   libraries.	   E.	   coli	   was	   plated	   on	   LB	   agar	  
(kanamycin	   at	   30	   µg/mL	   ,	   or	   gentamicin	   at	   5	   µg	   /mL)	   and	   liquid	   cultures	   were	  
grown	   in	   LB	   broth	   supplemented	   with	   the	   appropriate	   antibiotics	   (kanamycin	   at	  
100µg/mL	  or	  gentamicin	  at	  10	  µg/mL).	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Table	  A-­‐1:	  Strains	  and	  Plasmids	  used	  in	  Appendix	  A	  
Name	   Description	   Reference	  
B.	  burgdorferi	  strains	  
B31-­‐A3	   Infectious	  derivative	  of	  wild-­‐type	  B31-­‐MI,	  lacks	  cp9	   (8)	  
B31-­‐A34	   derivative	  of	  non-­‐infectious	  clone	  B31-­‐A	  that	  also	  lacks	  lp56;	  high	  transformation	  effeciency	   (6)	  
A34-­‐XAZ1	  
derivative	  of	  A34	  in	  which	  the	  ospA	  promoter-­‐lacZBb*	  cassette	  





promoter-­‐less	  Borrelia	  codon-­‐optimized	  lacZBb	  gene	  on	  the	  
shuttle	  vector	  pBSV2G	  with	  BspHI	  restriction	  site	  added	  




pBH-­‐lacZBb*	  with	  the	  ospC	  promoter	  driving	  expression	  of	  
lacZBb	   this	  study	  




derivative	  of	  B.	  burgdorferi	  shuttle	  vector	  pBSV2	  that	  contains	  
the	  constitutive	  flaB	  promoter	  followed	  by	  a	  unique	  EcoRI	  site;	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ospA	  promoter-­‐lacZ	  fusion	  on	  cp26	  
	   The	   ospA	   promoter	   was	   amplified	   from	   B31-­‐A3	   (Table	   A-­‐1)	   genomic	   DNA	  
(gDNA)	   using	   forward	   primer	   CGCGGATCCCCTGAAAGTCCCAAAACTGGG	   and	  
reverse	   primer	   CCCCCCTCATGATATATTCTCCTTTTAT,	   which	   added	   BamHI	   and	  
BspHI	   sites	   (in	   bold),	   respectively,	   to	   the	   5’	   and	   3’	   ends,	   and	   cloned	   into	   pCR2.1	  
(Invitrogen).	   The	   insert,	   confirmed	   by	   sequencing,	   was	   digested	   with	   BamHI	   and	  
BspHI	  and	  ligated	  into	  appropriately	  digested	  pBH-­‐lacZBb*	  (9),	  creating	  pBHospAp-­‐
lacZBb*	   (Table	   A-­‐1).	   To	   construct	   an	   allelic	   exchange	   vector	   that	   would	   mediate	  
insertion	   of	   the	   ospAp-­‐lacZBb	   fusion	   into	   cp26,	   the	   fragment	   containing	   the	   ospA	  
promoter	   driving	   lacZBb	   and	   the	   flgBp-­‐aacc1	   (conferring	   gentamicin	   resistance)	  
was	  excised	  from	  pBHospAp-­‐lacZBb*	  (Table	  A-­‐1)	  with	  restriction	  enzymes	  MluI	  and	  
KpnI,	   and	   the	   overhangs	   were	   filled-­‐in	   or	   removed,	   respectively,	   with	   T4	   DNA	  
polymerase.	   This	   fragment	   was	   ligated	   into	   the	   Topo-­‐XL-­‐based	   plasmid	   used	   to	  
make	  pKK83	  (10),	  which	  contains	  the	  intergenic	  region	  between	  chbC	  and	  resT	  and	  
a	  unique	  BglII	   site.	  The	  resulting	  plasmid,	   termed	  pXAZ1	  (Table	  A-­‐1),	  was	  used	   to	  
transform	  B.	  burgdorferi	  clone	  A34	  (Table	  A-­‐1).	  
Library	  construction	  
	   Genomic	  DNA	  was	  isolated	  from	  a	  mid-­‐log	  phase	  culture	  of	  B31-­‐A3	  (Table	  A-­‐
1),	  a	   low-­‐passage	  infectious	  clone	  of	  B.	  burgdorferi	   that	  retains	  all	  plasmids	  except	  
cp9	   (8),	   using	   the	   Genomic	   DNA	   Kit	   (Qiagen,	   Valencia,	   CA).	   	   gDNA	   was	   partially	  
digested	   for	   1	   hour	   with	   dilutions	   (1,	   1:2,	   1:4,	   1:8,	   and	   1:16)	   of	   the	   restriction	  
enzyme	  Tsp5091.	  Tsp5091	  recognizes	   the	  site	  AATT	  (5’-­‐3’)	  and	  therefore	  cuts	   the	  
AT-­‐rich	   B.	   burgdorferi	   genome	   frequently.	   To	   terminate	   restriction	   endonuclease	  
activity,	   EDTA	   was	   added	   to	   the	   samples.	   Small	   aliquots	   were	   analyzed	   on	   an	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agarose	   gel	   to	   visualize	   the	   extent	   of	   digestion	   (Figure	   A-­‐1).	   All	   samples	   were	  
combined	   and	   separated	   on	   a	   1X	   TAE	   0.8%	   agarose	   gel	   using	   1X	   TAE	   buffer	  
containing	   1mM	   guanosine	   5′-­‐triphosphate.	   DNA	   bands	   corresponding	   to	   100-­‐
300bp,	  300-­‐850bp,	  and	  850bp-­‐2kb	  were	  purified	  using	  the	  MinElute	  Gel	  Extraction	  
Kit	  (Qiagen).	  The	  shuttle	  vector	  pBSV2*flaBp	  (Amit	  Sarkar,	  unpublished,	  (11))	  was	  
digested	   with	   EcoRI,	   end	   phosphates	   removed	   with	   Antarctic	   Phosphatase,	   and	  
purified	   from	   an	   agarose	   gel	   as	   described	   above.	   500ng	   of	   linearized	   vector	   and	  
equivalent	  molar	  amounts	  of	  insert	  DNA	  fragments	  were	  used	  for	  ligations	  (1:1	  ratio	  
of	  vector	  to	  insert).	  For	  example,	  for	  500ng	  of	  the	  6700bp	  vector,	  15ng	  of	  the	  100-­‐
300bp	   fragments	   were	   used.	   1/10	   of	   the	   ligation	   mix	   was	   used	   to	   transform	  
electrocompetent	   Top10	  E.	   coli	   (Invitrogen).	   Aliquots	   of	   transformed	  E.	   coli	   were	  
plated	  on	  LB-­‐agar	  containing	  kanamycin	  to	  determine	  the	  number	  of	  transformants	  
in	   the	   library	  and	  to	  screen	   for	  presence	  of	   inserts	  by	  PCR.	  Plasmid	  DNA	  from	  the	  
complete	  library	  was	  used	  to	  transform	  A34-­‐XAZ1	  (Table	  A-­‐1),	  the	  derivative	  of	  B.	  
burgdorferi	  A34	  carrying	  the	  ospA	  promoter-­‐lacZ	  fusion	  on	  cp26.	  
Sequencing	  DNA	  inserts	  
	   For	   both	   E.	   coli	   and	   B.	   burgdorferi	   colonies,	   library	   clone	   inserts	   were	  
amplified	   directly	   from	   colonies	   PCR	   using	   a	   flaB	   promoter	   3’	   out	   primer	  
(TTTTATCATGGAGGAATGATATATGATTATC)	   and	   a	   library	   reverse	   primer	  
(ACTTTATGCTTCCGGCTCGT).	  PCR	  reactions	  were	  diluted	  1:10	  and	  used	  directly	  as	  
templates	   for	   Sanger	   sequencing	  with	   the	   same	  primers.	  The	  B.	   burgdorferi	   genes	  
corresponding	  to	  the	  insert	  sequences	  were	  identified	  using	  BLAST	  (NCBI)	  against	  
the	  B.	  burgdorferi	  B31	  genome	  in	  order	  to	  assess	  the	  variability	  of	  inserts	  present	  	  
within	  the	  library.	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Screening	  for	  β-­‐galactosidase	  
Approximately	   400uL	   5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl-­‐β-­‐D-­‐galactopyranoside	   (X-­‐gal;	  
Roche	  Diagnostics,	  Indianapolis,	  IN)	  dissolved	  in	  DMSO	  (10mg/mL)	  was	  	  
spread	   on	   B.	   burgdorferi	   plates	   after	   colony	   formation.	   Plates	   were	   incubated	  
overnight	  at	  37°	  before	  assessing	  β-­‐galactosidase	  activity.	  
Electrophoresis	  and	  Immunobotting	  	  
Endogenous	  OspA	  production	  in	  B.	  burgdorferi	  was	  assessed	  using	  SDS-­‐PAGE	  
as	   previously	   described	   (12).	   Briefly,	   B.	   burgdorferi	   was	   harvested	   from	   late-­‐log	  
phase	  cultures	  grown	  in	  BSKII	  and	  washed	  twice	  in	  HEPES-­‐NaCl	  (HN)	  buffer	  (50mM	  
each;	   pH	   7.6)	   before	   lysis	   in	   Laemmli	   sample	   buffer	   containing	   2-­‐β-­‐
mercaptoethanol.	   Approximately	   107	   bacteria	   were	   loaded	   per	   lane	   in	   a	   10%	  
acrylamide	  gel.	  Protein	  gels	  were	  stained	  with	  Coomassie	  Brillant	  Blue	  (Bio-­‐Rad)	  or	  
prepared	  for	  immunoblotting.	  
For	   Western	   Blots,	   proteins	   were	   electrophoretically	   transferred	   to	  
nitrocellulose	  membranes	  (Bio-­‐Rad	  Trans	  blot	  Transfer	  Medium,	  Bio-­‐Rad,	  Hercules,	  
CA).	  Membranes	  were	  blocked	  with	  5%	  non-­‐fat	  milk	   in	  TBST	  (Tris-­‐buffered	  saline	  
with	   0.1%	   Tween	   20).	   Monoclonal	   mouse	   anti-­‐OspA	   (H5332)	   (13)	   at	   1:200,	  
monoclonal	   mouse	   anti-­‐β-­‐galactosidase	   (Santa	   Cruz	   Biotechnology	   Inc.)	   at	   1:100,	  
and	   monoclonal	   mouse	   anti-­‐FlaB	   (H9724)	   (14)	   at	   1:200	   were	   used	   to	   probe	  
membranes.	  Primary	  antibodies	  were	  diluted	   in	  TBST	  with	  or	  without	  5%	  milk.	  A	  
horseradish-­‐peroxidase	   conjugated	   secondary	   anti-­‐mouse	   antibody	   was	   diluted	  
1:10,000	   in	   TBST	   with	   5%	   milk.	   Immunoreactivity	   was	   visualized	   using	   the	  
Supersignal	  West	  Pico	  Chemiluminescence	  substrate	  (Thermo	  Scientific)	  and	  X-­‐ray	  
film	  (Labscientific	  Inc.,	  NJ).	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Results	  
ospAp-­‐lacZBb*	  fusion	  in	  B.	  burdorferi	  
I	   have	   previously	   demonstrated	   that	   the	   lacZ	   gene,	   which	   codes	   for	   β-­‐
galactosidase	   activity,	   accurately	   reflects	   endogenous	   gene	   expression	   in	   B.	  
burgdorferi	  (15).	  Thus,	  I	  decided	  to	  utilize	  this	  genetic	  tool	  in	  my	  library	  screen	  for	  
the	   ospA	   repressor.	   To	   stably	   introduce	   an	   ospA	   promoter-­‐lacZ	   fusion	   into	   B.	  
burgdorferi	  without	  the	  possibility	  of	  the	  fusion	  gene	  being	  lost,	  I	  created	  a	  suicide	  
vector	   to	   insert	   ospAp-­‐lacZBb	   along	   with	   the	   flgBp-­‐aacc1	   cassette	   (conferring	  
gentamicin	   resistance)	   by	   allelic	   exchange	   between	   the	   resT	   and	   chbC	   genes	   on	  
cp26.	  Foreign	  DNA	  has	  been	  inserted	  into	  this	  locus	  before	  (10)	  without	  affecting	  in	  
vitro	   growth	   or	   infectivity	   during	   the	   mouse-­‐tick	   cycle.	   By	   inserting	   the	   ospA	  
promoter-­‐lacZ	   fusion	   into	  the	  endogenous	  cp26	  plasmid,	   I	  was	  free	  to	  use	  a	  stable	  
and	  highly	  transformable	  cp9	  based	  shuttle	  vector	  (pBSV2)	  for	  library	  construction.	  
Furthermore,	  cp26	  is	  presumably	  at	  a	  lower	  copy	  number	  than	  pBSV2,	  which	  should	  
minimize	   any	   gene	   dosage	   affects	   of	   the	   hypothetical	   repressor	   on	   the	   ospA	  
promoter.	  To	  ensure	   that	   I	  would	  get	  a	  high	   frequency	  of	   transformation	  with	   the	  
libraries	  plasmids	  produced	  in	  E.	  coli,	   I	  used	  the	  B.	  burgdorferi	  high	  passage	  clone,	  
A34	   (Table	   A-­‐1)	   (6),	   which	   lacks	  many	   plasmids	   and	   importantly	   two	   restriction	  
modification	   systems	   that	   severely	   reduce	   transformation	   frequency	   (16-­‐18).	   A34	  
was	  transformed	  with	  the	  allelic	  exchange	  vector	  pXAZ1	  (Table	  A-­‐1),	  adding	  ospAp-­‐
lacZBb*	   to	   cp26	   (see	   above).	   One	   transformant,	   which	   showed	   β-­‐galactosidase	  
activity	   on	   solid	  medium	  when	   screened	  with	   X-­‐gal,	   was	   chosen	   to	   take	   forward.	  
This	  clone,	  referred	  to	  as	  A34-­‐XAZ1	  (Table	  A-­‐1),	  exhibited	  stable	  and	  consistent	  β-­‐
galactosidase	  activity	  and	  did	  not	  display	  any	  growth	  defects	  in	  liquid	  or	  solid	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media.	  	  
Plasmid	  expression	  libraries	  in	  E.	  coli	  
	   A	  derivative	  of	   the	  B.	  burgdorferi	   shuttle	  vector,	  pBSV2,	  which	  replicates	   in	  
both	  E.	  coli	  and	  B.	  burgdorferi	  and	  has	  the	  constitutive	  flaB	  promoter	  followed	  by	  a	  
unique	   EcoRI	   site	   (Amit	   Sarkar,	   unpublished	   (11)),	   was	   used	   to	   construct	   the	   B.	  
burgdorferi	   expression	   libraries.	   This	   plasmid,	   pBSV2*flaBp	   (Table	   A-­‐1)	   was	  
linearized	   with	   EcoRI	   and	   the	   terminal	   phosphates	   removed	   to	   minimize	   empty	  
vector	  self-­‐ligation.	  To	  prepare	  the	  B.	  burgdorferi	  inserts,	  genomic	  DNA	  was	  isolated	  
from	   a	   low-­‐passage	   infectious	   clone,	   B31-­‐A3	   (Table	   A-­‐1),	   which	   retains	   all	   of	   the	  
endogenous	   plasmids	   (except	   cp9)	   and	   presumably	   encodes	   the	   ospA	   repressor.	  
gDNA	  was	  partially	  digested	  with	  dilutions	  of	  Tsp5091	  (Figure	  A-­‐1).	  DNA	  digested	  
with	  Tsp5091	  has	  EcoRI-­‐	  compatible	  3’	  overhangs,	  but	  Tsp5091	  lacks	  the	  C/G	  in	  the	  
recognition	   sequence	   (i.e.	   the	   5’-­‐3’	   recognition	   site	   for	   EcoRI	   is	   GêAATTC,	   while	  
Tsp5091	  recognizes	  êAATT,	  where	  ê	  represents	  the	  cleavage	  site),	  making	  Tsp5091	  
restriction	   sites	  more	   frequent	   in	   the	  A/T	   rich	  B.	   burgdorferi	  genome.	   Vector	   and	  
insert	  DNA	  were	  separated	  on	  agarose	  gels	  using	  TAE	  buffer	  containing	  guanosine	  
5′-­‐triphosphate	  to	  minimize	  damage	  to	  DNA	  during	  UV-­‐exposure.	  Digested	  genomic	  
DNA	  was	   divided	   into	   3	   different	   size	   fragments	   to	   create	   3	   different	   expression	  
libraries.	   The	   small	   insert	   size	   (100-­‐300bp)	  was	   chosen	   to	   include	  DNA	   encoding	  
any	  small	  proteins	  or	  RNAs	  that	  might	  repress	  the	  ospA	  promoter	  while	  eliminating	  
any	   degraded	  DNA	   smaller	   than	   100bp.	   These	   smaller	   fragments	  will	   likely	   ligate	  
into	   the	   vector	   more	   efficiently	   but	   will	   require	   more	   clones	   to	   obtain	   full	   B.	  
burgdorferi	   genome	   coverage.	   A	   middle-­‐sized	   insert	   of	   300-­‐850bp	   was	   picked	   to	  
cover	  entire	  or	  mostly	  complete	  open	  reading	  frames	  (ORFs),	  as	  the	  average	  ORF	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Figure	  A-­‐1:	  Partial	  digestion	  of	  B31-­‐A3	  gDNA	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Figure	  A-­‐1	  legend:	  A	  1%	  TAE	  agarose	  gel	  was	  used	  to	  separate	  partial	  digestion	  of	  
B31-­‐A3	  gDNA.	  Lanes	  are	  as	   indicated.	  Dilutions	  of	  Tsp5091	  (1:2,	  1:4,	  1:8,	  1:16)	  or	  
undiluted	   Tsp5091	   were	   used	   in	   restriction	   digest	   reactions	   for	   1	   hour,	   which	  
randomly	  cut	  the	  gDNA	  to	  varying	  degrees	  compared	  to	  undigested	  gDNA	  (lane	  2).	  
The	  1kB	  plus	  DNA	   ladder	   from	   Invitrogen	   (lane	  1,	   ladder)	  was	  used	  as	   a	   guide	   in	  
purification	  of	  the	  small-­‐,	  medium-­‐,	  and	  large-­‐sized	  inserts	  from	  the	  agarose	  gel	  to	  
be	  used	   in	   library	  construction.	  The	   three	  distinct	  bands	  present	   in	   the	  undiluted,	  
1:2	   and	   1:4	   TSp5091	   digests	   lanes	   represent	   the	   A/T-­‐rich	   region	   of	   nonrandom	  
repeats	  from	  lp21,	  which	  contains	  few	  restriction	  sites	  (19).	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size	  in	  B.	  burgdorferi	  is	  507bp	  for	  the	  plasmids	  and	  992bp	  for	  the	  chromosome	  (20).	  
Lastly,	  a	  large-­‐sized	  insert	  (850bp-­‐2kB)	  was	  chosen	  to	  cover	  any	  large	  ORFs	  and	  to	  
provide	   additional	   genome	   coverage.	   Equivalent	   amounts	   of	   gel-­‐extracted	   vector	  
and	   insert	   DNAs	   were	   used	   for	   ligations.	   E.	   coli	   transformed	   with	   ligations	   were	  
combined	   and	   propagated	   to	   produce	   plasmid	   DNA	   after	   aliquots	   were	   plated	   to	  
assess	   genome	   coverage	   and	   insert	   sequences.	   	   For	   the	   small	   sized	   insert	   library,	  
3,000-­‐20,000	  transformants	  were	  recovered	  from	  1/10	  of	  the	  ligation	  mix.	  Of	  these	  
clones,	   80-­‐90%	   contained	   inserts.	   After	   5	   E.	   coli	   transformations	   (approximately	  
42,000	  independent	  transformants),	  3x	  coverage	  of	  the	  B.	  burgdorferi	  genome	  was	  
obtained.	  	  
Introducing	  and	  characterizing	  the	  libraries	  in	  A34-­‐XAZ1	  
	   Although	   E.	   coli	   has	   been	   used	   to	   study	   gene	   regulation	   of	   B.	   burgdorferi	  
genes,	  I	  wanted	  to	  screen	  for	  the	  ospA	  repressor	  in	  its	  native	  bacterium	  to	  facilitate	  
expression	   and	   folding	   of	   the	   putative	   repressor	   and	   to	   control	   for	   any	   accessory	  
cofactors	   required	   for	   repression	   of	   ospA.	   10-­‐20ug	   of	   plasmid	   DNA	   from	   the	  
complete	  small-­‐size	  insert	  library	  in	  E.	  coli	  was	  used	  to	  transform	  A34-­‐XAZ1,	  the	  B.	  
burgdorferi	   clone	   containing	   the	   ospA	   promoter-­‐lacZ	   fusion	   on	   cp26	   (Table	   A-­‐2).	  
Transformed	  B.	  burgdorferi	  was	  allowed	  to	  recover	  in	  10mL	  BSK	  II	  overnight	  before	  
the	  addition	  of	  antibiotics.	  The	  following	  day,	  half	  of	  the	  culture	  was	  used	  to	  make	  a	  
permanent	   glycerol	   stock	   and	   the	   remaining	   half	   was	   plated	   in	   solid	   media	  
containing	   antibiotics.	   X-­‐gal	   was	   added	   to	   plates	   a	   few	   days	   after	   colonies	   were	  
visible.	   Although	   some	   colonies	   remained	  white	   after	   treatment	  with	   X-­‐gal,	   those	  
clones	   still	   produced	   OspA	   protein	   when	   lysates	   were	   probed	   with	   an	   anti-­‐OspA	  
antibody.	  Random	  colonies	  were	  screened	  by	  PCR	  to	  determine	  the	  proportion	  of	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Table	   A-­‐2:	   Representative	   inserts	   in	   small	   library	   Borrelia	   burgdorferi	  
transformants	  
	  
clone	   alignment	   size-­‐bp	   gene*	  
1	   lp38	   94	   	  	  
	   chromosome	   216	  
diphosphate-­‐-­‐fructose-­‐6-­‐phosphate	  1-­‐
phosphotransferase	  
2	   lp28-­‐2	   137	   	  	  
3	   chromosome	   206	   molecular	  chaperone	  DnaK	  
	   cp32-­‐7	   126	   	  
4	   chromosome	   233	   protein	  kinase	  C1	  inhibitor	  (pkcI)-­‐Mg2+	  transport	  protein	  (mgtE)	  
5	   chromosome	   109	   hypothetical	  protein	  
6	   chromosome	   155	   hypothetical	  protein	  
7	   lp25	   74	   	  	  
	   lp36	   72	   	  
8	   chromosome	   168	   purine-­‐binding	  chemotaxis	  protein	  (cheW-­‐2)	  
9	   chromosome	   184	   N-­‐acetylmuramoyl-­‐L-­‐alanine	  amidase,	  putative	  
10	   chromosome	   318	   PTS	  system,	  maltose	  and	  glucose-­‐specific	  IIABC	  component	  
11	   lp28-­‐2	   291	   	  	  
12	   chromosome	   113	   hypothetical	  protein	  
13	   chromosome	   117	   xylulokinase	  (xylB)	  
14	   chromosome	   251	   hypothetical	  protein	  
15	   chromosome	   205	   phnP	  protein	  (phnP)	  
16	   cp32-­‐8	   160	   	  	  
	   cp32-­‐7	   160	   	  
	   cp32-­‐3	   160	   	  
	   cp32-­‐1	   160	   	  
17	   chromosome	   163	   3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐CoA	  synthase	  	  
	   chromosome	   134	   50S	  ribosomal	  protein	  L9	  
18	   chromosome	   149	   hypothetical	  protein	  
19	   chromosome	   127	   membrane-­‐associated	  protein	  p66	  
20	   chromosome	   188	   	  flagellar	  MS-­‐ring	  protein	  
21	   chromosome	   147	   DNA-­‐directed	  RNA	  polymerase	  subunit	  beta'	  
22	   chromosome	   135	   lysyl-­‐tRNA	  synthetase	  
23	   chromosome	   181	   50S	  ribosomal	  protein	  L5	  
24	   lp25	   159	   	  	  
25	   chromosome	   179	   ribonuclease	  Z	  
26	   chromosome	   173	   hypothetical	  protein	  
27	   chromosome	   211	   ATP-­‐binding	  protein	  (ylxH-­‐2)	  
28	   lp28-­‐2	   194	   	  	  
	   lp28-­‐3	   194	   	  
	   lp28-­‐4	   180	   	  
	   lp38	   180	   	  
	   lp36	   60	   	  
29	   lp36	   100	   	  	  
	   lp56	   99	   	  
	   lp21	   74	   	  
30	   chromosome	   151	   elongation	  factor	  Tu	  
 215 
31	   chromosome	   89	   chromate	  transport	  protein,	  putative	  -­‐	  hypothetical	  protein	  
32	   lp28-­‐1	   93	   different	  portions	  of	  lp28-­‐1	  with	  variable	  identity-­‐	  vlsE?	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	   lp28-­‐1	   93	   	  
	  	   lp28-­‐1	   93	   	  	  
*	  inserts	  that	  mapped	  to	  regions	  without	  annotated	  genes	  are	  left	  blank	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clones	   containing	   an	   insert	   and	   the	   resulting	   PCR	   fragments	   were	   subsequently	  
sequenced	  to	  identify	  the	  gene(s)	  covered	  (Table	  A-­‐2).	  The	  identities	  of	  these	  inserts	  
were	  random	  and	  covered	  both	  the	  chromosome	  and	  plasmid-­‐encoded	  genes.	  Some	  
sequenced	  inserts	  displayed	  homology	  to	  regions	  on	  several	  plasmids	  (see	  clones	  7,	  
16,	  28,	  and	  29	  in	  Table	  A-­‐2),	  indicating	  genes	  in	  a	  paralogous	  family	  that	  are	  present	  
on	  many	  of	  the	  B.	  burgdorferi	  plasmids,	  whereas	  others	  had	  homology	  to	  2	  different	  
regions	  within	  the	  genome,	  indicating	  the	  presence	  of	  2	  distinct	  inserts	  (Table	  A-­‐2,	  
clones	  1	  and	  3),	  and	  one	  clone	  (Table	  A-­‐2,	  clone	  32)	  mapped	  to	  different	  sites	  on	  the	  
same	   plasmid,	   presumably	   indicating	   several	   copies	   of	   the	   same	   gene	   or	   silent	  
cassettes.	  Many	  of	  the	  plasmid	  borne	  sequences	  mapped	  to	  unannotated	  regions,	  in	  
which	   the	   gene	   column	   was	   left	   empty	   in	   Table	   A-­‐2.	   An	   average	   of	   4,000	  
independent	   clones	   arose	   from	   each	   B.	   burgdorferi	   transformation.	   Sequencing	  
results	  (Table	  A-­‐2)	  implied	  that	  clones	  were	  both	  random	  and	  variable,	  so	  after	  10	  
successful	  transformations,	  I	  assumed	  at	  least	  3X	  genome	  coverage	  in	  B.	  burgdorferi	  
had	  been	  achieved	  for	  the	  small-­‐insert	  library.	  	  
Expansion	  of	  the	  middle-­‐sized	  insert	  library	  
A	   similar	   protocol	   was	   used	   to	   create	   the	   middle-­‐sized	   insert	   library.	   The	  
initial	  characterization	  of	  the	  library	  inserts	  in	  E.	  coli	   indicated	  that	  3X	  coverage	  of	  
the	   B.	   burgdorferi	   genome	   had	   been	   obtained.	   However,	   after	   transforming	   the	  
library	  DNA	  into	  A34-­‐XAZ1	  (Table	  A-­‐1),	  transformants	  primarily	  contained	  two	  	  
distinct	   inserts.	   Theses	   inserts	   mapped	   to	   two	   regions	   in	   the	   B.	   burgdorferi	  
chromosome,	   spanning	   base	   pairs	   454832-­‐455306	   and	   887773-­‐888449.	   The	   first	  
mapped	  to	  an	   internal	  3’-­‐5’	   region	  of	  gyrase	  B	  (gyrB).	  The	   later	  region	  mapped	  to	  
phosphomannomutase	  (cpsG)	  and	  excinuclease	  ABC	  subunit	  B	  (uvrB),	  including	  the	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intergenic	   region	   between	   the	   two	   genes.	   I	   hypothesized	   that	   expression	   of	   these	  
particular	   inserts	   provided	   B.	   burgdorferi	   with	   a	   selective	   advantage	   and	   that	  
resulted	  in	  the	  higher	  transformation	  frequencies	  of	  these	  particular	  library	  clones,	  	  
but	  this	  was	  not	  the	  case,	  as	  neither	  of	  these	  clones	  transformed	  into	  B.	  burgdorferi	  
more	   efficiently	   than	   the	   empty	   pBSV2*flaBp	   shuttle	   vector.	   I	   subsequently	  
discovered	  that	  the	  plasmid	  DNA	  isolated	  after	  the	  expansion	  of	  this	  library	  in	  E.	  coli	  
predominately	  contained	  those	  two	  specific	  inserts.	  Several	  attempts	  were	  taken	  to	  
remake	   this	   library	   but	   none	   produced	   3X	   genome	   coverage.	   Often,	   the	   vector	  
remained	  uncut	  or	  self-­‐ligated	  without	  an	  insert	  fragment.	  	  
Large-­‐sized	  insert	  library	  
	   Similar	   difficulties	   were	   encountered	   when	   making	   the	   large-­‐sized	   insert	  
library.	  After	  transforming	  the	   ligation	  mix	   into	  E.	  coli,	   it	  was	  determined	  that	   less	  
than	  50%	  of	  clones	  screened	  by	  PCR	  contained	  inserts.	  Although	  3X	  B.	  burgdorferi	  
genome	   coverage	   was	   eventually	   achieved,	   the	   high	   proportion	   of	   empty	   vector	  
hindered	  any	  attempts	  to	  sub-­‐clone	  this	  library	  into	  B.	  burgdorferi.	  	  
	  
Conclusions	  
	   I	   was	   able	   to	   demonstrate	   the	   feasibility	   of	   creating	   a	   B.	   burgdorferi	  
expression	  library	  in	  E.	  coli	  and	  subsequently	  moving	  it	  into	  B.	  burgdorferi	  to	  screen	  
for	  repression	  of	  ospA.	  However,	  inserts	  in	  this	  intial	  library	  were	  small	  in	  size	  and	  
none	  of	  the	  small-­‐insert	  clones	  repressed	  lacZ	  from	  the	  ospA	  promoter.	  I	  intended	  to	  
construct	   three	  different	  genomic	   libraries,	  but	   technical	  difficulties	  prevented	   the	  
completion	  of	  the	  middle-­‐sized	  and	  large-­‐sized	  insert	  libraries.	  The	  most	  prevalent	  
complication	  was	   the	  high	   rate	  of	   recovering	  pBSV2*flaBp	   (Table	  A-­‐1)	  without	   an	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insert.	  This	  was	  due	  to	  both	  undigested	  vector	  coming	  through	  and	  re-­‐ligation	  of	  the	  
empty	  shuttle	  vector,	  despite	  using	  new	  EcoRI	  enzyme	  and	  Antarctic	  phosphatase	  to	  
remove	   end	   phosphates,	   respectively.	   Additionally,	   the	  middle-­‐sized	   library	   upon	  
expansion	   in	   E.	   coli	   primarily	   contained	   two	   distinct	   inserts.	   Although	   these	   two	  
inserts	   did	   not	   transform	  more	   efficiently	   into	  B.	   burgdorferi,	   it	   is	   likely	   that	   they	  
were	   favored	   in	  E.	   coli	   and	   thus	   out-­‐competed	   other	  B.	   burgdorferi	   inserts	   during	  
overnight	  growth,	  since	  characterization	  of	  the	  library	  directly	  after	  transformation	  
revealed	   random	   inserts	   of	   varying	   sizes	   had	   been	   ligated	   into	   the	   pBSV2*flaBp	  
shuttle	  vector.	  	  This	  was	  unfortunate	  due	  to	  time-­‐limitation	  but	  a	  few	  changes	  in	  the	  
protocol	  might	  make	  this	  project	  successful.	  	  
	   First,	   in	   order	   to	   assure	   that	   the	   vector	   was	   efficiently	   digested	   and	   to	  
minimize	   re-­‐ligation,	   I	   would	   use	   a	   linearized	   vector	   made	   available	   by	   a	  
commercial	   retailer.	   In	   addition	   or	   alternatively,	   I	   would	   use	   a	   counterselectable	  
marker	  to	  eliminate	  the	  recovery	  of	  empty	  shuttle	  vector.	  rpsL	  has	  been	  described	  
as	   a	   counterselectable	   marker	   for	   use	   in	   B.	   burgdorferi	   (21),	   as	   well	   as	   in	   other	  
bacteria	   including	   E.	   coli	   (22).	   The	   use	   of	   streptomycin	   and	   a	   sensitive	   rpsL	   gene	  
would	   limit	   the	   recovery	   of	   the	   empty	   shuttle,	   which	   would	   greatly	   aid	   in	   the	  
recovery	   of	   a	   complete	   large-­‐sized	   insert	   library.	   Additionally,	   using	   a	   host	   other	  
than	   E.	   coli	   to	   propagate	   the	   expression	   libraries	   could	   possibly	   reduce	   any	  
preferential	   expansion	   of	   certain	   B.	   burgdorferi	   genes	   in	   E.	   coli.	   Perhaps	   a	   more	  
promising	  approach	  would	  be	  to	  use	  a	  constitutive	  B.	  burgdorferi	  promoter,	  which	  is	  
not	  recognized	  in	  E.	  coli,	  to	  express	  the	  B.	  burgdorferi	  gDNA	  inserts,	  although,	  I	  am	  
not	  aware	  of	  any	  B.	  burgdorferi	  promoters	   that	  satisfy	   these	  criteria.	  Lastly,	   I	   sub-­‐
cloned	  the	  libraries	  created	  in	  E.	  coli	  to	  screen	  for	  the	  ospA	  repressor	  directly	  in	  B.	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burgdorferi.	   I	   chose	   to	   use	   B.	   burgdorferi	   B31	   clone	   A34	   because	   it	   is	   highly	  
transformable	  with	   shuttle	   vectors,	   i.e.	   I	   could	   achieve	   full-­‐library	   coverage	   easier	  
than	  if	  I	  had	  used	  a	  low-­‐passage	  infectious	  clone.	  	  However,	  A34	  does	  not	  retain	  all	  
of	   the	  plasmids	  nor	   has	   it	   been	  demonstrated	   that	  A34	   can	   repress	  OspA,	   thus,	   it	  
might	   not	   be	   the	   best	   background	   for	   screening	   my	   expression	   libraries	   for	   the	  
putative	  ospA	   repressor.	  During	   this	   project,	   a	   clone	   of	  B.	   burgdorferi	   that	   is	   both	  
infectious	   and	   is	   highly	   transformable	   with	   shuttle	   vectors	   was	   identified.	   This	  
clone,	   S9	   (23),	   lacks	   linear	   plasmid	   56	   (lp56)	   and	   the	   gene	   bbe02,	   both	   of	   which	  
encode	  restriction	  modification	  genes	  (16-­‐18).	  S9	  has	  been	  taken	  through	  the	  entire	  
infectious	  cycle	  of	  B.	  burgdorferi	  and	  thus	  produces	  and	  then	  represses	  OspA	  at	  the	  
appropriate	   times.	   Using	   S9	   as	   the	   background	   to	   screen	   for	   the	   ospA	   repressor	  
would	  ensure	  that	  all	  factors	  necessary	  for	  repression	  are	  available.	  	  	  
	   Although	   my	   attempts	   at	   identifying	   an	   ospA	   repressor	   were	   unfruitful,	  
defining	  the	  mechanisms	  involved	  in	  OspA	  regulation	  remains	  a	  significant	  area	  of	  
interest.	  Knowing	  how	  OspA	  is	  repressed	  would	  open	  a	  new	  door	  to	  understanding	  
how	   B.	   burgdorferi	   senses	   and	   adapts	   to	   the	   different	   environments	   during	   its	  
infectious	  cycle	  and	  could	  perhaps	  shed	  light	  on	  how	  other	  organisms	  regulate	  their	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